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Abstract 
 
Post-transplant lymphoproliferative disease (PTLD) is a life threatening complication of 
transplantation, often associated with the B-lymphotrophic Epstein-Barr virus (EBV). In order 
to further our understanding of the relationship between EBV infection and PTLD, a series of 
clinical and laboratory studies were undertaken. A multicentre United Kingdom study defined 
current outcomes and prognostic factors for patients with PTLD arising after solid organ 
transplant. A study to define incidence and risk factors for EBV reactivation and PTLD 
amongst patients undergoing allogeneic haematopoietic stem cell transplant (allo-HSCT) 
revealed greatly reduced risk amongst patients with Non-Hodgkin lymphoma previously 
treated with Rituximab. Complementary laboratory studies to explore the pathophysiology of 
EBV reactivation after allo-HSCT demonstrated that the virus maintains selectivity for, and 
can drive the expansion of, circulating CD27
+
 memory B-cells; these are normally scarce for 
many months after transplant. Investigations were also performed to examine the role of cell 
survival, DNA damage signalling and mutations as possible drivers of clonal selection in 
EBV-infected B-cell cultures, as an in vitro model for PTLD. Finally, work was undertaken to 
characterise EBV-epitope specific T-cell responses expanding in patients successfully treated 
with donor lymphocyte infusion for Rituximab-refractory PTLD arising after allo-HSCT.
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1. Introduction 
 
1.1 Beginnings 
February 2014 marked the 50
th
 anniversary of the discovery of the first human tumour virus, 
Epstein-Barr virus (EBV). This milestone in biomedical research has its origins in a chance 
meeting between Dennis Burkitt, an Irish surgeon working in Uganda, and Anthony Epstein, a 
pathologist in training at the Middlesex Hospital Medical School, United Kingdom
1
. It was 
during an evening seminar delivered by Burkitt at the Middlesex Hospital that Epstein first 
learnt of Burkitt’s work describing a novel form of tumour affecting East African children, 
characterised by a curious localisation to the jaw and aggressive clinical course – Burkitt 
lymphoma (BL). Detailed epidemiological observation had shown that this lymphoma was 
restricted to geographical areas with high temperatures and rainfall, and in light of this Burkitt 
and his colleagues postulated that a virus might be responsible. Working at the time on Rous 
sarcoma virus, an agent which causes tumours in chickens, Epstein was enthused by this idea 
and promptly set about trying to identify a virus in specimens of BL transported from Africa. 
Working with his research assistant, Yvonne Barr, 3 years without success followed until late 
one evening in February 1964 when Epstein finally observed virus particles inside cultured 
BL cells using electron microscopy
2
. Subsequent work confirmed the presence of Epstein-
Barr Virus, as it came to be known, in almost all cases of African (endemic) BL. It was also 
found in a proportion of non-African (sporadic) BL, as well as in cases arising in individuals 
with Acquired Immunodeficiency Syndrome (AIDS) due to Human Immunodeficiency virus 
(HIV) infection.  
 
In the years that followed this seminal discovery, EBV was linked to numerous other disease 
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entities (Table 1). Thus, in 1968 EBV was shown to be the agent responsible for infectious 
mononucleosis (IM), a usually self-limiting lymphoproliferative disease characterised by 
fever, pharyngitis, lymphadenopathy and marked fatigue
3
. It was also causally implicated in 
diseases originating from epithelial cells, in particular nasopharyngeal carcinoma (NPC), a 
major cause of mortality in southern China, in which EBV is always found
4
. Furthermore, it 
was found to be associated with other forms of B-lymphocyte (B-cell) malignancy, including 
cases of classical Hodgkin lymphoma (HL)
5
, as well as diseases arising from T-cells
6,7
 or 
Natural Killer (NK)-cells
8
. 
 
Remarkably, EBV was also discovered to be the cause of lymphomas in organ transplant 
recipients. Thus, human organ transplantation had been pioneered in the early 1960s, 
facilitated by the introduction of the immunosuppressive drugs Azathioprine and then 
Cyclosporin. However, transplant physicians had soon noticed a worrying increase in the 
incidence of cancer in their patients. These were frequently lymphomas, which developed 
within 1 - 2 years of transplant and which were usually fatal. Although an infective cause was 
suspected, the agent responsible remained elusive until the landmark discovery, reported in 
June 1980, that EBV had been found in a lymphoma from a patient with a renal transplant
9
. 
Subsequently, EBV would be confirmed as an aetiological agent in many cases of what came 
to be known as post-transplant lymphoproliferative disease (PTLD). To this day, PTLD 
remains a significant cause of morbidity and mortality amongst transplant recipients, and an 
important paradigm in research. 
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Diseases 
Infectious mononucleosis 
X-linked lymphoproliferative disease 
Haemophagocytic lymphohistiocytosis 
Chronic active EBV 
Hairy oral leukoplakia 
Multiple sclerosis 
 
B-cell lymphomas 
Post-transplant lymphoproliferative disease 
Burkitt lymphoma 
Classical Hodgkin lymphoma 
Diffuse large B-cell lymphoma 
Acquired immunodeficiency syndrome lymphomas 
Primary effusion lymphoma 
 
T- and NK-cell lymphomas 
Haemophagocytic lymphohistiocytosis T-cell lymphoma 
Nasal NK/T-cell lymphoma 
 
Epithelial cell malignancies 
Nasopharyngeal carcinoma 
Gastric carcinoma 
 
Other malignancies 
Leiomyosarcoma 
 
Table 1. EBV-Associated Pathologies 
Since its discovery EBV has been associated with a wide range of non-malignant and 
malignant disease entities
10
. 
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1.2 B-Cell Biology 
Humeral Immune Responses 
EBV is primarily a B-lymphotrophic virus, and thus an appreciation of B-cell biology is 
crucial for understanding EBV and its associated pathologies. As mediators of the humeral 
arm of the adaptive immune system, the principal role of B-cells is to generate 
immunoglobulins (Ig), also known as antibodies
11
. These glycoproteins, secreted by plasma 
cells, bind target antigens to mediate numerous immune effects including elimination of 
bacterial pathogens via complement-activation, triggering of macrophage-mediated 
phagocytosis and recruitment of other immune cells. Antibodies are comprised of 2 identical 
immunoglobulin heavy (IgH) chains and 2 identical Ig light (IgL) chains, covalently linked to 
each other by disulphide bonds. Located at the amino terminus of each chain is a variable 
domain (VH for the heavy chain; VL for the light chain) containing 3 areas of highly variable 
amino acid sequence, known as complementarity-determining regions (CDR). When brought 
together in the overall structure of the antibody molecule, the CDRs collectively form an 
antigen binding site, which facilitate binding to specific target antigens. Meanwhile, the 
remainder of the Ig chains comprise 1-3 conserved constant (C) domains, the configuration of 
which determines which of 5 functionally distinct antibody classes the molecule belongs to: 
IgM, IgD, IgG, IgA or IgE. Mature B-cells express surface Ig complexed with the molecules 
CD79a and CD79b, constituting the B-cell receptor (BCR)
12
. 
 
Early B-Cell Development 
The earliest events in B-cell development occur in the bone marrow (Figure 1). It is here that 
B-cell precursors develop from haematopoietic stem cells, and where Ig genes undergo ‘VDJ 
recombination,’ a process that contributes significantly to the generation of antibody 
1. Introduction 
Page 5  
 
 
Figure 1 Early B-Cell Development 
During B-cell development RAG-mediated VDJ recombination results in rearrangement of 
germ-line Ig sequences in a process that contributes hugely to Ig diversity by randomly 
bringing together sequences that generate the variable domains of IgH and IgL chains. The 
IgH chain undergoes rearrangement of VDJ segments at the pro-B-cell stage. The rearranged 
chain is expressed at the cell surface in combination with a surrogate light chain and CD79α 
(Igα) and CD79β (Igβ) molecules, a complex that comprises the pre-BCR. At the pre-B-cell 
stage, the IgL chain undergoes rearrangement of VJ segments, and this replaces the surrogate 
light chain generating the final BCR. Mature naive B-cells simultaneously expressing surface 
Ig with IgM and IgD constant regions, as a consequence of alternative splicing, are released 
into the circulation. Multiple regulatory mechanisms ensure that only B-cells successfully 
expressing Ig with a single specificity, and which lack self-reactivity, are generated. Figure 
adapted from  Fried & Bonilla
13
. 
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diversity
14
. In humans, the Ig genes are located on separate chromosomes: chromosome 14 
(IgH locus), chromosome 2 (κ IgL locus) and chromosome 22 (λ IgL locus). In the germline, 
each IgH locus contains multiple variable (V), diversity (D), and joining (J) segments, and 
each IgL locus contains multiple V and J segments. As B-cells progress through the early 
stages of their development, they randomly recombine these gene segments to form a single 
‘rearranged’ sequence that codes for each Ig V domain. Recombination events occur in 
sequence and define distinct stages of B-cell development. Thus the IgH gene first undergoes 
recombination during the ‘pro-B-cell’ stage, when single D and J segments recombine, after 
which a V segment recombines with the DJ segment. Subsequently, the rearranged VDJ 
sequence is expressed with a constant domain at the ‘large pre-B-cell’ stage. Later, 
rearrangement of the IgL segments occurs at the ‘small pre-B-cell’ stage, resulting in 
expression of a functional κ or λ IgL molecule. These VDJ recombination events are mediated 
by the recombination activating gene (RAG) recombinase complex, encoded by RAG1 and 
RAG2. This cleaves DNA at specific recombination signal sequences (RSS) flanking each V, 
D and J gene segment, after which DNA repair enzymes, including those of the non-
homologous end joining (NHEJ) repair pathway, repair the DNA breaks
15
. Importantly, the 
VDJ recombination process is regulated by multiple mechanisms in order to ensure that B-
cells express a single functioning BCR
16,17
. Thus, as each cell contains 2 copies of the Ig loci, 
a mechanism known as ‘allelic exclusion’ ensures that productive rearrangement of 1 copy 
prevents further rearrangement and expression of the other. Furthermore, if both Ig 
rearrangements are non-productive, resulting in the inability to express a functional Ig chain, 
then further differentiation of the cell is prevented. Moreover, in order to prevent the 
generation of autoreactive B-cell responses, cells bearing BCRs which recognise self-antigens 
are eliminated via the induction of apoptosis or anergy.    
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Naive B-cells 
Consequent upon these early B-cell differentiation events, antigen-inexperienced naive B-
cells are released from the marrow into the circulation, where they typically constitute around 
70% of the total B-cell pool
18
. These cells are identifiable by simultaneous expression of 
surface IgM and IgD (and absence of the surface marker CD27, as described later), resulting 
from alternative splicing of IgH mRNA transcript, such that the recombined VDJ region can 
be associated with C regions of either Ig class
14
. Notably, the earliest emigrants from the bone 
marrow are known as transitional B-cells, which typically make up less than 5% of B-cells in 
healthy individuals
19-22
. Characteristically these cells express high levels of CD24, CD38 and 
CD10, which are gradually down-regulated as they differentiate into mature naive B-cells. A 
high proportion of transitional B-cells are thought to exhibit self-reactivity, and these are 
deleted such that only around 50% successfully develop into mature B-cells
22
. The latter 
circulate through the blood and secondary lymphoid tissues until they either encounter 
cognate antigen or otherwise apoptose. 
 
B-Cell Activation 
Antigen encounter by B-cells, typically in the follicular areas of secondary lymphoid tissues, 
initiates B-cell activation and differentiation
12,23,24
. Antigen binding triggers the aggregation 
of BCR complexes, resulting in activation of the Src family kinases LYN, BLK and FYN, as 
well as SYK and BTK tyrosine kinases. During this process, targets in the CD79a and CD79b 
subunits of the BCR are phosphorylated and a large ‘signalosome’ complex assembles, 
composed of the BCR, kinases and other important adaptor molecules including CD19, CD21 
and BLNK. This triggers a signalling cascade resulting in pleiotropic downstream effects 
including modulation of gene expression, changes to cell metabolism, cytoskeletal 
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reorganisation and cell-cycle entry. However, effective B-cell activation also requires 
additional co-stimulatory signals, without which antigen-stimulated B-cells would either 
apoptose or become anergic
23
. T-cell independent antigens, such as the lipopolysaccharide 
(LPS) component of Gram-negative bacterial membranes and unmethylated CpG DNA of 
bacteria or viruses, provide intrinsic co-stimulatory signals in the form of ‘pathogen-
associated molecular patterns’ (PAMPs) which are recognised by Toll-like receptors25,26. 
However, most other antigens are T-cell dependent and require additional signalling provided 
by CD4
+
 (helper) T-cells
23
. Thus, within 6 hours of BCR engagement, B-cells exhibit cell-
cycle entry and begin to proliferate
27
, after which they up-regulate the chemokine receptor 
molecule CCR7 which triggers B-cell migration to the border between follicular and T-cell 
areas of secondary lymphoid tissues
28
. It is here that B-cells present antigen to CD4
+
 T-cells. 
Thus, antigen-bound BCR complexes are internalised by B-cells, after which antigen is 
processed to generate peptides that are presented at the cell surface by MHC-class II 
molecules. T-cell receptor (TCR)-binding to the MHC-peptide complex triggers activation of 
the CD4
+
 T-cells, which thereafter provide co-stimulatory signals via cell-cell contact and 
cytokine secretion. 
 
The most important of the co-stimulatory signals provided by CD4
+
 T-cells is the binding of 
CD40 ligand (CD40L, also known as CD154), which is upregulated on activated T-cells, to 
CD40 on B-cells
29
. Other important signals include binding of CD28, also upregulated on 
activated T-cells, to CD86 on activated B-cells
30
, and secretion of the cytokine IL4. These 
interactions trigger a multitude of signalling events, operating via NFkB and other signalling 
pathways, which supporting B-cell survival, proliferation and further differentiation. Notably, 
the ability of CD40L to act as a potent stimulator of B-cells is evident from its use to generate 
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B-cell lymphoblasts in vitro. Thus, in one approach, resting B-cells cultured on a layer of 
mouse fibroblasts stably transfected with the coding region for human CD40L, in the presence 
of the cytokine IL4, rapidly differentiate into activated lymphoblasts
31,32
. These maintain 
proliferation for several weeks with repeated stimulation. 
 
Within 1 to 2 days of initial antigen encounter, B-cells begin to proliferate
23
. Thereafter, 
stimulated B-cells undergo 1 of 3 principal fates
33
. As such, some cells differentiate into 
extra-follicular plasma cells, which produce low-affinity IgM antibodies. Other cells re-enter 
the circulation as early memory B-cells. Meanwhile, some B-cells establish areas of marked 
proliferation within lymphoid follicles known as ‘germinal centres’ (GC)34-36 (Figure 2). In 
these GC structures, B-cells exhibit massive clonal expansion and undergo further 
diversification of their Ig genes in order to generate plasma cells that produce high-affinity 
antibody, as well as memory B-cells. Importantly, differentiation into plasma cells versus GC 
B-cells is influenced by key transcriptional regulators. Thus, plasma cell differentiation is 
dependent upon up-regulation of Blimp1 and MUM1 (IRF4), whilst GC differentiation 
depends on expression of the transcriptional repressor BCL6, an important marker of GC B-
cells
37-40
.  
 
Germinal Centre Reactions 
During GC formation, activated B-cells first differentiate into rapidly proliferating 
centroblasts that express BCL6
34,35
. Characteristically these cells also upregulate activation-
induced cytosine deaminase (AID), an enzyme that plays a central role in 2 essential 
processes in GC B-cell maturation: somatic hypermutation (SHM) and class switch  
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Figure 2. Germinal Centres 
Events occurring during germinal centre (GC) transit. Following antigen-encounter, naive B-
cells become activated and seed a GC. The cells first differentiate into centroblasts and exhibit 
massive clonal expansion in the dark zone of the GC. Here they undergo somatic 
hypermutation (SHM), mediated by the enzyme AID which is upregulated in GC cells. SHM 
introduces mutations into the variable region of the Ig sequence which may alter the affinity 
of antigen-binding. During affinity selection, B-cells that have acquired mutations which 
improve antigen-binding receive signals promoting cell survival and proliferation, whereas 
other cells either apoptose or become anergic. Selected cells then transit to the light zone of 
the GC where they differentiate into centrocytes and undergo Ig class-switch recombination 
(CSR). During CSR, the IgH variable region recombines with an alternative constant region, 
belonging to either the IgG, IgA or IgE antibody classes, in an AID-dependent mechanism. 
These GC processes are regulated by follicular dendritic-cells (FDCs) and CD4+ T-cells 
which engage in cell-cell contacts and secrete cytokines. Amongst the key signalling events is 
interaction of CD40L expressed on activated CD4
+
 T-cells with CD40 on B-cells. Plasma 
cells with the capacity to produce high affinity Ig of alternative classes subsequently exit the 
GC. Memory B-cells also leave the GC and these can rapidly respond to future antigen-
encounter. Figure adapted from Kuppers
41
.    
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recombination (CSR)
42-45
. SHM facilitates the generation of high-affinity antibodies by 
introducing additional mutations into Ig genes
46
. Thus AID targets cytidine nucleotide 
residues localised in the V regions of Ig loci resulting in their deamination, after which error 
prone repair mechanisms mediated by enzymes including Pol η and θ can result in the 
introduction of random mutations. This can result in amino acid changes in IgH and IgL 
variable domains which alter the binding affinity of the BCR for its antigen. Subsequently, as 
centroblasts differentiate into centrocytes they are subjected to selection by follicular dendritic 
cells (FDCs), in a process known as affinity maturation
47
. B-cells which have acquired SHM 
mutations that confer improved affinity for target antigens are selected in preference to cells 
that bind antigen less avidly.  
 
CSR is the mechanism through which B-cells, which initially express IgD and IgM antibody, 
alter their expression to alternative Ig classes
15,46
. This is beneficial because each of the Ig 
classes possess unique functional characteristics, determining properties such as antibody 
tissue distribution, the capacity to interact with other immune cells and the ability to 
polymerise. At the molecular level CSR is mediated by an AID-dependent mechanism that 
recombines the rearranged VDJ Ig region with an alternative CH region corresponding to the 
different Ig classes. In particular AID introduces double-stranded breaks in switch (S) regions, 
which consist of tandem repeats of short G-rich sequences (20-80 bp), located downstream of 
each CH region. Intervening DNA sections are removed, after which the DNA ends are 
reunited by end joining recombination. Notably, this process is regulated by CD4
+
 T-cells and 
FDCs via cell-cell contacts and the secretion of cytokines including IL4, IL10, IL13, IL21 and 
TGFβ, which influence the frequency of specific switching events48. 
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Importantly, AID is also responsible for the generation of mutations in non-Ig genes in B-
cells. These mutations characteristically occur in the 5' non-translated promoter regions of 
affected genes, and resemble the SHM events in Ig genes. Thus, GC B-cells were first shown 
to possess mutations within the BCL6 gene
49
. Thereafter numerous other genes have been 
shown to be targeted, including known oncogenes and tumour suppressors
50,51
. Importantly, 
such mutations have also been found in several forms of lymphoma
52-57
, implicating AID in 
tumourigenesis. Furthermore, AID has been linked to the generation of chromosomal 
translocations
58-60
.  Notably, AID-induced mutations are only thought to affect actively 
transcribed genes because the open chromatin configuration associated with gene 
transcription is necessary for AID to access DNA. 
 
Memory B-Cells 
Memory B-cells are antigen-experienced cells that persist for many years after a primary 
immune response
18,23
. On secondary antigen encounter they respond by rapidly differentiating 
into plasma cells that produce high-affinity antibodies. In keeping with this, they can be 
distinguished from antigen-inexperienced naive B-cells because they are larger in size, 
possess mutated Ig genes and secrete high quantities of antibody following in vitro 
stimulation. Notably, expression of the TNF-receptor superfamily molecule CD27 has also 
been recognised as a reliable marker of B-cell memory in recent years. Thus, stimulation of 
B-cells bearing surface CD27 results in up to 100-fold more antibody secretion compared to 
that of CD27
-
 cells
61,62
. Furthermore, CD27
+
 B-cells cells possess somatically mutated Ig V 
region genes, whilst those lacking CD27 are non-mutated
63,64
. Moreover, immunised 
individuals carry antigen-specific B-cells exclusively within the CD27
+
 B-cell subset
65
. An 
important caveat, however, is the consistent finding of a small population (around 1%) of 
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circulating B-cells which lack CD27 surface expression but which are larger than naive B-
cells, possess mutated V regions and have undergone class-switching, and which are thus 
known as CD27
-
 memory B-cells
66-69
.  
 
In light of the above, 2 principal circulating memory B-cell subsets can be identified using the 
surface markers CD27, IgM and IgD
18,63
 (Figure 3). Thus, whereas antigen-inexperienced 
naive B-cells are reliably identified as CD27
-
IgM
+
IgD
+
 cells, CD27
+
 memory B-cells, 
comprising around 30% of all B-cells, can be further separated into 2 generally equal 
fractions. Thus, class-switched memory (CSM) B-cells are CD27
+
IgM
-
IgD
-
 antigen-
experienced cells which have transited through a GC reaction, where they have acquired Ig 
gene mutations and undergone switching to IgG, IgA or IgE classes. Meanwhile, a second 
subset of so-called ‘non-switched memory’ (NSM) B-cells possess mutated Ig genes and 
exhibit surface CD27
+
 but they have not undergone class switching and thus retain surface 
IgM and IgD. Notably, a further memory B-cell subset are the so-called ‘IgM only’ memory 
B-cells. These exhibit a CD27
+
IgD
-
IgM
+
 phenotype, carry mutated Ig genes, and constitute 
around 1% of circulating B-cells. 
 
Interestingly, there has been considerable debate as to the origins of the NSM B-cell subset
18
. 
In particular, one hypothesis to explain why these cells possess mutated Igs but are not class-
switched suggests that they derive from T-cell dependent pathways in the context of an 
abortive GC reaction, such that SHM occurs but CSR does not
63
. This view is supported by 
data showing that CD27
+
IgM
+
 B-cells exhibit ‘off-target’ mutations in BCL6, taken as 
evidence of GC transit, and moreover that they appear to be clonally related to CSM B-cells
70
. 
However, this has been disputed by subsequent data which failed to show any clonal  
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Figure 3. B-Cell Surface Markers 
B-cells at different developmental stages can be identified by characteristic surface markers. 
The earliest B-cell emigrants from the bone marrow are transitional B-cells, which bear 
surface IgD and IgM, and also express high levels of CD38 and CD24, and also CD10. These 
markers are down-regulated as these cells differentiate into mature naive B-cells. Following 
antigen encounter, naive B-cells ultimately differentiate into antibody-secreting plasma cells 
which are CD38
++
, CD20
-
 and CD138
+
. Memory B-cells (and plasma cells) can be 
distinguished from naive B-cells because they upregulate the TNF-receptor superfamily 
molecule CD27. CSM B-cells result from T-cell dependent antigen stimulation and GC 
transit, and undergo SHM and Ig class switching from IgM /IgD to either IgG, IgA or IgE. A 
small proportion of memory B-cells lack surface CD27 but have still undergone class 
switching and are known as 'CD27-negative' memory B-cells. A minority of CD27
+
 B-cells 
also retain IgM but lose IgD; these 'IgM-only' memory B-cells are also considered to be GC-
derived. NSM B-cells express CD27 and undergo SHM but retain surface IgM and IgD; their 
origin remains controversial (dotted lines); they may arise from T-cell independent antigen-
stimulated pathways located in the spleen or via early exit from the GC.  
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relationships to CSM subsets
71
. Meanwhile a second hypothesis proposes that they may arise 
through a T-cell independent mechanism that occurs outside of GC
72,73
. This has been 
supported by evidence that CD27
+
IgM
+
 B-cells are retained in individuals with genetic 
conditions that abrogate GC development. Thus hyper-IgM syndrome is an inherited 
condition in which mutations in the genes for CD40 or CD40L interfere with normal B- and 
T-cell co-operation during immune responses
74,75
. As a consequence, GC do not form in these 
individuals, their B-cells fail to undergo class switching and they exhibit an excess of IgM 
antibody. Nevertheless, they retain somatically mutated circulating CD27
+
IgM
+
 B-cells
72,73,76
. 
Similarly, NSM B-cells are also found in patients with X-linked lymphoproliferative disease 
(XLP), in whom loss of a functional SAP protein prevents CD4
+
 T-cell help for the 
production of antibody responses
68,77,78
, and those with common variable immunodeficiency 
(CVID) resulting from mutations in ICOS
79
; both groups also fail to develop GC. Such 
evidence has formed the basis for proposing that the CD27
+
IgM
+
 B-cells may in fact be 
circulating splenic marginal zone cells, which arise following T-cell independent antigenic 
stimulation and which undergo SHM outside of GC. Supporting this is the finding that 
CD27
+
IgM
+
 B-cells are markedly reduced in asplenic individuals
80
, and that they may be 
clonally related to splenic B-cells
73
. In addition, it has been proposed that these CD27
+
IgM
+
 
B-cells may acquire Ig mutations prior to antigen exposure, through so called ‘pre-
diversification,’ in the spleen73,81. Evidence in favour of this is the observation that infants 
less than 2 years old, in whom T-cell independent responses are thought to be absent, possess 
mutated CD27
+
IgM
+
 cells which retain a polyclonal repertoire, consistent with a lack of 
antigen driven stimulation
73,81
. However, a major criticism of this view is the failure to detect 
AID in splenic B-cells
82
. 
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1.3 Epstein-Barr Virus 
Taxonomy and Structure 
EBV is a member of the herpesvirus family of double-stranded DNA viruses
10
. This family, 
characterised by the potential to establish chronic infections, contains over 100 members, 
several of which are known to infect humans. Notable examples of the latter include Herpes 
Simplex Virus (HSV), which causes oral and genital infections, Varicella Zoster Virus 
(VZV), the cause of Chicken Pox and Shingles, and Cytomegalovirus (CMV) which causes 
multi-system disease, particularly in the immunocompromised. EBV belongs to the 
gammaherpesvirus subfamily, along with Kaposi Sarcoma Herpes Virus (KSHV). As a 
member of the lymphocryptovirus (LCV) genus, EBV is closely related to other LCVs that 
cause B-cell transforming infections in non-human primate species including Old World 
monkeys such as the rhesus macaque, and New World monkeys including the marmoset
83-86
. 
 
EBV consists of a linear double-stranded DNA genome packaged inside a protein capsid, 
surrounded by tegument proteins and a glycoprotein-containing lipid envelope
87
. The genome 
is approximately 172 Kb in length, making it very large compared to most other viruses, and 
has the potential to code for approximately 80 proteins (Figure 4). The prototypic B95.8 strain 
of EBV, isolated from a patient with IM, was the first herpesvirus to be fully cloned and 
sequenced in 1984 (Accession no. V01555)
88
. Notably, this strain contains a deletion of 
approximately 11.8kb which has subsequently been repaired by insertion of corresponding 
sequence isolated from the Raji-BL strain
89
, generating a hybrid reference sequence 
(Accession no. NC_007605). In addition, several other complete virus sequences, mainly 
derived from EBV-positive tumours, have recently been published
90-96
. The EBV genome is 
flanked by a number of terminal repeats (TR) which mediate genome circularisation. The  
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Figure 4. The EBV Genome 
EBV possesses a double-stranded DNA genome that is approximately 172 Kb in length. 
When packaged inside its virion the genome is linear. Flanking terminal repeats mediate 
circularisation to the episomal form found in latent infection. The genome has potential to 
code for approximately 80 proteins in total. Of these, only a limited number are expressed 
during latent infection. Latent proteins (red arrows) comprise the 6 EBV nuclear antigens 
(EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA-leader protein (LP)), 3 latent 
membrane proteins (LMP1, LMP2A and LMP2B) and BHRF1. A series of non-coding RNAs 
are also expressed (blue arrows) including the 2 EBV-encoded RNAs (EBERs), and a 
complex of highly spliced polyadenylated transcripts known as the BamHI A rightward 
transcripts (BARTs) from which multiple micro RNAs (miRNAs) are derived. A second 
cluster of miRNAs originate from the BHRF1 region. Figure courtesy of Dr A. Bell, 
University of Birmingham. 
EBNA1 EBNA2
EBNA3A
EBNA3B
EBNA3C
LMP1
LMP2
BART 
miRNAs
EBERs
EBNA-LP
EBV genome
BHRF1
miRNAs
1. Introduction 
Page 18   
 
sequence also contains several internal repeat regions, and separate latent and lytic origins of 
replication. By convention, the EBV genome sequence has been annotated with reference to 
fragments generated by BamHI restriction endonuclease digestion (labelled BamHI A-Z, a-e). 
EBV isolates are generally classified into 2 major subtypes, principally based on 
polymorphisms within the EBV nuclear antigens EBNA2, EBNA3A, EBNA3B and 
EBNA3C
97
. Type I viruses appear to predominate within most human populations
10
, and 
show an enhanced ability to transform B-cells in comparison to Type II viruses, largely due to 
differences in the EBNA2 gene
98,99
. In addition, minor polymorphisms in several other 
regions including EBNA1
100
, LMP1
101
 and BHRF1
102,103
 have been used to define intra-typic 
strains. Interestingly, studies have used these EBV genome polymorphisms to propose that 
immunocompromised
104
 and  immunocompetent individuals
105
 may carry multiple EBV 
strains. 
 
Latent Infection 
EBV is principally trophic for B-cells, in which it establishes chronic latent infection
10,87
. 
However it can also infect epithelial cells in healthy carriers, and T-cells, NK-cells and 
smooth muscle cells in the context of disease. Much of our knowledge of EBV latency has 
been obtained through in vitro experimentation, making use of the virus’s ability to transform 
B-cells into lymphoblastoid cells lines (LCLs)
87
. In these, the virus genome is carried in each 
cell as multiple extracellular double-stranded DNA episomes, and viral gene expression is a 
restricted to a small number of products, which exert pleiotropic effects on the cellular 
phenotype leading to transformation (Figure 4). Protein products comprise 6 EBNAs, 
(EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA-leader protein (LP)), 3 latent 
membrane proteins (LMP1, LMP2A and LMP2B) as well as the viral BCL2 homologue 
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BHRF1. In addition, EBV also expresses a series of non-coding RNAs including 2 non-
polyadenylated, EBV-encoded RNAs (EBERs) and a complex of highly spliced 
polyadenylated transcripts of uncertain coding potential known as the BamHI A rightward 
transcripts (BARTs) which are precursors of more than 40 micro RNAs (miRNAs). Together  
this combination of gene expression is known as the ‘Latency III’ pattern, and in addition to 
being observed in LCLs it is found in infected B-cells from patients with IM and most PTLD 
tumours
106
. In Latency III, all of the EBNA proteins are expressed from individual mRNA 
species that are differentially spliced from a long primary transcript originating from either of 
2 alternative upstream viral promoters, Cp or Wp, located in the BamHI C or W regions
107-110
 
(Figure 5). Activation of both promoters is dependent on the B-cell specific host transcription 
factor PAX-5 (also known as BSAP)
111,112
. Notably, switching from Wp to Cp occurs early 
after B-cell infection due to the trans-activating effects of both EBNA1 and EBNA2 on Cp. 
Meanwhile, LMP1 and LMP2A/B are expressed from separate promoters located in the 
BamHI N region, where their expression is dependent upon transactivation by EBNA2
113-115
. 
 
Alternative Forms of Latency 
In addition to Latency III, EBV exhibits other patterns of gene expression. These were first 
described in the context of EBV-related tumours but may also be important for EBV 
persistence in the normally infected host. Thus, in many examples of BL, a ‘Latency I’ pattern 
is observed, characterised by expression of just EBNA1, the EBERs and the BARTs. In this, 
EBNA1 expression is driven from a primary transcript expressed from the Qp promoter 
located in the BamHI Q region
116,117
. However, in some forms of BL an alternative ‘Wp 
Latency’ is observed, in which transcription from the Wp promoter leads to expression of all 
EBNAs except EBNA2, in addition to BHRF1
118-121
. This pattern, present in 15% or more of  
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Figure 5. Patterns of EBV Latent Gene Expression 
Transcripts expressed in different forms of EBV latency are shown below a schematic 
illustration of the linear EBV genome. In the Latency III pattern of expression, seen in LCLs 
and in most PTLDs, all EBNA proteins and BHRF1 are expressed from the BamHI W and C 
promoters (Wp and Cp), and the 3 LMP proteins are expressed from promoters in the BamHI 
N region. By contrast, in the Latency I pattern found in most endemic BLs, expression is 
limited to a single nuclear antigen, EBNA1, from a promoter in BamHI Q (Qp). Wp Latency 
is an alternative pattern of expression, found in around 15% of endemic BL tumours, in which 
transcription from the Wp promoter results in expression of all EBNAs, except EBNA2, and 
BHRF1. In the Latency II pattern, found in NPC and EBV-positive HL, expression of EBNA1 
from the Qp promoter is accompanied by that of the LMPs. The non-coding EBER and BART 
RNAs, from which the BART miRNAs are derived, are found in all forms of Latency. The 
BHRF1 miRNAs are thought to be generated from Wp/Cp-initiated transcripts and are 
predominantly found in Latency III infection. Figure adapted from Rowe et al.
122
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endemic BL tumours, occurs when an EBV strain exhibits a deletion including the EBNA2 
region, although it is currently unclear why activation of the Wp promoter is favoured over 
the Qp promoter. Interestingly, Latency I BL cell lines may also alter their pattern of gene 
expression when passaged in vitro, resulting in Latency III expression
123,124
. 
 
The Latency II pattern of virus gene expression was first identified in NPC biopsies
125-127
 and 
was subsequently identified in gastric carcinoma
128,129
, HL
130,131
, and T-cell and NK-cell 
lymphomas
132
, amongst others. In this, EBNA1 expressed from the Qp promoter is found 
along with the EBERs and BARTs as in Latency I, but these are also accompanied by 
expression of LMP1, LMP2A and LMP2B regulated by an EBNA2-independent mechanism.  
 
Notably, the factors that determine why different cell types, and different malignancies, 
exhibit alternative expression patterns remains imperfectly understood. However, it is clear 
the B-cells can support all forms of latency, whereas non-B-cells exhibit more restricted 
expression patterns. This may be explained, at least in part, by the fact that non-B-cells lack 
the transcription factor PAX-5, which is required for activation of the Cp and Wp promoters 
essential for Latency III expression
111,112
.  
 
Latent Gene Products 
The function of individual EBV latent gene products has been elucidated largely through 
experimentation using recombinant forms of EBV, in which viral genes have been 
manipulated. This work has shown that disrupted expression of any one of EBNA1, EBNA2 
EBNA3A, EBNA3C or LMP1 results in either complete or significant abrogation of B-cell 
transformation
87
. 
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EBNA1 
EBNA1 is a DNA binding protein which is essential for maintenance and replication of the 
viral episome, acting by binding to and recruiting other factors to the viral latent origin of 
replication, OriP
133,134
. For this reason it is the only EBV protein found in all EBV-infected 
cells. In addition, the protein acts as a transactivator of viral gene expression, enhancing  
transcription from both the Cp promoter
135,136
 and of LMP1
137
. It also negatively regulates its 
own transcription from the alternative EBNA1 promoter Qp
138,139
. Notably, the EBNA1 
protein contains a glycine–glycine–alanine (gly–gly–ala) repeat sequence, which prevents its 
proteasomal degradation and also interferes with MHC class I-restricted presentation, 
resulting in evasion of EBNA1-specific CD8
+
 T-cell responses
140,141
.  
 
EBNA2 and EBNA-LP 
EBNA2 is an essential effector of viral transformation, as demonstrated by the inability of the 
P3HR1 strain, which carries a deletion of EBNA2, to transform B-cells
99,142
. Acting as a 
master transcription factor that, along with EBNA-LP, is expressed shortly after infection, 
EBNA2 activates target cellular genes which drive the host cell into cell-cycle, as well as 
triggering expression of the other EBNA proteins from the EBNA2-dependent Cp 
promoter
143
, along with LMP1 and LMP2A
114
. The activity of EBNA2 is mediated, at least in 
part, by interaction with the DNA binding protein J-recombination-binding protein (RBP-J), 
which targets it to promoters containing the RBP-Jκ sequence144,145. Among the cellular 
targets which are upregulated by EBNA2 is the proto-oncogene c-myc
146
. EBNA-LP is 
encoded by the leading part of the EBV primary latent transcript. Its coding region includes 
an area of BamHI W repeats and therefore multiple isoforms of differing size can arise from a 
single infected cell
147
. The number of BamHI repeats varies between isolates
148,149
. Whilst it is 
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not essential, EBNA-LP increases the efficiency of B-cell transformation
150,151
. Furthermore, 
the presence of fewer than 5 BamHI W repeats impairs transformation
149
. In particular, 
EBNA-LP is thought to interact with EBNA2 to regulate transcriptional targets including 
LMP1
151-153
.  
 
EBNA3 Family 
The EBNA3A, -3B and -3C proteins are related nuclear proteins which act as transcriptional 
regulators of multiple viral and cellular genes. EBNA3A and -3C are essential for 
transformation. They function as repressors of proteins associated with apoptosis, such as 
BIM (BCL2L11)
154
, as well as senescence, including  p16INK4A
155,156
 and p14ARF 
(CDKN2A)
156
. They also appear to have important roles in the disruption of cell cycle 
checkpoints, including the G2 to M transition
157
. EBNA3C has also been reported to modulate 
DNA-damage signalling associated with proliferation-induced oncogenic stress
158
. In contrast, 
EBNA3B is dispensable for effective transformation, although its conservation in various 
LCV viruses implies an important role in vivo
159
. Recently, it has been reported to function as 
a tumour suppressor in mice infected with EBV carrying EBNA3B deletions
160
. 
 
LMP1 
LMP1 is the major transforming oncogene of EBV
161
. It is essential for B-cell transformation 
in vitro
162,163
, and for the tumourigenesis of EBV-infected B-cells in mouse models
164
. LMP1 
functions as a viral oncogene, as demonstrated by its ability to induce oncogenic 
transformation in rodent fibroblast cell lines
165-167
. The structure of LMP1 consists of an 
amino-terminal cytoplasmic tail which tethers it to the plasma membrane, a transmembrane 
domain made up of 6 loops, and a long carboxy-terminal cytoplasmic tail which contains 
1. Introduction 
Page 24   
 
signalling domains which activate multiple cell signalling pathways. Amongst these are C-
terminal activation regions 1 and 2 (CTAR1 and CTAR2) which trigger signalling events 
through the NFκB pathway by interacting with TRAF and TRADD adaptor proteins
168-174
. 
Other signalling pathways through which LMP1 operates include the MAP kinase
175,176
, 
JAK/STAT
177
 and phosphatidylinositol 3-kinase (PI3-K) pathways
178
. LMP1 functions as a 
constitutively active receptor of the tumour necrosis factor receptor superfamily
179,180
.  In 
doing so, it acts as a functional mimic of the CD40 signalling pathway. Thus, CD40 can 
substitute for LMP1 in mediating proliferation and survival in LCLs in vitro
163,181
. 
Furthermore, it can at least partially substitute for CD40 in vivo
182
. The signalling events that 
originate from LMP1 exert pleiotropic effects on the host cell, to establish the transformed 
phenotype. Thus, LMP1 causes up-regulation of anti-apoptotic proteins such as BCL2
183,184
, 
drives cells into cycle
163
, and triggers the stimulation of multiple cytokines including IL6, IL8 
and IL10
185,186
, amongst many other effects.     
 
LMP2 
The LMP2 gene encodes 2 different protein isoforms, LMP2A and LMP2B, neither of which 
are essential for B-cell transformation
187
. Nevertheless, LMP2A has been shown to influence 
multiple signalling pathways, and in particular is thought to mimic signal transduction events 
normally triggered via the BCR. Thus, work using LCLs and mouse models has shown that 
the LMP2A terminal cytoplasmic domain constitutively phosphorylates downstream targets 
of the BCR including LYN, SYK, BLNK, BTK, RAS, PI3K, NFκB and MAP kinases188. 
Notably, expression of LMP2A can also act to block signalling that would normally result 
from BCR cross-linking
189,190
, preventing lytic cycle entry in LCLs
191
; this may be an 
important role for LMP2A during chronic infection in vivo. Furthermore, LMP2A can support 
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the survival and proliferation of B-cells lacking surface Ig in mouse models
192-194
, and this 
may explain some of its contribution to malignancy. Meanwhile, LMP2B is thought to play a 
role in antagonising the activity of LMP2A
195,196
.        
 
BHRF1 
BHRF1 is a homologue of the anti-apoptotic cellular protein BCL2, and is dispensable for B-
cell transformation
197
. Although originally thought to be expressed exclusively in virus lytic 
cycle, it is now known to be persistently expressed in Latency III LCLs, in which it is may 
confer resistance to apoptotic signals
121
. Notably, in Wp-restricted BL, BHRF1 is expressed 
as a consequence of deletions which remove the EBNA2 gene and bring the BHRF1 gene into 
close proximity to the highly active Wp promoter. Expression of BHRF1 in Latency I BL cell 
lines, which normally lack BHRF1, has been shown to enhance cell survival in the face of 
apoptotic triggers
121
.    
 
Non-Coding RNA Transcripts 
EBV also produces a series of apparently non-coding RNA species during latent infection. 
These include the EBER1 and EBER2 transcripts, which are ubiquitously and abundantly 
expressed in all EBV-infected cells
198,199
, such that their detection by in situ hybridisation 
forms the basis of a widely adopted method for establishing EBV infection
200
. EBERs are 
dispensable for B-cell transformation in vitro
201
. Although their function remains largely 
obscure, they have been implicated in various roles which may be relevant to EBV 
pathogenesis
202
. These include conferring resistance to apoptosis triggered by innate IFN-
mediated immune responses
203-205
, as well as enhancing proliferation of EBV-infected cells
206-
208
 and the induction of tumourigenesis
208-210
.  
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The BARTs are a group of highly differentially spliced RNAs that are also ubiquitously 
expressed. These contain a series of open reading frames, the protein-coding potential of 
which remains controversial
211
. However, they also code for 1 of 2 clusters of micro-RNAs 
produced by the EBV genome; the other is located adjacent to the BHRF1 open reading 
frame. Although the function of these viral micro-RNAs is currently poorly characterised, 
they may play important roles in the negative regulation of gene expression 
212,213
. Indeed, 
targets of the EBV micro-RNAs include viral LMP1, LMP2A and DNA polymerase, as well 
as cellular genes PUMA and CXCL11
213
.   
 
Lytic Cycle 
Like other herpesviruses, EBV periodically exhibits lytic cycle activity, in order to generate 
new virus particles necessary for transmission of the virus between individuals
10
. Notably, 
around 5% of cells within an LCL exhibit spontaneous lytic cycle entry at any one time. Lytic 
cycle is orchestrated by a large number of EBV genes, which are expressed in a sequential 
cascade
87
. The principal switch from latency to lytic cycle entry is mediated by activation of 
the immediate-early (IE) lytic genes BZLF1
214-219
 and BRLF1
216,220
, which encode the 
proteins ZEBRA  (also known as EB1 or Zta) and Rta respectively. These transactivate a 
number of downstream early (E) lytic genes, many of which encode enzymes and other 
proteins necessary for viral DNA replication. Notably, replication of the viral DNA is initiated 
from a distinct origin of replication from that used for latent genome maintenance, ori-lyt
221
. 
Subsequent amplification of the EBV genome is followed by expression of the late (L) lytic 
cycle genes, most of which encode structural proteins necessary for the manufacture of the 
capsids into which the viral genomes are subsequently packaged. These include the gene 
BLLF1 which encodes the envelope glycoproteins gp350 and gp220
222,223
, and BALF4 which 
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encodes the glycoprotein gp110
224
. Once assembled, viral capsids bud through the nuclear 
membrane before fusing with the plasma membrane, after which they are released by 
exocytosis, in such a way that the host cell is eventually lysed. 
 
1.4 In Vitro B-Cell Transformation by EBV 
Key Events 
In vitro B-cell transformation is initiated when resting B-cells are incubated with preparations 
of EBV, resulting in infection via interaction of the viral envelope glycoproteins gp350 and 
gp42 with their respective host cell targets, complement receptor CR2 (CD21)
225
 and the HLA 
class II molecules
226,227
. Notably, quantitative studies have demonstrated that delivery of just 
a single EBV genome to the host cell nucleus is required to initiate viral transcription
228
. 
Within 2 days of infection, almost all EBV Latency III proteins are detectable and induction 
of cellular DNA synthesis is accompanied by acquisition of blastoid morphology and up-
regulation of numerous surface markers associated with B-cell activation, including CD23, 
CD30, CD39, CD70, as well as the cell adhesion molecules leukocyte function associated 
molecule-1 (LFA-1; CD11a/18), LFA-3 (CD58) and intercellular adhesion molecule-1 
(ICAM-1; CD54)
87,229-233
. Within 5 days of initial infection, microscopic colonies of 
proliferating lymphoblasts are apparent and the LCL is considered to be fully transformed 
within a few weeks. 
 
Selective Outgrowth of LCLs 
Several aspects pertaining to B-cell transformation remain imperfectly understood. In 
particular, recent interest has focused on the possibility that selective outgrowth of EBV-
infected B-cells occurs during transformation. Thus, it is increasingly apparent that only a 
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proportion (1 – 10% in some estimations) of infected B-cells ever grow out to contribute to an 
established LCL
234,235
. Furthermore, additional selective processes may operate in the weeks 
following infection, and several groups (including our own) have demonstrated oligoclonal 
and thereafter monoclonal outgrowth of LCLs over a period of 3 to 4 months
236-239
. 
Intriguingly, this does not appear to occur in mitogen-stimulated B-cell blasts, which remain 
polyclonal when cultured for a similar period
236
. 
 
Interestingly, Nikitin et al. have recently proposed a model in which interactions between 
EBV proteins and DNA damage response (DDR) signalling pathways are considered 
important in determining selective outgrowth within the first few days of B-cell infection
158
. 
As such, several pathways exist for sensing, and responding to, DNA damage caused by 
exogenous and endogenous genotoxic insults, in order to maintain genomic integrity. Thus, 
the DDR kinase ATM, and its downstream target Chk2, are activated in response to the 
appearance of aberrant double-stranded DNA breaks, the presence of which is signalled by 
phosphorylation of histone H2AX at the site of these breaks
240
. Similarly the DDR kinase 
ATR, and its target Chk1, are activated in response to single-stranded DNA breaks
241
. These 
kinases relay signals to other factors, with extensive cross-talk, leading to imposition of cell 
cycle arrest, senescence or apoptosis, mediated by the master tumour suppressor protein p53, 
as well as inducing DNA repair machinery. Importantly, rapid or uncontrolled replication, 
including that driven by oncogenes such as c-myc, may result in oncogenic replication stress 
which also activates these pathways
242,243
. In view of this, Nikitin et al. have proposed that a 
period of very rapid proliferation (hyperproliferation) in the first few days after EBV-
infection, thought to be a consequence of unhindered EBNA2-induced oncogene activity, 
causes replication stress resulting in activation of the ATM/Chk2 pathway and impaired LCL 
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outgrowth
158
. In this model, EBNA3C is subsequently thought to play an important role by 
acting as a transcriptional repressor that subsequently opposes EBNA2 activity, thus 
attenuating DDR activation and facilitating the outgrowth of LCLs with stable rates of 
proliferation. 
 
Meanwhile, the factors determining clonal outgrowth in more established LCLs are largely 
obscure, and it remains to be seen whether machinery such as DDR signalling pathways are 
important for this phenomenon. However, it is notable from experiments in which LCLs have 
been generated from naive B-cells (carrying unmutated Ig VH regions), that many of the 
clones which come to dominate these cultures exhibit mutated Ig HV regions
236
. Importantly, 
these mutations are consistent with AID-induced SHM events, and furthermore they appear to 
be acquired during in vitro culture; interestingly, whilst LCLs do not undergo spontaneous Ig 
class-switching, this can be still be triggered by treatment with CD40L, IL4 and IL21, stimuli 
known to induce class switching in uninfected naive B-cells
236
. In keeping with these 
findings, AID, which is not expressed in resting B-cells, is upregulated in LCLs
236,244-246
. 
Such observations are interesting because, as discussed later, they inform debates about the 
role GC play in EBV colonisation in vivo. However, they also raise the possibility that AID-
induced mutations might be an important influence on clonal selection. Regarding this, it is 
notable that Epeldegui et al. have reported that LCLs accumulate ‘off-target’ AID-induced 
mutations in the genes BCL6 and p53 in the first few months after infection
244
. It is possible 
that AID-induced mutations such as these, as well as mutations generated by other 
mechanisms, might confer proliferative or survival advantages that influence clonal LCL 
outgrowth.    
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EBV as Mutagen 
Relevant to the above discussion is a wider discourse as to how EBV might interact with 
DDR signalling pathways, and whether it can directly induce genetic changes in host cells. As 
such, a growing body of evidence shows that other oncogenic viruses can both trigger and 
manipulate DDR pathways, resulting in genomic instability
247,248
. For example, the DNA 
tumour viruses Simian Virus 40 (SV40), Adenovirus, and Human Papilloma Virus (HPV), all 
inactivate the p53 tumour suppressor; with SV40 large T antigen
249,250
, Adenoviral EIB p55
251
 
and HPV E6
249,252
 proteins respectively. As a consequence of unhindered cell cycle 
progression, infected cells exhibit considerable genetic instability.  
 
In the case of EBV, much of the evidence that it interacts with DDR pathways relates to its 
lytic cycle activity. Thus, although linear viral genomes produced by lytic cycle replication 
can trigger ATM, BZLF1 mediates repression of p53 checkpoint signalling in order to stall 
cells in S phase, to facilitate further viral replication
253
. Additionally, BZLF1 has been shown 
to effect the rapid destruction of p53 by promoting its ubiquitinylation and proteasomal 
degradation
254
. Meanwhile, in human epithelial cells, the lytic cycle protein BGLF5 has been 
implicated in the generation of genomic instability by directly damaging DNA and inhibiting 
expression of DNA repair proteins
255
.  
 
Regarding latent gene expression, early studies of latently infected B-cells showed that LCLs 
retain functional p53 activity and respond appropriately to DNA damaging insults by 
undergoing p53-mediated apoptosis
256,257
. This led to the conclusion that, unlike other DNA 
tumour viruses, latent EBV infection is primarily non-mutagenic
257
. Nevertheless, more recent 
evidence has increasingly implicated EBV latent gene expression in causing genetic 
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aberrations. Thus, EBV latent proteins have been shown to cause genomic instability when 
expressed in an EBV-negative BL background
258
; EBNA1 reportedly induces reactive oxygen 
species leading to double-stranded DNA breaks, LMP1 transcriptionally downregulates ATM, 
and EBNA3C causes mitotic spindle checkpoint disruption
259,260
. Furthermore, Lacoste et al. 
showed that LCLs, but not mitogen-stimulated B-cell blasts, frequently exhibit cytogenetic 
abnormalities including deletions, insertions and translocations in the first few weeks after 
infection
237
; although it is notable that the chromosomal defects were almost entirely non-
clonal, suggesting that they occurred as isolated events that were not propagated.  
Interestingly, many of the cytogenetic abnormalities associated with EBV result from 
telomeric defects
237,258
. Consistent with this, EBV has been implicated in causing telomeric 
dysfunction by displacing the telomere capping protein TRF2, by a mechanism that may 
involve EBNA1
237,258,261,262
. Ultimately, although such studies are intriguing it nevertheless 
remains challenging to reconcile them with an apparent evolutionary strategy to maintain long 
term asymptomatic persistent infection. The full extent to which EBV infection directly 
contributes to genomic instability remains to be fully characterised. 
  
1.5 In Vivo Colonisation by EBV 
Primary Infection 
Orally transmitted in saliva, EBV initially colonises cells within the oropharynx
10
 (Figure 6). 
EBV is commonly acquired asymptomatically from parents or siblings during infancy. This is 
the principal mode of transmission in the developing world, where almost all individuals 
acquire the virus in the first decade of life, most by the age of 3 years
263,264
. In contrast, 
around 50% of those in the developed world remain EBV-negative by the end of the first 
decade of life, probably as a consequence of alternative hygiene practices
265
. A proportion of  
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Figure 6. Primary EBV Infection 
Primary EBV infection usually occurs asymptomatically during infancy but it may cause IM 
if delayed until after adolescence. Orally transmitted, EBV initially establishes infection in the 
oropharynx. Although some uncertainty remains regarding the earliest events, the virus 
probably first targets submucosal B-cells, with secondary infection of oropharyngeal 
epithelial cells in which productive lytic cycle occurs. Alternatively, EBV may target 
epithelial cells directly. Thereafter, latently infected B-cells, at least some of which express 
the Latency III growth transforming pattern of viral gene expression, accumulate in the 
oropharynx and circulation. An immune response, primarily involving CD8
+
 and CD4
+
 T-
cells directed against lytic and latent EBV antigens, subsequently controls the acute infection. 
EBV avoids elimination by establishing low level chronic latency within circulating resting 
memory B-cells, in which viral gene expression is highly restricted. Figure adapted from 
Young and Rickinson
266
. 
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those who become infected after adolescence develop IM. Thus, cohort studies have reported 
that 25 - 77% of university students who acquire EBV develop IM, and that the predominant 
mode of transmission in this group is kissing
267,268
. Interestingly, around 5% of individuals in 
the developed world never acquire EBV
10
. 
 
In IM, an incubation period of between 30 and 50 days follows initial virus expose
269
. By the 
time symptoms develop, high titres of infectious virus are detectable in oral secretions as a 
result of lytic replication within the oropharynx
270
. Simultaneously, latently infected B-cells 
accumulate in the blood and tonsils, some of which are transformed lymphoblasts positive for 
EBNA2 and LMP1, consistent with a Latency III pattern of viral gene expression
271-273
. This 
is accompanied by lymphocytosis, principally involving expansion of activated CD8
+
 T-
cells
274,275
. The latter is thought to cause much of the symptomology of IM, and therefore 
CD8
+
 T-cell frequency, rather than circulating EBV DNA, has been correlated with the 
appearance of symptoms
276
. Notably, high levels of EBV are detectable in oral secretions for 
weeks after resolution of symptoms and the clearance of elevated circulating EBV DNA
277
.   
 
Site of Initial Infection 
The earliest events in primary EBV infection remain relatively obscure, largely because the 
symptoms of IM do not present until several weeks after initial virus exposure. Given this, 
one unresolved issue regards the target cell of initial EBV infection. Thus, following early 
work in which EBV DNA and lytic viral transcripts were detected in epithelial cells in 
cytological preparations of IM tonsils, it was proposed that oropharyngeal epithelium is the 
site of initial infection
278
. However, more weight is now given to the alternative view that B-
cells infiltrating the oropharyngeal mucosa are the initial target. Supporting this, IM tonsil 
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histology has failed to show EBV-infected epithelium, although small numbers of lytically 
infected B-cells have been detected
271,273
. Furthermore, individuals with the inherited 
immunodeficiency X-linked agammaglobulinaemia (XLA), in whom mutation of Bruton’s 
tyrosine kinase (BTK) causes deficiency of all mature B-cells
279
, show no evidence of EBV 
infection in blood or throat washings; moreover, they lack detectable EBV-specific T-cell 
responses, which even transient infection of tonsillar epithelium could be expected to 
generate
280
. 
 
In vitro experiments exploring EBV infection of epithelial cells have also informed this 
discussion. Thus, in comparison to B-cells, which are readily infected by EBV, epithelial cell 
infection is normally highly inefficient. This is consistent with a lack of CD21, the principal 
receptor for EBV, from epithelial cells. However, it is notable that rates of epithelial cell 
infection can be significantly increased by using strains of EBV in which gp350, the viral 
ligand for CD21, has been inhibited with an antibody
281
 or has been knocked out
282
, 
suggesting that gp350 may actually inhibit EBV binding to epithelial cells. Furthermore, the 
efficiency of epithelial cell infection can be dramatically enhanced if virus is first loaded onto 
B-cells
282,283
. Thus EBV virions appear to bind to the surface of B-cells in large numbers 
without being internalised, after which they can efficiently transfer to CD21-negative 
epithelial cells. This process may be facilitated  by the unmasking of additional ligands after 
gp350 binding to CD21 on B-cells.
282
 Such evidence supports the view that B-cells are the 
initial target of primary infection, after which secondary spread to epithelial tissues may 
occur. 
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Primary Immune Response 
Antibody responses to EBV infection have principally been studied in the context of IM
10
. Of 
these, the earliest detectable is an IgM antibody response to viral capsid antigen (VCA), 
comprising several late lytic cycle viral proteins, which is diagnostic of primary infection. 
This is subsequently followed by an IgG response to VCA, accompanied by responses to a 
range of other lytic and latent proteins, all of which remain detectable (generally at lower 
levels) during the chronic carrier state. These include neutralising IgG responses to membrane 
antigen (MA), which predominantly comprises the gp350 envelope glycoprotein. Notably, 
anti-gp350 antibodies have been trialled clinically in an attempt to prevent primary EBV 
infection
284
. However, the overall contribution of humeral responses in controlling EBV 
remains unclear. Interestingly, IM is also associated with a polyclonal increase in non-EBV-
specific antibodies of all classes, which include heterophile antibodies that can agglutinate 
sheep and horse erythrocytes. This forms the basis of the widely employed Paul-Bunell-
Davidsohn test (Monospot test) for IM
285,286
. 
 
Cell-mediated immunity conferred by cytotoxic CD8
+
 T-cells, plays a crucial role in the 
control of both primary and chronic EBV infection
10,287
. Interestingly, the marked CD8
+
 T-
cell lymphocytosis observed during IM was initially not thought to be EBV-specific, but 
rather a product of ‘bystander-’288 or ‘superantigen-’289 driven expansion. However, 
oligoclonal T-cell receptor usage in IM was consistent with antigen-driven expansion
290
, and 
the subsequent application of immunological techniques, including IFN-γ Elispot assays and 
MHC tetramer staining, revealed that the majority of T-cells are indeed EBV-specific
291-299
. 
Notably, CD8
+
 T-cell responses during acute IM are usually dominated by those against IE 
and early lytic antigens
292,293,295,296
. Thus, 25-50% of CD8
+
 T-cells in HLA-B8 positive 
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individuals with IM are regularly specific for the RAK epitope of BZLF1
293
, whilst up to 25% 
of CD8
+
 T-cells in HLA-A2.01 positive individuals are specific to either the YVL epitope of 
the IE protein BRLF1 or the GLC epitope of the early protein BMLF1
296
. Meanwhile, CD8
+
 
T-cell responses to latent antigens typically occur later in IM, and are of lesser 
magnitude
295,296
. These are usually dominated by responses against the immunodominant 
EBNA3 family proteins, although in certain MHC I backgrounds responses against other 
antigens may predominate
291
. Notably, most of the T-cells which expand during acute IM bear 
activation markers such as CD38 and HLA-DR and are positive for the proliferation marker 
Ki-67
293,295
. During convalescence, most of these undergo apoptosis, probably due to loss of 
antigenic drive as EBV latent gene expression assumes a more restricted pattern (see below). 
Thus, CD8
+
 T-cells isolated from individuals with IM readily apoptose in vitro if not rescued 
by antigenic or cytokine stimulation
300,301
. Although CD4
+
 T-cell responses have not been 
characterised to the same extent as those of CD8
+
 T-cells, recent work has been facilitated by 
the identification of CD4
+
 EBV epitopes. This reveals that CD4
+
 T-cells also undergo marked 
expansion during IM, albeit at lower levels than CD8
+
 T-cells
302
. 
 
The role of NK-cells in controlling EBV infection is less established than that of T-cells. 
However, NK-cells also undergo expansion during acute IM
268,303
. Furthermore, they can 
impair B-cell transformation if added to cultures within the first few days of infection, acting 
at least in part through secretion of IFN-γ304. Recent studies have also shown that depletion of 
NK-cells from mice containing reconstituted human haematopoiesis results in increased 
symptoms and tumour formation following EBV infection, largely through failure to control 
viral lytic activity
305
. A specific NK-cell subset enriched in the tonsils of chronic EBV 
carriers, which is less mature than most circulating NK-cells and which secretes high amounts 
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of IFN-γ, appear to control in vitro EBV transformation most effectively306,307. 
 
Chronic Infection 
Following primary infection, EBV assumes the chronic carrier state
10
. In this, EBV virions are 
continuously, or periodically, shed into the saliva as a consequence of productive lytic cycle 
within the oropharynx
277,308
. The cellular origin of viral shedding during chronic infection is 
debated; although EBV does replicate within oral epithelium in disease states such as oral 
hairy leukoplakia
309,310
, the current evidence favours lytic infection of submucosal B-cells as 
the principal source of virus in healthy individuals
311,312
. Meanwhile, EBV establishes chronic 
latent infection of the B-cell system, which constitutes its principal reservoir. Thus, an 
estimated 1 - 50 per 10
6 
circulating B-cells are thought to carry viral genomes in healthy 
immunocompetent adults
313,314
. Strikingly, these are found almost exclusively within the 
memory B-cell subset, as demonstrated by landmark studies in which B-cell subsets were 
isolated using magnetic beads or flow cytometric sorting and then tested using PCR assays 
specific for the EBV genome
315-317
. Subsequently, EBV-infected B-cells were shown to 
possess somatically mutated Ig genes, confirming their memory B-cell status
318
. Interestingly, 
the infected memory B-cells appear to be in a resting state, as demonstrated by cell-cycle 
analysis and staining for Ki-67
314,315
. Moreover, EBV gene expression is thought to be limited 
to a highly restricted pattern in these cells. Thus, the only reliably detected EBV transcripts 
found in circulating B-cells from healthy carriers are those for EBERs, BARTs and 
LMP2A
315,319,320
; although EBNA1 transcripts have also been detected by some
315,320
. 
However, it has been suggested that the bulk of circulating B-cells may, in fact, only express 
the EBERs and BARTs, an expression pattern dubbed ‘Latency 0’266,321. By restricting its 
gene expression in this way, EBV is able to escape EBV-specific T-cell responses directed 
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again latent antigens and establish chronic infection.  
 
During the chronic carrier state, surveillance by EBV-specific immune responses maintains 
strict control of viral infection. This is predominantly mediated by EBV-specific CD8
+
 
memory T-cells, with reactivity to lytic and latent antigens. These constitute a relatively high 
proportion of the total CD8
+
 T-cell population in healthy carriers. Thus, it has been estimated 
that up to 2% of all CD8
+
 T-cells may be specific for EBV lytic epitopes
322-324
, and up to 1% 
for latent epitopes
324
. Unlike the T-cells observed in acute IM, those found in chronic 
infection exhibit a predominantly CD38
-
, HLA-DR
-
 and Ki-67
-
 resting phenotype
293
 but these 
are presumably able to respond rapidly to any reappearance of growth-transformed 
lymphoblasts. Notably, CD4
+
 T-cell responses are also detected during chronic infection, and 
although they are present at around 10-fold lower frequency than those of corresponding 
CD8
+
 T-cells
302
, they recognise a broader distribution of latent and lytic antigens
325-327
. They 
predominantly exhibit a TH1 phenotype and generate IFN-γ, although they also exhibit direct 
cytotoxic function
326-328
. 
 
Alternative Models for EBV Persistence 
The mechanism by which EBV achieves selective colonisation of the memory B-cell 
compartment has been much debated (Figure 7). One model, proposed by Thorley-Lawson 
and colleagues
329
, originates from studies which examined tonsillar B-cells isolated from 
healthy EBV carriers, in which the only infected B-cells found to exhibit an EBV Latency III 
expression pattern possessed a naive phenotype
321,330
. Based on this finding, it was proposed 
that EBV gains entry to memory B-cells via a GC-dependent mechanism. Thus, it is argued, 
virions originating from the oropharynx (or acquired exogenously) target naive tonsillar B- 
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Figure 7. Alternative Models of EBV Persistence 
The mechanism by which EBV establishes chronic latency in the resting memory B-cell 
compartment remains controversial. In the prevailing GC-dependent model
329
 it is proposed 
that EBV initially infects naive B-cells resulting in a Latency III growth transforming 
infection. This may drive the infected cells to enter a GC reaction, during which the naive B-
cells acquire a memory B-cell phenotype, undergoing SHM and CSR. Latent viral gene 
expression may be progressively down-regulated to Latency II and Latency I patterns, before 
resting memory B-cells bearing EBV expressing a highly restricted pattern of gene expression 
exit the GC into the circulation. Alternatively, EBV may enter B-cell memory by a GC-
independent route. Thus it may infect pre-existing memory B-cells directly41, or it may infect 
both naive and memory B-cells with equal efficacy (as it does in vitro) but with preferential 
survival or proliferation of the latter
331
. It has also been proposed that circulating EBV-
infected B-cells may undergo plasma cell differentiation and exit into the secondary lymphoid 
tissues, accompanied by a switch to virus lytic cycle. This may result in the generation of new 
EBV virions that can then infect other B-cells (or epithelial cells), establishing a cycle that 
maintains the latent EBV reservoir. Figure adapted from Young and Rickinson
266
. 
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cells, establishing a Latency III transforming infection. The latter is believed to mimic normal 
B-cell antigenic stimulation, driving the EBV-infected B-cells to initiate a GC reaction
332
. 
Thereafter, as the B-cells transit through the GC, undergoing further expansion, they down-
regulate viral gene expression to the more restricted Latency II and Latency I patterns. 
Ultimately, the GC B-cells differentiate into memory B-cells, which exit into the circulation 
as long-lived cells in a resting state. In these, EBV is transcriptionally silent, thus evading T-
cell responses directed against EBV latent antigens. Based on other evidence that terminal 
differentiation of B-cells into plasma cells is associated with initiation of EBV lytic cycle 
271,273,333-335
, it is also proposed that infected memory B-cells may subsequently differentiate 
into plasma cells, triggering production of new virions. The latter may infect new naive B-
cells, thus maintaining the EBV memory B-cell reservoir. 
 
Although widely referenced, the GC-dependent model is not favoured by all, and alternative 
GC-independent models have been suggested (Figure 7). Thus it has been argued that EBV 
may preferentially infect pre-existing memory B-cells
41,272
, or that both naive and memory B-
cells may be infected but with preferential survival or proliferation of the latter
331
. Such 
proposals have cited several criticisms of the GC-dependent model. Thus, it is notable that 
EBV can infect naive and memory B-cells with equal efficacy in vitro
336
, and it is therefore 
unclear why the virus would not directly colonise memory B-cells in vivo. Moreover, several 
histological studies have failed to demonstrate EBV within GC. Thus, analysis of tonsil 
sections from patients with IM has shown that EBV typically localises to extra-follicular 
areas, rather than GC
271-273
. Furthermore, analysis of Ig gene sequences from these specimens 
showed these to be dominated by clones with an absence of ongoing Ig hypermutation, 
refuting GC localisation; even rare EBER
+
 cells within the GCs had memory genotypes 
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distinct from the adjacent GC reaction
272
. These findings have subsequently been supported 
by work on tonsillar B-cell suspensions from chronic carriers and patients with IM, showing 
that EBV is concentrated in cells with an extra-follicular, rather than GC, phenotype
331
. 
However, the virus has been reported within (occasional) GC cells in tonsillar tissues from 
healthy chronic carriers in other studies
337
. 
 
Strong support for GC-independent models also comes from evidence of EBV persistence 
within the NSM B-cell subset. This was first observed in individuals with XLP which, as 
described above, results in a lack of GC formation and inability to generate CSM B-cells, 
although NSM subsets are retained. Patients with XLP often develop a life-threatening EBV-
driven lymphoproliferative disease following primary EBV infection, survivors of which 
become chronic EBV carriers. Given that NSM B-cells may arise independently of GC, as 
discussed previously, the finding that EBV genomes are concentrated within the NSM subset 
of such individuals has been interpreted as evidence against the GC-dependent model of EBV 
entry in memory
338
. Subsequently, EBV has also been detected in NSM B-cells from healthy 
carriers, as well as in individuals with IM, albeit at lower levels than those found in CSM B-
cells
331
. Notably, the recent demonstration that LCLs established from naive B-cells may 
accumulate Ig mutations adds additional weight to the view that GC transit is not required
236
. 
Collectively, such studies provide compelling evidence that EBV is not exclusively dependent 
on a GC route into B-cell memory.  
 
1.6 PTLD 
Solid Organ Transplantation 
Solid organ transplantation provides definitive treatment for end-stage organ failure. 
1. Introduction 
Page 42   
 
Allografts can be harvested from cadaveric or living donors, and with the exception of renal 
allografts, donor and recipient HLA-antigens are not usually matched. Transplant recipients 
are managed indefinitely with immunosuppressive agents to prevent alloreactive immune 
responses, which would otherwise result in organ rejection
339
. Commonly used agents are 
cyclosporin and tacrolimus, both of which inhibit calcineurin, a serine-threonine phosphatase 
which mediates IL2 secretion and T-cell activation. Others agents target purine synthesis in 
lymphocytes, including the purine analogue azathioprine, and mycofenolate mofetil which 
inhibits inosine monophosphate dehydrogenase which is required for synthesis of guanosine. 
Glucocorticoids are also commonly used as adjunctive therapy, particular to treat episodes of 
organ rejection. The prolonged state of immunosuppression caused by these agents exposes 
patients to a range of opportunistic infections
340
 and malignant complications
341
, amongst 
which are uncontrolled herpesvirus infections and PTLD. 
 
Allogeneic Haematopoietic Stem Cell Transplantation 
Allo-HSCT is used to treat malignant haematological conditions including leukaemia, 
myelodysplasia, lymphoma and myeloproliferative disorders, as well non-malignant 
conditions such as bone marrow failure syndromes, haemoglobinopathies and congenital 
immunodeficiency
342
. The process of allo-HSCT involves delivery of preparative 
conditioning followed by infusion of donor-derived haematopoietic stem cells contained in a 
stem cell graft (Figure 8). The latter is usually collected from the peripheral blood of donors 
following treatment with granulocyte-colony-stimulating factor (GCSF), which mobilises 
stem cells into the peripheral circulation; compared to bone marrow, peripheral blood stem 
cell (PBSC) grafts produce more rapid immune recovery
343,344
. Donors are typically HLA-
matched siblings or unrelated individuals, although umbilical cord blood grafts or  
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Figure 8. Overview of Allogeneic Haematopoietic Stem Cell Transplantation 
During the course of allo-HSCT patients receive preparative conditioning comprising 
cytotoxic chemotherapy+/- radiotherapy, after which donor haematopoietic stem cells, usually 
in the form of a GCSF-mobilised PBSC graft, are infused on ‘Day 0’. Immune reconstitution 
takes many months. Following a period of neutropenia, donor stem cell ‘engraftment’ occurs 
once the neutrophil count is >1.0 x10
9
/L. Lymphocyte reconstitution occurs in a characteristic 
order, with NK-cells recovering first, followed by CD8
+
 T-cells, then B-cells (which are 
almost entirely CD27
-
 naive B-cells) and CD4
+
 T-cells. Patients are exposed to numerous 
complications during allo-HSCT. Thus, GvHD is a potentially life threatening alloreactive 
immune response, largely originating from mature donor T-cells transferred in the stem cell 
graft. Acute GvHD usually occurs within the first 100 days after transplant and 
characteristically involves the skin, liver and gut. Chronic GvHD occurs later and may 
involve multiple organ systems, including the skin and joints. Infective complications are 
caused by bacterial, fungal and viral pathogens; the latter frequently include herpesviruses. 
Figure adapted from Mackall et al.
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haploidentical donors may also be used where a donor is not available.  
 
It was originally believed that all anti-tumour effects resulting from allo-HSCT were due to 
the cytotoxic action of the preparative conditioning, and that the stem cell graft was just a 
means of providing haematopoietic system rescue. Thus, in conventional allo-HSCT 
myeloablative doses of cytotoxic chemotherapy, often accompanied by radiation, are used. 
However, studies conducted over the last 4 decades have led to the recognition of  important 
graft-versus-leukaemic (GvL) immune effects mediated by donor-derived T-cells, and NK-
cells
345,346
. Consequently, non-myeloablative (also known as reduced intensity conditioning or 
RIC) transplants, which use less toxic forms of preparative conditioning and instead rely on 
GvL effects, have been adopted. These are better tolerated by older and less fit patients and 
have thus become the predominant form of allo-HSCT. Although these can be complicated by 
states of mixed host and donor chimerism, this is managed with additional donor lymphocyte 
infusions (DLI)
347
. Patients undergoing allo-HSCT are also at risk of graft-versus-host-disease 
(GvHD), a potentially fatal alloreactive immune response in which donor T-cells react to 
antigens in recipient tissues
348
. Consequently, patients are treated with additional 
immunosuppressive agents to prevent (or treat) GvHD. Therefore they usually receive 
cyclosporin for the first few months after transplant. Furthermore, graft T-cell depletion 
(TCD) results in significantly reduced incidence of GvHD. This is commonly performed 
using either anti-thymocyte globulin (ATG)
349,350
, which specifically targets T-cells, or 
Campath (Alemtuzumab)
351,352
, a cytolytic monoclonal antibody specific to CD52 expressed 
on most lymphocytes. 
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Immune Reconstitution after Allo-HSCT 
It takes many months for the transplanted haematopoietic system to reconstitute following 
allo-HSCT, and during this time patients are at high risk from infectious complications
353
 
(Figure 8). Individual cell types reconstitute in a predictable order after allo-HSCT
342,354
. 
Thus, following a short period of absolute pancytopenia, neutrophils (and other granulocytes), 
monocytes and NK-cells are the first cell types to recover to normal levels. These are 
followed by erythrocytes and platelets, before the eventual recovery of T- and B-cells. 
Notably, lymphocyte reconstitution is a prolonged process which occurs by 2 alternative 
pathways. In the first, new antigen-inexperienced cells differentiate from lymphocyte 
progenitors arising from recently engrafted donor haematopoietic stem cells
355
. In the second, 
reconstitution occurs through peripheral expansion of mature cells which have been carried 
across in the graft
356
. NK-cells, the first lymphocyte subset to recover, reconstitute almost 
exclusively through the first of these pathways. Normal NK-cell frequency is usually reached 
by 1 - 2 months following transplant, after which their numbers often become supra-normal. 
In contrast, T-cell recovery predominantly occurs through thymus-independent expansion of 
mature T-cells carried across in the graft. This ‘homeostatic expansion’ is driven by normal T-
cell regulatory pathways, involving cytokines such as IL7 and IL15 which respond to T-cell 
lymphopenia
280,357
, and is also stimulated by the presence of antigens present at the time of 
transplant
358
. Notably, the potential for T-cells to reconstitute from lymphoid progenitors is 
often severely limited by thymic incompetence, resulting from the effects of ageing, therapy 
and GvHD, which impairs the thymus-dependent maturation of naive T-cells
359,360
. The 
reconstitution of CD4
+
 T-cells often lags behind that of CD8
+
 T-cells, and this is reflected in 
reversal of the normal CD4/CD8 ratio which persists for many months after transplant
361
. This 
may be due to a relative insensitivity of CD4
+
 T-cells to the homeostatic mechanisms which 
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drive the peripheral expansion of CD8
+
 T-cells
361
. 
 
B-cell reconstitution is characterised by undetectable or low levels of circulating B-cells for 
around the first 2 months following allo-HSCT, after which there is a gradual increase in B-
cell frequency, often culminating in supra-normal levels by 1-2 years after transplant
342,354,362
. 
B-cell recovery derives almost entirely from the differentiation of donor B-cell progenitors, as 
opposed to peripheral expansion of mature B-cells carried across in the graft. Thus, the 
circulating B-cell pool is dominated by CD27
-
IgD
+
 antigen-inexperienced naive B-cells for 
many months after transplant, with a concurrent paucity of CD27
+
 memory B-cells which 
lasts for at least 12 months
363-365
. Furthermore, these naive B-cells exhibit a transitional cell 
phenotype, reflecting their recent emergence from the bone marrow, which gradually resolves 
over time
21,366,367
. However, some recipient B-cells may also persist after transplant, more 
commonly after reduced intensity conditioning
368
. Notably, levels of serum Ig remain normal 
for some time, due to the persistence of long–lived recipient-derived plasma cells, which 
appear to be relatively resistant to chemotherapy
369
. However, these levels subsequently drop, 
and recipients invariably become seronegative to antigens against which they (or their donor) 
were previously immunised
370,371
, and therefore re-vaccination is required. Consistent with 
this, allo-HSCT recipients are particularly vulnerable to infections by encapsulated bacteria 
such as Haemophilus influenza and Streptococcus pneumonia, against which neutralizing 
antibodies normally provide a first line of defence
372-374
. They also exhibit poor responses to 
immunisation after transplant, such that vaccination is generally not recommended until 6 
months afterwards
375
. The deficiency of  humeral immunity that follows allo-HSCT is likely 
to reflect an impairment of T-cell dependent B-cell responses and GC development, 
consequent upon delays in CD4
+
 T-cells reconstitution, as well as impaired recovery of other 
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important cells contributing to the secondary lymphoid tissue microenvironment, including 
follicular dendritic cells
376,377
. B-cell maturation is also highly susceptible to damage by the 
toxic effects of GvHD and its treatment, and patients who experience even a limited episode 
of GvHD show significantly impaired B-cell reconstitution and GC development
377-379
. 
 
Deranged Host-Virus Balance after Transplant 
A measureable decrease in EBV-specific immunity accompanies the state of general 
immunocompromise that follows transplantation. Thus, EBV-specific T-cell responses are 
reduced in solid organ transplant patients taking even relatively low levels of 
immunosuppressive therapy
380,381
. Meanwhile, EBV-specific T-cells are absent or 
significantly reduced for at least 6 months after allo-HSCT
382,383
. As a consequence, 
transplant patients often exhibit impaired control of EBV, consistent with the view that cell-
mediated immunity is crucial for exerting long-term control over EBV infection. Thus solid 
allograft recipients shed increased levels of EBV into the throat
381
. Furthermore, otherwise 
asymptomatic transplant recipients may develop increased levels of circulating EBV DNA 
(otherwise known as ‘EBV DNAemia,’ or ‘EBV reactivation’) as measured by PCR384. 
Notably, patients with established PTLD exhibit significantly elevated levels of EBV DNA, 
and therefore quantitative EBV-specific PCR (EBV qPCR) testing is now widely used as a 
clinical tool to aid diagnosis, to assess response to therapy, and to identify those with 
impending PTLD, as discussed in more detail later.  
 
Regarding the basis of the increased EBV loads observed in transplant patients, it is apparent 
that EBV DNA can be detected in both cellular and plasma fractions of blood. However,  
although EBV can always be found in the cellular compartment it is only consistently found 
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in plasma when circulating EBV loads are very high or when PTLD is present
384
. EBV DNA 
in plasma is thought to comprise either fragments of free viral DNA released from EBV-
infected cells that have been destroyed, or possibly viral DNA packaged into virions
385
. 
Meanwhile, cell-associated viral genomes principally result from an expansion of latently 
infected B-cells. Importantly, Babcock et al. demonstrated that solid organ allograft recipients 
with EBV DNAemia carry EBV genomes almost exclusively within the IgD
-
 memory B-cell 
compartment
386
, and this was later confirmed by others
387
. Notably, it was originally assumed 
that the increased circulating EBV DNA found in transplant patients would originate from an 
expansion of B-cell lymphoblasts exhibiting a Latency III pattern of virus gene expression, as 
found in PTLD tumours. However, Babcock et al. reported that the IgD
-
 memory B-cells in 
which EBV is found are in a resting state, as determined by cell-cycle analysis
386
. 
Furthermore, EBV gene expression, as detected by RT-PCR, revealed an absence of EBNA2 
in these cells
386
. Therefore, it was concluded that EBV DNAemia in transplant patients results 
from an accumulation of latently infected memory B-cells, existing in a resting state with 
highly restricted EBV gene expression. As such, these cells are identical to the latently 
infected B-cells that comprise the main EBV reservoir in healthy immunocompetent 
individuals
315-317
.  
 
Presentation and Epidemiology 
The clinical presentation of PTLD may be highly variable but it commonly involves 
lymphadenopathy, often accompanied by systemic features including fever, sweats and 
weight loss
388
. Patients with EBV-associated disease may also develop a sore throat, similar 
to that observed in acute IM. PTLD may also present with manifestations including 
encephalitis, hepatitis or a fulminant sepsis-like picture that rapidly leads to multi-organ 
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failure, particularly in the allo-HSCT setting. A high incidence of extranodal disease is 
observed, with involvement of the gastrointestinal tract occurring most frequently. Disease 
affecting the transplanted organ is also relatively common. On occasions, PTLD is also 
diagnosed at post-mortem, highlighting the need for improved vigilance and early recognition 
of the condition. PTLD can occur at any time after solid allograft but it is most common 
during the first year
389
. Notably, disease occurring more than 1 year after transplant is less 
likely to be associated with EBV
390,391
. Meanwhile, most cases of PTLD arising after allo-
HSCT occur within the first 6 months, peaking in incidence at around 2-3 months
392
.  
 
The reported incidence of PTLD varies from <1% up to 10% in most studies, although rates 
are highly variable with regard to transplant and host-related risk factors. Amongst risk 
factors for PTLD arising after solid allograft, the intensity of iatrogenic immunosuppression, 
and in particular the degree of T-cell suppression, is a fundamental determinant of PTLD risk. 
In particular, the cumulative level of immunosuppression is likely to be more important than 
the individual immunosuppressive agents used, because studies seeking to compare drugs 
have generated conflicting data
393
. However, agents that are specifically T-cell depleting, such 
as the anti-CD3 monoclonal antibody OKT-3 and ATG have been associated with a 
particularly high incidence of disease
389,394-398
. Patients undergoing cardiothoracic or intestinal 
transplants are at greater risk than those receiving liver or renal transplants, consistent with 
the requirement for more intensive immunosuppression with the former
389,395,399-401
. 
Interestingly, the incidence of lymphoma in renal transplant patients who lose their graft and 
subsequently cease immunosuppression reverts to pre-transplantation levels
402
.  
 
Importantly, negative EBV serological status at the time of transplant is also a major risk 
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factor for PTLD, and incidence is increased further when solid allografts are derived from an 
EBV seropositive donor
395,402-405
. For example, Ho et al. reported a 20-fold higher incidence 
in PTLD amongst EBV seronegative solid organ transplant recipients
405
. This reflects the 
consequence of undergoing primary EBV infection in the context of immunocompromise. 
Furthermore, it explains the elevated risk of PTLD, and shorter intervals from transplant to 
disease onset, observed amongst paediatric solid allograft recipients
389,406
. 
 
Specific to the allo-HSCT setting, several risk factors for PTLD (or EBV DNAemia), all of 
which are principally related to the degree of graft T-cell suppression, have been 
identified
392,407-420
. Thus, T-cell depletion using ATG or Campath is associated with 
significantly increased incidence of PTLD; T-cell replete transplants rarely develop PTLD. 
Interestingly, Campath is thought to be associated with lower risk than ATG because it also 
eliminates B-cells from the donor graft
392,407
. Other recognised risk factors are unrelated 
and/or HLA-antigen-mismatched donors, the occurrence of acute or chronic GvHD, 
increasing age at transplant and re-transplantation
392
. 
 
Pathological Subtypes  
PTLD includes a heterogeneous spectrum of pathological subtypes that are categorised 
according to the World Health Organisation (WHO) classification system for PTLD
388,421
 
(Table 2). These include early benign proliferations, polymorphic disease and malignant 
monomorphic PTLD. It has been assumed that monomorphic lymphoma may arise from the 
early and polymorphic types, although this process remains poorly characterised
422
. The 
frequency of each type varies between transplant and patient groups, but the commonest 
forms are polymorphic PTLD and the diffuse large B-cell lymphoma (DLBCL) subtype of  
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Histological Type Approximate Frequency 
Early PTLD 5% 
      Plasmacytic hyperplasia  
      IM-like PTLD  
Polymorphic PTLD 15-20% 
Monomorphic B-cell PTLD >70% 
      Diffuse large B-cell lymphoma  
      Burkitt lymphoma  
      Plasmacytoma-like lymphoma  
      Plasmablastic lymphoma  
      Other  
Monomorphic T-cell PTLD <5% 
      Peripheral T cell lymphoma  
      Other  
Classical Hodgkin lymphoma PTLD <5% 
  
Table 2. WHO Classification of PTLD 
PTLD is a heterogeneous disease, with multiple pathological types. The most common forms 
are DLBCL-PTLD (which comprise >90% of monomorphic B-cell PTLD lesions) and 
polymorphic PTLD. Table adapted from the WHO Classification of Tumours of 
Haematopoietic and Lymphoid Tissues 2008
421
. 
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monomorphic B-cell PTLD.  
 
Early PTLD includes plasmacytic hyperplasia (PH) and IM-like PTLD subtypes. These are 
benign B-cell proliferations that are almost always EBV-associated, as determined by EBER 
in-situ hybridisation. They develop within the first year after transplant and usually occur in 
the context of primary EBV infection
423,424
. In PH, lymphoid tissues retain their architecture 
and contain sheets of plasma cells with scattered large EBER
+
 B-cell immunoblasts, whereas 
IM-like PTLD lesions resemble true IM, showing at least partial preservation of lymphoid 
architecture and paracortical infiltrates containing plasma cells and large numbers of EBER
+
 
B-cell immunoblasts and reactive T-cells. Molecular analysis reveals polyclonal (or 
oligoclonal) IgH rearrangements in both subtypes
425
. 
 
Polymorphic PTLD lesions are typically EBV-associated and, as their name suggests, contain 
a diverse range of lymphoid cells, including small and intermediate-sized lymphocytes, 
immunoblasts and plasma cells that characteristically efface the underlying tissue 
architecture
426,427
. Malignant features, including nuclear atypia, necrosis and a high mitotic 
rate, may also be present. The lesions contain a mixture of EBER
+
 B-cells, usually showing 
IgL restriction, and reactive T-cells. Molecular analysis typically reveals monoclonal IgH 
gene rearrangements
425
. 
  
The monomorphic B-cell PTLD category includes the DLBCL subtype, which makes up over 
90% of cases, as well as rarer BL and plasma cell subtypes
428
. The DLBCL subtype exhibits 
histology typical of DLBCL occurring in immunocompetent individuals. Notably, there is 
variable positivity for EBV, ranging from 50 – 70% in many studies. In most cases these 
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lesions exhibit monoclonal IgH rearrangements. Of the other monomorphic B-cell PTLD 
lesions, the BL subtype resembles sporadic BL, and most cases are EBV-associated. Typical 
BL morphology is observed including the classical ‘starry sky’ appearance, and the tumour 
cells are positive for CD20, CD10 and BCL6, and negative for BCL2. Immunohistochemistry 
for Ki-67 reveals a proliferation fraction close to 100% and molecular studies show clonal 
IgH rearrangements and MYC translocation. Meanwhile, plasma cell myeloma and 
plasmacytoma-like lesions are rare subtypes composed of mature plasma cells
429,430
. In 
keeping with this they are usually negative for CD20 and PAX5 but positive for CD138. They 
show variable positivity for EBERs and exhibit IgL restriction and monoclonal IgH 
rearrangements. Notably, they may secrete monoclonal Ig into the serum or urine. 
 
The monomorphic T/NK-cell PTLDs make up only a minority of PTLD lesions. This 
category encompasses the full spectrum of lesions recognised in immunocompetent 
individuals, the commonest subtype being peripheral T-cell lymphoma not otherwise 
specified
421
. Most of the T-cell lesions are negative for EBV
431
, whilst the majority of NK-cell 
PTLD tumours show positivity for EBERs
432
. The T-cell lesions show clonality of TCR genes 
and NK-cell tumours exhibit clonal EBV episomal DNA.  
 
Occasional PTLD cases are also of classical HL type
433,434
.  Unlike in the non-transplant 
setting, almost 100% of post-transplant cases are positive for EBV. Histology demonstrates 
findings typical of classical HL, with HRS cells and a background composed of small 
lymphocytes, histiocytes and eosinophils. The RS cells exhibit a characteristic phenotype, 
being positive for CD30, CD15 and EBV, with weak or heterogeneous positivity for CD20. 
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EBV Gene Expression 
In EBV-associated B-cell PTLD, Latency III viral gene expression is typically detected by 
immunohistochemical or molecular methods
435
. This supports the notion that EBV is a key 
aetiological agent in PTLD, actively driving cell proliferation. Consistent with this, PTLD-
like tumours expressing the Latency III pattern have been documented in animal models 
including cottontop tamarins injected with EBV
436
, or SCID mice inoculated with PBMCs 
from EBV seropositive individuals
437
. Meanwhile, rarer types of EBV-associated PTLD, 
including BL, plasma cell, and HL types exhibit more restricted forms of viral latency, as 
occur in equivalent tumour types in immunocompetent individuals. However, some B-cell 
PTLD lesions also exhibit more restricted forms of latency, and there is often heterogeneity of 
latency type within individual PTLD lesions
438-440
. Thus, although cells expressing EBNA2 
and LMP1 are found in most tumours, the proportion of these is often highly variable
439,441-443
. 
Furthermore, the number of cells positive for EBV is often greater than the number of cells 
positive for EBNA2 and LMP1, suggesting that some of the cells may express Latency I, and 
some cells express LMP1 in the absence of EBNA2, indicating Latency II expression
439
. 
Consistent with these findings, Latency I Qp transcripts have been detected in some PTLD 
tumours, in addition to Latency III Cp and Wp transcripts
439
. 
  
EBV lytic cycle gene expression has also been documented within many B-cell PTLD 
tumours
439,442-444
. Interestingly, in some cases there has been failure to show full progression 
through to late lytic cycle gene expression
439,443
, suggesting the occurrence of abortive lytic 
cycle activity. As lytic cycle expression is often limited to only a small number of cells in 
PTLD tumours its relevance to tumour pathogenesis has remained uncertain. Indeed, it is 
notable that drugs such as aciclovir, which impair EBV lytic cycle activity in vitro, have 
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failed to prevent or effectively treat PTLD. Nevertheless, recent findings have increasingly 
suggested that lytic cycle expression, whether or not it results in productive virus, might be 
important for tumourigenesis
445-448
. Thus, lytic cycle defective LCLs fail to develop PTLD-
like tumours in SCID mice models
445
. This effect may be mediated, at least in part, by up-
regulation of paracrine factors such as IL6 mediated by IE lytic gene expression
445,446
.  
 
Some cases of PTLD are negative for EBV, and the aetiology of these remains poorly 
characterised
449,450
. However, it is apparent that EBV-negative tumours often show an 
increased number of cellular mutations, as discussed below. It has been proposed that they 
may represent previously EBV-positive tumours that have lost the EBV genome, perhaps due 
to the acquisition of mutations that render the proliferative effects of EBV redundant. In 
support of this, some BL cell lines may lose their EBV genomes in culture
451,452
. It has also 
been suggested that they arise as a consequence of alternative infectious agents such as 
KSHV
453-455
, although this has been disputed
456
.  
 
Histogenesis 
Studies seeking to establish the histogenesis of B-cell PTLD tumours have shown that the 
majority of lesions arise from GC-experienced cells
457-461
 (Figure 9). As such, mutational 
analysis of IgH V regions has shown that most PTLD tumours possess mutated Ig genes, 
consistent with GC transit. Furthermore, evidence of ongoing SHM in these lesions strongly 
indicates their GC origin; interestingly, in some biopsies CD4
+
 T-cells and FDCs have been 
found to be absent, suggesting that SHM might have occurred in the absence of normal GC 
physiology
458
. Additional immunohistochemical analysis, using markers including BCL6, 
MUM1 (IRF4) and CD138, have also confirmed that most PTLD tumours arise from either  
1. Introduction 
Page 56   
 
 
Figure 9. Histogenesis of PTLD Lesions 
Immunophenotypic and molecular markers can be used to identify the stage of normal B-cell 
development from which B-cells malignancies are likely to originate. Positivity for BCL6 
identifies cells of GC origin, MUM1 those of late (centrocyte) and post-GC origin, and 
CD138 those of plasmablastic and plasma cell origin. Analysis of SHM mutations identifies 
pre-GC cells as those lacking SHM, post-GC cells as those with intraclonally uniform SHM, 
and centroblast GC cells as those with intraclonally diverse SHM. Notably, DLBCL arising in 
immunocompetent individuals can be separated into 2 principal categories: germinal centre B-
cell (GCB) DLBCL are BCL6
+
/MUM1-/CD138- and carry a better prognosis than activated 
B-cell (ABC) DLBCL which derive from late or post-GC cells which are 
BCL6
+
/MUM1
+
/CD138-. Malignancies from plasmablastic or plasma cells stages are BCL6-
/MUM1
+
/CD138
+
. Applying this scheme to B-cell PTLD, it can be seen that the majority of 
DLBCL-type PTLD and polymorphic PTLD lesions are of late or post GC B-origin, although 
a small proportion of DLBCL-PTLD lesions are of GCB type. Figure adapted from 
Kuppers
462
.  
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GC or post-GC B-cells
461,463
. Notably, recent studies have used high throughput genomic 
techniques to categorise DLBCL in immunocompetent individuals into clinically important 
subtypes, such that GC B-cell (GCB) or activated B-cell (ABC) lesions are now recognised 
464
, with 5 year survival rates of 75% for GCB types, compared to 30% for ABC DLBCL
465
. 
According to this scheme, the majority of PTLD lesions of DLBCL (and polymorphic) type 
fall into the ABC category.  
 
Interestingly, some of the studies mentioned above have also shown that PTLD lesions may 
arise from cells which exhibit inactivating mutations in previously productive Ig genes
458-460
. 
Thus, they contain IgH genes in which stop codons, deletions or other changes prevent 
expression of a functional IgH chain. This is remarkable because such 'crippling' mutations 
would normally be incompatible with survival of these B-cells during GC transit due to 
affinity selection. Notably, inactivating mutations such as these had already been identified in 
HL at the time they were found in PTLD
466,467
. In light of these findings it is hypothesised that 
EBV may confer essential survival and proliferative signals sufficient for the rescue of GC B-
cells that would otherwise be destined for elimination. Furthermore, a selective advantage 
may be gained by cells which have lost the BCR through inactivating mutations, as they are 
no longer subject to regulatory mechanisms which operate through BCR signalling pathways. 
 
The host versus donor origin of B-cells found in PTLD has also been investigated, revealing 
differences between transplant settings. Thus, PTLD arising after solid organ transplant is 
usually of recipient origin, although cases of donor-derived PTLD are also found; these are 
more common after liver or lung allografts, and frequently involve the donor organ
468-471
. In 
contrast, almost all cases of PTLD arising after allo-HSCT are of donor origin, although 
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recipient-derived tumours have been reported
415,472,473
. These patterns reflect important 
differences in the biology of these transplant settings, such that host B-cells are usually 
ablated by allo-HSCT transplant conditioning. Furthermore, relatively few donor B-cells are 
transferred to the recipient during the course of solid organ transplantation.  
 
Genetic Aberrations 
Efforts to characterise genetic abnormalities associated with PTLD have thus far failed to 
demonstrate any consistent changes. However, monomorphic lesions, those arising later after 
transplant and EBV-negative cases appear to exhibit greater frequency of genetic aberrations. 
Thus, conventional cytogenetics has revealed more abnormalities in monomorphic compared 
to polymorphic PTLD lesions
474-476
. Indeed, Djokic et al. found cytogenetic abnormalities in 
72% of monoclonal B-cell PTLD tumours, in comparison to 15% of polymorphic PTLD 
lesions, with none found in early PTLD. The most frequent clonal abnormalities in the 
monomorphic PTLDs were trisomies of chromosomes 9 and 11, followed by rearrangements 
of 8q24 (containing c-Myc), 3q27 (BCL6) and 14q32 (IgH and Tcl1). Lesions with trisomy of 
chromosomes 9 or 11 were associated with EBV-positive DLBCL occurring early after 
transplant and showed improved survival, whereas rearrangements containing c-Myc were 
correlated with poor outcome
475
. Meanwhile, studies using comparative genomic 
hybridisation (CGH) have identified chromosomal imbalances already known to occur in non-
transplant NHL, as well as some alterations unique to PTLD
325,328
. Thus, Poirel et al. reported 
chromosomal imbalances in 52% of PTLD lesions, and these were associated with worse 
clinical outcome
476
. These included gains of 8q24 (c-Myc), 3q27 (BCL6) and 18q21 (BCL2), 
and loss of 17p13 (p53). Notably, EBV-negative tumour status was associated with a greater 
number of chromosomal alterations.   
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Regarding specific mutations, early studies to identify changes in known oncogene and 
tumour suppressor genes revealed mutations of c-Myc, N-Ras and p53 in monoclonal 
PTLDs
391,425,477,478. Furthermore, 5’ non-coding region mutations of BCL6 have been detected 
in most monomorphic PTLD tumours, and around half of polymorphic PTLD lesions, and 
these have been associated with aggressive clinical outcome
479
. More recently, single 
nucleotide polymorphism (SNP) arrays have been used to analyse PTLD tumours. In one 
study, deletions targeting loci at the known fragile sites FRA1B, FRA2E and FRA3B were 
found to be more common in DLBCL arising in post-transplant versus immunocompetent 
individuals 
480
. Meanwhile, an Affymetrix array identified prognostic markers amongst 36 
cases of post-transplant DLBCL, showing gains of 1q or 18q that were significantly 
associated with poor overall survival
481
. Notably, a small number of studies have also 
performed gene expression profiling on PTLD tumours, and these have shown distinct 
profiles when comparing PTLD lesions to immunocompetent NHL, or EBV-positive versus 
EBV-negative lesions
482-484
. 
 
Interestingly, attempts have also been made to identify genotypes that might predispose to the 
development of PTLD. In particular, several studies have focussed on polymorphisms within 
cytokine genes
485-491
. For example, a genotype known to cause low production of IFN-γ has 
been associated with increased risk of EBV reactivation after allo-HSCT, as well as greater 
incidence of PTLD arising in patients with renal and liver allografts
485-487
. Similarly 
polymorphisms within the genes TNFα, TGFβ1, IL1, IL10, IL12 and CC chemokine ligand 2 
(CCL2) have all been associated with the development of PTLD
489-491
. Meanwhile, a small 
number of studies have sought to identify associations between HLA types and PTLD
492-494
. 
In one study, HLA-A26 was shown to confer a 3-fold increase in the risk of PTLD after solid 
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allograft if present in either the recipient or the donor
494
. However, it is apparent that neither 
this, nor any of the other HLA-associations identified thus far, has been reproduced between 
studies. Overall, such insights, like those from the other studies discussed in this section, need 
to be evaluated in larger prospective studies. 
 
1.7 Management of PTLD 
Differences between PTLD arising after solid organ transplant and allo-HSCT mean that they 
require differing management strategies, and this is reflected in the following discussion. 
However, common to both transplant settings is a paucity of high quality data to guide clinical 
decision-making. Indeed, management practices have thus far been based almost entirely on 
expert opinion, retrospective analyses and a small number of prospective phase 2 studies, 
rather than on randomised controlled phase 3 trials. 
 
Prophylaxis 
Aside from the use of adoptive cellular approaches, as discussed below, there are currently no 
accepted strategies to prevent PTLD. However, pre-transplant screening of recipient and 
donor EBV serostatus allows the identification of high risk seronegative recipients. This 
provides the opportunity to avoid, where possible, T-cell depleting agents in these patients. 
Furthermore, it conceivably allows selection of a donor who is not EBV seropositive. 
Although some have advocated the prophylactic treatment of EBV seronegative patients with 
antiviral agents such as (val-) ganciclovir, or intravenous Ig, there is currently no robust data 
to support this practice
388,495,496
. 
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Pre-emptive Management 
As patients with (EBV-associated) PTLD develop high levels of circulating EBV DNA, EBV 
qPCR monitoring has been evaluated as means to identify patients with impending PTLD. 
This allows the institution of ‘pre-emptive’ management, comprising reduction of 
immunosuppression (RI) to facilitate endogenous EBV-specific T-cell responses, and/or the 
administration of Rituximab, a humanised anti-CD20 monoclonal antibody which effectively 
depletes B-cells and can prevent or treat PTLD
497
.  
 
In the solid organ transplant setting, evidence to support EBV qPCR monitoring and pre-
emptive management is limited. It is apparent that many otherwise asymptomatic patients 
develop transiently raised EBV loads, and some exhibit chronically elevated levels, with no 
clear relationship to the development of PTLD
384,470,567-569
. Consequently, current guidelines 
do not support the routine use of EBV qPCR monitoring, except in EBV seronegative 
recipients of an organ from a seropositive donor, or in recipients of a cardiothoracic or 
intestinal transplant who have a particularly high risk of developing PTLD
388,495
. If these 
patients exhibit high EBV loads, it is advised that they receive thorough clinico-radiological 
assessment for evidence of PTLD, and should be considered for pre-emptive RI. However, the 
routine use of pre-emptive Rituximab therapy is not currently supported for solid organ 
allograft recipients. In contrast, EBV DNA monitoring and pre-emptive therapy is widely 
accepted as the current standard of care in the allo-HSCT setting. Thus, several retrospective 
studies have shown this approach to be effective, resulting in lower rates of PTLD than in 
historic patient cohorts
498-501
. Reflecting this, guidelines from the Second European 
Conference on Infections in Leukemia have advocated EBV qPCR monitoring for all patients 
undergoing high risk allo-HSCT (principally defined as unrelated, HLA-mismatched or T-cell 
1. Introduction 
Page 62   
 
deplete transplants), comprising weekly testing for at least 3 months after transplant
496
. It is 
advised that patients who develop high-level EBV DNAemia should receive pre-emptive 
treatment including RI and Rituximab therapy. 
 
Despite the above recommendations regarding post-transplant EBV qPCR monitoring, it 
should be noted that there is currently no consensus as to optimal qPCR methodology. Thus, 
assays measuring EBV DNA within whole blood, plasma and PBMCs have all been 
employed
384
. PBMC-based assays are generally impractical for routine clinical purposes, due 
to the time required for cell separation. However whole blood and plasma assays are both 
widely used; there is some evidence to suggest that whole blood assays may be more 
sensitive, whereas plasma assays may be more specific for the diagnosis of PTLD
384
. 
Furthermore, there is no standardised definition as to what constitutes a raised EBV load; 
results produced by qPCR assays in different laboratories may vary by several logs
502,503
. 
These limitations have been acknowledged in current guidelines, which state that PCR 
thresholds for intervention should be determined locally
496
. Notably, the WHO have recently 
endorsed a whole virus EBV B95.8 preparation to be used in the standardisation of EBV 
qPCR assays
504
. 
 
Interestingly, it has also been suggested that the predictive value of post-transplant monitoring 
could be improved by combining EBV qPCR with measurement of T-cell responses. Thus, 
Clave et al. reported that patients who spontaneously settle EBV DNAemia after allo-HSCT 
had a significantly higher proportion of EBV tetramer-positive CD8
+
 T-cells than those 
requiring Rituximab
505
. Furthermore, Annels et al. showed that 6 of 8 patients treated with 
Rituximab for EBV DNAemia after allo-HSCT developed T-cell responses, comprising 
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increased CD3
+
 T-cell counts and EBV-specific tetramer-positive cells
506
. Given these 
findings, pre-emptive Rituximab therapy was successfully withheld from 2 of 3 prospectively 
monitored patients who developed EBV DNAemia. More recently, Worth et al. reported a 
monitoring strategy in which CD3
+
 T-cell counts were considered when deciding whether to 
pre-emptively treat paediatric recipients of allo-HSCT
507
. All patients who developed 
significant EBV DNA within the first 3 months after -transplant were treated, whereas those 
reactivating after 3 months were only treated if their CD3
+
 T-cell count was less than 0.3 
x10
9
/L. Consequently, Rituximab was successfully withheld from 6 patients who would 
normally have been treated. Although such strategies may prove valuable, they carry 
implications in terms of financial costs and practicality, and require validation in large 
prospective studies. 
 
Management of Established PTLD 
In the solid organ transplant setting, the treatment of CD20
+
 B-cell PTLD typically involves 
RI, followed by chemo-immunotherapy
508
. Unfortunately, the scope for RI is often limited by 
the potential for triggering alloreactive responses, which can lead to organ rejection and death. 
Although overall response rates to RI when used alone are reportedly as high as 45% in 
retrospective studies
509,510
, the only prospective study to examine this showed response in 
only 1/16 (6%) cases
511
. Notably, surgery and/or radiotherapy may be curative where disease 
is localised to a single site
509,510
. No role for antiviral therapies is currently supported by 
existing data
508
.  
 
Most patients who remain unresponsive to RI are treated with Rituximab, with or without 
cytotoxic chemotherapy. A large body of evidence has demonstrated the benefit of Rituximab 
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in the treatment of CD20
+
 NHL developing in immunocompetent patients. Meanwhile, 3 
prospective studies have examined the use of Rituximab monotherapy (R-mono) for PTLD 
arising after solid organ transplant
512-514
. These have shown it to be well tolerated, and have 
reported complete remission rates of around 20 – 50% following 4 weekly infusions. 
However, early disease progression is common after R-mono, with around 60% of patients 
progressing within 12 months of treatment. As a consequence, Rituximab has often been used 
in combination with anthracycline based cytotoxic chemotherapy (R-chemo), the commonest 
regimen being CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone). Several 
retrospective studies have shown that increasing the intensity of PTLD treatment by using R-
chemo leads to improved response rates of up to 100%, with overall survival rates of around 
60% at 12 months
515-518
. However, this appears to be at the cost of toxicity, and treatment-
related mortality up to 31% has been reported.  
 
Deciding whether to initiate treatment with R-mono or R-chemo is challenging, not least 
because of a lack of robust data facilitating prognostication. Indeed, there is currently no 
universally agreed prognostic scoring system for PTLD
388
. Notably, British Committee for 
Standards in Haematology guidelines recommended R-mono for patients with low risk PTLD, 
and R-chemo for patients with aggressive disease
508
. Here, low risk disease has been defined 
as PTLD arising in patients aged less than 60 years, with normal LDH and good performance 
status, based on the study by Choquet et al., which included only 43 patients
513
. Interestingly, 
an alternative approach of ‘sequential therapy’ has been proposed by Trappe et al., in which 
all patients with CD20
+
 PTLD are initially treated with 4 weekly infusions of R-mono, 
followed by a 4 week break from therapy, after which 4 (3 weekly) cycles of CHOP 
chemotherapy are delivered
519
. The aim of this strategy is to reduce toxicity by using R-mono 
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to initially debulk disease, leading to improved performance status and thus tolerability for R-
CHOP. This was evaluated in 70 patients in the prospective phase II study PTLD-I, the largest 
prospective study on PTLD to date, showing an overall response rate of 60% after R-mono, 
rising to 90% after R-CHOP (CR rate of 67%), with a median overall survival of 79 
months
519
. A treatment-related mortality of 10.6% was associated with the delivery of CHOP.  
 
In the allo-HSCT setting, first line treatment for established PTLD is R-mono in combination 
with RI, where feasible. Reported response rates to such therapy are around 70%
520,521
. 
However, the management of patients who fail to respond to Rituximab is often challenging. 
In contrast to the SOT setting, outcomes following cytotoxic chemotherapy are extremely 
disappointing, with up to 100% mortality
520,521
. This is likely to be a consequence of increased 
toxicity in this patient group, such that allo-HSCT recipients are invariably unable to tolerate 
cytotoxic chemotherapy. 
 
Cellular Therapy for PTLD 
In recent years, a growing body of evidence has demonstrated an important role for adoptive 
cell therapy in the treatment of PTLD
522
. These therapies aim to treat, or prevent, PTLD by 
infusing EBV-specific T-cells in order to reconstitute virus-specific immunity and generate 
anti-tumour responses. Thus, patients with PTLD arising after allo-HSCT have been treated 
with DLI, which contain EBV-specific T-cells whenever the donor is EBV-seropositive, with 
response rates of around 70%
523-526
. However, because DLI contain unselected CD8
+
 T-cells 
their use may be complicated by potentially life threatening GvHD; in the largest study of 
outcomes following DLI, Doubrovina et al. reported a rate of DLI-related acute GvHD of 
17% amongst 32 patients treated
525
.  
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Given the limitations of unselected T-cell therapy, preparations of EBV-specific cytotoxic T-
lymphocytes (EBV CTLs) have been developed for clinical use. These are generated in vitro 
by repeatedly stimulating PBMCs from EBV-seropositive donors with irradiated autologous 
or HLA-matched LCLs, in the presence of IL2, for a period of 2-3 months. EBV CTLs 
generated from transplant donors have been shown to provide highly effective prophylaxis 
against PTLD amongst individuals undergoing allo-HSCT; Heslop et al. reported that none of 
101 patients treated prophylactically developed PTLD
527,528
. Furthermore, EBV CTLs have 
been successfully used as pre-emptive therapy or as treatment for established PTLD in solid 
allograft and allo-HSCT settings
525,527-530
.  
 
Notably, one important limitation of EBV-specific CTLs are the long periods of time required 
to generate them in sufficient quantities in vitro. However, to circumvent this problem, 
cryopreserved banks of EBV CTLs have been generated from third party donors, and these 
cells have been used to treat partially HLA-matched recipients
531,532
.  This approach was 
evaluated by Haque at al. in a prospective phase 2 study, in which 33 patients with 
progressive PTLD (31 of whom were solid allograft recipients) were treated with 
cryopreserved third party EBV CTLs
531
. No hypersensitivity or alloreactive responses were 
observed and an overall response rate of 52% at 6 months was observed. In a long term 
follow-up report, 12 of 14 patients who achieved CR remained alive and free of disease after 
4 – 9 years533. Based on this experience a new third party EBV CTL bank has recently begun 
operating in the UK, led by Prof Mark Vickers from the University of Aberdeen. 
 
In recent years, new innovations have contributed to the advancement of adoptive 
immunotherapy. These include methods for the rapid generation of EBV-specific CTLs. Thus 
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Moosmann et al. have developed an approach in which donor PBMCs are stimulated 
overnight with pools of EBV antigen-derived peptides, after which EBV-specific cells are 
selected by IFN-γ surface capture and immunomagnetic bead separation534. Infusion of the 
selected EBV-specific T-cells produced lasting responses in 3 of 6 patients with PTLD (3 
patients had very advanced disease at the time of administration and therefore may have had 
limited potential to respond). Meanwhile, similar techniques have been used to select T-cells 
specific to just the EBNA1 antigen, infusion of which led to responses in 7 of 10 patents with 
EBV DNAemia or PTLD after allo-HSCT
535
. Notably, CTLs preparations containing cells 
specific to multiple viruses have also recently been developed
536,537
. Simultaneously targeting 
EBV, CMV and adenovirus, these multi-virus specific CTLs are designed to provide effective 
prophylaxis to some of the most serious viral complications affecting transplant recipients.   
 
1.8 Aims of Current Work 
A series of independent but complementary studies related to a central theme of EBV-
associated PTLD were undertaken with the aim of extending our understanding in the 
following areas: 
 
Retrospective Clinical Studies (Chapters 3 and 4) 
In order to define the current clinical problem posed by PTLD, and to provide important 
context for the subsequent studies presented in this thesis, 2 retrospective clinical studies 
related to PTLD were undertaken. Thus, Chapter 3 presents the results of a multicentre United 
Kingdom study carried out to explore Rituximab era outcomes and prognostic factors for 
PTLD arising after solid organ transplant. Meanwhile, Chapter 4 presents the results of a 
study to characterise incidence, risk factors and outcomes for EBV reactivation and PTLD 
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arising in patients after T-cell deplete allo-HSCT. 
 
Studies on the Persistence of EBV Following Allo-HSCT (Chapter 5) 
The pathophysiology of EBV reactivation and PTLD following allo-HSCT remains 
imperfectly characterised.  In particular, the nature of EBV persistence during the course of 
allo-HSCT, and how the reconstituting B-cell system might be altered during EBV 
reactivation, has not been explored in any detail. In healthy individuals, EBV is normally 
carried at low frequency within the memory B-cell compartment. Therefore, it is intriguing 
that EBV DNAemia typically occurs around 2 to 3 months following allo-HSCT, when the B-
cell system is characterised by a predominance of CD27
-
IgD
+
 naive B-cells and a marked 
deficiency of CD27
+
 memory B-cells. To explore this apparent paradox, blood samples 
collected from a cohort of patients undergoing allo-HSCT were analysed to determine the 
properties of circulating EBV-infected cells. 
 
Modelling the Clonal Evolution of PTLD in Vitro (Chapter 6) 
Previous studies in this and other laboratories have demonstrated that in vitro B-cell 
transformation by EBV is accompanied by clonal outgrowth of LCLs, such that over a period 
of several weeks polyclonal cultures tend towards oligoclonality and thereafter to 
monoclonality. This has been proposed as a possible model for PTLD. As such, factors which 
may influence the clonal outgrowth of LCLs in vitro might also be relevant to the 
hypothesised progression of early polyclonal B-cell proliferations to monoclonal lymphomas. 
In this chapter some of the processes which may influence clonal outgrowth are explored. In 
particular, the role of DNA damage response signalling and the acquisition of AID-associated 
mutations will be assessed as possible contributing factors.   
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DLI for Rituximab-Refractory PTLD (Chapter 7) 
The introduction of Rituximab has led to a marked improvement in outcomes for patients 
developing PTLD following allo-HSCT. However, a proportion of patients remain refractory 
to Rituximab and are at significant risk of mortality. For such individuals, adoptive cellular 
therapy with DLI or EBV CTLs is increasingly being used. In this chapter, we describe 2 
patients with Rituximab-refractory PTLD who were successfully treated with DLI. For both, 
detailed analysis of EBV antigen epitope-specific T-cell responses following DLI infusion 
was undertaken, yielding insights relevant to the future optimisation of cellular therapy.
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2. Materials and Methods 
 
2.1 Retrospective Study of PTLD Arising After Solid Organ Transplantation 
This retrospective study invited participating centres to submit data on patients over 16 years 
of age with biopsy-proven PTLD diagnosed between 2000 and 2012. Data was collected from 
4 clinical centres: University Hospital Birmingham, Birmingham, UK; The Royal Free 
Hospital, London, UK; St James's University Hospital, Leeds, UK.; The Freeman Hospital, 
Newcastle-upon-Tyne, UK. Due to case-finding and data retrieval limitations, submitted cases 
represent a proportion of total incident PTLD cases. All clinical, radiological and pathological 
data were critically reviewed and cases were excluded where they failed to meet inclusion 
criteria or where a minimal data set was not available. The study was conducted in line with 
National Research Ethics Service guidance for Service Evaluation and was registered with 
NHS Research and Development departments at each centre. Dr Sridhar Chaganti, Consultant 
Haematologist at University Hospital Birmingham, was the study lead. 
 
Histopathology reports were used to categorise cases into pathological subtypes in accordance 
with the WHO classification system for PTLD
421
 (Table 2). Cases were considered to be 
EBV-associated if EBV EBER in situ hybridisation and/or LMP1 immunohistochemistry 
were positive, or if significant EBV DNAemia was detected by EBV qPCR; negative staining 
for LMP1 in the absence of EBER in situ hybridisation was not considered sufficient to 
exclude EBV-association and such cases were classified as equivocal. Disease stage was 
determined from available clinical, bone marrow and radiological data, the latter comprising 
computed tomography (CT) and/or positron emission tomography (PET), in accordance with 
the Ann Arbor staging system
538,539
, including the Lugano classification
540
 for primary 
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gastrointestinal lesions. 
 
Response to therapy was evaluated on the basis of submitted clinical and radiological data and 
was categorised into complete remission (CR), partial remission (PR) or no remission (NR), 
in line with the Cheson criteria.
541
 Owing to the nature of the study, the timing and modality 
of response evaluation were determined clinically. Overall survival was calculated from the 
date of diagnosis to the date of death or last follow-up. Event-free survival was calculated 
from date of diagnosis to date of discontinuation of treatment for any reason, initiation of new 
treatment, disease progression, or death from any cause. Progression-free survival was 
calculated from date of diagnosis to date of disease progression or death from any cause. 
Factors influencing selection of R-mono versus R-CHOP were analysed using univariate and 
multivariate logistic regression. Predictors of overall survival were analysed using univariate 
and multivariate Cox proportional hazards modelling. 
 
2.2 Retrospective Study of EBV Reactivation and PTLD Following Allo-HSCT 
This retrospective study examined adult patients undergoing consecutive T-cell deplete allo-
HSCT at University Hospital Birmingham between May 2009 and September 2012. All 
participants provided written consent for clinical data collection and the study was registered 
with the University Hospital Birmingham’s Research and Development department. All 
patients received myeloablative or RIC preparative conditioning according to institutional 
protocols, followed by PBSC grafts. T-cell depletion was with in vivo Alemtuzumab, 
typically comprising 10mg daily intravenously from day -7 to day -3 before stem cell 
infusion, or with ATG. GvHD prophylaxis comprised cyclosporin, with or without 
methotrexate, or mycophenolate mofetil. All patients received aciclovir prophylaxis for a 
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minimum of 3 months following transplant. 
 
Patients were monitored with EBV qPCR whole blood assay, with testing scheduled every 1 - 
2 weeks for the first 6 months post-transplant and intermittently thereafter
542
. For the purpose 
of this study, EBV reactivation was defined as a single positive EBV qPCR result exceeding 
the assay limit of sensitivity of 500 genomes/ml, whist high-level EBV reactivation was 
defined as a single result ≥20,000 genomes/ml. Patients exceeding the high-level EBV 
threshold were assessed for possible PTLD and received pre-emptive treatment with up to 4 
weekly infusions of Rituximab 375 mg/m
2
. Cases of PTLD were diagnosed in accordance 
with recently published definitions for biopsy-proven or probable disease arising after allo-
HSCT, the latter including radiologic evidence of disease in association with EBV 
DNAemia
496
.  
 
Cumulative incidence of EBV reactivation following allo-HSCT was estimated, taking the 
competing risk of death into account. Cumulative incidence curves were compared using the 
Log Rank test. Univariate and multivariate analysis of risk factors for EBV reactivation were 
performed using Cox proportional hazards modelling. Acute GvHD was treated as a time-
dependent covariate. Overall survival was calculated from transplant to the time of death from 
any cause; surviving patients were censored at last follow-up. Non-relapse mortality was 
calculated from transplant to the time of death without relapse, which was considered a 
competing event. The effect of post-transplant (pre-emptive) Rituximab therapy on overall 
survival or non-relapse mortality was analysed using Cox testing, considering Rituximab as a 
time-dependent covariate; patients who died from PTLD were excluded from this analysis to 
eliminate the effect of PTLD-related mortality. The effect of pre-transplant Rituximab therapy 
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on overall survival or non-relapse mortality was analysed using Cox testing. All analyses 
were carried out in Stata 12. 
 
2.3 Biological Samples 
Work presented in Chapters 5, 6, and 7 made use of the following donor materials: 
 
Patients Undergoing Allo-HSCT  
Blood samples (and clinical data) were collected from patients undergoing allo-HSCT at 
University Hospital Birmingham, UK under the National Research Ethics Service (NRES) 
committee  approved ‘Study of immune reconstitution following stem cell transplantation,’ 
(Chief Investigator, Prof Paul Moss, University of Birmingham). Additional samples (and 
clinical data) were collected from Nottingham University Hospital, UK under the NRES 
approved ‘Study of Epstein-Barr virus after transplantation’ (Chief Investigator, Dr David 
Burns, University of Birmingham).      
 
Healthy Adult Donors 
Blood samples were obtained from healthy laboratory donors under the NRES committee 
approved study ‘Epstein-Barr virus infection of human lymphocytes and the pathogenesis of 
virus associated lymphomas’ (Chief Investigator, Dr Andrew Bell, University of 
Birmingham). Apheresis cones (buffy coats) from healthy adult donors were also obtained via 
NHS Blood and Transplant (NHSBT) under the same ethics. 
 
Umbilical Cord Blood 
Samples of umbilical cord blood were collected from Birmingham Women's Hospital via the 
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University of Birmingham Human Biomaterials Resource Centre, with appropriate ethical 
approval.  
 
Cell Lines  
Namalwa-BL is a Latency III EBV-positive BL line with 2 stably integrated copies of the 
EBV genome
543
. AKBM cells are a derivative of the EBV-positive Japanese BL cell line 
Akata, stably transfected with a GFP reporter (pHEBO-BMRF1p-rCD2/GFP) under the 
control of the promoter for the EBV lytic cycle BMRF1 gene
544
. Kem-BL and Rael-BL are 
endemic EBV-positive Latency I BL lines
100,545
. Kem-BL clone h10 is an EBV-negative 
subclone of Kem-BL. HEK293 is a human embryonic kidney cell line immortalised by the 
adenoviral early region
546
. The HEK293-2089 cell line is a derivative of HEK293, stably 
transfected with a bacterial artificial chromosome (2089) containing the genome of the 
standard laboratory EBV strain B95-8 and a hygromycin resistance gene
547
. The HEK293-
BZLF1-KO cell line is a derivative of HEK293, stably transfected with a recombinant EBV 
BAC in which the IE gene BZLF1 gene has been inactivated
548
. The CD40L mouse L-cell 
line is the LTK
-
 mouse fibroblast cell line stably expressing human CD40L
549
. 
 
2.4 Maintenance of Cell Lines 
EBV-transformed LCLs and BL cell lines were maintained in RPMI 1640 medium (Gibco or 
Sigma) supplemented with 10% v/v foetal calf serum (BioSera), 2mM L-glutamine (Gibco) 
and 500 U/ml penicillin and streptomycin (Gibco), known henceforth as standard B-cell 
medium. Mitogen-stimulated blasts were maintained as described below. HEK293-2089 and 
HEK293-BZLF1-KO cells were maintained in standard B-cell medium, supplemented with 
100μg/ml hygromycin. CD40L L-cells and LTK- cells were maintained in DMEM medium 
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(Gibco) supplemented with 10% v/v FCS, 2mM L-glutamine (Gibco) and 500 U/ml penicillin 
and streptomycin (Gibco). All cells were cultured at 37°C with 5% CO2. 
 
2.5 Isolation and Storage of Peripheral Blood Mononuclear Cells 
Blood samples were diluted 1:1 in phosphate buffered saline (PBS) and then overlaid onto 
15ml Lymphoprep (Axis-Shield) in 50ml tubes. Samples were then centrifuged at 1800rpm 
(without brake) for 30 minutes at room temperature. The top layer containing serum and 
platelets was then removed with a transfer pipette and discarded, after which the buffy coat 
layer was collected. The cells were then washed twice in PBS or RPMI 1640 and either used 
immediately, transferred to 1.5ml microcentrifuge tubes and frozen as pellets at -20°C, or 
transferred to cryovials in RPMI 1640 medium supplemented with 20% FCS and 10% v/v 
dimethylsulphoxide (DMSO) and cryopreserved in liquid nitrogen. Cryopreserved cells were 
subsequently thawed by incubating cryovials in a 37°C water bath for approximately 1 minute 
before adding them drop-wise to RPMI 1640 medium or MACS buffer supplemented with 
10% FCS, after which they were washed at least once according to requirement. 
 
2.6 Surface Immunophenotyping of PBMCs with Flow Cytometry 
Immunophenotyping of allo-HSCT patient and healthy adult donor PBMCs was performed by 
staining thawed PBMCs with up to 8-colour combinations of the antibodies listed in Table 3. 
2.5 x10
5
 – 1.0 x106 PBMCs were washed in MACS buffer before resuspending them in 50μl 
of MACS buffer containing a mixture of fluorochrome-conjugated antibodies at 
predetermined concentrations. The cells were incubated on ice in the dark for 30 minutes 
before washing in cold MACS buffer, after which they were resuspended in MACS buffer for 
analysis. Samples were stored at 4°C in the dark and analysed within 2 hours of staining.  
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Marker Fluorochrome Clone Manufacturer No. 
CD3 eFluor 450  UCHT1 eBioscience 48-0038 
CD3 APC-eFluor 780 UCHT1 eBioscience 47-0038 
CD4 APC SK3 eBioscience 17-0047 
CD8 PerCP-Cy5.5 SK1 Biolegend 344709 
CD10 PerCP-eFluor 710 SN5c eBioscience 46-0108 
CD14 Pacific Blue  M5E2 Biolegend 301828 
CD14 APC MEM-15 Abcam ab60901 
CD19 PE-Cy7 HIB19 eBioscience 25-0199 
CD20 Alexa Fluor 700  2H7 Biolegend 56-0209 
CD23 APC-Cy7  EBVCS-5  Biolegend 338520 
CD24 APC-eFluor 780 SN3 eBioscience 47-0247 
CD27 PE M-T271 BD 555441 
CD30 APC BerH8 BD 563500 
CD38 APC HIT2 Biolegend 303510 
CD45 Alexa Fluor 700  HI30 Biolegend 304023 
CD56 Pacific Blue  MEM-188 Biolegend 304629 
CD56 PE HCD56 Biolegend 318306  
EBNA-LP* Unconjugated JF186
147
 In house NA 
IgA APC IS11-8E10 Miltenyi 130-093-113 
IgD FITC IA6-2 Biolegend 348206  
IgD PerCP-Cy5.5 IA6-2 Biolegend 348208 
IgG FITC G18-145 BD 555786 
IgM APC-Cy7 MHM-88 Biolegend 314519  
Kappa PE MHK-49 Biolegend 316508  
Kappa APC MHK-49 Biolegend 316510 
Ki-67* FITC B56 BD 556026 
Lambda FITC MHL-38 Biolegend 316606 
Phospho-H2AX* eFluor 660 CR55T33 eBioscience 50-9865 
TCR αβ Alexa Fluor 488 IP26 Biolegend 306711 
Table 3. Antibodies for Flow Cytometry 
Up to 8-colour combinations of the mouse anti-human monoclonal antibodies shown here 
were used to stain PBMCs and cell lines during the course of these studies. *Intracellular 
staining. 
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Sytox Blue (Invitrogen) was added to the samples around 5 minutes before analysis to 
facilitate dead cell discrimination. Stained cells were acquired on an LSRII (BD Biosciences) 
and a minimum of 30,000 lymphocyte and/or 2500 CD19
+
 events were recorded. Data was 
analysed using FacsDIVA software (BD Biosciences). In all flow cytometry panels, 
lymphocytes were gated on forward (FSC) and side scatter (SSC), after which doublets, dead 
cells, CD14
+
 monocytes and/or CD3
+
 and/or CD56
+
 events were excluded as appropriate. 
Lymphocyte counts determined by analysis of blood using automated haematology analysers 
(performed in clinical laboratories) were used to derive lymphocyte subset cell counts. 
 
2.7 Flow Cytometric Cell Sorting 
Cell sorting was performed using a MoFlo Cell Sorter (Beckman Coulter). When sorting 
PBMCs isolated from allo-HSCT patients or healthy adults, 0.5-1.0 x10
7
 PBMCs were stained  
in MACS buffer on ice for 30 minutes using the following mix of fluorochrome-conjugated 
antibodies at predetermined concentrations: CD27 PE, IgD PerCp-Cy5.5, CD19 PE-Cy7, 
CD14 APC and CD3 APC-efluor 780 (Table 3). After gating lymphocytes on FSC and SSC, 
doublets and CD14
+
 monocytes were excluded before sorting CD19
+
IgD
+
CD27
-
 naive B-
cells, CD19
+
CD27
+
 memory B-cells and CD19
-
 non-B-cells into tubes containing 250 μl FCS. 
Reanalysis confirmed that the purity of sorted cells was typically >98%. 
 
In order to assay EBV genomes in single cells, a proportion of sorted naive and memory B-
cells were subsequently re-sorted into 96-well plates containing 5μl of lysis buffer (see 
Section 2.8), depositing 1 cell per well. As a comparator, AKBM cells were induced to enter 
lytic cycle by exposure to 100µg/ml F(ab’)2 goat anti-human IgG antibody (Cappel) for 48 
hours before sorting single GFP-positive cells as above. The reliability of single cell sorting 
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was confirmed by visual inspection of 96-well plates under a light microscope, and also by 
sorting EBV-positive and EBV-negative Kem-BL cells mixed in known proportions, which 
were subsequently assayed using EBV qPCR (as shown in Section 5.10). 
 
2.8 Extraction and Purification of DNA 
Genomic DNA was extracted from pellets of 0.25 - 5.0 x10
6
 cells using the DNeasy Blood 
and Tissue kit (Qiagen), according to the manufacturer’s instructions. DNA was eluted in 50 – 
100μl DEPC treated PCR grade water (Ambion) as appropriate to cell input. DNA 
concentration was determined using a NanoDrop™ spectrophotometer and samples were 
stored at -20 °C. Where cell input was <0.25 x10
6
, including when cells were FACS-sorted 
into 96-well pates, DNA was extracted in situ by incubating cells in lysis buffer (50 mM KCl, 
10 mM Tris-HCl, pH 8.3, 2 mM MgCl2, 0.5% Tween-20, 0.4 mg/mL Proteinase K) at 55°C 
for 2 hours followed by 95°C for 15 minutes to inactivate the Proteinase K. 
  
2.9 TaqMan qPCR to Estimate EBV DNA Load 
EBV qPCR Assay 
To quantitate EBV genomes, real time quantitative PCR (qPCR) amplification of the EBV 
polymerase gene BALF5 (EBV pol) and of the cellular gene beta-2-microglobulin (β2M) 
gene was performed in a multiplex assay, using the primers (Alta Bioscience, University of 
Birmingham) and probes (Eurogentec) shown in Table 4. PCR amplification was performed 
using TaqMan Universal PCR Master Mix (ABI Applied Biosystems) which contains PCR 
buffer, MgCl2, AmpliTaq Gold, dNTPs and ROX (a passive reference dye). For each reaction, 
20μl of a mix containing 1x TaqMan Universal PCR Master Mix, primers and probes at the 
final concentrations given in Table 4 and PCR grade water (Ambion) to make up the final  
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volume, was added to wells of a 96-well PCR plate. To each well, 5μl of DNA was then 
added in duplicate or triplicate. On each plate, alongside test samples, standards consisting of 
DNA from the Namalwa-BL cell line (known to contain 2 integrated copies of the EBV 
genome) serially diluted in PCR-grade water to generate a set of 8 concentrations ranging 
from 4 x10
4
 copies/μl to 1 copy/μl were included, as well as a no-template control. Wells 
were sealed with Microamp Optical Caps (Applied Biosystems) and the plates were shaken to 
mix the reagents before centrifuging at 1000rpm. The plates were then analysed in an ABI 
Prism 7500 Sequence Detection System (Applied Biosystems), using the thermal cycling 
conditions shown in Table 4. 
 
Analysis of EBV qPCR Data 
qPCR data was analysed using Applied Biosystems 7500 software version 2.0.5. Namalwa 
standards were used to generate pol and β2M calibration curves, from which test sample copy 
number values were determined. EBV loads were calculated as the number of pol copies per 
10
6
 cells (assuming 2 β2M copies per diploid cell). 
 
2.10 Determination of EBV Gene Expression Using RT-PCR 
EBV gene expression was measured using a panel of TaqMan PCR assays designed to detect 
selected latent and lytic cycle transcripts. Due to the small of amounts of RNA available, a 
modified version of our existing method
550
 was used which employed a pre-amplification step 
and a high throughput 48:48 Dynamic Array Integrated Fluidics Circuit (Fluidigm). In 
addition, a reference plasmid containing a single copy of each target amplicon was designed 
such that absolute numbers of each transcript could be determined
551
. 
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TaqMan PCR Assays 
Forty-five EBV-specific TaqMan PCR assays, each consisting of a forward and reverse 
primer and a FAM/TAMRA-labelled probe, were designed to detect a range of EBV latent 
and lytic transcripts; full sequence details are provided in the Appendix (Table 26). 
Endogenous control assays to detect glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 
assay ID hs99999905.m1), β2M (assay ID hs00187842) and phosphoglycerate kinase 1 
(PGK1, assay ID hs99999906.m1) were obtained from Life Technologies. 
 
Plasmid for Absolute Quantitation 
To perform absolute rather than relative quantitation of transcript levels, a 4951bp DNA 
sequence containing each of the 45 EBV target amplicons and 3 cellular target amplicons was 
designed
551
. This sequence was commercially synthesised and cloned into pUC57 by 
GenScript. The resulting plasmid (AQ-plasmid) was diluted in PCR-grade water to generate a 
range of 10-fold serial dilutions containing 10
5
 to 10
1
 copies/µl. 
 
RNA Isolation and DNA Synthesis 
Total RNA was extracted from approximately 5 x10
4
 CD27
+
 sorted memory B-cells from 
allo-HSCT patients, using the RNeasy Micro kit (Qiagen), or up to 5 x10
6
 cells from EBV-
positive reference cell lines using the Nucleospin RNA kit II (Macherey Nagel); both kits 
include a DNAse I step. Total RNA was then reverse transcribed into cDNA using qScript 
cDNA SuperMix (Quanta Biosciences), including approximately 5ng RNA in a final reaction 
volume of 3µl for transplant samples or 400ng RNA in a final reaction volume of 20µl for cell 
lines.  
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Specific Target Amplification 
An aliquot of cDNA (1.25 µl) was subsequently pre-amplified for 12 (cell lines) or 14 
(transplant patient samples) cycles using 2.5µl TaqMan® PreAmp Master Mix (Life 
Technologies) and 1.25µl 2x primer mix containing 45 EBV and 3 cellular 20 x Taqman 
assays diluted in DNA suspension buffer (10 mM Tris, pH 8.0, 0.1 mM EDTA) according to 
the manufacturer’s protocol. These pre-amplified samples were then diluted 1:5 in DNA 
suspension buffer prior to loading on a 48:48 Dynamic Array IFC (Fluidigm) alongside the 
PCR assays, according to the manufacturer’s protocol. To enable absolute quantitation, the 
48:48 array also included dilutions of the AQ-plasmid (corresponding to 10
5
, 10
4
, 10
3
, 10
2
 and 
10
1
 copies per µl input sample) which had been subjected to the appropriate number of pre-
amplification cycles. Once assembled, the 48:48 array was loaded into a Biomark HD system 
(Fluidigm) and the PCR amplification performed using the standard v1 protocol.  The data 
was analysed using the Biomark Real Time PCR Analysis Software v2.0.  
  
2.11 Determination of Chimerism Using Microsatellite Analysis 
To determine recipient or donor origin of CD27
+
 B-cells from allo-HSCT patients, DNA 
extracted from  approximately 1.0 x10
4
 FACS-sorted CD27
+
 memory B-cells was sent for 
microsatellite marker analysis, performed by the Clinical Pathology Accredited West 
Midlands Regional Genetics Laboratory, Birmingham, UK. Samples were compared to pre-
transplant recipient and donor samples using at least 2 polymorphic microsatellite markers. 
The results were reported as percentage of donor or recipient origin. 
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2.12  Determination of EBV Strains in Allo-HSCT Patients and Donors 
PCRs for EBNA3B and EBNA3C 
To identify EBV strains in allo-HSCT patients and donors, DNA extracted from PBMCs was 
subjected to nested and semi-nested PCR amplification of polymorphic regions of EBNA3B 
and EBNA3C using published primers
552
 shown in (Table 5). PCR was performed using the 
Expand High Fidelity PCR System (Roche) which contains a mixture of Taq DNA 
polymerase and a second DNA polymerase possessing a 3'-5' exonuclease proofreading 
activity to improve fidelity. This system reportedly has 3-fold better DNA synthesis fidelity 
compared to standard Taq DNA polymerase, with an estimated error rate of 8.3 x10
-6
 bp 
compared to 2.6 x10
-5
 bp
553
. Care was taken to avoid cross contamination, including the use 
of a dedicated PCR room with an ultraviolet (UV) irradiation facility to set up assay mixes, 
and alternative set-up areas when handling first and second round PCR products. Non-
template controls were included for all assays.  
 
Reactions were performed in 0.5 ml PCR tubes, each of which contained 5 μl of template 
DNA, a final concentration of 1x Expand High Fidelity Buffer containing 1.5 mM MgCl2, 2.6 
units of Expand High Fidelity Enzyme mix (containing Taq DNA polymerase), 200 μM each 
of dATP, dGTP, dTTP and dCTP, 1 μM each of forward and reverse primers, in a final 
volume of 50 μl made up with PCR grade water (Ambion). PCR amplification was performed 
in an Eppendorf Thermocycler using the conditions shown in Table 5. Completed PCR 
reactions were stored at -20°C. 
 
Identification and Purification of the PCR Products 
Second round PCR products were separated by electrophoresis in 1.5% agarose gels in 1x  
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TBE running buffer (89 mM Tris-borate, 2 mM EDTA, pH 8.3), alongside 1kb DNA ladder 
(Invitrogen). Care was taken to avoid cross contamination by using alternate lanes. Gels were 
stained with ethidium bromide and bands visualised using a UV transilluminator (Geneflow). 
Appropriately sized bands were cut out of gels using a new scalpel blade each time and placed 
into 1.5 ml microcentrifuge tubes. PCR products were extracted using the Qiaquick Gel 
Extraction Kit (Qiagen) according to the manufacturer’s instructions, eluted in 30μl of PCR 
grade water (Ambion) and stored at -20°C. 
 
Sanger Sequencing of PCR Products 
The purified second round EBNA3B and EBNA3C PCR products were Sanger sequenced, 
using the EBNA3B reverse primer and EBNA3C forward primer (Table 5). Each sequencing 
reaction contained approximately 200-500ng DNA and 3.2 pmol of primer, made up to a final 
volume of 10μl with PCR grade water (Ambion). Sequencing was performed using the 
‘Plasmid to Profile’ DNA sequencing service provided by the Functional Genomics 
Laboratory, University of Birmingham, UK. 
 
Analysis of Sequence Data 
Sequence data was analysed using the BioEdit software package version 7.2.0 (Ibis 
Therapeutics; http://www.mbio.ncsu.edu/bioedit/bioedit.html). Sequences were aligned to the 
corresponding regions of the reference B95-8 genome (Accession number NC_007605.1) 
using the ClustalW Multiple Alignment tool. Each chromatogram trace was manually 
inspected to verify any base changes relative to the EBNA3B and EBNA3C reference 
sequences.. 
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2.13 Intracellular Flow Cytometry for Ki-67 
To stain FACS-sorted CD27
+
 memory B-cells or LCLs for intracellular Ki-67, cells were first 
fixed in ice cold 70% ethanol and stored at -20°C for between 1 and 7 days. After washing 
twice in MACS buffer the cells were resuspended in 100 μl of MACS buffer plus 20 μl of 
anti-human Ki-67 FITC antibody or isotype control (BD Biosciences). After incubating for 1 
hour at room temperature in the dark, the cells were washed with several volumes of MACS 
buffer and then resuspended in a small volume for analysis. Cells were acquired on an Accuri 
flow cytometer (BD biosciences) and data was analysed using FlowJo version 7.6.5 software. 
 
2.14 Purification of CD19
+
 B-Cells  
CD19
+
 Dynabead Selection  
B-cells were positively selected from PBMCs isolated from apheresis cones and umbilical 
cord blood samples using pan-CD19 Dynabeads (Life Technologies) according to the 
manufacturer’s instructions. PBMCs were mixed with Dynabeads at a ratio of 4 beads per B-
cell (assuming B-cells comprise 5% of PBMCs), adjusted to a final concentration of 1 x10
7
 
beads/ml in cold RPMI 1640 with 1% FCS. Following incubation at 4°C for 30 minutes with 
gentle mixing, bead-bound cells were collected by attaching to a magnet for 2 minutes and 
then washing with 10 ml RPMI 1640 with 1% FCS; a total of 5 magnet/wash procedures were 
performed to ensure high purity of isolated B-cells. The Dynabeads were subsequently 
detached by incubating bead-bound B-cells with 10 μl DETACHaBEAD for every 25 μl of 
Dynabeads used, at a final concentration of 100 μl DETACHaBEAD per ml, at room 
temperature with gentle mixing for 45 minutes. Bead-free B-cells were finally recovered by 
making the mixture up to 10 ml with RPMI 1640 with 1% FCS before allowing the 
Dynabeads to attach to the magnet for 2 minutes, after which the supernatant containing free 
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CD19
+
 B-cells was recovered; the magnet/wash procedure was repeated to achieve maximal 
recovery of the B-cells. Purified cells were counted and stored at 4°C in standard B-cell 
medium for a maximum of 24 hours before usage. Purity of the recovered B-cells was 
typically >98%, as confirmed by flow cytometry for CD19 surface antigen.  
 
Flow Cytometric Cell Sorting 
As required, Dynabead-selected B-cells were FACS-sorted using a MoFlo cell sorter 
(Beckman Coulter). Up to 4 x10
7
 B-cells were stained in MACS buffer on ice for 30 minutes 
using predetermined concentrations of fluorochrome-conjugated antibodies against CD27 and 
IgD (Table 3). Subsequently, after excluding debris and doublets, CD27
-
IgD
+
 naive, 
CD27
+
IgD
-
 CSM and CD27
+
 IgD
+
 NSM B-cell subsets were sorted into tubes containing 250 
μl of FCS. Reanalysis confirmed that the purity of sorted cells was typically >98%. 
 
2.15 Generation of LCLs 
Preparation of EBV Supernatant 
2089 and BZLF1-knock out (BZKO) virus supernatants were prepared from HEK293-2089 
and HEK293-BZLF1-KO cell lines induced into lytic cycle by transfection with plasmids 
containing the BZLF1 viral transactivator (p509) and BALF4 (pRA) in the presence of 
lipofectamine. Supernatants were harvested 3 - 5 days following lytic induction, filtered with 
a 0.45μm membrane filter and then stored at -80oC until use. To determine the concentration 
of viral genomes present in the recovered supernatant, a DNA lysate was prepared from an 
aliquot by incubating with 2x lysis buffer (2x PCR buffer, 2% Tween20, and 0.2 mg/ml 
Proteinase K) at 55 
ο
C for 1 hour, followed by 95
 ο
C for 5 minutes to inactivate the Proteinase 
K. The prepared lysate was then tested using EBV qPCR. Viral supernatants used in this 
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study typically contained 1.0 x10
8
 – 2.5 x108 genomes/ml. 
 
B-Cell Infections 
2089 and BZKO LCLs were generated by incubating purified B-cells with virus supernatant 
at a multiplicity of infection (MOI; the ratio of virus particles to target cells) of 50 for 1 – 2 
hours at 37 
ο
C. Following centrifugation at 1600 rpm for 5 minutes, cells were re-suspended 
in standard B-cell medium, and then 0.5 – 4.0 x106 cells were added to either 48-, 24- or 12- 
well plate wells as appropriate to give an optimal cell density for transformation. Cultures 
were inspected daily and fed with fresh medium at least every 3 - 4 days. As cell numbers 
increased the cultures were transferred to larger size wells or flasks in order to maintain 
optimal seeding density. 
 
2.16 Generation of B-Cell Blasts 
B-cell blasts were generated from primary CD19
+
 B-cells by culturing them on mouse L-cell 
fibroblasts stably transfected with human CD40L, in the presence of human  interleukin-4 
(IL4)
554
. L-cells were irradiated with 100 Gray and then plated into 6cm tissue culture plates 
at 0.5 x10
6
 per well and allowed to adhere overnight. 0.5 – 4.0 x106 B-cells were then 
transferred onto the L-cell coated wells in 3 ml of Iscove's Modified Dulbecco's Medium 
supplemented with 10% human serum, 2 mM L-glutamine (Gibco), 500 U/ml penicillin and 
streptomycin (Gibco) and 50 ng/ml IL4 (Biolegend or Prospec). The blasts were maintained 
for up to 8 weeks by transferring them onto new L-cell coated wells in fresh media every 3-4 
days. In some cases, larger scale cultures were maintained by transferring up to 10 x10
6
 B-cell 
blasts onto 10 cm plates prepared with 2.5 x10
6
 irradiated L-cells per plate in 10 ml of 
medium. 
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2.17 Cell Counts in LCLs and B-Cell Blasts  
For experiments comparing growth rates of LCLs and B-cell blasts, cell counts were 
performed using a TC20 Automated Cell Counter with trypan blue dead cell exclusion. At 
each passage known cell numbers were re-cultured and increases recorded at the following 
passage were used to calculate growth rates, according to the exponential growth equation: 
     
NT = N0 x e
RT
 
 
where NT is the number of cells at time T, N0 is the initial number of cells, and R is the 
growth rate. Cells counts in early EBV-infected and B-cell blast cultures were performed 
using an Accuri flow cytometer (BD Biosciences). Aliquots of cell culture were analysed to 
determine events per μl of media after excluding debris. Non-viable, non-blastoid and blastoid 
subsets were identified as discussed in Section 6.2. Propidium iodide was added to culture 
medium 5 minutes before analysis for dead cell discrimination in selected experiments. 
 
2.18 Intracellular Flow Cytometry for EBNA-LP 
To stain LCLs for EBNA-LP, cells were washed in PBS and then fixed by resuspending them 
in 4% paraformaldehyde in PBS (pH 7.0) with vortexing. After incubating them at 37°C for 
10 minutes, the cells were centrifuged and resuspended in ice cold 90% methanol with 
vortexing, before storing them at -20 °C. The cells were subsequently washed twice in MACS 
buffer and then resuspended in 50 μl of MACS containing a 1/10 dilution of the anti-EBNA-
LP antibody JF186
147
. After incubating for 1 hour at room temperature, the cells were washed 
twice in MACS buffer and then resuspended in 50 μl of MACS containing a 1/1000 dilution 
of Alexa Fluor-488-conjugated goat anti-mouse secondary antibody (Invitrogen). After 
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incubating for 1 hour in the dark, the cells were washed twice in MACS buffer before being 
resuspended in a small volume for analysis. Cells were acquired on an Accuri flow cytometer 
(BD biosciences) and data was analysed using FlowJo version 7.6.5 software. 
 
2.19 Analysis of Proliferation with CFSE Labelling 
Proliferation kinetics in early LCLs and B-cell blasts were also assayed by labelling B-cells 
with CFSE, prior to infection or mitogen-stimulation. Labelling was performed by first 
washing purified B-cells 3 times with PBS (without FCS), and then thoroughly resuspending 
them at 1 - 2 x10
7
/ml in PBS. The cell suspension was then vortexed 1:1 with PBS containing 
CFSE to give a final concentration of 1.25μM. After incubating at 37°C for 10 minutes, 4-5 
volumes of RPMI 1640 containing 10% FCS was added to stop the labelling process, after 
which the cells were washed 3 further times in RPMI 1640 containing 10% FCS. Labelled 
cells were used to generate LCLs and B-blast cultures as described, and aliquots were 
analysed daily for up to 10 days using an Accuri flow cytometer (BD Biosciences). Data were 
analysed with FlowJo version 7.6.5 software (TreeStar). After excluding doublets and dead 
cells based on FSC and SSC profile, events within viable non-blastoid and blastoid gates were 
analysed to determine the number of events in each generation. CFSE data were subsequently 
analysed using 2 alternative methods. The first used the methodology of the FlowJo 
Proliferation Tool to calculate ‘Proliferation Index’ as the average number of divisions of 
responding cells (cells that have undergone at least 1 division)
555,556
. The second was that of 
Hawkins et al., which determines ‘Mean Division Number’ by fitting the number of cells in 
each cell division to a Gaussian distribution
557
. Illustrative examples are given in Section 6.2 
(Figures 52 and 54). 
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2.20 Intracellular Flow Cytometry for Phospho-H2AX 
To stain EBV-infected cultures and B-cell blasts for intracellular phospho-H2AX, cells were 
fixed and permeabilised in 4% paraformaldehyde and 90% methanol, as described in Section 
2.18. Prior to fixation, cells were labelled with the Fixable Viability Dye eFluor® 520 
(eBioscience) to allow dead cell discrimination, according to manufacturer’s instructions. For 
the comparison of phospho-H2AX in EBV-infected and B-cell blast cultures, B-cells were 
also labelled with Proliferation Dye eFluor® 450 (eBioscience) using a method similar to that 
for CFSE labelling, and mouse L-cells were labelled with CFSE, to aid discrimination of B-
cell blasts from contaminating L-cells. Fixed cells were subsequently washed twice in MACS 
buffer and then resuspended in 50 μl of MACS containing eFluor 660-conjugated mouse anti-
human phoso-H2AX antibody or isotype control (eBioscience) at predetermined 
concentrations. After incubation for 1 hour at room temperature in the dark, the cells were 
washed twice in MACS buffer before being resuspended in a small volume for analysis. Cells 
were acquired on an LSRII flow cytometer (BD biosciences) and data was analysed using 
FlowJo version 7.6.5 software. 
 
2.21 Determination of Clonality by IgVH CDR3 Spectratyping 
To determine the clonality of LCL and B-cell blasts cultures, IgVH spectratyping was 
performed by the West Midlands Genetics Laboratory using the IgH Gene Clonality Assay kit 
(Invivoscribe). Briefly, genomic DNA was amplified using PCR primers spanning the unique 
hypervariable CDR3 region of the IgH gene, with a forward PCR primer located in conserved 
framework region 1 (FR1) and a reverse primer in the J region. Fluorescently labelled PCR 
products (ranging in size from 270-350 bp) were subsequently separated on an ABI capillary 
gel electrophoresis platform and analysed using the Genemapper version 4.0 software 
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package (Applied Biosystems). Samples were tested alongside polyclonal and monoclonal 
controls supplied with the kit. 
 
2.22 Analysis of IgVH rearrangements 
IgVH PCR 
PCR amplification of the IgVH region (IgVH PCR) was performed using published 
primers
460,558
. These comprised a forward primer corresponding to a consensus sequence for 
the framework 1 (FR1c) region, and a mix of reverse primers including a consensus primer 
for JH1, JH2, JH4 and JH5 regions, and separate primers for JH3 and JH6 (Table 6). PCR 
reactions were set up in a dedicated room, and non-template and Namalwa DNA positive 
controls were included for all assays. Reactions were performed in 0.5 ml PCR tubes, each of 
which contained 5 μl of template DNA, a final concentration of 1x Expand High Fidelity 
reaction buffer with 1.5mM MgCl2 (Roche), 3.5 units of Expand High Fidelity enzyme mix 
(Roche), 200μM each of dATP, dGTP, dTTP and dCTP, 0.8μM of forward primer and 
0.26μM of each reverse primer, in a final volume of 50 μl made up with PCR grade water 
(Ambion). PCR amplification was performed in an Eppendorf Thermocycler using the 
conditions shown in Table 6. Completed PCR reactions were stored at -20°C until analysis. 
 
Identification and Recovery of the PCR Product 
Since analysis of the PCR products demanded better resolution than that provided by an 
agarose gel, non-denaturing polyacrylamide gels were used. 13μl of gel loading dye (1.25 
mg/ml bromophenol blue, 1.25 mg/ml xylene cyanol, 30% v/v glycerol) was added to 50μl of 
PCR product. Aliquots of 5μl and 50μl of sample were loaded in adjacent wells of a gel 
comprised of 8% acrylamide solution (BioRad), 0.07% w/v ammonium persulphate and  
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0.02% v/v N, N, N’, N’- tetramethylenediamine (TEMED, Sigma) in 1x TBE running buffer 
(89 mM Tris-borate, 2 mM EDTA pH 8.3). The 5μl aliquot was used to improve 
discrimination of the bands of interest. The size of the expected PCR products (~360bp) was 
determined by comparison to a 1kb DNA ladder (Invitrogen), which was run in parallel. 
Electrophoresis was carried out at 180V for ~2 hours. The gel was stained with ethidium 
bromide, and the bands were visualised by UV light using a transilluminator. The desired 
bands were sliced from the gel using a scalpel blade and placed in a 1.5ml microcentrifuge 
tube. The gel fragments were mashed using a 1000μl filter tip, before adding 350μl 2.5M 
ammonium acetate. The mixture was left shaking overnight at 37°C. The following day, the 
eluate was transferred to a fresh 1.5ml tube and the DNA precipitated by addition of 2.5 
volumes of 99% ethanol together with 2μg glycogen DNA carrier (Roche) in order to help 
visualise the pellet. The sample was incubated for 30 minutes at -70°C, and then pelleted by 
centrifugation at 13000 rpm for 30 minutes at 4°C. The DNA pellet was washed twice more 
in 70% v/v ethanol, air-dried and resuspended in 25μl PCR grade water. To estimate the 
quantity of the PCR product, a 3μl aliquot of DNA was analysed on a 2% agarose gel (1x 
TBE as running buffer), with comparison against a 1kb DNA ladder.  
 
TA Cloning in E. coli 
The purified PCR products were cloned using the TA cloning system, pGEM®-T Easy Vector 
System I (Promega). This system uses a linearised pGEM-T vector with a single 3′ 
deoxythymidine overhang present at both ends, which prevents recircularisation of the vector 
and provides an overhang compatible with non-template directed deoxyadenosine bases 
frequently added to the 3′ end of PCR products by DNA polymerases. Several features of the 
pGEM-T vector facilitate selection of bacteria successfully transformed with insert-containing 
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vector. Firstly, the pGEM-T plasmid carries an ampicillin resistance gene which allows 
transformed bacteria to be selected by growing in media containing ampicillin. Secondly, the 
vector carries a coding region for the α-peptide subunit of the β-galactosidase enzyme (lacZ 
gene) under the control of an IPTG promoter and spanning the cloning site. This allows 
blue/white colony selection when DH5α E.coli, which carry a deletion of the endogenous α-
peptide, are transformed and cultured on X-gal and IPTG-treated indicator plates. Thus, when 
vector without an insert is transformed into the bacteria, IPTG induces expression of the α-
peptide which restores β-galactosidase enzyme activity and results in hydrolysis of X-gal to a 
blue compound which colours the bacterial colonies. However, in a vector containing an 
insert successfully ligated into the cloning site the α-peptide coding region in disrupted, such 
that transformed colonies will appear white. Finally, the pGEM-T vector carries EcoRI 
restriction enzyme recognition sites, flanking the cloning site. These facilitate a 
straightforward method for confirming the presence of an appropriately sized insert by 
subjecting purified plasmid DNA to EcoRI digestion, followed by DNA electrophoresis. 
Notably, the pGEM-T vector also contains an M13 primer sequence adjacent to the cloning 
site which can be used to sequence the insert. 
 
Ligation of PCR Products into pGEM-T Vector 
For each PCR product, 3.5μl DNA was combined with 0.5 μl pGEM®-T Easy vector, 5 μl 2x 
Rapid Ligation Buffer and 1 μl T4 DNA ligase (Promega) in a 1.5 ml microcentrifuge tube. 
After mixing, tubes were incubated overnight (or for up to 72 hours) at 4°C. A positive 
control using supplied insert DNA, and a vector-only control, were also set up. 
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E.coli Transformation 
DH5α competent cells (prepared as below) were thawed on ice and 50 μl added to each 10 μl 
ligation mix in a 1.5 ml microcentrifuge tube. After incubating on ice for at least 5 minutes, 
the cells were heat-shocked by transferring the tubes to a 42°C water-bath for 2 minutes 
before returning to ice for 1 minute. 1 ml L-broth (without ampicillin) was added to the tubes, 
which were then incubated at 37°C for 1 hour in a heating block with gentle mixing. The 
tubes were then centrifuged at 8,0000 rpm for 3 minutes in a microcentrifuge, after which the 
supernatant was tipped off to leave approximately 100 μl which was used to re-suspend the 
bacterial pellet by gentle pipetting. The cell suspension was then spread onto freshly prepared 
LB agar plates supplemented with 100 μg/ml ampicillin and coated with 80 μl 2% Xgal 
(Calbiochem) and 20 μl 100mM IPTG (Promega) and the plates were incubated at 37°C 
overnight. The following day, white colonies (corresponding to bacterial clones carrying 
inserts) were picked and inoculated into 2ml L-broth supplemented with 100 μg/ml ampicillin 
in 15ml tubes. These were then grown up by incubation at 37°C overnight in an orbital 
shaker. 
 
Analysis of Recombinant Plasmids  
Plasmid DNA was purified from the bacterial cultures using the QIAprep Spin Miniprep Kit 
(Qiagen), according to the manufacturer’s instructions and DNA was eluted in 50μl PCR 
grade water. In order to confirm the presence of appropriately sized PCR products in the 
recombinants, an aliquot of each plasmid preparation was digested using FastDigest EcoRI 
restriction endonuclease (Thermo Scientific). 2 μl plasmid DNA was mixed with 2 μl 10x 
FastDigest Green Buffer,  1 μl FastDigest EcoRI enzyme and 15 μl PCR grade water 
(Ambion). After incubating at 37°C for 15 minutes, the samples were separated by 
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electrophoresis in 1.5% agarose gels in 1x TBE alongside 1kb DNA ladder (Invitrogen). The 
gel was stained with ethidium bromide and bands visualised using a UV transilluminator. 
Plasmid preparations containing inserts of appropriate size were subsequently analysed by 
DNA sequencing. 
  
Preparation of Competent Cells 
DH5α competent-cells were prepared based on the method described by Inoue et al.559 
Approximately 10-12 DH5α colonies were added to 250 ml SOB media (containing 20 g 
bacto-tryptone, 5 g yeast extract, 10 ml 250 mM KCl, 0.5 g NaCl, pH 7, plus 20 mM Mg salts 
in each litre) and grown at room temperature to an optical density of A600 = 0.6. The culture 
was then split, and following incubation on ice for 10 minutes, the cells were centrifuged at 
2500xg (3000rpm in Beckmann J-6B) for 10 minutes at 4°C. The cell pellet was resuspended 
in ice-cold TB (containing 10 mM Pipes, 15mM CaCl2, 260 mM KCl adjusted to pH 6.7 with 
KOH, before addition of 55 mM MnCl2) and, following incubation on ice for a further 10 
minutes, was centrifuged again at 2500xg for 10 minutes. The pellet was then resuspended in 
20 ml ice-cold TB to which 1.5 ml of DMSO was added. Finally, after incubation on ice for a 
further 10 minutes, aliquots of the DH5α cells in sterile 1.5ml microcentrifuge tubes were 
flash-frozen in liquid nitrogen and stored at -80°C. 
 
Sequencing IgVH Products 
Plasmid clones (at least 20 per sample) were Sanger sequenced by priming from the M13 
sequence present on the pGEM-T vector. Each sequencing reaction contained 200-500 ng 
plasmid DNA and 3.2 pmol M13 forward primer, made up to a final volume of 10 μl with 
PCR grade water (Ambion). Sequencing was performed using the ‘Plasmid to Profile’ DNA 
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sequencing service provided by the Functional Genomics Laboratory, University of 
Birmingham, UK. 
 
Analysis of IgVH Sequences 
Sequence data was analysed using the BioEdit software package version 7.2.0 (Ibis 
Therapeutics). Each chromatogram trace was manually inspected and ambiguous bases were 
corrected if required. Sequences were subsequently analysed with the IMGT/V-QUEST 
database
560
 (http://www. IMGT.org) in order to identify the V, D and J segments used in each 
IgVH rearrangement, the number of SHM mutations present in the V segment and the amino 
acid sequence of the CDR3 region. 
 
2.23 Analysis of BCL6 and p53 Mutations in LCL Cultures 
PCR for BCL6 and p53 Sequences 
Selected regions of the cellular BCL6 and p53 genes were PCR amplified using published 
primers (Table 7). Non-template controls were included for all assays. Reactions were 
performed in 0.5 ml PCR tubes, each of which contained 0.5 - 1.0 μg of template DNA, a 
final concentration of 1x Expand High Fidelity Buffer containing 1.5 mM MgCl2, 3.5 units of 
Expand High Fidelity Enzyme mix (containing Taq DNA polymerase), 200μM each of dATP, 
dGTP, dTTP and dCTP, 2 µM each of forward and reverse primers, in a final volume of 50 μl 
made up with PCR grade water (Ambion). PCR amplification was performed in an Eppendorf 
Thermocycler using the conditions shown in Table 7. Completed PCR reactions were stored 
at -20°C. 
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TA Cloning in E. coli 
BCL6 and p53 PCR products were separated by electrophoresis on agarose gels and purified, 
as described in Section 2.12. Subsequently, the purified PCR products were cloned using the 
pGEM® Easy Vector System I (Promega) and sequenced as described in Section 2.22. A total 
of 10 plasmid clones were analysed for each sample time point. 
 
Analysis of BCL6 and p53 sequences 
Sequence data was analysed using the BioEdit software package version 7.2.0 (Ibis 
Therapeutics). Sequences were aligned to the BCL6 intron 1 (accession number AY189709) 
and complete p53 gene (accession number HSU94788) sequences using the ClustalW 
Multiple Alignment tool. Each chromatogram trace was manually inspected and any base 
changes relative to the BCL6 and p53 reference sequences were individually verified. The 
number of mutated sequences and total number of mutations were scored for each time point. 
 
2.24 Interferon Gamma Elispot 
To enumerate EBV-specific T-cells in PBMCs or donor lymphocytes for Patients A and B 
(Chapter 7) interferon-gamma (IFN-γ) release Elispot assays were performed on cells 
stimulated with CD8
+
 and CD4
+
 T-cell EBV epitope peptides, as listed in Tables 8 and 9. As 
described previously
325
, 96-well polyvinylidene difluoride-backed plates were first coated 
with a 15 μg/ml concentration of the anti-IFN-γ monoclonal antibody 1-DIK (Mabtech) and 
then blocked with RPMI 1640 containing 10% FCS. 1 x10
5
 or 2 x10
5
 cells were then added to 
wells, in duplicate or triplicate where numbers allowed, alongside peptides at a final 
concentration of 5 μg/ml. Wells containing an equivalent volume of DMSO without peptide 
were  used  as  a  negative  control.  Plates  were  incubated  overnight  at  37
°
C  in  5% CO2  
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Peptide 
HLA 
restriction 
Protein 
Amino acid 
coordinates 
Latent or lytic 
VEI B44:02 EBNA3B 657-666 Lat 
EEN B44:02 EBNA3C 281-290 Lat 
KEH B44:02 EBNA3C 335-343 Lat 
CLG A02:01 LMP2 426-434 Lat 
FLY A02:01 LMP2 356-364 Lat 
LLW A02:01 LMP2 329-337 Lat 
YLL A02:01 LMP1 125-133 Lat 
YVL A02:01 BRLF1 109-117 Lyt 
GLC A02:01 BMLF1 280-288 Lyt 
FLD A02:01 BALF4 276-284 Lyt 
TSL* DRB1 01:01 EBNA1 515-528 Lat 
GPW* DRB1 01:01 EBNA3A 780-799 Lat 
MVF* DRB1 05:01 EBNA1 563-577 Lat 
EDL* DRB1 05:01 EBNA3A 364-383 Lat 
LDL** DRB1 05:01 BLLF1 61-81 Lyt 
TDA** DRB1 05:01 BNRF1 1238-1252 Lyt 
SNP* DRB5 01:01 EBNA1 474-489 Lat 
LEK** DRB5 01:01 BXLF2 126-140 Lyt 
SDD* DQB1 06:02 EBNA3C 386-400 Lat 
 
Table 8. IFN-γ Elispot Assay Peptides for Patient A 
Individual or combined pools of peptides corresponding to HLA antigen-specific EBV 
epitopes were used to stimulate PBMCs from Patient A. *CD4+ T-cell latent antigen pool, 
**CD4+ T-cell lytic antigen pool. 
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Peptide 
HLA 
Restriction 
Protein 
Amino acid 
coordinates 
Latent or lytic 
RYS A24:01 EBNA3A 246-253 Lat 
TYS A24:01 EBNA3B 217-225 Lat 
TYG A24:01 LMP2 419-427 Lat 
RPGK B07:02 EBNA1 72-80 Lat 
IPQ B07:02 EBNA1 528-536 Lat 
RPP B07:02 EBNA3A 379-387 Lat 
QPR B07:02 EBNA3C 881-889 Lat 
YPR* B07:02 BNRF1 1247-1257 Lyt 
TPS* B07:02 BFRF3 127-137 Lyt 
SRL* B14:01 BMLF1 435-444 Lyt 
LQH* Cw08 BZLF1 101-115 Lyt 
VYG DRB1 07:01 EBNA1 509-528 Lat 
PRS DRB1 07:01 EBNA2 276-295 Lat 
SRD** DRB1 07:01 BARF1 185-199 Lyt 
MVF DRB1 15:01 EBNA1 563-577 Lat 
EDL DRB1 15:01 EBNA3A 364-383 Lat 
LDL** DRB1 15:01 BLLF1 61-81 Lyt 
TDA** DRB1 15:01 BNRF1 1238-1252 Lyt 
SNP DRB5 01:01 EBNA1 474-489 Lat 
LEK** DRB5 01:01 BXLF2 126-140 Lyt 
ILR** DRB4 01:01 EBNA3C 771-790 Lat 
 
Table 9. IFN-γ Elispot Assay Peptides for Patient B 
Individual or combined pools of peptides corresponding to HLA antigen-specific EBV 
epitopes were used to stimulate PBMCs from Patient B. *CD8
+ 
T-cell pool, **CD4
+
 T-cell 
pool. 
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and the cells were then discarded. A biotinylated anti-IFN-γ monoclonal antibody, 7-B6-1 
(Mabtech), was then added at 1 μg/ml and incubated for 2 hours at room temperature, 
followed by streptavidin-conjugated alkaline phosphatase (Mabtech) for an additional 1 hour. 
Washes were performed between all steps of the assay with PBS, PBS-Tween or RPMI 1640 
as appropriate. Individual cytokine-producing cells were finally detected using an alkaline 
phosphatase-conjugated substrate kit (BioRad). Spots were counted using an automated 
Elispot plate reader. Results are expressed as spot-forming cells (SFC) per 2 x10
5
 cells. 
 
2.25 Tetramer Staining 
Further analysis of EBV-specific T-cells in Patient A (Chapter 7) was performed using MHC 
class I tetramer staining. Thawed PBMCs were incubated at 37°C for 15 min with pre-titrated 
volumes of APC-conjugated HLA A*0201 tetramers for EBV epitopes YVLDHLIVV 
(BRLF1 aa 109-117), GLCTLVAML (BMLF1 aa 280-288) and CLGGLLTMV (LMP2 aa 
426-434).
296,326
 After washing in PBS, the cells were stained with LIVE/DEAD fixable violet 
dead cell stain (Life Technologies) according to the manufacturer’s instructions, before 
surface markers were stained with pre-determined concentrations of CD3-AmCyan and CD8-
PE antibodies (BD Biosciences) as described in Section 2.6. After washing, the cells were 
acquired on an LSRII flow cytometer, excluding doublets and dead cells. Data were processed 
using FlowJo software version 7.6.5 (Tree Star). Absolute numbers of tetramer-specific T-
cells were calculated from lymphocyte subset frequencies, determined as described in Section 
2.6. 
 
2.26 Immunohistochemistry and EBER in situ Hybridisation 
For immunohistochemistry, sections from paraffin-embedded biopsy material were first 
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dewaxed in Histoclear for 10 min, rehydrated and then quenched in 0.3% hydrogen peroxide 
for 15 minutes. The slides were subsequently boiled in citrate buffer pH 6.0 for 10 minutes for 
antigen retrieval (40 minutes for BZLF1 staining). After blocking with casein, the slides were 
incubated overnight at 4°C with primary antibodies against the following antigens diluted in 
PBS with 0.5% Tween20: EBNA1 (1:1000), EBNA2 (1:2), LMP1 CS1-4 (Dako; 1:25), 
LMP2A 15F9 (Santa Cruz; 1:100), BZLF1 (neat) and gp350 (1:1000). After 3 washes in 
PBS/Tween20, slides were incubated for 30 minutes at room temperature with appropriate 
peroxidase-conjugated secondary antibodies (Dako). After 3 washes with PBS/Tween20, 
100μl diaminobenzidine (Dako) was applied to each slide for visualisation, counter-staining 
with Meyer’s Haematoxylin. EBER in situ hybridisation (EBER ISH) was performed with a 
Leica automated Bond system, using an EBER probe in combination with an anti-fluorescein 
antibody and Bond Polymer Refine Detection (Leica Biosystems), according to 
manufacturer’s instructions. 
3. Results  
Page 107  
 
3. PTLD Arising after Solid Organ Transplant: A UK Multicentre Study of 
Outcomes with Rituximab Monotherapy versus R-CHOP 
 
PTLD occurs in up to 10% of solid allograft recipients and carries a high risk of mortality. 
Many cases of PTLD are associated with EBV, in which the virus is thought to play a key 
pathogenic role. Thus, whereas immunocompetent individuals possess effective CD8
+
 and 
CD4
+
 T-cell responses that maintain long-term control over chronic EBV infection, in 
transplant recipients iatrogenic T-cell compromise may trigger opportunistic accumulation of 
EBV-transformed B-cells, leading to PTLD. Regarding the management of these patients, RI 
on its own is often insufficient to produce sustained disease remission
511
. Consequently, first 
line therapy for CD20
+
 B-cell PTLD usually comprises R-mono, or Rituximab in combination 
with CHOP chemotherapy (R-CHOP). However, deciding between these therapies may be 
challenging.  Although studies have shown that R-mono is safe and can produce satisfactory 
response rates, concerns have been raised regarding a lack of durable remissions
519,561
. 
Whereas CHOP chemotherapy can deliver long-term remissions, high levels of toxicity have 
been reported
376,509
. Optimal selection between these initial therapies is also complicated by 
the lack of an accepted prognostic scoring system for PTLD
388
. Given these issues, a 
retrospective study was undertaken to gather data from solid allograft recipients from the UK 
diagnosed with PTLD. The principal aim was to characterise outcomes and prognostic factors 
for patients managed in the Rituximab era.  
 
3.1 Patient Characteristics 
This retrospective study invited 4 UK centres to submit data on patients aged over 16 years 
with biopsy-proven PTLD diagnosed between 2000 and 2012. A total of 72 cases meeting the 
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inclusion criteria were identified and median follow-up was 38 months. Patient characteristics 
are summarised in Table 10. These included 34 liver, 32 renal and 6 cardiothoracic transplant 
recipients. The median age at histological diagnosis was 47 years (range 16 - 72 years) and 
68% were male. The median time from transplant to diagnosis of PTLD was 93 months 
(range 2 – 302 months), with 83% of cases occurring after 1 year. Disease staging, assigned 
using the Ann Arbor staging system, revealed that 51% of patients had stage ≥2 disease at 
presentation. Notably, extranodal disease was common, with 69% of patients exhibiting 
involvement of at least 1 extranodal site and 17% exhibiting 2 or more sites. Of these, the 
gastrointestinal tract was the most commonly involved, in 39% of cases. 
 
3.2 Histopathology 
Histopathology reports were used to categorise cases according to pathological subtype, using 
the WHO classification system for PTLD
421
 (Figure 10A). This identified 14 polymorphic 
lesions, 45 B-cell monomorphic lesions (including 35 DLBCL, 3 plasmacytoma-like and 2 
plasmablastic lymphoma subtypes), 8 cases of B-cell PTLD of unspecified subtype, 1 
monomorphic T-cell lymphoma and 4 HL types. EBV-association, defined as positivity for 
EBER in situ hybridisation and/or LMP1 immunohistochemistry, or concurrent high-level 
EBV DNAemia, was noted in 54% of cases (Figure 10B); this is likely to be an underestimate 
because adequate assessment of EBV status was not available for 17 cases. Notably, EBV-
association was found to be significantly associated with disease presenting within a year of 
transplant (χ2 P = 0.004) and polymorphic disease (χ2 P = 0.07; borderline significance). 
Furthermore, for 16 cases where EBV and CD30 status were both known, positivity was 
significantly associated (χ2 P = 0.04). 
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    N % 
Age at diagnosis of PTLD 
     Median years (range) 
 
47 (16-52)  
Sex 
     Male 
     Female 
 
49 / 72 
23 / 72  
 
68 
32 
Transplant Type 
     Liver 
     Renal 
     Cardiothoracic 
 
34 / 72 
32 / 72 
  6 / 72 
 
47 
44 
  8 
Onset 
     Early (<1 year) 
     Late  (≥1 year) 
 
12 / 72 
60 / 72 
 
17 
83 
B Symptoms 
     Yes 
 
27 / 51 
 
53 
No. of Extranodal Sites 
     0 
     1 
     ≥2 
 
20 / 70 
38 / 70 
12 / 70 
 
29 
54 
17 
Extranodal Sites 
     Gut 
     Liver 
     Lung     
     Spleen 
     CNS 
     Marrow 
     Subcutaneous 
     Skeletal 
     Renal 
 
27 / 70 
13 / 70 
  7 / 70 
  7 / 70 
  5 / 70 
  4 / 62 
  3 / 70 
  3 / 70 
  2 / 70 
 
39 
19 
10 
10 
  7 
  6 
  4 
  4 
  3 
Stage 
     I 
     II 
     III 
     IV 
 
25 / 70 
  9 / 70 
10 / 70 
26 / 70 
 
36 
13 
14 
37 
ECOG PS 
     0-1 
     2-4 
 
44 / 69 
25 / 69 
 
64 
36 
Serum LDH 
     Elevated 
 
30 / 59 
 
51 
 
Table 10. Patients with PTLD Arising after Solid Organ Transplant 
Baseline characteristics for 72 adult patients with biopsy-proven PTLD arising after solid 
organ transplant included in the study. 
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Figure 10. Pathology of PTLD Cases Arising after Solid Organ Transplant 
A. PTLD cases categorised according to the WHO Classification for PTLD 2008
421
. B. Cases 
were identified as EBV-associated if EBER in situ hybridisation and/or LMP1 
immunohistochemistry were positive, or if significant EBV DNAemia was detected by EBV 
qPCR; negative staining for LMP1 in the absence of EBER in situ hybridisation was not 
considered sufficient to exclude EBV-association and such cases were classified as equivocal 
EBV Positive 
54%
Equivocal or 
Unknown
24%
EBV Negative
22%
Monomorphic B DLBCL
49%
Monomorphic B NOS
7%
Plasmacytoma-like or 
plasmablastic
7%
Hodgkins
6%
T Cell
1%
Unspecified
11%
Polymorphic
19%
A. Pathology
B. EBV Association
EBV DNAemia (5.6%)
EBER+ and / or LMP1+ (48.6%)
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3.3 Treatment 
Table 11 summarises the first line therapy used for all study patients. In 4 patients, this 
comprised RI in the absence of immuno-chemotherapy; all patients had undergone radical 
surgery and had no evidence of disease on subsequent imaging. Three patients received 
palliative treatment from diagnosis because they were moribund. For the remaining 65 
individuals, first line treatment comprised RI in combination with Rituximab and/or 
chemotherapy. Initial therapy was with R-mono in 16/72 (22%) and R-CHOP in 34/72 (47%).  
 
In order to understand how baseline characteristics influenced the selection of R-CHOP 
versus R-mono, statistical analysis was performed using logistic regression (Table 12). This 
statistical test generates odds ratios (OR), which express the strength association between 
independent and dependent variables – it is the odds of an outcome occurring in one group 
divided by the odds of the outcome occurring in the other group. This revealed that R-CHOP 
was more likely to be used in cases with advanced stage (OR 6.7, P = 0.01), onset more than 1 
year after transplant (OR 7.3, P = 0.03), lack of EBV association (OR 0.1, P = 0.002) and 
monomorphic versus polymorphic histology (OR 14.5, P = 0.003). In a multivariate logistic 
model, advanced stage (OR 10.7, P = 0.06) and monomorphic histology (OR 8.8, P = 0.03) 
retained significance as variables favouring the selection of R-CHOP. 
 
3.4 Treatment Tolerability and Outcomes 
Due to the retrospective nature of the study, detailed information on treatment-related toxicity 
was not available. However, of those treated with R-mono, 15/16 (94%) completed at least 4 
infusions, with no treatment-related mortality (Table 13). Of these, 4 patients subsequently 
received R-CHOP for consolidation of response (2 patients) or for relapsed and/or refractory  
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Initial Treatment N % 
R-Monotherapy 16 / 72 22 
R-CHOP 34 / 72 47 
Other Therapy 
 
     Surgery + RI 
     Palliation 
     ABVD 
     CHOP (no R) 
     CTD 
     Other chemo 
 
22 / 72 
 
     4 
     3 
     3 
     3 
     3 
     6 
 
 
31 
Table 11. Initial Treatment 
Reduction of immunosuppression (RI) in combination with R-Mono or R-CHOP comprised 
initial therapy for the majority of patients with PTLD arising after solid organ transplant. 
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Univariate Analysis Odds Ratio P 
Age 1.0 0.13 
Male Sex 2.0 0.31 
Transplant Type - 0.91 
Late Onset  (≥1 year) 7.3 0.03 
B Monomorphic Pathology 14.5 0.003 
EBV-association 0.1 0.002 
Stage ≥3 6.7 0.01 
Extranodal Disease 1.2 0.77 
≥2 Extranodal sites All R-CHOP - 
Elevated LDH 1.4 0.59 
ECOG PS ≥ 2 1.3 0.70 
   
Multivariate Analysis Odds Ratio P 
Late Onset  (≥1 year) 6.1 0.17 
B Monomorphic Pathology 8.8 0.03 
EBV-association 0.3 0.22 
Stage ≥3 10.7 0.06 
 
Table 12. Factors Influencing Selection of R-CHOP versus R-Mono 
Factors associated with the selection of R-CHOP as first line therapy for PTLD arising after 
solid organ transplant were analysed using univariate logistic regression. Significant factors 
(P < 0.05) were subsequently analysed in a multivariate logistic regression model, in which 
monomorphic pathology and advanced stage (borderline P value) retained significance. 
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Regimen N 
Treatment 
Completed 
Deaths on 
Treatment Response 
 
 
R-Mono 
 
 
16 
 
≥ 4 Infusions: 
15 / 16 (94%) 
 
 
0 / 16  (0%) 
 
 
ORR     13 / 16 (81%) 
CR        10 / 16 (63%) 
PR          3 / 16 (19%) 
NR         3 / 16 (19%) 
 
 
R-CHOP 
 
 
34 
 
≥ 6 Cycles: 
23 / 34 (68%) 
 
 
4 / 34  (12%) 
 
 
ORR       25 / 30 (83%) 
CR          19 / 34 (56%) 
PR            6 / 34 (18%) 
NR            5 / 34 (15%) 
n/a           4 / 34 (12%) 
Table 13. Treatment Tolerability and Response 
The number of infusions of Rituximab or cycles of R-CHOP delivered to patients with PTLD 
arising after solid organ transplant are shown, as are deaths observed on treatment and 
response to therapy. CR indicates complete response; PR, partial response; NR, no response; 
ORR, overall response rate (CR + PR); n/a, not available. 
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disease (2 patients). One patient was changed to R-CHOP due to poor response. Of those who 
received R-CHOP as initial therapy, 23/34 (68%) completed at least 6 cycles, and 4 patients 
died whilst on treatment. 
 
Response to therapy was evaluated on the basis of submitted clinical and radiological data and 
was categorised into complete remission (CR), partial remission (PR) or no remission (NR), 
in line with the Cheson criteria
541
. The overall response rate (ORR) to R-mono was 81% (10 
CR, 3 PR and 3 NR; Table 13). This was similar to that of R-CHOP at 83% (19 CR, 6 PR, 5 
NR and 4 undetermined; χ2 P = 0.67). Of those who received R-mono as initial therapy, 1 
patient subsequently received R-CHOP for consolidation and remained in long term 
remission, whereas 4 patients exhibited NR or subsequently progressed and died despite 
further chemotherapy in 3 cases. Survival outcomes for R-mono and R-CHOP were 2 year 
event-free survival of 62% and 54% (P = 0.77), 2 year progression-free survival of 67% and 
58% (P = 0.47) and 2 year overall survival of 74% and 59% (P =0.52) respectively (Figure 
11). 
 
3.5 Predictors of Outcome 
Predictors for overall survival were assessed using Cox analysis (Table 14). This statistical 
test generates hazard ratios (HR), which express the risk of an event occurring in relation to 
an independent variable - it is the ratio of the hazard rates (the chance of an event occurring 
over time) in one group compared to another group. Amongst all study patients, significant 
baseline predictors of (inferior) survival were age ≥50 years (HR 2.9, P = 0.006), stage ≥2 
disease (HR 4.0, P = 0.01), ECOG performance status ≥2 (HR 2.1, P = 0.05), and elevated 
LDH (HR 2.2, P = 0.08 borderline significance). Extranodal disease, histology, EBV- 
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Figure 11. Overall Survival by Initial Therapy 
Overall survival amongst patients with PTLD arising after solid organ transplant initially 
treated with R-Mono or R-CHOP chemotherapy. Kaplan-Meier curves were compared with 
the Log Rank test. A significant difference was not observed. 
R-Mono
R-CHOP
P = 0.52
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Univariate Analysis HR 95% CI P 
Age ≥ 50 years 2.9 1.4 – 6.2 0.006 
Male sex 0.9 0.4 – 1.9 0.75 
Late onset 0.6 0.3 – 1.4 0.24 
B Monomorphic  pathology 1.1 0.4 – 2.9 0.85 
EBV association 1.1 0.5 – 2.2 0.88 
Stage ≥ 2 4.0 1.4 – 11.4 0.01 
Stage ≥ 3 2.2 1.0 - 4.9 0.05 
Extranodal disease 1.0 0.5 – 2.2 0.96 
≥2 Extranodal sites 1.6 0.7 – 3.8 0.28 
Elevated LDH 2.2 0.9 – 5.6 0.08 
ECOG PS ≥ 2 2.1 1.0 – 4.5 0.05 
    
Multivariate Analysis HR 95% CI P 
Age ≥ 50 years 3.5 1.4 – 8.7 0.008 
Stage ≥ 2 3.5 1.1 – 10.7 0.03 
Elevated LDH 1.1 0.4 – 3.2 0.80 
ECOG PS ≥ 2 2.0 0.8 – 5.0 0.15 
 
Table 14. Predictors of Overall Survival 
Factors predicting for overall survival amongst patients treated with either R-mono or R-
CHOP as first line therapy for PTLD were analysed using Cox regression. Factors significant 
in univariate analysis were subsequently analysed in a multivariate Cox proportional hazards 
model. In this, age ≥50 years and stage ≥2 disease retained significance as predictors of 
inferior survival. HR indicates hazard ratio; CI, confidence interval. 
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association and time from transplant were not predictive. In multivariate analysis, age>50 
years (HR 3.5, P = 0.008) and advanced stage (HR 3.5, P = 0.03) retained significance. 
Importantly, amongst those treated with R-mono or R-CHOP, response to initial therapy was 
highly predictive of overall survival (overall response, HR 0.2, P < 0.0001; complete 
response, HR 0.1, P < 0.0001). 
 
Sufficient data was available to apply the well validated 5 point international prognostic index 
(IPI) for de novo DLBCL to patients treated with R-CHOP or R-mono. This showed that 
those with 3 or more points had significantly inferior overall survival (78% vs 48% at 2 years; 
P = 0.046). However, a 4-point modified prognostic index (MPI) comprising age>50 years, 
stage ≥2 disease, ECOG performance status ≥2 and elevated LDH was found to be superior 
for the current dataset (Figure 12). Using this, patients treated with R-mono or R-CHOP with 
low risk disease (<2 points) had significantly improved survival compared to those with high 
risk disease (≥2 points), with 2 year overall survival of 90% versus 43% (P = 0.001;). 
Notably, comparison of outcomes for R-mono versus R-CHOP within high risk or low risk 
groups revealed no significant differences in survival (. However, there was a trend towards 
inferior response amongst patients with high risk disease treated with R-mono compared to R-
CHOP (CR rate 1/6 [17%] versus 9/16 [56%]; χ2 P = 0.16), which was not observed for low 
risk disease. 
 
3.6 Discussion 
There is currently a paucity of data to inform the management of PTLD arising after solid 
organ transplant. In seeking to address this problem we collected data from several leading 
UK clinical haematology centres, resulting in one of the largest case series of its kind.  
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Figure 12. Survival by 4-Point Modified Prognostic Index 
Overall survival amongst patients initially treated with R-mono or R-CHOP was determined 
according to a 4-point modified IPI scoring system, in which 1 point was assigned for each of 
the following baseline factors: age >50 years, stage ≥2 disease, ECOG performance status ≥2, 
elevated LDH. Patients with high risk disease (scoring ≥2 points) had significantly (P = 
0.001) inferior survival compared to those with low risk disease (scoring 0-1 points). Curves 
were compared with the Log Rank test. 
P = 0.001
Low Risk
High Risk
0-1 Points
2-3 Points
4 Points
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Consistent with the heterogeneous nature of PTLD, considerable variability was observed in 
baseline pathological and clinical characteristics of included patients. Thus, although the 
majority of cases were monomorphic B-cell PTLD of DLBCL type or polymorphic PTLD, 
each of the principal WHO pathological categories of PTLD were encountered. At least 54% 
of cases were found to be EBV-associated, although this is likely to be an underestimate for 
the reasons detailed above. The majority (83%) of cases were late onset, perhaps explained by 
the exclusion of children from the study. Extranodal disease was very common, occurring in 
71% of patients, and it was particularly striking how frequently PTLD involved the 
gastrointestinal tract, apparent in 39% of patients. Whilst this may reflect the relatively large 
amount of nodal tissue found occupying the gastrointestinal tract within Peyer’s patches, it 
also suggests that the gut microenvironment may be important for the development of PTLD.  
 
The principal focus of the study was to examine outcomes with R-mono versus R-CHOP as 
initial therapy for CD20
+
 B-cell PTLD. Importantly, it should be stressed that due to the 
retrospective nature of the study this comparison was biased by the lack of randomisation 
between R-mono and R-CHOP treatments;  such a randomisation would almost certainly be 
unethical in the context of a prospective RCT. However, in order to mitigate for this 
limitation, we examined differences in the baseline factors that may have influenced selection 
of treatment between the groups. Thus, patients who received R-CHOP were found to exhibit 
more advanced stage, later onset disease, lack of EBV-association and monomorphic 
histology. Because these factors have variously been associated with inferior outcomes, it is 
apparent that R-mono was generally reserved for a prognostically favourable group.  
 
Acknowledging these differences, outcomes were found to be similar with both initial 
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therapies. Thus, overall response rates to R-mono and R-CHOP were 81% and 83% 
respectively. Although overall survival at 2 years was marginally better for those treated with 
R-mono, at 74% versus 69%, this difference was not statistically significant and the survival 
curve for both groups subsequently plateaued at around 60% (Figure 11). These results 
compare favourably with those reported in previous studies
512-519
. However, caution should be 
exercised in seeking to draw such comparisons due to the significant variation between 
cohorts in different studies. Furthermore, prior studies have typically applied a single form of 
therapy to all patients
512-514
, rather than selecting between therapies according to baseline 
factors, as occurs in routine clinical practice. Importantly, concerns have previously been 
raised about relatively high rates of relapse, despite initial responses, when R-mono is used as 
initial therapy. However, the finding in the present study that 11/16 (69%) patients treated 
with R-mono exhibited durable remissions without the need for further therapy, confirms that 
R-mono can be efficacious when used for selected patients with favourable disease. 
 
Patients with PTLD are at particular risk of treatment-related toxicity, often due to significant 
co-morbidities associated with the primary indication for transplant and co-existing 
complications. With regard to treatment tolerability, it was unfortunate that detailed 
information on the toxicities encountered was not available for the present study. However, 
we did find that all but one of the patients treated with R-mono completed at least 4 infusions; 
the only patient not doing so changed therapy due to poor response rather than toxicity. In 
contrast, considerably fewer patients completed a minimum of 6 cycles of R-CHOP, and 4 
patients died on treatment. As such, our data are consistent with that of other studies, 
confirming that R-CHOP is associated with significantly greater toxicity that R-mono
515-518
. 
However, the rate of toxicity compared favourably with that found in other studies, where 
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treatment-related mortality as high as 31 % has been reported
562
. Notably, in the PTLD-1 trial, 
mortality associated with CHOP chemotherapy was 11%
519
. This is almost identical to the 
level of toxicity found in our study (12%), and therefore it arguably remains an open question 
as to whether sequential therapy, as evaluated in the PTLD-1 trial, is indeed superior to 
treating from the outset according to baseline risk stratification. 
 
Several previous studies have sought to characterise prognostic factors for PTLD arising after 
solid allograft, variously reporting that advanced age, late onset disease, advanced stage, 
extranodal disease, number of disease sites, poor performance status, LDH, 
hypoalbuminaemia, monomorphic disease and EBV negativity may predict for inferior 
outcome
513,563-566
. However, there is a noticeable lack of concordance between these studies, 
presumably due to the limited size of their cohorts and heterogeneity of patient characteristics. 
Consistent with this, a validated and universally agreed prognostic scoring system does not 
currently exist for PTLD
388
, contributing to the challenge of selecting appropriate initial 
therapy. In the present study, we found that older age, advanced stage, poor performance 
status and raised serum LDH were associated with significantly inferior overall survival. 
Response to therapy was also significantly associated with overall survival. However, we 
failed to demonstrate prognostic associations for factors including EBV association, 
polymorphic versus monomorphic disease, late onset disease and extranodal disease. It may 
be that the study was too underpowered to detect some associations. However, it is notable 
that other large retrospective studies of PTLD have also failed to show that EBV association 
is prognostic
564,566
. Using these factors we designed a modified 4 point IPI that modelled our 
data very well. This principally differs from the standard de novo DLBCL IPI due to the 
exclusion of extranodal disease as a variable, because this was not prognostic for our series; 
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probably as a consequence of the high rates of extranodal disease identified in all patients. It 
remains to be seen how well our scoring system will apply to other PTLD series. Ultimately, 
large prospective studies, undertaken on well-defined patient cohorts, will be required to 
refine prognostication amongst patients with PTLD. 
 
Some patients exhibit very poor outcomes, irrespective of initial treatment. Indeed, 
individuals with a modified IPI score of 4/4 had a median survival of only 10 months. It is 
therefore clear that R-mono or R-CHOP are inadequate for such patients, and that novel 
treatment strategies, with low toxicity, are urgently required. Regarding this, several emerging 
therapies are yet to be evaluated in the setting of PTLD. These include novel therapeutic 
monoclonal antibodies targeting CD20, such as Ofatumumab and Obinutuzumab
567
. 
Similarly, Brentuximab-vedotin is an anti-CD30 antibody linked to a cytotoxic molecule that 
has shown efficacy for refractory HL
568
, and which is currently being evaluated in a phase II 
study for PTLD
569
. Meanwhile, a number of novel small molecule inhibitors have shown 
promising results in other B-cell malignancies and may also prove efficacious for PTLD. 
Amongst these is the BTK inhibitor Ibrutinib which has delivered excellent preliminary 
results for the treatment of chronic lymphocytic leukaemia (CLL) and Mantle-cell lymphoma, 
and is currently being evaluated for the treatment of DLBCL in the immunocompetent 
setting
570
. A range of other small molecule inhibitors are either currently available or in 
development. Importantly, access to large cohorts of clinically annotated PTLD tumour 
material will benefit the development of targeted therapy, and will aid in the design of new 
agents; it is hoped that the data collected in the present study may support such efforts. 
Finally, although adoptive immunotherapy with EBV CTLs has proved to be effective rescue 
therapy for PTLD
531
, this approach is yet to be assessed as standard treatment for PTLD. To 
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address this important issue, an RCT designed to evaluate third party derived EBV CTLs as 
first-line treatment for PTLD arising after solid organ transplantation is currently being 
developed by Dr Chaganti of University Hospital Birmingham. 
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4. EBV Reactivation and PTLD after Allo-HSCT: Greatly Reduced Risk in 
Patients with Non-Hodgkin Lymphoma Previously Treated with Rituximab 
 
PTLD is also a life threatening complication of allo-HSCT
520,571,572
. In this setting, almost all 
cases arise from donor-derived EBV-transformed B-cells. These opportunistically expand in 
the state of T-cell immunocompromise resulting from preparative conditioning and 
immunosuppressive therapy. The incidence of PTLD arising after allo-HSCT varies 
significantly in relation to graft T-cell depletion (TCD), ranging from <1% without TCD, to 
>10% with TCD in some series
392,407-419420
. Other important risks factors include the use of 
unrelated and/or HLA-antigen mismatched donors, the occurrence of severe GvHD and older 
age. 
 
Of the alternative forms of TCD available, several studies have reported significantly elevated 
rates of PTLD (or EBV reactivation) following ATG
392,416,419,420
. Meanwhile, the anti-CD52 
monoclonal antibody Campath has been associated with a lower incidence of disease, 
reportedly 0.4-1.3% in initial studies
392,407
. Unlike ATG, which selectively depletes T-cells, 
Campath targets all lymphocytes. Therefore, the risk associated with using Campath to 
deplete T-cells may be offset by it simultaneous depletion of B-cells. However, it is notable 
that initial studies examining the risks associated with Campath involved first and second 
generation rat antibodies (Campath-1M and -1G), whereas relatively few studies have 
examined the third generation humanised antibody Campath-1H (Alemtuzumab), which has 
now superseded the other antibodies in routine clinical practice
573
. Alemtuzumab has a much 
longer half-life than Campath-1G (15-21 days, compared to less than 24 hours) and is known 
to cause prolonged delays in the reconstitution of both general
521,522
 and EBV-specific 
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immunity
383
. Consequently, it might contribute to an increased risk of PTLD compared to the 
earlier antibodies. In the largest series to specifically explore the risk of EBV reactivation and 
PTLD in Alemtuzumab-treated patients, Carpenter et al. reported a relatively high incidence 
of EBV reactivation, in 40.3% at 2 years post-transplant amongst 111 patients, although only 
1 case of PTLD (0.9%) was observed
409
. Meanwhile, smaller series have reported the 
incidence of PTLD following Alemtuzumab to be between 2.3% and 9.5%
412,414,415,500
. 
 
The introduction of Rituximab has significantly improved PTLD-related mortality following 
allo-HSCT
521
. In particular, the pre-emptive administration of Rituximab to individuals 
developing raised levels of circulating EBV DNA, an indicator of emergent PTLD identified 
by EBV qPCR monitoring, has led to a marked reduction in mortality relative to historic 
cohorts
498,499,501,506,507
. However, there remains marked inter-centre variation in EBV qPCR 
methodology and a lack of consensus as to the optimal virus load thresholds to trigger 
intervention
384,502,503
. Alternative strategies for the prevention of PTLD include the 
prophylactic infusion of donor-derived EBV CTLs
527
. However, although efficacious, this 
approach has not been widely adopted, probably due to the significant logistical burdens and 
financial costs. Alternatively, it has been proposed that peri-transplant Rituximab (Rituximab 
delivered shortly before or after transplant) might be an effective method of prophylaxis
574
. 
 
In order to explore these issues, and to provide important context for the studies described 
later in this thesis, work was undertaken to define the incidence, kinetics and risk factors for 
EBV reactivation and PTLD amongst a large cohort of adult patients undergoing 
Alemtuzumab or ATG-conditioned TCD allo-HSCT. 
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4.1 Incidence and Kinetics of EBV Reactivation and PTLD 
This study includes 196 adult patients undergoing first TCD allo-HSCT at University Hospital 
Birmingham, UK. Median follow-up was 28 months, and overall survival was 72% at 1 year 
post-transplant, with non-relapse mortality of 4.6% at 100 days and 15.0% at 1 year. Patient 
characteristics are summarised in Table 15. In vivo Alemtuzumab was used in 186 (95%) 
patients, whilst 10 (5%) received ATG.  Reduced intensity conditioning was used in 159 
(81%) of patients. 
  
All allo-HSCT recipients were monitored with EBV qPCR whole blood assay, with testing 
scheduled every 1-2 weeks for the first 6 months post-transplant and intermittently thereafter. 
Monitoring revealed a cumulative incidence of EBV reactivation (defined as a single positive 
EBV qPCR test above the threshold of sensitivity of 500 genomes/ml) of 48% (CI 41 - 55%) 
at 1 year for Alemtuzumab-conditioned transplants and 80% (41% - 95%) for ATG-treated 
transplants (Figure 13A). More importantly, cumulative incidence of high-level EBV 
reactivation (defined as a single test ≥ 20,000 genomes/ml) was 18% (CI 13 - 24%) and 30% 
(CI 7% - 58%) respectively (Figure 13B). 
 
The distribution of EBV reactivation and high-level EBV reactivation events are shown in 
Figure 14, revealing that both occurred most frequently between 8 and 16 weeks after 
transplant. Notably, no cases of high-level EBV reactivation occurred in the first 4 weeks 
after transplant, whilst 3 (7%) were observed more than a year afterwards. All 3 high-level 
EBV reactivations following ATG-conditioned transplants occurred within the first 8 weeks, 
earlier than those after Alemtuzumab. Furthermore, analysis of the interval between initial 
EBV qPCR positivity and high-level reactivation (Figure 14C) revealed rapid progression in 
4. Results 
Page 128   
 
  N % 
 
Age 
 
Median years (range) 
 
51 (16 – 71) 
 
    
Sex Male 126 64 
 Female  70 36 
    
Diagnosis AML/MDS 104 53 
 NHL  29 15 
 ALL  18   9 
 HL  11   6 
 CLL  12   6 
 MPD  11   6 
 Other  11   6 
    
Donor Unrelated 133 68 
 Sibling  63 32 
    
HLA antigen mismatches None 155 80 
 1 or more  38 20 
    
Stem-cell source PBSC 196 100 
    
Intensity Reduced intensity 159 81 
 Myeloablative  37 19 
    
Conditioning Flu Mel 129 66 
 Cy TBI  37 19 
 BEAM 
+
/- Flu  15   8 
 Other  15   8 
    
T-cell depletion Alemtuzumab 186 95 
 ATG  10  5 
    
Acute GvHD Grade ≥2  67 34 
 
Table 15. Characteristics of Patients Undergoing T-Cell Deplete Allo-HSCT 
Incidence and risk factors for EBV reactivation were analysed in 196 patients undergoing T-
cell deplete allo-HSCT. 
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Figure 13. Incidence of EBV Reactivation after T-Cell Deplete Allo-HSCT 
Cumulative incidence of EBV DNAemia was determined for patients receiving either ATG or 
Alemtuzumab T-cell depletion. A. Incidence of EBV qPCR positivity (>500 genomes/ml). B. 
Incidence of high-level EBV DNAemia (>20,000 genomes/ml). Cumulative incidence curves 
were compared with the Log Rank test. 
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Figure 14. Kinetics of EBV Reactivation after Allo-HSCT 
A. Interval from transplant to first EBV qPCR-positive test (≥500 genomes/ml). B. Interval 
from transplant to high-level EBV reactivation (≥20,000 copies/ml). C. Interval from first 
EBV qPCR-positive test to high-level EBV DNAemia. The proportion of patients exhibiting 
high-level EBV reactivation within 2 weeks of initial EBV qPCR positivity is indicated. 
        EBV qPCR Positivity
0 
- 4
4 
- 8
8 
- 1
2
12
 - 
16
16
 - 
20
20
 - 
24
24
 - 
28
28
 - 
32
32
 - 
36
36
 - 
40
40
 - 
44
44
 - 
48
48
 - 
52 >5
2
0
10
20
30
Time post transplant (weeks)
F
re
q
u
e
n
c
y
        High Level EBV
0 
- 4
4 
- 8
8 
- 1
2
12
 - 
16
16
 - 
20
20
 - 
24
24
 - 
28
28
 - 
32
32
 - 
36
36
 - 
40
40
 - 
44
44
 - 
48
48
 - 
52 >5
2
0
5
10
15
Time post transplant (weeks)
F
re
q
u
e
n
c
y
        Interval to High Level EBV
0
0 
- 1
1 
- 2
2 
- 3
3 
- 4
4 
- 5
5 
- 6
6 
- 7
7 
- 8
8 
- 9
9 
- 1
0
10
 - 
11
11
 - 
12 >1
2
0
5
10
15
20
Time from EBV qPCR positivity to 2.0x10
4
 copies / ml (weeks)
F
re
q
u
e
n
c
y
        EBV qPCR Positivity
0 
- 4
4 
- 8
8 
- 1
2
12
 - 
16
16
 - 
20
20
 - 
24
24
 - 
28
28
 - 
32
32
 - 
36
36
 - 
40
40
 - 
44
44
 - 
48
48
 - 
52 >5
2
0
10
20
30
Alemtuzumab
ATG
Time post transplant (weeks)
F
re
q
u
e
n
c
y
A.
B.
C.
83%
4. Results 
Page 131  
 
many patients, such that in 34 (83%) the interval was less than 2 weeks, and 13 (32%) 
patients already exhibited high-level reactivation at first EBV qPCR positivity. 
 
In total, 41 patients developed high-level EBV reactivation. Of these, 11 were concurrently 
diagnosed with PTLD (Table 16), 3 of whom had received ATG-conditioned transplants. The 
median interval between first EBV load ≥20,000 copies/ml and radiographically documented 
disease, comprising CT or PET-CT imaging in all cases, was only 7 days (range 0 – 16 days). 
Biopsy material was subsequently obtained in 4 patients, with confirmation of PTLD in all 
cases. Histology comprised 2 cases of EBV-positive polymorphic PTLD (one patient also had 
early PTLD of IM subtype documented in a separate lesion), 1 case of EBV-positive 
monomorphic PTLD of DLBCL subtype and 1 case of PTLD of unspecified subtype. Of 
these, 7/11 (64%) had B symptoms documented at presentation and 9/11 (82%) had stage ≥3 
disease. 
 
4.2 Pre-Emptive Management 
Figure 15 summarises the management of all patients who developed EBV reactivation 
≥20,000 copies/ml. A total of 41 patients with high-level EBV reactivation, including 11 
diagnosed with PTLD as described above, were treated pre-emptively with up to 4 weekly 
infusions of Rituximab. Of these, all 30 without evidence of PTLD, and 8/11 (73%) of those 
with PTLD, had complete responses (defined as sustained resolution of EBV loads to 
undetectable levels and complete radiological remission of disease where present). Three 
patients with PTLD showed refractoriness to Rituximab (Figure 16). Patients 6 and 9, who 
both had nodal PTLD, exhibited initial resolution of EBV DNAemia in response to Rituximab 
but this recrudesced shortly afterwards. Patient 5, who had nodal PTLD with probable EBV  
4. Results 
Page 132   
 
T
a
b
le
 1
6
. 
P
a
ti
en
ts
 w
it
h
 P
T
L
D
 A
ri
si
n
g
 a
ft
er
 A
ll
o
-H
S
C
T
 
P
T
L
D
 w
as
 d
ia
g
n
o
se
d
 i
n
 1
1
 o
f 
1
9
6
 p
at
ie
n
ts
 u
n
d
er
g
o
in
g
 T
-c
el
l 
d
ep
le
te
 a
ll
o
-H
S
C
T
. 
O
f 
th
es
e,
 3
 h
ad
 r
ec
ei
v
ed
 T
-c
el
l 
d
ep
le
ti
o
n
 w
it
h
  
A
T
G
 a
n
d
 8
 w
it
h
 A
le
m
tu
zu
m
ab
. 
F
o
ll
o
w
-u
p
 
(m
o
n
th
s)
 
 
4
8
 
1
3
 
1
1
 
2
9
 
5
 
8
 
3
4
 
6
 
1
5
 
1
2
 
1
3
 
O
u
tc
o
m
e
, 
c
a
u
se
 o
f 
d
ea
th
 
 
A
li
v
e 
D
ie
d
, 
R
el
ap
se
 
D
ie
d
, 
R
el
ap
se
 
A
li
v
e 
D
ie
d
, 
P
T
L
D
 
D
ie
d
, 
P
T
L
D
 
A
li
v
e 
D
ie
d
, 
P
T
L
D
 
D
ie
d
, 
R
el
ap
se
 
A
li
v
e 
A
li
v
e 
H
is
to
lo
g
y
 
   
P
T
L
D
 N
O
S
 
 
D
L
B
C
L
 
  
P
o
ly
m
o
rp
h
ic
 
P
o
ly
m
o
rp
h
ic
 
  
S
ta
g
e 
 
IE
 
II
I 
II
I 
II
I 
IV
 
II
I 
II
I 
IV
 
II
 
II
I 
II
I 
B
 s
y
m
p
to
m
s 
 N
 
Y
 
Y
 
Y
 
Y
 
N
 
N
 
Y
 
Y
 
Y
 
N
 
P
e
a
k
 E
B
V
 l
o
a
d
 
(c
o
p
ie
s/
m
l)
 
 
9
3
0
,0
0
0
 
4
,3
4
6
,7
9
0
 
1
,0
8
1
,9
3
0
 
2
,7
0
4
,3
8
0
 
2
,1
5
0
,6
5
0
 
5
7
,0
3
9
 
3
2
9
,5
4
2
 
1
,8
0
5
,4
9
0
 
9
4
,9
4
5
 
9
4
,7
8
9
 
4
9
4
,7
9
4
 
In
te
r
v
a
l 
to
 
d
ia
g
n
o
si
s 
(d
a
y
s)
 
 
1
6
 
1
6
 
3
 
7
 
9
 
1
 
7
 
2
 
1
 
2
 
7
 
O
n
se
t 
o
f 
H
ig
h
 
E
B
V
 D
N
A
em
ia
 
(d
a
y
s)
 
 
2
9
 
1
1
9
 
5
2
 
7
1
 
1
1
9
 
8
4
 
7
1
 
5
6
 
9
1
 
4
3
 
7
0
 
D
o
n
o
r 
S
ib
li
n
g
 
U
n
re
la
te
d
 
U
n
re
la
te
d
 
S
ib
li
n
g
 
U
n
re
la
te
d
 
U
n
re
la
te
d
 
U
n
re
la
te
d
 
U
n
re
la
te
d
 
S
ib
li
n
g
 
U
n
re
la
te
d
 
U
n
re
la
te
d
 
T
C
D
 
A
T
G
 
A
le
m
tu
zu
m
ab
 
A
T
G
 
A
le
m
tu
zu
m
ab
 
A
le
m
tu
zu
m
ab
 
A
le
m
tu
zu
m
ab
 
A
le
m
tu
zu
m
ab
 
A
le
m
tu
zu
m
ab
 
A
le
m
tu
zu
m
ab
 
A
T
G
 
A
le
m
tu
zu
m
ab
 
C
o
n
d
it
io
n
in
g
 
C
y
 
C
y
 T
B
I 
F
L
A
M
S
A
 
F
lu
 M
el
 
F
lu
 M
el
 
F
lu
 M
el
 
C
y
 T
B
I 
F
lu
 M
el
 
F
lu
 M
el
 
F
lu
 C
y
 
F
lu
 M
el
 
S
e
x
 
M
 
M
 
F
 
M
 
M
 
M
 
F
 
M
 
M
 
M
 
F
 
A
g
e
 
(y
ea
r
s)
 
1
6
 
3
4
 
5
6
 
6
3
 
5
7
 
4
3
 
2
9
 
6
4
 
5
7
 
5
4
 
4
2
 
D
ia
g
n
o
si
s 
A
A
 
A
M
L
 
A
M
L
 
A
L
L
 
A
M
L
 
H
L
 
A
M
L
 
M
D
S
 
A
M
L
 
C
L
L
 
A
L
L
 
N
o
. 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
1
0
 
1
1
 
4. Results 
Page 133  
 
 
Figure 15. Pre-Emptive Management of EBV Reactivation after allo-HSCT 
All patients with EBV DNAemia exceeding 20,000 copies/ml were treated with up to 4 
weekly infusions of Rituximab 375mg/m2. 11 patients were diagnosed with PTLD at 
initiation of therapy. Complete response (CR) was defined as sustained resolution of EBV 
DNAemia, and disease where evident. 
NR 
N = 3
Rituximab
N = 11
CR
N = 8
Rituximab
N = 30
No PTLD
N = 30
CR
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N = 11
High EBV load
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Figure 16. Patients with Rituximab-Refractory PTLD after Allo-HSCT 
Serial whole blood EBV loads for patients with PTLD in whom Rituximab therapy failed. All 
3 patients died despite use of cytotoxic chemotherapy in 2 of them. R indicates Rituximab; 
CHOP, cyclophosphamide / doxorubicin / vincristine/ prednisolone. 
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encephalitis showed no response in EBV load. All 3 patients died with progressive PTLD 
despite further treatment including CHOP chemotherapy in 2 cases. 
 
Given that some concerns have been raised about the safety of Rituximab use in patients after 
allo-HSCT
575,576
, the impact of pre-emptive Rituximab therapy on survival was analysed 
using Cox regression; 3 patients who died from PTLD were excluded from this analysis to 
eliminate the effect of PTLD-related mortality. This revealed no significant deleterious effect 
from pre-emptive Rituximab on overall survival (HR 1.45, CI 0.81 – 2.60; P = 0.211) or non-
relapse mortality (HR 1.44, CI 0.57 – 3.61; P = 0.44). 
 
4.3 Factors Predicting for EBV Reactivation 
Baseline predictors for EBV reactivation were analysed using univariate Cox regression 
(Table 17 and Figure 17). Of these, ATG versus Alemtuzumab was a highly significant risk 
factor for EBV reactivation (HR 4.6, CI 2.2 – 9.6; P < 0.0001). Age >50 years at transplant 
was also significantly associated with increased risk (HR 1.6, CI 1.1 - 2.3; P = 0.024). 
Notably, unrelated or HLA-antigen-mismatched donor status were not identified as risk 
factors. Although intensity of transplant conditioning was not significantly predictive overall, 
Flu Mel conditioning was associated with increased risk relative to Cy TBI (borderline 
significance) and other conditioning regimens. Analysis of these risk factors for high-level 
EBV reactivation did not reveal significant differences in this small dataset, probably due to 
lack of statistical power. However, a significant association between acute GvHD grade ≥2 
and risk of high-level EBV reactivation was observed (HR 2.54, CI 1.12 – 5.78; P = 0.026). 
  
Importantly, a diagnosis of NHL was associated with a highly significant reduction in the risk  
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EBV ≥ 500 copies/ml  EBV ≥ 20,000 copies/ml 
 HR 95% CI P 
 
HR 95% CI P 
Age    
 
   
> 50 Years 1.57 1.06 – 2.33 0.024 
 
1.48 0.76 – 2.90 0.252 
Sex    
 
   
Male vs Female 1.23 0.81 – 1.85 0.328 
 
1.43 0.72 – 2.86 0.309 
Diagnosis    
 
   
AML/MDS 1.00 - Ref 
 
1.00 - Ref 
NHL 0.10 0.03 – 0.32 0.0001 
 
- - No Events 
ALL 0.77 0.40 – 1.51 0.449 
 
0.67 0.20 – 2.20 0.505 
HL 0.76 0.33 – 1.76 0.519 
 
1.83 0.70 – 4.78 0.216 
CLL 1.08 0.54 – 2.18 0.828 
 
1.25 0.44 – 3.58 0.679 
MPD 0.91 0.42 – 2.00 0.820 
 
0.30 0.04 – 2.24 0.242 
Other 1.59 0.79 – 3.20 0.197 
 
0.63 0.15 – 2.65 0.526 
Donor    
 
   
Sibling vs Unrelated 1.27 0.86 – 1.87 0.233 
 
0.64 0.32 – 1.28 0.208 
HLA Mismatch    
 
   
≥1 Antigens 1.03 0.63 – 1.68 0.903 
 
0.96 0.42 – 2.18 0.921 
Intensity    
 
   
Myeloablative vs RIC 0.71 0.42 – 1.21 0.210 
 
0.78 0.33 – 1.86 0.578 
Conditioning    
 
   
Flu Mel 1.00 - Ref 
 
1.00 - Ref 
Cy TBI 0.64 0.37 – 1.09 0.099 
 
0.69 0.29 – 1.65 0.403 
BEAM+/- Flu No Events - - 
 
No Events - - 
Other 1.87 0.99 – 3.52 0.054 
 
0.39 0.12 – 1.27 0.117 
T Cell Depletion    
 
   
ATG vs Alemtuzumab 4.60 2.21 – 9.57 <0.0001 
 
2.35 0.72 – 7.63 0.155 
Acute GvHD    
 
   
Grade ≥2 1.50 0.91 – 2.50 0.115 
 
2.54 1.12 – 5.78 0.026 
Prior Rituximab    
 
   
Within 6 months 0.17 0.06 – 0.46 0.0005 
 
0.16 0.02 – 1.13 0.066 
Ever 0.35 0.19 – 0.64 0.0007 
 
0.40 0.14 – 1.12 0.081 
 
Table 17. Univariate Analysis of Risk Factors for EBV Reactivation after Allo-HSCT 
Risk factors for EBV reactivation ≥ 500 copies/ml or high-level EBV reactivation ≥ 20,000 
copies/ml were analysed using univariate Cox testing. Hazard ratios (HR) with 95% 
confidence intervals (95% CI) were determined for categories within each variable, relative to 
a reference category (Ref). 
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Figure 17. Incidence of EBV Reactivation by Diagnosis and Prior Rituximab Exposure 
Cumulative incidence of EBV reactivation or high-level EBV reactivation was determined for 
patients with AML/MDS or NHL (A and C), or patients who had received Rituximab within 6 
months prior to transplant or not (B and D). Cumulative incidence curves are compared with 
the Log Rank test. 
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of EBV reactivation (HR 0.10, 0.03 - 0.32; P < 0.0001). Thus, of 29 patients with NHL, only 
3 became EBV qPCR-positive (on days 57, 380 and 565 days post-transplant). Furthermore, 
no cases of high-level EBV reactivation were observed for those with NHL in the 2 years 
after transplant. This was apparent despite equivalent frequency and duration of EBV 
monitoring in comparison to other patients. Notably, the markedly reduced risk of EBV 
reactivation observed for patients with NHL was not similarly noted for those with HL; 6/11 
(55%) patients with HL exhibited EBV qPCR positivity, including 5 cases of high-level EBV 
DNAemia.  
 
In order to establish whether lack of EBV reactivation observed amongst patients with NHL 
was independent of other baseline factors, multivariate testing was performed using a Cox 
proportional hazards model including baseline factors age, diagnosis, type of TCD and 
transplant conditioning (Table 18). Within this analysis, a diagnosis of NHL remained highly 
predictive for lack of EBV reactivation (HR 0.16, CI 0.05 – 0.51; P = 0.002). 
  
4.4 Pre-Transplant Rituximab 
Given that a highly significant reduction in risk of EBV reactivation had been observed 
amongst patients with NHL, pre-transplant use of Rituximab was examined as a possible 
factor (Table 19). Thus, Rituximab use was documented in 28/29 (97%) patients with NHL, 
with the last infusion administered a median 3 months (IQR 2 – 5 months) before transplant. 
Prior Rituximab was also recorded in 11/12 (92%) patients with CLL but the last infusion of 
Rituximab was delivered substantially longer before transplant, at median 14 months (IQR 8 – 
23 months). Importantly, only 1/25 (4%) patients who received Rituximab less than 6 months  
before  transplant  reactivated  EBV  in  the  first year  - a  patient  with CLL who received  
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 EBV ≥ 500 copies/ml 
  HR 95% CI P 
Age     
     > 50 Years 1.46 0.85 – 2.50 0.168 
Diagnosis    
      AML/MDS 1.00 - Ref 
      NHL 0.18 0.06 – 0.58 0.004 
      ALL 0.90 0.46 – 1.77 0.762 
      HL 1.77 0.69 – 4.53 0.236 
      CLL 0.98 0.48 – 2.00 0.955 
      MPD 0.97 0.44 – 2.15 0.940 
      Other 2.50 0.94 - 6.64 0.067 
Conditioning    
       Flu Mel 1.00 - Ref 
       Cy TBI 0.77 0.39 – 1.52 0.452 
       BEAM
+
/- Flu No Events - - 
       Other 0.35 0.08 – 1.51 0.159 
T Cell Depletion    
      ATG vs Alemtuzumab 7.36 1.75 – 30.9 0.006 
 
Table 18. Multivariate Analysis of Risk Factors for EBV Reactivation after Allo-HSCT 
In a multivariate Cox proportional hazards model including the age, diagnosis, conditioning 
and T-cell depletion, NHL was a highly significant predictor for lack of EBV reactivation. 
Prior Rituximab therapy was also a highly significant predictor for lack of EBV reactivation 
in a separate model that excluded diagnosis. Significance for prior Rituximab was eliminated 
when diagnosis was included in this model. However, severe confounding between prior 
Rituximab therapy and diagnostic category was apparent. Hazard ratios (HR) with 95% 
confidence intervals (95% CI) were determined for categories within each variable, relative to 
a reference category (Ref). 
 
4. Results 
Page 140   
 
 
Table 19. Prior Rituximab Therapy and EBV Reactivation after Allo-HSCT 
The interval (months) between the last infusion of pre-transplant Rituximab and day 0 of the 
transplant is given for all study patients with NHL and CLL. The corresponding day of EBV 
reactivation or high-level EBV reactivation post-transplant is shown. EBV reactivation events 
occurring within 1 year after transplant appear in red, whilst those occurring after 1 year 
appear in blue. Only 1 patient who received Rituximab within 6 months prior to transplant 
reactivated EBV in the first year after transplant. 
EBV DNAemia 
after 1 year
EBV DNAemia 
within 1 year
Diagnosis
Rituximab: Months 
prior to transplant
Day EBV qPCR 
positive
Day EBV >20,000 
copies/ml
NHL 1 . .
NHL 2 . .
NHL 2 . .
NHL 2 . .
NHL 2 . .
NHL 2 . .
NHL 2 . .
NHL 2 . .
NHL 2 565 .
NHL 2 . .
NHL 2 . .
NHL 2 . .
NHL 2 . .
NHL 2 . .
CLL 2 372 .
NHL 3 . .
NHL 3 380 .
NHL 4 . .
NHL 4 . .
NHL 4 . .
NHL 4 . .
NHL 5 . .
CLL 5 78 78
NHL 6 . .
NHL 6 . .
NHL 7 . .
CLL 7 . .
CLL 9 29 43
CLL 10 104 .
CLL 14 . .
CLL 15 273 .
CLL 15 217 .
NHL 17 . .
NHL 24 57 .
NHL 29 . .
CLL 30 41 .
NHL 31 . .
CLL 37 218 337
CLL 47 85 99
NHL None . .
CLL None . .
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Rituximab 5 months prior to transplant and who developed high-level EBV reactivation on 
day 78. In contrast, 8/14 (57%) patients who received Rituximab more than 6 months before 
transplant developed EBV reactivation, including 3 patients with high-level EBV reactivation.  
 
In univariate Cox analysis, there was a highly significant association between pre-transplant 
Rituximab therapy and lack of EBV reactivation, using definitions of pre-transplant 
Rituximab of either ‘prior Rituximab ever’ (HR 0.35, CI 0.19 – 0.64; P = 0.0007) or a cut-off 
of 6 months prior to transplant (HR 0.17, CI 0.06-0.46; P = 0.0005). These differences did not 
persist in multivariate testing but this analysis was complicated for several reasons. Firstly, 
there was strong confounding between diagnostic category and prior use of Rituximab, such 
that almost all patients with NHL and CLL received Rituximab at some time before 
transplant. Secondly, there was uncertainty regarding what constitutes an appropriate cut-off 
(months before transplant) to use to define pre-transplant Rituximab. Finally, few patients 
with NHL reactivated EBV, even if they received Rituximab more than 6 months before 
transplant, unlike patients with CLL (Table 19). 
 
Regarding the safety of pre-transplant Rituximab, testing revealed no significant difference in 
overall survival for patients treated with Rituximab at any time before transplant (HR 0.72, CI 
0.41 – 1.28; P = 0.262) or within 6 months before transplant (HR 0.75, CI 0.38 – 1.5; P = 
0.420).  Similarly no significant differences were seen for non-relapse mortality for 
Rituximab given at any time before transplant (HR 0.93 CI 0.43 – 2.02; P = 0.856) or using a 
6 month cut-off (HR 0.91, CI 0.36 – 2.33; P = 0.845). An association between pre-transplant 
Rituximab (defined as any time before transplant or using a 6 month cut-off) and risk of either 
Grade ≥I or Grade ≥2 acute GvHD was also not observed.  
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4.5 Discussion 
This study reports incidence and risk factors for EBV reactivation and PTLD amongst 
patients undergoing TCD allo-HSCT at a major UK transplant centre, and includes the largest 
number of transplants using Alemtuzumab reported thus far. A relatively high overall 
incidence of EBV DNAemia was observed amongst Alemtuzumab-treated patients, with 48% 
of individuals exhibiting EBV qPCR positivity by 12 months post-transplant and 18% 
developing high-level EBV reactivation. This incidence was significantly higher amongst 
ATG-treated patients, with 80% exhibiting EBV qPCR positivity and 30% developing high-
level reactivation. Importantly, PTLD was diagnosed, coincident with high-level EBV 
reactivation, in 11 patients. Three of these had received ATG, whilst Alemtuzumab had been 
used in 8, giving a crude incidence of PTLD amongst Alemtuzumab-treated patients of 4.3%. 
This is greater than that reported in the study by Carpenter et al., in which only 0.9% of 
Alemtuzumab-treated patients developed PTLD
409
, although it is within the range report by 
other studies
412,414,415,500
. However, it is notable that around a third of patients in the Carpenter 
study received Alemtuzumab ‘in the bag’ (in which the drug is used to treat the stem cell graft 
in vitro, before it is infused into the recipient) rather than in vivo, whereas the latter was used 
for all patients in the present study. Higher peak concentrations and persistence of 
Alemtuzumab have been reported when it is used in vivo
577
, and this is also associated with 
delayed reconstitution of EBV-specific immunity
383
. These alternative approaches to TCD 
may account for at least some of the variation observed in PTLD incidence between these 
studies. 
 
Regarding the kinetics of EBV DNAemia, most cases of EBV reactivation occurred between 
2 and 4 months after transplant, with reactivations in ATG-treated patients typically occurring 
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earlier than in those treated with Alemtuzumab. However, some instances were documented 
up to and beyond 12 months. Given this, it is notable that recent guidelines have advised that 
high risk patients should be monitored for 3 months after allo-HSCT
496
. The current study 
supports extending this recommendation to 6 months, at least for Alemtuzumab-treated 
patients. Furthermore, given that over 80% of high-level reactivations were seen to occur 
within 2 weeks of initial EBV qPCR positivity, particular scrutiny should be exercised in the 
first weeks following initial EBV qPCR positivity. 
 
Amongst patients who developed high-level EBV reactivation, with or without PTLD, 
excellent response rates to pre-emptive Rituximab therapy were observed, with 38/41 (93%) 
patients exhibiting complete resolution of EBV DNAemia. However, 3 patients developed 
Rituximab-refractory PTLD and died from progressive disease, despite the use of cytotoxic 
chemotherapy in 2 of them. Unfortunately, although chemotherapy such as CHOP may 
achieve good outcomes for Rituximab-refractory disease in the setting of solid organ 
transplantation, this has not been the case for PTLD arising after allo-HSCT, where very poor 
outcomes are likely to be a consequence of increased toxicity in this patient group
520,572
. In 
light of these experiences we now recommend that all patients developing Rituximab-
refractory PTLD are treated with EBV CTLs. Notably, some studies have recently raised 
concerns about the safety of Rituximab in recipients of allo-HSCT, demonstrating a possible 
excess of infectious complications, although an effect on survival has not been 
established
507,575,576
. Given this, it is notable that the use of pre-emptive Rituximab was not 
associated with an increase in mortality in the present study, although this analysis was based 
on a relatively small number of events and it may have lacked statistical power.  
 
4. Results 
Page 144   
 
Of possible predictors for EBV reactivation we found that ATG treatment, older age at 
transplant and the occurrence of acute GvHD were all significant risk factors. In this respect, 
our data agree with previous studies on risks associated with EBV reactivation and PTLD 
after allo-HSCT
392
. However, the most striking finding was a dramatically reduced incidence 
of EBV reactivation and PTLD amongst patients with a diagnosis of NHL. Therefore, 
individuals with NHL exhibited a highly significant reduction in the risk of EBV reactivation 
in both univariate and multivariate analyses, and no patients with NHL exhibited high-level 
reactivation. Whilst our data should be treated with some caution due to the retrospective 
nature of the study, our observation is intriguing because it raises the possibility that 
Rituximab therapy delivered prior to transplant might be responsible for this effect. In support 
of this we found that individuals with HL did frequently experience EBV reactivation - 
patients with HL do not routinely receive treatment with Rituximab. Furthermore, our 
observations are consistent with the anecdotal description by Savani et al. of an absence of 
EBV reactivation after allo-HSCT in 38 patients who received Rituximab prior to, or 
concurrent with, transplantation
574
. Although our findings have not been observed in other 
studies of EBV reactivation and PTLD after allo-HSCT, this may be because these studies 
pre-date the routine use of Rituximab for patients with NHL
392,407
, or because they have not 
specifically analysed the risks associated with NHL
408,410,411,416-419
. Notably, in the study by 
Carpenter et al., NHL showed a trend towards lower incidence of EBV reactivation (HR 0.68; 
CI 0.25–1.85) but this was not statistically significant (P = 0.45); however it is unknown what 
type of NHL these patients had, or indeed whether they had ever received Rituximab
501
.  
 
It light of the above, it is possible that Rituximab delivered shortly before transplant might be 
a highly effective alternative to pre-emptive strategies for managing PTLD. Conceivably, 
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Rituximab might prevent EBV reactivation through 1 of 2 alternative mechanisms. Firstly, it 
has a half-life of up to 18 days, with levels remaining detectable in the serum for up to 3 
months after administration, and it is known to deplete circulating B-cells for around 6 
months
497
. As such, prior Rituximab might contribute to a delay in the recovery of B-cells 
post-transplant. Indeed, van Dorp et al. demonstrated a significantly reduced rate of B-cell 
reconstitution in patients who had received Rituximab within 6 months prior to transplant
578
. 
Alternatively, Rituximab may act by reducing recipient pre-transplant virus burden. 
Interestingly, the latter supposes that it is predominantly recipient-derived virus that most 
commonly leads to EBV reactivation. With regard to this, a small number of (largely 
anecdotal) studies have demonstrated that patients with EBV reactivation or PTLD arising 
after allo-HSCT acquire a donor or third party EBV strain in approximately 50% of cases
579-
582
. However, it is notable that all such studies have been conducted in the setting of 
myeloablative transplantation; it is possible that RIC transplantation may increase the 
likelihood that recipient-derived virus is important for the pathogenesis of EBV reactivation 
and PTLD post allo-HSCT. 
 
To conclude, in this study we have examined EBV reactivation and PTLD amongst a large 
cohort of adult patients undergoing TCD allo-HSCT. Importantly, we describe the novel 
finding that risk of EBV reactivation appears to be greatly reduced amongst recipients with 
NHL. This suggests that Rituximab could be used as effective prophylaxis for PTLD arising 
after allo-HSCT. Ultimately, our data make a strong case for prospectively evaluating the role 
of Rituximab in allograft conditioning. 
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5. Studies on the Persistence of EBV in Patients Undergoing Allo-HSCT 
 
As we have seen, EBV reactivation is a relatively common event following allo-HSCT. 
Nevertheless, much of the pathophysiology of this process remains poorly characterised. 
Given that healthy individuals, and immunocompromised solid allograft recipients with raised 
circulating EBV loads, are thought to selectively harbour EBV in resting CD27
+
 memory B-
cells
315-317,386
, we were intrigued by the fact that most patients who reactivate EBV following 
allo-HSCT typically do so between 2 - 3 months after transplant, when the reconstituting B-
cell system usually contains few memory B-cells
363-365
. In order to investigate this apparent 
paradox, studies were undertaken to characterise the relationship between EBV reactivation 
and B-cell reconstitution in a cohort of patients undergoing allo-HSCT. 
 
5.1 Patients 
Study patients were recruited from those undergoing allo-HSCT at University Hospital 
Birmingham, UK (the same cohort as analysed in Chapter 4). As mentioned previously, all 
patients undergoing T deplete allo-HSCT at this centre (who are thus considered to be at 
increased risk of developing PTLD) are monitored using EBV qPCR analysis of whole blood 
samples, with testing performed every 1 - 2 weeks for at least 6 months post-transplant. This 
clinical EBV qPCR monitoring system was used to identify patients exhibiting high-level 
EBV reactivation who were subsequently approached and asked to provide a blood sample, 
prior to the routine administration of Rituximab to treat the EBV reactivation. 
 
Using this strategy, 13 patients who had undergone consecutive allo-HSCT and subsequently 
developed high-level EBV reactivation (defined here as an EBV load ≥2 x104 EBV copies/ml) 
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within 6 months of transplant were identified. Blood samples obtained from this ‘High EBV’ 
group were processed to isolate PBMCs which were then cryopreserved. In addition, samples 
were obtained for an age- and sex- matched control group of 16 allo-HSCT patients who did 
not develop high-level EBV reactivation at any time post-transplant; known as the ‘No/Low 
EBV’ group. Table 20 shows the characteristics of all study patients.  
 
High EBV Group 
For those in the ‘High EBV’ group, the age at transplant was median 57 years (range 34 – 67) 
and 10/13 (77%) patients were male. All patients had undergone reduced intensity preparative 
conditioning with FMC, apart from Patient 1 who underwent myeloablative conditioning with 
Cyclophosphamide/TBI. The indication for transplant was treatment of AML or 
myelodysplasia in 11/13 (85%) patients, with 1 patient undergoing transplantation for HL and 
another for CLL. None of the patients had evidence of primary disease relapse at the time of 
high-level EBV reactivation.  
 
Figure 18 shows plots of serial whole blood EBV qPCR testing for each patient in the High 
EBV group, indicating the time point at which each was bled during the EBV reactivation. 
Importantly, these plots demonstrate that each patient was bled at or near to the point of 
maximal EBV load during the reactivation. The kinetics of viral DNAemia were similar 
amongst these patients, with a median interval from transplant to first EBV qPCR positivity 
(defined as a single EBV qPCR test ≥500 genomes/ml) of 99 days (IQR 84 – 119 days). All 
patients showed a rapid expansion in EBV load, with a median interval from first EBV qPCR 
positivity to high-level EBV DNAemia of only 7 days (IQR 0 – 14 days).  The EBV load at 
first EBV qPCR positivity was median 2.9 x10
3 
genomes/ml, whilst the EBV load at the time  
5. Results 
Page 149  
 
High EBV Group       
No. Age Sex Diagnosis Donor Regimen 
Acute GvHD 
(grade) 
Peak EBV 
(copies/ml) 
PTLD 
1 34 M AML MUD Cy TBI C II+ 4,346,790 + 
2 57 M AML MUD FMC II+ 216,452  
3 57 M AML MUD FMC I 160,389  
4 55 M AML MUD FMC II+ 33,051  
5 64 M MDS MUD FMC II+ 1,805,490 + 
6 51 M AML MUD FMC I 141,098  
7 61 M AML MUD FMC  97,302  
8 48 M HL MUD FMC II+ 26,897  
9 57 F CLL MUD FMC II+ 154,0170  
10 57 M AML Sibling FMC I 94,945 + 
11 67 F MDS MUD FMC  1,670,830  
12 61 M AML MUD FMC II+ 535,988  
13 50 F AML Sibling FMC I 249,749  
         
No/Low EBV Group       
No. Age Sex Diagnosis Donor Regimen 
Acute GvHD 
(grade) 
Peak EBV 
(copies/ml) 
PTLD 
14 55 M AML MUD FMC  966  
15 61 M AML MUD FMC  1,798  
16 65 M AML Sibling FMC II+ 3,203  
17 51 F ALL Sibling FMC I 3,648  
18 57 M MDS MUD FMC I <500  
19 54 M ALL MUD FMC I 3,291  
20 54 F HL Sibling FMC II+ 4,241  
21 58 M T-PLL Sibling FMC  3,800  
22 62 M AML MUD FMC  1,339  
23 64 M AML MUD FMC I 1,230  
24 70 F AML MUD FMC  <500  
25 66 M AML MUD FMC II+ 1,370  
26 53 M AML Sibling FMC  <500  
27 61 M MDS Sibling FMC  550  
28 44 M MF MUD FMC  <500  
29 47 F AML MUD FMC I <500  
Table 20. High EBV and No/Low EBV Allo-HSCT Patients  
Characteristics for the High EBV (≥20,000 EBV copies/ml) and No/Low EBV (<5000 EBV 
copies/ml) groups of allo-HSCT patients are shown. 
5. Results 
Page 150   
 
 
High EBV 1
0 60 120 180 240 300
102
103
104
105
106
107
Days Post Transplant
C
o
p
ie
s
 /
 m
l
High EBV 2
0 60 120 180 240 300
10 2
10 3
10 4
10 5
10 6
10 7
Days Post Transplant
C
o
p
ie
s
 /
 m
l
High EBV 3
0 60 120 180 240 300
102
103
104
105
106
107
Days Post Transplant
C
o
p
ie
s
 /
 m
l
High EBV 4
0 60 120 180 240 300
10 2
10 3
10 4
10 5
10 6
10 7
Days Post Transplant
C
o
p
ie
s
 /
 m
l
High EBV 5
0 60 120 180 240 300
102
103
104
105
106
107
Days Post Transplant
C
o
p
ie
s
 /
 m
l
High EBV 6
0 60 120 180 240 300
10 2
10 3
10 4
10 5
10 6
10 7
Days Post Transplant
C
o
p
ie
s
 /
 m
l
High EBV 7
0 60 120 180 240 300
102
103
104
105
106
107
Days Post Transplant
C
o
p
ie
s
 /
 m
l
High EBV 8
0 60 120 180 240 300
10 2
10 3
10 4
10 5
10 6
10 7
Days Post Transplant
C
o
p
ie
s
 /
 m
l
†
†
5. Results 
Page 151  
 
 
Figure 18. Serial Whole Blood EBV Loads for High EBV Allo-HSCT Patients 
Patients with high-level EBV DNAemia were identified by routine clinical EBV qPCR 
monitoring. Blood samples were collected prior to the initiation of Rituximab, as indicated by 
the vertical lines. Values below the 500 EBV genome copies/ml sensitivity of the assay are 
displayed as 250 copies/ml.† indicates death of the patient within the first 300 days; Patient 5 
died from PTLD, Patient 6 from relapsed AML and Patient 9 from pneumonia. 
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of first high-level DNAemia was median 9.8 x10
4
 genomes/ml. Peak EBV load was median 
1.9 x10
5
 genomes/ml. 
 
Of those with high-level EBV reactivation, Patients 1, 5 and 10 were diagnosed with PTLD. 
For these, radiographic evidence of disease was documented at 16, 9 and 1 day(s) after first 
detection of the high EBV load respectively. All exhibited B symptoms at presentation and 
Ann-Arbor stage was III, IV and II respectively. A lymph node biopsy was performed for 
Patient 10, confirming EBER
+ 
polymorphic PTLD. A tissue biopsy was not obtained for 
Patients 1 and 5 and therefore a diagnosis of probable PTLD was made. 
 
All patients with high-level EBV DNAemia were treated pre-emptively with up to 4 infusions 
of Rituximab 375mg/m
2
. Twelve of the 13 patients had a complete response to Rituximab, 
with durable resolution of EBV DNAemia and disease where present (Figure 18). Although 
Patient 5 showed an initial response to Rituximab, with a reduction in EBV load to an 
undetectable level, this rapidly relapsed and the patient subsequently died from progressive 
PTLD.  
 
No/Low EBV Group 
For patients in the No/Low EBV group, median age at transplant was 57 years (44 – 70 years) 
and 12/16 (75%) were male. All patients had undergone reduced intensity transplantation with 
FMC conditioning. Notably, all had been recruited to the study prior to transplant and had 
been bled prospectively, such that cryopreserved PBMCs were available from them at time 
points around 3, 6 and 12 months post-transplant. Despite EBV qPCR monitoring with the 
same frequency and duration as those who developed high-level EBV reactivation, 5/16 
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(31%) of these patients remained EBV qPCR-negative after transplant, whilst the others 
exhibited only low-level EBV reactivation, with a maximal EBV load of only 4.2 x10
3
 
genomes/ml. 
 
Statistical Comparisons between High EBV and No/Low EBV Groups 
Samples from the High EBV group were collected at a median of 109 days post-transplant 
(IQR 92 – 141 days). For the purpose of statistical analysis, all comparisons were made to 
No/Low EBV group samples combined from 3 and 6 month time points, collected at a median 
of 112 days post-transplant (IQR 84 – 169 days). No statistical difference was observed for 
the distributions of post-transplant collection times (P = 0.624) for these groups. All statistical 
comparisons were made using the Mann-Whitney U test. 
 
5.2 Total Lymphocyte Counts 
Simultaneous with the collection of study blood samples, an automated haematology analyser 
was used to determine absolute lymphocyte counts (Figure 19). The No/Low EBV patients 
had lymphocyte numbers at 3, 6 and 12 months post-transplant of median 0.6 x10
9
 cells/L 
(IQR 0.6 – 0.9 x109 cells/L), 1.4 x109 cells/L (IQR 1.0 – 1.9 x109 cells/L) and 1.5 x109 cells/L 
(1.1 – 2.3 x109 cells/L) respectively. These values were noticeably lower than those of a 
control group of 10 healthy adult donors who had a median lymphocyte count of 1.9 x10
9
 
cells/L (IQR 1.4 – 2.3 x109 cells/L), which was within the reference range of the assay of 1.0 
– 4.0 x109 cells/L. The finding of marked lymphopenia which gradually recovered over 
several months is characteristic of lymphocyte reconstitution following allo-HSCT. Notably,  
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Figure 19. Lymphocyte Counts after Allo-HSCT 
Total lymphocyte counts were determined for No/Low EBV, High EBV and healthy adult 
donors using an automated haematology analyser. Median values are shown by the horizontal 
bars. No significant difference was observed between the High EBV and No/Low EBV 
groups. 
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patients with high-level EBV DNAemia had a median lymphocyte count of 1.0 x10
9
 cells/L 
(IQR 0.6 - 1.6 x10
9 
cells/L), which was not significantly different to those of the No/Low 
EBV group, matching for time post-transplant (P = 0.453).  
 
5.3 EBV Loads in PBMCs from Patients after Allo-HSCT 
Circulating EBV DNA (as measured by whole blood PCR) can either be cell-associated or 
extracellular; in the latter it is thought to exist either as fragments of DNA released from 
dying cells or encapsulated viral DNA
385
. With the aim of quantitating EBV genome load in 
the cellular compartment, DNA was extracted from PBMCs and then analysed using a highly 
sensitive in-house EBV qPCR assay. This quantitates both EBV genome copy number and 
equivalent cell number by simultaneously amplifying regions of EBV DNA polymerase and 
cellular β2M genes. Thus, the assay is able to determine average EBV genome copies per cell 
within a given population of cells; by convention values are reported as EBV copies per 10
6
 
cells. 
 
The in-house EBV qPCR assay was used to test PBMCs collected from all study patients and 
those from 27 healthy adult donors (Figure 20). Of the healthy adult controls, 19/27 (70%) 
had detectable EBV loads, amongst whom there was a median of 73 copies per 10
6
 PBMCs 
(IQR 19 – 187 copies per 106 PBMCs). These values are typical of a healthy adult population 
analysed with this assay
299,331,338
. Of the No/Low EBV group 47%, 64% and 73% had 
detectable EBV loads at around 3, 6 and 12 months after transplant, with median EBV loads 
amongst the positive patients of 6.0 x10
2 
copies per 10
6
 PBMCs (IQR 1.3 x10
2
 – 1.3 x103 
copies per 10
6
 PBMCs),  1.8 x10
3 
copies per 10
6
 PBMCs (IQR 7.8 x10
2
 – 1.1 x104 copies per 
10
6
 PBMCs) and 2.7 x10
3
 copies per 10
6
 PBMCs (IQR 2.4 x10
2
 - 9.8 x10
3 
copies per 10
6
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Figure 20. PBMC EBV Loads after Allo-HSCT 
EBV loads within PBMC preparations were determined for No/Low EBV, High EBV and 
healthy adult donors using EBV qPCR. The medians of positive values are shown by the 
horizontal bars. The dotted line represents the level of sensitivity of 10 copies/10
6
 PBMCs 
and undetected values are shown as having a value of 1. Loads in the High EBV group were 
significantly higher (P < 0.0001) than those of the No/Low EBV group for 3 – 6 month time 
points. 
Healthy
0
Months
No / Low EBV
3 6 12
10 - 1
100
101
102
103
104
105
106
107
Months
E
B
V
 c
o
p
ie
s
 /
 1
0
6
 P
B
M
C
High EBV
3 - 6
Months
P < 0.0001
No / Low EBV       High EBV     Healthy
5. Results 
Page 157  
 
PBMCs) respectively. As expected, the samples for patients with high-level EBV reactivation 
contained significantly (P < 0.0001) higher EBV loads, with a median of 5.9 x10
5
 copies per 
10
6
 PBMCs (IQR 1.6 x10
5
 – 1.1 x106 copies per 106 PBMCs). These values are amongst the 
highest ever detected from ex vivo samples in this laboratory. Comparison of the EBV loads 
generated by the whole blood and PBMC EBV qPCR assays showed a relatively poor 
correlation amongst High EBV patients (Appendix, Figure 67). Overall, these findings 
confirmed that the samples collected from High EBV patients contained very high cell-
associated EBV loads. 
 
5.4 Analysis of Main Lymphocyte Subsets 
A flow cytometry panel was designed to distinguish main lymphocyte subsets present within 
PBMCs from healthy adult donors (Figure 21). In this panel, a gate was set to include 
lymphocytes and monocytes on the basis of FSC/SSC profile, after which doublets, CD14
+
 
monocytes and non-viable cells were excluded. Events positive for the pan-lymphocyte 
marker CD45 were then gated to exclude, amongst other contaminating subsets, nucleated 
erythrocytes which may be increased in patients with haematological disease and which often 
possess a FSC/SSC profile similar to lymphocytes. Subsequently, the proportion of CD3
+
 T-
cells, CD3-CD56
+
 NK-cells and CD19
+
 B-cells were quantitated as a proportion of CD45
+
 
lymphocytes. Additional T-cell subsets were also identified, including CD4
+
 and CD8
+
 T-
cells (from which CD4/8 ratios could be determined), as well as CD3
+
CD56
+
 NK/T-cells. 
Furthermore, inclusion of an anti-T-cell receptor α/β antibody made it possible to distinguish 
TCR α/β positive and negative subsets, the latter allowing estimation of TCR γ/δ T-cells. 
Absolute numbers were subsequently calculated from corresponding lymphocyte counts.  
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Figure 21. Flow Cytometry Panel for Main Lymphocyte Subsets 
PBMCs were analysed with multicolour flow cytometry to identify lymphocyte subsets. 
Staining of a representative healthy donor is depicted. After (A) gating on lymphocytes and 
(B) excluding doublets, (C) CD14
+
 monocytes and non-viable cells were excluded and CD45
+
 
lymphocytes were gated. Thereafter, (D) CD19
+
 B-cells, CD3
+
 T-cells and (E) CD3-CD56
+
 
NK-cells were identified. (F) CD3
+
 T-cells were further analysed to identify CD4
+
 T-cells, 
CD8
+
 T-cells, CD3
+
CD56
+
 NK/T-cells and TCRαβ+ T-cells. 
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Using this flow cytometry panel, PBMCs from the No/Low EBV and High EBV groups were 
analysed in order to characterise immune reconstitution after allo-HSCT in the absence, or 
presence, of high-level EBV DNAemia (Figures 22 and 23). PBMCs from 10 healthy controls 
were also tested. 
 
T-Cells and NK-cells 
Analysis of the healthy controls revealed T-cells, as expected, to be the most frequent subset, 
comprising a median 71% (IQR 68 – 75%) of CD45+ lymphocytes (Figure 22). Meanwhile 
NK-cells made up 20% (IQR 16 – 22%) of cells. Within the CD3+ T-cell subset, a median 
CD4/8 ratio of 2.0 was observed and 4.3% were NK/T-cells (Figure 23). Furthermore, 96% of 
CD3
+
 T-cells were positive for TCR α/β, suggesting that up 4% of cells were TCR γ/δ+.  
 
In comparison to healthy donors, analysis of PBMCs from the No/Low EBV control group 
revealed a marked numerical deficiency of all subsets. Notably, NK-cells were the first 
lymphocytes to reconstitute after transplant, comprising 51% (IQR 43 – 59%) of all 
circulating lymphocytes at 3 months. Thereafter, T-cells replaced these as the most common 
subset by 6 months. Further analysis of T-cell subsets revealed a similar proportion of CD8
+
 
and CD4
+
 T-cells to that found within healthy individuals at the 3 month time point, although 
a disproportionate increase in CD8
+
 T-cells at later time points resulted in reversal of the 
normal CD4:8 ratio (Figure 23). 
 
Comparison of data from the High EBV and No/Low EBV groups (matching for time post-
transplant) revealed no significant differences in either the proportion or absolute frequency 
of T-cells (including CD8
+
, CD4
+
 and NK/T T-cell subsets) or NK-cells (Figures 22 and 23). 
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Figure 22. T-Cells and NK-Cells after Allo-HSCT 
T- and NK-cell subsets were determined for No/Low EBV, High EBV and healthy adult 
donors. Upper plots show values as a percentage of CD45
+
 lymphocytes, whilst the lower 
plots show cell numbers. Median values are depicted by the horizontal bars. No significant 
differences were observed between High EBV and No/Low EBV groups. 
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Figure 23. CD4
+
, CD8
+
 and NK/T-Cell Subsets after Allo-HSCT 
CD4
+
 T-cell, CD8
+
 T-cell, CD4:8 ratios and NK/T-cell subsets were determined for No/Low 
EBV, High EBV and healthy adult donors. Except for CD4:8 ratios, all values are a 
percentage of CD3
+
 T-cells. Median values are depicted by the horizontal bars. No significant 
differences were observed between High EBV and No/Low EBV groups. 
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B-cells 
In the healthy controls, B-cells comprised a median 6.1% (IQR 5.1 – 6.2%) of CD45+ 
lymphocytes, with median 116 cells/μl (IQR 86 – 123 cells/μl; Figure 24). In comparison, in 
the No/Low EBV group, the median percentage of B-cells was 9% at 3 months post-
transplant (IQR 4 – 16%), exceeding that found in the healthy donors, although absolute cell 
numbers were considerably lower at 57 cells/μl (IQR 31-169 cells/μl). However, by 6 months 
approximately normal B-cell frequency was observed, with a median of 109 cells/μl (IQR 80 
– 227 cells/μl). Furthermore, by 12 months post-transplant, B-cell numbers were supranormal, 
comprising 10% (IQR 8 – 14%) of circulating lymphocytes, with median 162 cells/μl (IQR 
100 – 263 cells/μl).  
 
Importantly, the proportion of B-cells was increased in the High EBV group compared to the 
No/Low EBV group (matching for time post-transplant) at 17% (IQR 7 – 24%) versus 8% 
(IQR 5% - 15%), with borderline significance (P = 0.079; Figure 24). The absolute number of 
B-cells was also increased with median 168 cells/μl (96 – 182 cells/μl) compared to 92 
cells/μl (IQR 49 – 188 cells/μl) although this analysis lacked statistical significance (P = 
0.178). 
 
5.5 Characterisation of B-Cell Subsets 
A second multicolour flow cytometry panel was designed to analyse B-cell subsets (Figure 
25). In this panel, a gate was set to include lymphocytes and monocytes on the basis of 
FSC/SSC profile, after which doublets, CD14
+
, CD3
+
, CD56
+
 and non-viable cells were all 
excluded before gating on CD19
+
 B-cells. In this way, great care was taken to exclude non-B-
cell contaminants; CD3
+
 T-cells present after HSCT often exhibit CD27 positivity and thus  
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Figure 24. B-Cells after Allo-HSCT 
B-cells were enumerated in No/Low EBV, High EBV and healthy adult donors. The upper 
plot shows values as a percentage of CD45
+
 lymphocytes, and the lower plot shows cell 
numbers. Median values are depicted by the horizontal bars. The proportion of B-cells in the 
High EBV group was higher than that of the No/Low EBV group with borderline significance 
(P = 0.079). A non-significant (P = 0.178) increase in cell number was also observed. 
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Figure 25. Flow Cytometry Panel for B-Cell Subsets 
PBMCs were analysed with multicolour flow cytometry to identify B-cell subsets. Staining of 
a representative healthy donor is depicted. After (A) gating on lymphocytes (B) doublets were 
excluded after which (C) CD14
+
 monocytes, CD3
+
 T-cells, CD56
+
 NK-cells and non-viable 
cells were excluded, and CD19
+
 B-cells were gated. Thereafter (D) CD27
-
IgD
+
 naive, 
CD27
+
IgD
-
 CSM, CD27
+
IgD
+
 NSM and CD27
-
IgD
-
 other B-cell subsets were identified. 
Plasmablasts (PB) were identified as a CD38
++
 subset of CSM cells. Transitional B-cells 
(Trans) were identified as a CD38
++
CD24
++
 and CD10
+
 subset of naive B-cells. 
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can be misinterpreted as CD27
+
 memory B-cells unless care is taken to exclude them from the 
CD19
+
 population. CD19
+
 B-cells were then separated on the basis of surface IgD and CD27 
staining into CD27
-
IgD
+
 naive B-cells, CD27
+
IgD
-
 CSM B-cells, CD27
+
IgD
+
 NSM B-cells 
and CD27
-
IgD
-
 B-cells. This panel was also designed to identify additional subsets by co-
staining for CD24, CD38, CD10 and CD20. As such, transitional B-cells could be identified 
as a subset of the naive B-cells on the basis of CD38
++
CD24
++
 staining, with additional 
phenotypic confirmation provided by CD10
+
 surface expression. Furthermore, plasmablasts 
could be identified as a CD38
++
 subset of CD19
+
CD27
+
 B-cells.  
 
Using this panel, PBMCs from No/Low EBV and High EBV groups were compared to each 
other and those from 10 healthy donors. Representative staining data is shown in Figure 26, 
and a summary for all patients is shown in Figure 27. This revealed notable differences in the 
balance of naive and memory B-cells in these groups. In healthy donors, naive B-cells were 
shown to be the most common subset, comprising 68% (IQR 59 – 75% ) of all B-cells, of 
which only a small proportion exhibited a transitional cell phenotype, at a median 7% (IQR 5 
– 8%; Figure 28). Meanwhile CD27+ B-cells comprised median 29% of B-cells (IQR 22 – 
40%; Figure 27). 
 
Unlike in the healthy controls, almost all B-cells in the No/Low EBV patients were found to 
exhibit a naive phenotype, and this pattern persisted that for at least 12 months post-transplant 
(Figure 27). Furthermore, these naive B-cells showed a predominantly transitional cell 
phenotype that gradually declined over time (Figure 28). Consistent with these findings, a 
marked delay in the reconstitution of CD27
+
 memory B-cells was observed (Figure 27). Even 
at 12 months post-transplant, memory B-cells were only median 9% (IQR 4 – 12%) of total  
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Figure 26. Memory B-Cell Expansion in Patients with EBV DNAemia after Allo-HSCT 
Staining for B-cell subsets is shown for representative No/Low EBV, High EBV and healthy 
adult donors. The No/Low EBV patient (Patient 17) was bled 98 days post-transplant when 
EBV load was undetectable by the clinical whole blood EBV qPCR assay. The High EBV 
patient (Patient 9) was bled 101 days post-transplant during a high-level EBV reactivation 
when EBV load was 1.54 x10
6 
copies/ml. CD27
+
 B-cells are scarce in the No/Low EBV 
patient compared to the healthy individual. A striking increase in the proportion of CD27
+
 B-
cells is observed in the High EBV patient. 
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Figure 27. Variation in Memory and Naive B-Cells with EBV Load after Allo-HSCT 
Memory (CD27
+)
 and naive (CD27
-
IgD
+)
 B-cell subsets were determined for No/Low EBV, 
High EBV and healthy adult donors. The upper plots show values as a percentage of CD19
+
 
B-cells and the lower plots show cell numbers. Median values are depicted by the horizontal 
bars. A highly significant increase in both the percentage (P < 0.0001) and number (P < 
0.0001) of memory B-cells was seen in the High EBV group in comparison to the No/Low 
EBV group.  
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Figure 28. Transitional B-Cells after Allo-HSCT 
Transitional B-cells (CD27
-
IgD
+
CD38
++
CD24
++
) were determined for No/Low EBV, High 
EBV and healthy adult donors. A. Representative flow cytometry plots for each group 
showing the gate used to identify transitional B-cells. B. Summary of data for all donors. 
Values are shown as a percentage of naive (CD27
-
IgD
+
) B-cells. Median values are depicted 
by the horizontal bars. Naive B-cells exhibit a predominantly transitional B-cell phenotype 
following allo-HSCT that resolves over time. No significant difference was observed between 
High EBV and No/Low EBV groups. 
3 6 12
0
20
40
60
80
100
Months
%
 o
f 
N
a
iv
e
 B
 C
e
ll
s
3 - 6
Months
Healthy
Months
No/Low EBV      High EBV   Healthy
B.
A.
CD24
C
D
3
8
7.3%86% 78%
HealthyNo / Low EBV High EBV
C
D
1
9
+
 C
D
2
7
-
Ig
D
+
5. Results 
Page 169  
 
B-cells, and a corresponding delay in the recovery of absolute memory B-cell numbers was 
found.  
 
However, analysis of B-cell phenotypes in the High EBV group revealed a striking difference 
to the No/Low EBV group, with marked increases in both the proportion and number of 
CD27
+
 memory B-cells. Thus, in the High EBV group, CD27
+
 B-cells were found to make up 
median 49.1% (IQR 13.7 – 60.8%) of total B-cells. This was a highly significant (P < 0.0001) 
increase compared to No/Low EBV patients (matching for time post-transplant), in whom 
memory B-cells were only median 2.3% (IQR 1.5 – 6.5%). Furthermore, a highly significant 
(P < 0.0001) increase was observed in the absolute number of memory B-cells, with median 
49 cells/μl (IQR 21.6 – 89.4 cells/μl) in the High EBV group compared to 4.1 cells/μl (IQR 
0.7 – 6.9 cells/μl) for No/Low EBV patients. These findings are highly suggestive that 
memory B-cell expansions are associated with high-level EBV DNAemia following allo-
HSCT.  
 
Data were also analysed to characterise the proportion of B-cells with CSM and NSM 
phenotypes (Figure 29). In healthy donors, CSM were shown to comprise median 13% (IQR 9 
– 15%) of B-cells, whereas NSM made up median 15% (IQR 13 – 18%). Importantly, in High 
EBV patients almost all of the expanded memory B-cell population was seen to exhibit a 
CSM phenotype, with very few NSM cells apparent (Figure 29).  
 
The proportion of CD27
+ 
memory B-cells exhibiting plasmablastic phenotype (CD38
++
) was 
also determined (Figure 30). As expected, in the healthy controls these comprised only a 
small proportion of memory B-cells, at median 5% (IQR 3 – 9%). However, analysis of High  
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Figure 29. Variation in B-Cell Subsets with EBV Load after Allo-HSCT 
Naive (CD27
-
IgD
+
), CSM (CD27
+
IgD
-
), NSM (CD27
+
IgD
+
) and -/- (CD27
-
IgD
-
) B-cell 
subsets were determined for No/Low EBV and High EBV groups at 3 - 6 months post-
transplant, as well as for healthy donors. The upper plot shows values as a percentage of 
CD19
+
 B-cells, and the lower plot shows cell numbers. Median values are depicted by the 
horizontal bars. 
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Figure 30. Plasmablastic Phenotype of Memory B-Cells after Allo-HSCT 
The proportion of CD27
+
 memory B-cells exhibiting a plasmablastic phenotype (CD38
++
) was 
determined for the High EBV group and healthy donors. A. Representative healthy and High 
EBV donors. B. Summary of data for healthy and High EBV donors. All values are a 
percentage of CD19
+
CD27
+
IgD
-
 memory B-cells. Median values are depicted by the 
horizontal bars. A highly significant increase in the proportion of plasmablasts was observed 
in the High EBV group (P < 0.0001). 
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EBV patients revealed, remarkably, that the majority of CD27
+
 B-cells possessed 
plasmablastic phenotype, comprising median 88% (IQR 72% - 95%). 
 
5.6 Surface Immunoglobulin Expression 
An additional flow cytometry panel was designed to analyse B-cell surface Ig expression 
(Figure 31). After gating to identify CD19
+
 B-cells (in the same way as for the B-cell flow 
cytometry panel; Figure 25), cell-subsets were determined according to surface Ig-M, -D, -G 
or -A expression. Figure 32 shows data for 9 of the High EBV patients with the greatest 
proportion of CD27
+
 B-cells, and 3 healthy controls. This revealed that a substantial 
proportion of the CD27
+
 B-cells present in each patient were positive for surface IgG, and to a 
lesser extent surface IgA. This confirms that the majority of CD27
+
 B-cells found in patients 
with EBV DNAemia after allo-HSCT have undergone class switch recombination and can 
therefore be considered as true memory B-cells. 
 
5.7 CD27
+
 B-Cell Expansions are Coincident with EBV Reactivation  
Further investigation was undertaken to ascertain if the CD27
+
 B-cells expansions detected in 
patients with high-level EBV DNAemia appear co-incident with EBV reactivation or whether 
they are pre-existing (Figure 33). For 6 High EBV patients, cryopreserved PBMCs were 
available from time points preceding the EBV reactivation. From these, samples were selected 
that had been collected a median of 32 days (range 16-73 days) before those at the point of 
high-level EBV DNAemia. DNA extracted from these cells was analysed using the in-house 
EBV qPCR assay, and this confirmed that the EBV loads in these were significantly 
(<0.0001) lower than in the corresponding high-level EBV reactivation samples; they were 
similar to those from the No/Low EBV patients. The PBMCs were then analysed using the  
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Figure 31. Flow Cytometry Panel for Surface Immunoglobulins 
PBMCs were analysed with multicolour flow cytometry to analyse surface Ig expression. 
Staining of a representative healthy donor is shown. CD19
+
 B-cells were first gated using the 
same method as for Figure 25. Thereafter, CD27 and IgM staining was used to identify naive 
(CD27-IgM
+
), IgM
-
 memory (CD27
+
/
-
IgM
-
) and IgM
+
 memory (CD27
+
IgM
+
) subsets. Each of 
these subsets was co-stained with IgG and IgA, showing that only the IgM
-
 memory subset 
was positive for either. IgD staining of the IgM
+
 memory subset was used to distinguish NSM 
(IgD
+
) and IgM only (IgD
-
) subsets. 
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Figure 32. Surface Immunoglobulin Expression on B-Cells after Allo-HSCT    
B-cell surface Ig expression was analysed for High EBV patients and healthy controls.  A. 9 
High EBV patients, ordered from greatest to lowest proportion of memory B-cells. B. 3 
healthy donors. All values are a percentage of CD19
+
 B-cells. The following B-cell subsets 
were identified: Naive (CD27
-
IgM
+
), NSM (CD27
+
IgM
+
IgD
+
), IgM only (CD27
+/-
IgM
+
IgD
-
), 
IgG CSM (CD27
+/-
IgG
+
), IgA CSM (CD27
+/-
IgA
+
), Ig Null (CD27
+/-
IgG
-
IgA
-
).  
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Figure 33. Analysis of Samples Preceding EBV Reactivation 
For 6 High EBV patients, samples collected a median of 32 days (range 16-73 days) prior to  
those at the point of high-level EBV DNAemia were analysed. A. EBV load in PBMCs. B. 
Lymphocyte count. C. CD19
+
 B-cells (upper plot, proportion of CD45
+
 lymphocytes; lower 
plot, cell number). D. CD27
+
 memory B-cells (upper plot, proportion of CD19
+
 B-cells; lower 
plot, cell number). The samples preceding EBV reactivation were significantly different (P < 
0.05) from those at the time of EBV reactivation for all variables except lymphocyte count. 
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main lymphocyte and B-cell subset flow cytometry panels. These analyses showed that both 
the proportion and frequency of CD19
+
 and CD27
+
 memory B-cells in the earlier time points 
were significantly (P < 0.05 in all cases) lower than in the EBV reactivation samples. 
Furthermore, these were similar to those found in the No/Low EBV controls at corresponding 
time points. Overall, it was concluded that the CD27
+
 memory B-cell expansions found in 
patients at the point of high-level EBV DNAemia are not pre-existing, and are probably the 
result of de novo expansion associated with EBV DNAemia.  
 
5.8 Correlation of EBV Loads with Lymphocyte Subset Frequency 
Noting that CD27
+
 B-cells are expanded in patients with EBV DNAemia following allo-
HSCT, further analysis was undertaken to more fully characterise the relationship between 
EBV load and the absolute number of different lymphocyte subsets in these patients. 
Therefore, EBV loads detected in PBMCs were correlated against T-cell, NK-cell, total B-cell 
and CD27
+
 B-cell numbers for all study patients (Figure 34). No significant correlations 
between EBV load and T-cell, NK-cell or total B-cells were observed. However, a highly 
significant correlation was observed between EBV load and the CD27
+
 B-cell subset (P < 
0.0001). This provided good evidence to suggest that CD27
+
 B-cells are the main site of EBV 
persistence in patients with EBV DNAemia following allo-HSCT. 
 
5.9 Analysis of Bulk Sorted Subsets 
We went on to seek direct evidence that EBV is predominantly found in the expanded CD27
+
 
memory B-cell subset in patients following allo-HSCT, by using EBV qPCR to analyse 
FACS-sorted lymphocyte subsets. This was performed by staining 5 – 10 x106 PBMCS on 
each occasion, which were then sorted using a MoFlo cell sorter (Figure 35) to isolate CD27
-
 
5. Results 
Page 177  
 
 
Figure 34. Correlation of EBV Load with Lymphocyte Subsets after Allo-HSCT 
EBV load in PBMCs was correlated against the number of T-cells, NK-cells, B-cells and 
CD27
+
 memory B-cells for all study patients, using Pearson correlation. A highly significant 
(positive) correlation was only seen for the memory B-cell subset (r = 0.61; P <0.0001). 
B Cells
0 100 200 300 400 500
101
102
103
104
105
106
107
Cells /  l
E
B
V
 c
o
p
ie
s
 /
 1
0
6
 P
B
M
C
Memory B Cells
0 50 100 150 200
101
102
103
104
105
106
107
Cells /  l
E
B
V
 c
o
p
ie
s
 /
 1
0
6
 P
B
M
C
T Cells
0 1000 2000 3000 4000
101
102
103
104
105
106
107
Cells /  l
E
B
V
 c
o
p
ie
s
 /
 1
0
6
 P
B
M
C
NK Cells
0 500 1000 1500
101
102
103
104
105
106
107
Cells /  l
E
B
V
 c
o
p
ie
s
 /
 1
0
6
 P
B
M
C
r = -0.10  P = 0.452 r = -0.04  P = 0.787
r = 0.01  P = 0.922 r = 0.61  P < 0.0001
5. Results 
Page 178   
 
 
Figure 35. FACS-Sorting of Lymphocyte Subsets from Patients after Allo-HSCT 
PBMCs were FACS-sorted on a MoFlo cell sorter. Representative sorting for High EBV 
Patient 12 is depicted. A. Lymphocytes and monocytes were gated. B. Doublets were 
excluded C. CD14
+
 monocytes were excluded D. CD19
+
 B-cells were gated, excluding 
CD3
+
 T-cells. E. Staining with CD27 and IgD was used to identify B-cell subsets. In this 
way 3 subsets were isolated: CD27
+
 memory B-cells, CD27
-
IgD
+
 naive B-cells, and non-B-
cells comprising all CD19
-
 lymphocytes and monocytes.  
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IgD
+
 naive, CD27
+
 memory and CD19
-
 non-B-cell subsets. DNA was extracted from the 
sorted populations and analysed, alongside DNA from unsorted PBMCs, using EBV qPCR.  
 
Figure 36 shows the result of analyses for High EBV Patients 6, 9, 11 and 12. For each 
patient, EBV genomes were found to be highly enriched in the CD27
+
 B-cell subset, as they 
are in healthy individuals. Therefore, median 1.2 x10
7
 genomes per 10
6
 cells was recorded for 
the CD27
+
 B-cell subset. In comparison, few genomes (on average <1% of the load found in 
the CD27
+
 subset) were detected in either the naive-B-cell or non-B-cell subsets, comprising 
median 7.8 x10
4
 genomes per 10
6
 naive B-cells, and median 1.1 x10
5 
genomes per 10
6
 non-B-
cells. 
 
5.10 Single Cell Sorting Studies 
Having confirmed that EBV genomes are selectively present within the CD27
+
 B-cell subset 
in High EBV patients, single cell FACS-sorting was then undertaken to determine what 
proportion of these cells carry EBV. This involved FACS-sorting cells into CD27
-
IgD
+
 and 
CD27
+
 B-cells subsets, as described previously, before depositing single cells into individual 
wells of a 96-well plate containing lysis buffer. In total 48 individual cells of each type were 
tested using the in-house EBV qPCR assay. This approach was initially validated in 2 ways. 
Firstly, single cells were FACS-sorted into individual wells of a 96-well plate and then the 
cells were counted using a light microscope. This confirmed that a single cell was present in 
(almost) all wells (data not shown). Secondly, cells from an EBV-positive and EBV-negative 
BL cell line were mixed in known proportions before depositing single cells into 96 well 
plates, which were then tested using EBV qPCR (Figure 37A). This revealed a proportion of 
EBV-positive  wells that closely approximated  the known proportion of EBV-positive and  
5. Results 
Page 180   
 
 
Figure 36. EBV Loads in FACS-Sorted Lymphocyte Subsets from Allo-HSCT Patients  
FACS-sorted lymphocyte subsets isolated from High EBV patients 6, 9, 11 and 12 were 
analysed using EBV qPCR. In each patient, a highly significant enrichment of viral genomes 
was seen in the CD27
+
 memory B-cell subset. Relatively low levels of EBV DNA were 
detected in naive B-cell and non-B-cell subsets. 
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Figure 37. EBV qPCR Analysis of Single FACS-Sorted B-Cells 
To determine the proportion of EBV-positive cells, single cells (N = 48) were FACS-sorted 
into individual wells of a 96-well plate and then tested with EBV qPCR. A. The assay was 
first validated by FACS-sorting mixtures of EBV-positive and EBV-negative Kem-BL cells 
comprising 100%, 50% or 25% EBV-positive cells. The proportion of EBV qPCR-positive 
wells was similar to that expected. B. FACS-sorted naive (CD27
-
IgD
+
) and memory 
(CD27
+
) B-cells from High EBV patients 6, 9, 11 and 12 were tested, demonstrating that up 
to 92% of memory B-cells were positive for EBV DNA. 
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EBV-negative BL cells in the sorted mixtures. 
 
Having validated the approach, single CD27
-
IgD
+
 naive and CD27
+
 memory B-cells from 
Patients 6, 9, 11 and 12 were FACS-sorted into 96 well plates which were then tested with 
EBV qPCR (Figure 37B). Overall this showed that approximately 80% of the CD27
+
 memory 
B-cells present in these patients harbour EBV genomes. Furthermore, none of the naive B-
cells from any of the 4 patients tested positive for EBV genomes. This supports our other data 
to confirm that EBV is selectively carried within the CD27
+
 B-cell subset in these patients. 
 
Using this single cell sorting approach, it was also possible to estimate the genome copy 
number within individual CD27
+
 B-cells (Figure 38). Thus, a median of 19 genomes per cell 
(IQR 10 – 29 genomes per cell) were detected amongst EBV-positive cells from the 4 High 
EBV patients. Importantly, the relatively narrow copy number distribution provides a strong 
indication that most of the circulating EBV genomes in these patients exist in the context of a 
latent viral infection. By contrast, the median cellular EBV copy number in a productively 
infected cell (EBV-positive Akata BL cells induced into lytic cycle by IgG crosslinking) was 
2.4 x10
4
 genomes per cell (IQR 2.5 x10
3
 - 5.7 x10
4
 genomes per cell), reflecting the massive 
genome amplification that occurs during virus replication (Figure 38). Overall, these data 
suggest that high-level EBV DNAemia following allo-HSCT is predominantly an 
accumulation of latently infected CD27
+
 B-cells. 
 
5.11 Quantitative Analysis of EBV Gene Expression in CD27
+
 B-cells  
We speculated that EBV might be driving the expansion of CD27
+
 B-cells in patients with 
EBV DNAemia through a growth transforming infection. Therefore, further investigation was  
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Figure 38. EBV Copy Number in Single Memory B-Cells after Allo-HSCT 
EBV genome copy number/cell was determined by analysing single FACS-sorted CD27
+
 
memory B-cells with EBV qPCR. The distribution of EBV copies in individual cells from 
High EBV patients 6, 9, 11 and 12 is shown. Only cells positive for EBV DNA are displayed. 
Medians are depicted by the horizontal bars. As a comparator, AKBM cells induced into virus 
lytic cycle were also analysed. AKBM cells are a derivative of the EBV-positive Akata-BL 
cell line stably transfected with a GFP reporter under control of the BMRF1 EBV lytic cycle 
gene promoter. Single GFP
+
 cells in lytic cycle were FACS-sorted and then tested with EBV 
qPCR. EBV copy number distributions for the High-EBV patients were consistent with 
latently, rather than lytically, infected cells; lytic cells contain a substantially greater number 
of genomes. Notably, a small proportion of AKBM cells had a lower number of EBV copies; 
these cells are likely to be in the early stages of replication, such that they are expressing the 
IE gene BZLF1 but are yet to replicate their viral DNA. Data for sorted AKBM cells courtesy 
of Dr A. Bell, University of Birmingham. 
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undertaken to determine viral gene expression in these cells using RT-PCR. Importantly, 
whereas previous studies have examined virus gene expression in ex vivo samples using non-
quantitative RT-PCR methods
315,319,320,386,583,584
, quantitative RT-PCR was employed. This 
was performed using a novel technique recently established in our laboratory, involving a 
Fluidigm gene expression array chip with the capacity to simultaneously analyse up to 48 
different transcripts from very small amounts of RNA
551
. These were quantified relative to a 
specifically designed plasmid standard, carrying all of the target sequences. In this way, target 
transcripts could be properly quantitated relative to one another. 
 
To perform this analysis, PBMCS from Patients 6, 9 and 12 were first FACS-sorted to isolate 
CD27
+
 B-cells, from which total RNA was extracted and then converted to cDNA. This was 
then analysed using the Fluidigm gene expression array to quantify target EBV latent and 
lytic transcripts, and cellular transcripts used as normalisation controls. Data was compared to 
that from EBV-positive cell lines including LCLs expressing the Latency III pattern of gene 
expression, the Rael-BL cell line expressing Latency I, and the Akata-BL cell line induced 
into lytic cycle. 
 
Initially, viral transcripts levels were analysed by expressing them relative to those of the 
cellular housekeeping gene PGK1 (Figure 39A). This revealed similar, albeit marginally 
lower, levels of the EBER1 transcript compared to that found in LCLs. This provided good 
evidence to confirm that EBV is indeed harboured at high frequency in the CD27
+
 B-cell 
subset in these patients. However, this finding was not reproduced for other viral transcripts, 
which were seen to be several logs lower than in the LCLs; representative data for EBNA1 
transcripts are  shown in  Figure 39A. This  suggests  that the  EBV genomes found in most  
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Figure 39. EBV Gene Expression in FACS-Sorted CD27
+
 B-Cells 
Quantitative RT-PCR analysis was used to determine EBV gene expression in FACS-sorted 
memory (CD27
+
) B-cells from High EBV patients 6, 9 and 12, and EBV-positive cell lines. 
A. Expression of EBER1 and EBNA1 normalised to the cellular transcript PGK1 in patient 
samples and LCLs. Median values are shown by the horizontal bars. Patient samples 
contained similar levels of EBER1 as found in LCLs but much lower levels of EBNA1 B. 
Patterns of EBV gene expression normalised to EBNA1. Patient samples showed a Latency 
III pattern similar to the Latency III cell line CD
+
OKU LCL and unlike the Latency I cell line 
Rael-BL. Patient samples contained low levels of BZLF1 and gp350 lytic transcripts, unlike 
the high levels seen in AKBM cells induced into lytic cycle. 
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CD27
+
 B-cells in these patients express EBERs but are otherwise transcriptionally silent.  
 
However, in a secondary analysis, viral transcript levels were then expressed relative to those 
of the EBNA1 gene, which is expressed in all forms of latency (Figure 39B). Doing so 
revealed a common transcriptional pattern for the patient samples that closely resembled that 
of the Latency III LCLs, characterised by high levels of Cp-initiated EBNA transcripts, 
EBNA2 and LMPs. Notably, this was clearly different from that of Latency I Rael-BL. 
Furthermore, unlike the induced Akata-BL cells, there were only low levels of the EBV lytic 
cycle genes BZLF1 and Gp350. Overall, these data suggest that the majority of CD27
+
 B-cells 
isolated from patients with high-level EBV DNAemia after allo-HCT carry EBV genomes 
expressing a highly restricted pattern of latent gene expression, but a minority of cells do 
appear to exhibit Latency III expression (with little evidence of lytic cycle expression).  
 
5.12 Activation and Proliferation Status of CD27
+
 Cells 
Cell Size  
Data presented in Section 5.5 (Figure 30) shows that many of the CD27
+
 memory cells found 
in High EBV patients exhibit a plasmablastic phenotype. Given this, further investigations 
were undertaken to explore the activation and proliferation status of these cells. Thus, given 
that lymphocytes are known to increase in size as they transition from an inactive resting state 
into their activated forms, cell size measurements collected during flow cytometry were 
analysed. Thus, values for FSC (forward scatter; a flow cytometric parameter which is 
primarily a measure of cell size) were compared for different B-cell subsets (Figure 40). In 
order to control for day-to-day variation in baseline FSC voltages, these values were corrected 
by expressing them relative to the total lymphocyte population for each sample. Using this  
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Figure 40. Analysis of Cell Size in B-Cell Subsets after Allo-HSCT 
Cell size was analysed as an indicator of activation status. A. The FSC and SSC profile of 
naive (CD27
-
IgD
+
) and memory (CD27
+
) B-cells from a representative High EBV patient, 
demonstrating the larger size (higher FSC) of the memory B-cells. B. Cell size was analysed 
for naive (CD27
-
IgD
+
), memory (CD27
+
IgD
-
) and plasmablastic (CD27
+
CD38
++
) B-cells in 
healthy donors (N=10), and naive and memory subsets from High EBV patients (N=13). FSC 
is expressed relative to the size of the total lymphocyte population for each sample. Memory 
B-cells from High EBV patients had a similar size ratio to that of plasmablasts in healthy 
donors, suggesting a state of activation. 
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approach, the size of CD27
-
IgD
+
 naive, CD27
+
 memory and CD27
+
CD38
++
 plasmablast B-
cells from healthy individuals was found to differ, as expected. Thus, naive B-cells were the 
smallest cells (average size ratio of 0.90; smaller than the average lymphocyte), whilst CD27
+
 
B-cells were larger (average size ratio 0.98; similar to the average lymphocyte) and 
plasmablasts were the largest cells (size ratio 1.16; larger than the average lymphocyte). 
Subsequently, analysis of B-cell subsets in High EBV patients revealed that the CD27
+
 B-
cells had a positive size ratio (average size ratio of 1.24) similar to that of plasmablasts from 
healthy individuals (Figure 40). This supports the view that the CD27
+
 B-cells are in a state of 
activation.  
 
Ki-67 Staining 
To investigate further, flow cytometric measurement of Ki-67 was then performed to 
determine the proliferation status of the CD27
+
 B-cell expansions; Ki-67 is a marker known to 
be expressed exclusively in proliferating cells
585
. To do so, FACS-sorted naive (CD27
-
IgD
+
) 
and memory (CD27
+
) B-cells were first fixed and permeabilised in ethanol before performing  
intracellular staining with a FITC-conjugated anti-Ki-67 antibody or isotype control, after 
which the cells were analysed with flow cytometry (Figure 41). Two LCL lines were stained 
as positive controls, and these exhibited an average of 68% Ki-67
High
 events, in keeping with a 
state of proliferation. In comparison, as expected, both naive and memory B-cells from a 
healthy individual showed <1% Ki-67
High 
events, confirming that they are almost entirely 
resting. Meanwhile, naive B-cells from High EBV patients 6, 9 and 12 showed an average of 
only 5% Ki-67
High
 events, confirming that they are also predominantly resting. However, in 
marked contrast, the CD27
+
 memory B-cell subset from these patients contained an average 
of 50%  Ki-67
High
 cells. This  suggests that  a proportion  of the  memory  B-cells present in  
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Figure 41. Expression of Ki-67 in Memory B-Cells after Allo-HSCT 
Ki-67 expression was determined using intracellular flow cytometry. A. FACS-sorted naive 
(CD27
-
IgD
+
) and memory (CD27
+
) B-cells from a healthy individual and an (unsorted) LCL 
positive control were stained with an anti-Ki-67 antibody  (filled histogram) or isotype control 
(unfilled histogram). B. FACS-sorted naive and memory B-cells from High EBV patients 6, 9 
and 12 were analysed. C. Summary of data for 3 High EBV patients and 2 LCLs (N=2). A 
high proportion of FACS-sorted memory, but not naive, B-cells from the High EBV patients 
were positive for Ki-67. 
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patients with high-level EBV DNAemia after allo-HSCT may be actively proliferating. 
  
5.13 Determination of Surface Immunoglobulin Light-Chain Status 
To assess the clonality of CD19
+
 B-cells and CD27
+
 memory B-cells in High EBV patients, 
cells were stained for surface κ and λ IgL and analysed with flow cytometry (Figure 42). The 
B-cells from healthy individuals showed polytypic IgL, with κ/λ ratios ranging from 1.3 - 1.9 
and 1.3 – 2.0 for total B-cells and CD27+ B-cells respectively. For the 13 High EBV patients, 
analysis of total B-cells also revealed polytypic IgL, albeit with more variability, with κ/λ 
ratios of 0.4 - 6.9. However, analysis of the CD27
+
 memory B-cells showed evidence of IgL 
restriction (defined as a κ/λ ratio <0.1 or >10) in 4 patients, 2 of whom had PTLD. Thus High 
EBV Patients 3 and 10 showed moderate κ restriction, with κ/λ ratios of 11.0 and 11.7 
respectively, whilst Patient 5 showed clear κ restriction with a ratio of 134. Meanwhile, 
Patient 12 showed clear λ restriction with a κ/λ ratio of 0.01. 
 
5.14 Donor or Recipient Origin of CD27
+
 B-cells 
To investigate whether the CD27
+
 memory B-cells observed in patients with high-level EBV 
reactivation were of donor or recipient origin, DNA extracted from FACS-sorted CD27
+
 B-
cells was analysed using microsatellite analysis, performed by the West Midlands Genetics 
Laboratory. This approach is routinely used to monitor the proportion of transplant donor-
derived total lymphocytes or T-cells in patients following allo-HSCT, in order to determine 
the degree of donor chimerism. Comparing to previously determined recipient and donor 
microsatellite marker profiles, using at least 2 informative markers in each case, the CD27
+
 B-
cells derived from patients 6, 9 and 12 were all shown to be of 100% donor origin (data not 
shown). 
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Figure 42. Immunoglobulin Light Chain Expression on B-Cells after Allo-HSCT 
Surface κ and λ IgL status was determined for total CD19+ B-cells and CD27+ memory B-
cells from High EBV patients and healthy controls. Medians are indicated by the solid 
horizontal lines. Dotted horizontal lines mark kappa/lambda ratios of 0.1 and 10. Of 13 High 
EBV patients analysed, 4 had memory B-cells which showed evidence of IgL restriction, as 
determined by a ratios of <0.1 or >10. 
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5.15 Origin of Virus Strains after Allo-HSCT 
Work was also undertaken to investigate the origin (recipient or donor) of EBV strains present 
in patients with EBV reactivation after allo-HSCT. To do so, PCR was used to amplify 
sections of the EBNA3B and EBNA3C virus genes known to exhibit high levels of 
polymorphism. These were then sequenced and compared to a B95.8 reference sequence. This 
approach was used to analyse a series of patients for whom DNA was available from a) the 
recipient at the point of EBV reactivation, b) the recipient before transplant, and/or c) the 
donor. Notably, the PCR reactions were either nested (EBNA3B) or semi-nested (EBNA3C) 
to achieve the high levels of sensitivity necessary for successful amplification from samples 
containing little EBV DNA. All PCR reactions were carried out using high-fidelity DNA 
polymerase to minimise the risk of artefactual base changes, and all efforts were made to 
avoid cross contamination. 
 
Unfortunately, only a limited number of samples were available to screen, and of these 
several could not be used because it proved impossible to amplify sequences from either the 
pre-transplant or donor samples. Nevertheless EBNA3B and EBNA3C sequences were 
successfully amplified for 8 patients (Table 21). These included 3 of the High EBV patients 
studied in preceding sections of this chapter, whilst the remaining 5 were other allo-HSCT 
patients for whom DNA was available. In interpreting the results, it is important to recognise 
several caveats. Firstly, the degree of confidence with which conclusions can be drawn 
regarding the origin of EBV strains varies depending on the samples available for each 
patient. Secondly, multiple EBV strains may simultaneously persist in one individual, and 
therefore the sequences identified may belong to the dominant strain of several present. 
Finally, third party infections should also be considered. 
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The results for individual patients were interpreted as follows: 
 In patients A and B, where all 3 samples were available, donor origin of the 
reactivation strain could be determined with a high degree of confidence because 
reactivation and donor sequences were identical, and there were several informative 
differences compared to the recipient pre-transplant strain. 
 
 In patient C, the reactivation strain was identical to that of the donor for both 
amplicons. However, the strain could not be determined from the pre-transplant 
recipient strain. Furthermore, it is notable that in this case the donor was a sibling, 
which increases the likelihood that donor and recipient shared a common strain of 
virus. Given this the result remains equivocal.  
 
 In patient D, donor origin was suggested by identical matching between reactivation 
and donor strains, although in the absence of a recipient pre-transplant sample it 
cannot be excluded that this strain was also present in the recipient originally 
 
 In patient E, donor origin was suggested by multiple differences between the 
reactivation sample and that of the recipient pre-transplant strain, although alternative 
explanations include that this was a minor strain in the recipient prior to transplant, or 
that a third party infection occurred 
 
 In patient F recipient origin was suggested by identical matching between reactivation 
and recipient pre-transplant samples, although in the absence of a donor sample it 
cannot be excluded that this strain was also present in the donor. 
 
 In patient G, sequences were only available for EBNA3C for the reactivation and 
recipient pre-transplant samples, which were identical. Whilst this may imply recipient 
origin of the reactivation strain, noting that the donor was sibling from who sequence 
information was not available, the result is equivocal. 
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 In patient H, recipient origin was suggested by multiple differences between the 
reactivation sample and that of the donor, although alternative explanations are that 
this was a minor strain in the donor, or that third party infection occurred 
 
Overall, despite the caveats mentioned above, these data suggest that EBV strains present 
during reactivation originate from either donor or recipient. 
 
5.16 Discussion 
Studies exploring EBV infection in immunocompromised transplant patients have generally 
focussed on recipients of solid organ allografts. Given this, several aspects pertaining to the 
pathophysiology of EBV reactivation complicating allo-HSCT have remained poorly 
characterised. As EBV is known to selectively colonise the circulating CD27
+
 resting memory 
B-cell pool in healthy individuals
315-317
, as well as in solid allograft recipients
386,387
, we were 
particularly intrigued by the apparent paradox that EBV most commonly reactivates around 2-
3 months post allo-HSCT, when the reconstituting B-cell compartment normally contains 
scarce quantities of CD27
+
 B-cell memory
363-365
. Speculating as to possible explanations for 
this, we first considered that EBV genomes might be detected in the naive B-cell pool after 
allo-HSCT. Earlier work has suggested that EBV infects naive B-cells in the tonsils of healthy 
individuals
321,330
. Finding such cells in the circulation of allo-HSCT patients would therefore 
be remarkable. However, the alternative possibility, that EBV maintains selectivity for 
circulating B-cell memory after allo-HSCT, would be equally noteworthy. This would raise 
important questions as to how this exclusivity is mediated in the context of the reconstituting 
immune system following allo-HSCT. 
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Study Patients and Sample Collection 
We successfully collected blood samples from 13 patients with high-level EBV reactivation, 3 
of whom were concurrently diagnosed with PTLD. Importantly, these samples were all 
collected at, or near to, the time of peak EBV reactivation, and prior to pre-emptive 
Rituximab therapy. This challenging task was achieved through an innovative approach that 
made use of routine post-transplant EBV qPCR monitoring. Thus, patients were followed 
prospectively, and those who developed significantly elevated EBV DNA were bled as soon 
as possible afterwards. 
 
Our approach to sample collection is remarkable, because it differs substantially from that 
employed by most previous studies of EBV persistence following transplantation. Thus, 
Babcock et al.
386
 and other authors have typically collected samples from patients after solid 
organ allograft, sampling at arbitrary time points without the benefit of prospective EBV 
qPCR monitoring. This is potentially problematic because solid allograft patients often exhibit 
only modestly elevated EBV loads, and these are often chronically raised
384,495,586-588
. 
However, as elegantly demonstrated by the serial whole blood EBV qPCR plots displayed in 
Figure 18, allo-HSCT patients typically exhibit a very rapid and vigorous expansion in EBV 
load that frequently reaches extremely high levels, and which usually occurs during the first 
few months after transplant. Consequently, our approach allowed us to collect blood samples 
containing exceptionally high levels of EBV DNA which, crucially, contained cells that had 
only just appeared in the circulation. Therefore, we were able to study the earliest events 
during EBV reactivation. 
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EBV Loads 
The EBV qPCR assay was used to show that PBMCs isolated from High EBV patients did 
indeed possess extremely high levels of EBV DNA. This is important because it confirms that 
much of the EBV DNA present in patients experiencing EBV reactivation following allo-
HSCT is cell-associated. Such information is not provided by the clinical whole blood EBV 
qPCR assay, which is unable to distinguish EBV DNA present in plasma from that in the 
cellular compartment. Notably, comparison of the EBV loads generated by the whole blood 
and PBMC EBV qPCR assays showed a poor correlation. Although this could reflect 
measurement errors in either assay, it is considerably more likely to indicate variability in the 
proportion of EBV DNA found in cellular versus extracellular compartments.  
 
Interestingly, as shown in Figure 20, it was also apparent that many patients in the No/Low 
EBV group also had somewhat elevated EBV loads in comparison to healthy controls; these 
were around the upper limit of normal observed in the healthy controls. This demonstrates 
that the in house EBV qPCR assay, when used to test PBMCs, is a considerably more 
sensitive technique than the clinical whole blood EBV qPCR assay. More importantly, it 
provides evidence that many patients maintain low levels of circulating EBV during the 
course of allo-HSCT. This is in agreement with previous data that immunocompromised 
transplants patients often have generally increased levels of EBV DNA, and also highlights 
that the presence of circulating EBV DNA per se is insufficient to trigger EBV reactivation.  
  
T-Cell and NK-Cell Reconstitution 
Considerable effort was made to characterise immune reconstitution following allo-HSCT in 
study patients. This revealed patterns of cell recovery amongst the No/Low EBV group that 
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closely resembled those reported by previous studies of immune reconstitution
342,354
. Thus, 
NK-cells were the first lymphocyte subset to recover, predominating in the first months 
following transplant, after which T-cells gradually became the most frequent cell type, with 
reversal of the CD4/CD8 T-cell ratio also apparent. We had speculated that High EBV 
patients might display delayed or otherwise altered levels of T- or NK-cells, which might 
account for the occurrence of EBV DNAemia in these patients. However, this was not the 
case and no significant differences were identified when the No/Low EBV and High EBV 
groups were compared, matching for time after transplant.  
 
These data are interesting when they are considered in the context of  proposals that T-cell 
monitoring might be introduced as an adjunct to EBV qPCR monitoring, to better predict 
which patients should be treated pre-emptively with Rituximab. Thus, Annels et al.
506
 and 
Worth et al.
507
 have both suggested that total CD3
+
 T-cell counts in excess of 300 cells/μl at 
the time of EBV reactivation may identify patients who will spontaneously resolve EBV 
DNAemia, without the need for Rituximab. Meanwhile, other work has suggested that 
detection of EBV-specific T-cell responses at the time of EBV-reactivation is useful in 
identifying those at risk of progressing to PTLD
505,506,589
. Given these findings, it is notable 
that 7/13 patients in our series had CD3
+
 T-cell counts over 300 cells/μl at the time of high-
level EBV reactivation, although it is unknown whether these included EBV-specific T-cell 
responses.  Clearly, in the absence of serial T-cell counts or data on EBV-specific immunity it 
is impossible to predict the outcome for High EBV patients if Rituximab had not been 
delivered. Nevertheless it is intriguing to consider whether these patients might have settled 
their EBV reactivation spontaneously.  
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CD27
+
 Memory B-Cell Expansion 
Analysis of B-cell reconstitution in the No/Low EBV patients revealed prolonged deficiency 
of CD27
+
 memory B-cells that persisted up to and beyond 12 months after transplant. As 
such, our data agree with previous studies of B-cells after allo-HSCT
363-365
, and support the 
interpretation that B-cells reconstitute primarily from newly engrafted donor-derived stem 
cells, rather than by expansion of mature cells transferred across with the graft. 
 
However, a strikingly different pattern was found in High EBV patients, most of whom were 
found to have significant expansions in both the proportion and absolute number of 
circulating CD27
+
 B-cells. Indeed, several patients had CD27
+
 B-cell levels that were supra-
normal in comparison to healthy donors. These data were interpreted as strong circumstantial 
evidence that EBV DNAemia is accompanied by the accumulation of B-cells exhibiting a 
memory B-cell phenotype. Subsequently, this was confirmed by using EBV qPCR to analyse 
FACS-sorted B-cell subsets. For all 4 patients tested this showed enrichment of genomes 
within the CD27
+
 B-cell population, yielding some of the highest EBV loads recorded in ex 
vivo samples in our laboratory, and importantly relatively few (<1%) genomes were found 
within the naive B-cell and non-B-cell subsets. Although it was not possible to confirm the 
memory status of these CD27
+
 cells by molecular means (Ig sequencing was attempted but 
proved impossible due to the small quantities of DNA available) we were able to demonstrate 
surface expression of IgG or IgA on these CD27
+
 B-cell expansions, consistent with them 
being genuine B-cell memory. 
 
These data clearly show that EBV maintains selectivity for the memory B-cell pool following 
allo-HSCT. In this respect our findings agree with Babcock et al. and others who have 
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explored EBV persistence in the solid organ transplant setting
386,387
. Furthermore, they show 
that EBV reactivation can drive the peripheral expansion of these memory B-cells to 
remarkably high levels, even when these cells are normally scarce following allo-HSCT. 
Notably, using single cell sorting experiments we showed that up to 90% of CD27
+
 B-cells in 
patients with EBV DNAemia after allo-HSCT carried EBV genomes (whereas no genomes 
were present in CD27
-
IgD
+
 naive B-cells). This contrasts with the study by Babcock et al. in 
which the highest frequency of EBV-infected cells detected was around 1 in 60 B-cells
386
, and 
even more starkly with the healthy carrier state in which only around 0.001% of memory B-
cells are thought to carry EBV. 
 
Having demonstrated a clear relationship between EBV and B-cell memory following allo-
HSCT, it is nevertheless important to note that we cannot fully exclude the possibility of at 
least some low level carriage of EBV genomes within the naive B-cell compartment. Thus, 
although cell sorting experiments showed enrichment of EBV DNA within the CD27
+
 B-cell 
subset, viral genomes were still detected within sorted naive B and non-B-cell subsets at 
relatively high levels compared to those expected for total B-cells from healthy donors; 
although even a small amount of contamination from the CD27
+
 B-cell subset during FACS-
sorting could explain these findings. In addition, the single sorting experiments only sampled 
48 individual cells, and thus EBV-positive
 
naive B-cells may have been missed by sampling 
error. Furthermore, not every High EBV group patient had particularly raised levels of CD27
+
 
B-cells. In accounting for this, it is notable that there was a relatively wide distribution of 
EBV loads amongst patients with high-level EBV DNAemia, and those with lower loads 
typically had lower CD27
+
 cell frequencies, as one might expect. It is possible that the CD27
+
 
B-cells in these patients may have contained increased EBV genome copies/cell compared to 
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patients with higher CD27
+
 B-cell levels. However, this might also be taken as evidence of 
EBV carriage within CD27
-
 B-cells, or even non-B-cell subsets. The significance of these 
findings remains to be tested, as lack of CD27
+
 B-cells in these patients meant they were not 
investigated further in the present studies. 
 
EBV Copy Number Per Cell 
Single cell sorting experiments were also used to show that EBV-positive CD27
+
 cells from 
the High EBV patients carried an average of 19 EBV genome copies/cell (Figure 38). 
Importantly, the distribution of EBV copies/cell in the allo-HSCT patients was found to be 
several logs lower than that seen for a cell line stimulated in vitro to enter lytic cycle. This 
provided good evidence that the bulk of cell-associated EBV genomes occur in the context of 
latent, rather than lytic, infection in these patients. 
 
Interestingly, our estimate of EBV genome copy number/cell  is similar to those provided by 
other studies which have examined transplant patients. Thus, Rose at al. used fluorescence in 
situ hybridisation (FISH) to demonstrate that EBV-infected cells in the circulation of 
paediatric solid allograft recipients carry 1 - 30 EBV copies/cell; interestingly, those with 
lower EBV loads were found to carry 1 - 2 copies/cell, whereas those with higher EBV loads 
carried some cells with a low number (1 - 2) of copies and other cells with a higher number 
(20-30) of copies
590
. Similarly, Calattini et al. used FISH to show 3 - 35 EBV copies/cell in B-
cells isolated from patients with EBV DNAemia after allo-HSCT
591
. These values contrast 
with estimates for healthy individuals of 2 - 5 copies/cell
313,592,593
, although higher estimates 
averaging around 50 copies/cell have also been made
331
. Meanwhile, although EBV copy 
number in established LCLs was originally reported to range from 5 – 800 copies/cell594, a 
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more recent study used FISH to show around 50 copies/cell
595
. Interestingly, the latter study 
found only 1 - 2 copies/cell in newly infected B-cells but copy number was found to amplify 
to around 20 copies/cell by 3-4 weeks after infection
595
. This intriguing observation leads us 
to speculate that this process may also occur in vivo, and therefore the CD27
+
 B-cells from 
High EBV patients which were found to carry fewer copies/cell (Figure 38) might have been 
infected more recently and/or undergone fewer cell divisions.         
 
EBV Gene Expression 
EBV gene expression was analysed using a novel quantitative RT-PCR method that used 
standardisation against a plasmid containing target EBV sequences, such that different 
transcript levels could be directly compared to each other. For all 3 High EBV patients 
analysed, a complete range of EBV Latency III gene targets were detected in FACS-sorted 
CD27
+
 B-cells. Furthermore, when normalised to EBNA1 transcript levels, the expression 
patterns were easily distinguished from those present in a Latency I BL cell line, or Akata BL 
triggered to exhibit lytic cycle expression. However, normalisation of transcript levels to the 
cellular gene PGK1 revealed EBERs to be expressed at reasonably similar levels to those in 
an LCL but all other viral transcripts were found at disproportionately low levels. This 
probably indicates that only a minority of circulating EBV genomes express the Latency III 
programme in these patients, whilst the bulk of genomes are transcriptionally inactive, except 
for EBERs. However, it could also indicate that levels of Latency III RNAs in vivo are 
considerably lower than those seen in EBV transformed LCLs established in vitro. 
 
Our data are notable in the context of prior studies of EBV gene expression. Thus, RT-PCR 
analysis of circulating lymphocytes from healthy individuals has shown the only consistently 
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detectable EBV transcripts, other than the EBERs and BARTs, to be LMP2A and in some 
studies EBNA1
314,318,319
. These findings have been used to postulate that a highly restricted 
pattern of expression defines the normal carrier state, contrasting with the Latency III 
expression pattern found in PTLD tumours and LCLs. Meanwhile, attempts to analyse EBV 
gene expression in circulating lymphocytes from immunocompromised transplant patients 
have shown mixed results. Thus, Babcock et al. demonstrated only LMP2A expression in 1 of 
4 solid organ transplant patients analysed. Whereas, Qu et al. showed LMP2A expression in 
several solid organ transplant patients, with additional LMP1 transcripts in patients with 
higher EBV loads
584
. Furthermore, Hopwood et al. showed that healthy cardiothoracic 
transplant patients often exhibit either LMP2A expression alone, or alongside one or more 
additional transcripts including EBNA3C, LMP1 or lytic genes, whilst patients with PTLD 
often exhibited a pattern consistent with Latency III including lytic transcripts
583
. This 
demonstrates a notable degree of heterogeneity in the currently available data. However, it 
should be noted that these studies have all used non-quantitative nested RT-PCR methods, 
which give no indication of the relative abundance of transcripts, and therefore they should be 
interpreted with caution. 
 
Activation and Proliferation Status of CD27
+
 B-cells 
Since Babcock et al. have previously demonstrated that EBV-infected B-cells isolated from 
the blood of solid allograft patients are in a resting state
386
, like those of healthy donors, we 
were surprised to find data contrary to this for patients after allo-HSCT. Thus, CD27
+
 
memory B-cells from High EBV patients were found to be strongly positive for CD38, 
suggesting plasmablastic phenotype. They were also considerably larger than resting naive 
and memory B-cells from healthy individuals. Most importantly, a significant proportion 
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(around 50% versus 90% in LCLs) were Ki-67
+
 by flow cytometry. Unfortunately, 
application of the techniques used by Babcock et al. was precluded by limited amounts of 
patient material in the current study. Nevertheless, taken together these data are highly 
suggestive that these CD27
+
 B-cells are activated and that at least a proportion of them are 
proliferating.  
 
These findings are particularly intriguing in light of our EBV gene expression data, which 
showed only low levels of growth transforming EBV Latency III transcripts in the CD27
+
 
memory B-cells from High EBV patients. Reconciling these apparently contradictory 
findings, we propose that circulating CD27
+
 B-cells may have recently exited nodal tissues, in 
which Latency III driven expansion is occurring in the majority of cells, as it does in PTLD. 
We suggest that down-regulation of EBV latent gene expression, from Latency III to more 
restricted patterns, may accompany egress into the circulation, and that progressive exit from 
cell cycle may follow this as a consequence. Indeed, EBV latent proteins typically have half-
lives greater than 24 hours, which might mean that the cells could continue to proliferate for 1 
- 2 divisions after transcription has ceased. Notably, successful identification of cells still 
exhibiting an activated and proliferating is likely to reflect collection of blood samples so 
soon after initiation of EBV reactivation in this study. 
 
Origin of the CD27
+
 B-cells 
In order to further define the pathophysiology of EBV reactivation in study patients, we also 
sought to identify the origin of circulating CD27
+
 B-cells in High EBV patients. Thus, in what 
to our knowledge is the first analysis of its kind, we demonstrated using microsatellite 
analysis that FACS-sorted CD27
+
 B-cells were of 100% donor origin in 3 patients tested. This 
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result is in keeping with the observation that most PTLD tumours arising after allo-HSCT are 
donor-derived.  
 
Despite this finding, uncertainty still remains as to whether circulating EBV-infected CD27
+
 
B-cells in High EBV patients originate from mature B-cells transferred across with the donor 
stem cell graft, or from naive B-cells which have newly differentiated from engrafted donor 
stem cells. At present, we can only speculate as to the exact mechanism. However, the former 
of these possibilities is supported by evidence that mature donor memory B-cells which 
remain responsive to stimulation have been detected in allo-HSCT recipients
596,597
. 
Furthermore, this mechanism is favoured by studies suggesting that graft T-cell depletion 
with ATG, which spares B-cells, leads to increased rates of EBV reactivation and PTLD than 
Alemtuzumab, which also depletes B-cells
392,407,409,415
. Alternatively, this effect may simply 
be a consequence of more profound T-cell depletion with ATG than with Alemtuzumab. On 
the other hand, the observation that EBV reactivation is often delayed until 2-3 months after 
transplant, which is typically when new B-lymphopoiesis begins, supports the competing 
possibility that EBV-infected B-cells usually originate from new naive B-cells. Of course, it 
may be that both phenomena occur, and that transplant conditioning may influence which 
mechanism predominates.  
 
Assuming that EBV-infected B-cells do originate from mature B-cells transferred across with 
the graft, a further consideration is whether EBV-infected resting memory B-cells from the 
donor undergo spontaneous outgrowth in the recipient. Against this, it has been shown that 
when PBMCs from a healthy EBV-infected donor are used to generate spontaneous LCLs in 
vitro, this does not occur by direct outgrowth of EBV-infected B-cells but rather occurs via a 
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2-step process in which EBV-infected B-cells first initiate viral replication, yielding new 
virions that subsequently infect other cells
598
. 
 
Origin of Virus Strains 
Work was also undertaken to determine the origin of EBV strains present in patients 
undergoing EBV reactivation, by comparing EBV sequence polymorphisms in transplant 
recipients, before and after transplant, with those in the donor where available. Bearing in 
mind the caveat that transplant patients may carry multiple virus strains
105
, this nevertheless 
revealed that the dominant post-transplant EBV strain may be of donor or recipient origin. 
Thus, our data agree with a limited number of case reports and small series which have 
previously shown that the post-transplant viral strain is identical to the recipient pre-transplant 
strain in only about half of cases
579-582
. However, it is notable that unlike previous studies, 
which have all been undertaken in patients receiving myeloablative conditioning, our data 
were generated from patients who had undergone RIC transplantation, which conceivably 
might have favoured retention of recipient viral strain post-transplant.  
 
These observations have potentially important implications for our understanding of the 
pathophysiology of EBV infection. Thus, the fact that both donor and recipient strains are 
found after transplant is evidence against spontaneous outgrowth of donor-derived resting 
memory B-cells, as this would invariably lead to acquisition of donor-derived virus strains. 
Furthermore, it also informs the debate as to whether B-cell depletion prior to allo-HSCT (as 
discussed in Chapter 4) operates by reducing levels of recipient-derived virus. Thus, the 
finding that patients often acquire the donor strain is evidence against this possibility. Finally, 
it also provides additional evidence that B-cells, rather than oropharyngeal epithelium, are the 
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principal reservoir of EBV infection. Indeed, if epithelial cells were a site of chronic EBV 
persistence, it could be expected that the pre-transplant strain would invariably be maintained.  
 
A Model for EBV Reactivation after Allo-HSCT 
In a synthesis of the data generated by this and previous studies, we can now propose a model 
for the events of EBV reactivation following allo-HSCT (Figure 43). As such, we suggest that 
underlying all instances of EBV DNAemia is a Latency III growth transforming infection 
which arises in nodal tissues as a consequence of immune compromise. This drives the 
proliferation of EBV-infected cells with a CD27
+
 memory B-cell phenotype, which 
subsequently transit into the circulation. Co-incident with this, there is probably down-
regulation of EBV gene expression and progressive exit from cell cycle, such that a 
proportion of cells temporarily remain Ki-67
+
. The source of the B-cells that contribute to the 
Latency III reactivation may be mature B-cells transferred across with the graft, or newly 
emergent B-cells. Similarly, the virus infecting these cells may derive from either the 
recipient or the donor. These mechanisms may be dictated by the type of transplant 
conditioning used, and the form of T-cell depletion, and/or the time taken for B-cells to 
reconstitute and thus appear as targets for transformation. Although this process is usually 
subclinical, it may progress to established PTLD in some patients if the Latency III-driven 
proliferation in nodal tissues continues, due to a lack of emergent EBV-specific T-cell 
responses or pre-emptive Rituximab therapy. 
 
Significance for Models of EBV Persistence  
Importantly, our finding that EBV maintains selectively for the CD27
+
 memory B-cell 
compartment after  allo-HSCT also carries significance for our understanding of how EBV  
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Figure 43. Model of EBV Reactivation Following Allo-HSCT 
CD27
+
 memory B-cells of transplant donor origin accumulate in the circulation of patients 
with EBV reactivation following allo-HSCT. Many of these cells are Ki-67
+
 and display an 
activated phenotype, although only a minority of Latency III transcripts are detected. We 
propose that these cells originate from a Latency III growth transforming infection taking 
place in the secondary lymphoid tissues (which may progress to PTLD if it is uncontrolled). 
Departure of virally infected cells into the circulation seems to be accompanied by down-
regulation of latent viral gene expression and progressive exit from cell cycle, such that a 
proportion of circulating cells remain Ki-67
+
 for some time. The events preceding this are less 
certain. EBV is found almost entirely within donor derived B-cells in this setting but it is 
unclear whether these are usually mature B-cells which have been carried across with the 
PBSC graft, or whether they derive from new naive B-cells which develop from recently 
engrafted donor haematopoietic stem cells. Although EBV-infected donor B-cells carried 
across with the graft might undergo direct outgrowth, this is not supported by in vitro 
evidence598. It is therefore more likely that uninfected donor B-cells are infected by EBV in 
the transplant recipient. The infecting virus may originate from infected donor B-cells which 
undergo productive lytic cycle following transfer, or from infected host cells (B-cells or 
epithelial cells) that have survived transplant conditioning.  
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achieves this selective colonisation,  in this and other settings. Thus, as mentioned previously, 
competing GC-dependent
329
 and -independent models
41,272,331
 have been proposed to explain 
the route by which EBV enters the B-cell memory reservoir. Considering these in relation to 
allo-HSCT, it is impossible to ignore the likelihood that GCs are significantly disrupted or 
even abolished by the process of allo-HSCT. Indeed, this is likely to be a consequence of the 
destruction of nodal tissues by conditioning therapy, and due to delays in the reconstitution of 
key cell types required for GC activity, including CD4
+
 T-cells. Notably, acute GvHD is well 
recognised to precede EBV reactivation, and it is known to significantly disrupt GC 
formation
377-379
. Consequently, it seems improbable that the circulating CD27
+
 B-cells which 
accumulate in patients with EBV DNAemia after allo-HSCT originate exclusively from naive 
B-cells of donor origin which have been driven through a GC reaction by EBV.  
 
Relevant to these issues, is the interesting finding that CD27
+
 B-cells found in High EBV 
patients were almost entirely confined to the CD27
+
IgD
-
 CSM subset, whereas few, if any, 
had a CD27
+
IgD
+ 
 NSM phenotype. This is remarkable because previous studies have shown 
that EBV can be found within the NSM subset; both in healthy individuals
331
, albeit at lower 
frequency than in the CSM subset, and in patients with genetic disorders that abolish normal 
GC physiology, such as XLP
338
. As discussed previously, the origin of the NSM subset 
remains controversial, although they may arise via GC-independent pathways principally 
located in the spleen
18,72,599,600
. Given these observations, it is challenging to explain why the 
CD27
+
 B-cells found in High EBV patients were almost entirely of CSM phenotype. In one 
interpretation, EBV may preferentially drive naive B-cells to differentiate into memory B-
cells with an exclusively CSM phenotype, in keeping with the GC-dependent model of EBV 
persistence. However, it is notable that our data showed the NSM subset to be impaired 
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relative to CSM cell in all allo-HSCT patients, including those from No/Low EBV patients. 
Thus, NSM cells probably recover at an even slower pace than CSM cells during normal B-
cell reconstitution. Given this, a more likely interpretation may be that EBV simply colonises 
the B-cell subsets available to it, operating via GC- independent pathways.  
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6. Modelling the Clonal Evolution of PTLD in Vitro 
 
Previous studies in this and other laboratories have demonstrated that EBV-transformed B-
cell cultures exhibit clonal outgrowth, such that over a period of several weeks polyclonal 
cultures tend towards oligoclonality and thereafter to monoclonality
236,238,239
. In contrast 
mitogen-stimulated B-cell blasts remain polyclonal for several weeks in culture
236
. 
Importantly, this process of clonal outgrowth in EBV transformed cultures may be a useful 
model to explore the pathogenesis of PTLD. Indeed, factors which may influence clonal 
outgrowth of LCLs in vitro might also be relevant to the progression of early polyclonal B-
cell proliferations to monoclonal lymphomas, reflecting the diversity observed in PTLD 
pathological subtypes. 
 
Much uncertainty remains regarding the processes which might underlie clonal selection and 
outgrowth. Among potential determinants of the contrasting results observed for EBV-
transformed versus B-cell blast cultures, are differences in proliferation and cell survival. 
Furthermore, recent evidence has suggested that DNA damage signalling and/or genomic 
instability may also be important. Thus, Nikitin et al. have described that early EBV-infected 
B-cells exhibit a period of hyperproliferation, causing genomic instability which triggers 
DNA damage response signalling and inhibition of outgrowth for some cells
158
. In order to 
explore these factors as possible determinants of clonal outgrowth, a series of investigations 
were undertaken to compare cell death, proliferation and DNA damage signalling in early 
EBV cultures with those present in mitogen-stimulated B-cell blasts.  
 
It is also possible that cellular mutations caused by EBV might act as an important 
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determinant of clonal selection, by promoting cell survival or proliferation. Indeed, EBV is 
known to induce expression of AID in LCLs
219,227-229
; as discussed previously this enzyme is 
responsible for the mutagenic processes SHM and CSR during B-cell development and has 
been implicated in tumourigenesis. Notably, this laboratory has previously shown that 
dominant clonotypes arising in EBV-infected naive B-cells cultures often contain AID-
induced Ig gene mutations, and these appear to undergo sequence diversification in vitro
601
. 
Furthermore, Epeldegui et al. have demonstrated that following EBV infection of total B-
cells, AID-associated mutations accumulate in non-Ig genes such as BCL6 and p53
244
. 
However, from this earlier study it remains uncertain to what extent these BCL6 mutations are 
de novo events, or whether pre-existing mutations are simply selected during the course of 
clonal outgrowth. To investigate this further, we also sought to characterise BCL6 and other 
‘off target’ AID-associated mutations in EBV cultures established from a range of alternative 
B-cell types, including naive and umbilical cord blood B-cells which do not contain pre-
existing mutations. 
 
6.1 Clonal Outgrowth in EBV and B-Cell Blast Cultures 
Generation of EBV and B-Cell Blast Cultures 
All of the experiments described in this chapter were conducted on EBV-infected or mitogen-
stimulated B-cell cultures. B-cells were isolated from healthy adult donors, or in some 
experiments from umbilical cord samples, using CD19 Dynabead separation. This resulted in 
highly purified B-cell populations (typically >98%), as demonstrated by flow cytometric 
evaluation for CD19 in Figure 44A. For several of the experiments, isolated B-cells were 
subsequently FACS-sorted into CD27
-
IgD
+
 naive, CD27
+
IgD
-
 CSM and CD27
+
IgD
+
 NSM B-
cell subsets as shown in Figure 44B. The 2089 strain of EBV was used to infect B-cells at an  
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Figure 44. Purification of B-Cells from Apheresis Cones and Umbilical Cord Blood 
B-cells were isolated using CD19 Dynabead magnetic separation. When required, they were 
then FACS-sorted into B-cell subsets using a MoFlo cell sorter. A. The purity of B-cells 
isolated with CD19 Dynabeads was confirmed by staining for surface CD19, typically 
revealing purities >98%. This is exemplified here by analysis of purified B-cells from 2 
donors stained with an anti-CD19 antibody (blue histograms) or isotype control (filled grey 
histograms). B. Dynabead purified B-cells were FACS-sorted into CD27
-
IgD
+
 naive, CD27
+
 
IgD
-
 CSM and CD27
+
 IgD
-
 NSM subsets using the gates depicted. 
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B.
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MOI of 50 to generate all EBV-infected cultures unless otherwise indicated. In parallel, 
mitogen-stimulated B-cell blasts were generated by culturing B-cells on irradiated mouse 
fibroblasts stably transfected with human CD40L in the presence of soluble human IL4
554
. 
 
Measurement of Clonal Outgrowth with IgH CDR3  Spectratyping  
Clonal outgrowth in EBV-transformed B-cell cultures was analysed using IgH CDR3 
spectratyping. Previous studies in this laboratory have primarily analysed B-cell clonality by 
sequencing across the VDJ region of the rearranged IgH chain in multiple PCR-generated 
clones; detection of multiple unique IgVH sequences provides evidence of polyclonality, 
whilst detection of identical sequences suggests monoclonality or oligoclonality. However, 
IgH CDR3 spectratyping provides an alternative measure of clonality, using a standardised set 
of primers in a multiplex PCR reaction, to amplify across the IgH CDR3 region
602
. This 
generates multiple fragments which differ in length according to VDJ usage, which are 
subsequently separated on a capillary gel electrophoresis platform to produce a spectratype. 
CDR3 spectratyping has the advantage that many thousands of VDJ rearrangements can be 
analysed in a single experiment, thus providing a greater depth of sampling. In polyclonal 
samples the spectratype approximates a standard distribution curve, whilst in oligoclonal or 
monoclonal samples certain peaks are enriched while others are reduced or absent. 
 
The IgH CDR3 spectratyping technique was initially used to confirm the earlier observation 
of clonal outgrowth within EBV transformed B-cell cultures (Figure 45). Thus LCLs 
generated from either total B-cells or naive B-cells were sampled at intervals following 
infection, and DNA prepared from these was tested to produce serial IgH CDR3 spectratypes. 
As  expected,  at 2 weeks following  infection  the  spectratypes  were  entirely  polyclonal.  
6. Results 
Page 215  
 
 
Figure 45. IgH CDR3 Spectratype Analysis of Clonal Outgrowth in LCLs 
The clonality of LCLs established from adult total B-cells or naive B-cells was analysed using 
IgH CDR3 spectratyping. This technique uses a set of primers to amplify across the IgH 
CDR3 region in a multiplex reaction, generating multiple fragments which differ in length 
(bp) according to VDJ usage. As shown, both cultures are polyclonal at the 2 week time point, 
as evidenced by spectratypes approximating a normal distribution. Thereafter the cultures 
demonstrate clonal outgrowth to oligoclonality and ultimately monoclonality, as apparent 
from the appearance of dominant peaks. 
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However, from 4 weeks there was emergence of dominant clonotypes, leading to readily 
apparent oligoclonality by 6 - 8 weeks after infection. Thereafter, progression to a single 
dominant clonotype was observed in both cases.  
 
As an independent validation of the spectratyping technique, multiple IgVH sequences were 
also obtained from the naive B-cell culture at 8 and 16 week time points (Table 22). As 
expected, this showed evidence of repeated IgH sequences with identical VDJ usage and 
CDR3 junctions at both time points, consistent with the emergence of oligoclonality. Notably, 
this also confirmed that infection with EBV can lead to the acquisition of AID-associated 
SHM events in naive B-cells. 
 
Comparison of Clonal Outgrowth in Alternative Cultures 
Previous studies have only examined clonal outgrowth in cultures generated by infecting 
mature total B-cells, or naive B-cells, with a wild type EBV strain. However, preliminary 
evidence from 2 prior experiments had suggested that EBV-infected cultures generated from 
umbilical cord blood B-cells may remain polyclonal, similar to the situation with mitogen-
stimulated B-cell blasts. Furthermore, since a small proportion of B-cells in EBV-infected 
cultures may spontaneously support virus replication, we speculated that EBV lytic cycle 
entry might also contribute to clonal outgrowth, possibly by triggering the secretion of soluble 
factors.  
 
Work was therefore undertaken to compare clonal outgrowth in cultures generated from 2 
healthy adults or 2 umbilical cord bloods, under the following conditions: (1) adult B-cells 
stimulated with  CD40L and  IL4 to form  blasts, (2) adult B-cells infected with a wild type  
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Table 22. IgVH Rearrangements for the Naive LCL 
IgVH rearrangements from 8 and 16 week time points for the naive LCL analysed by 
spectratyping in Figure 45 were cloned and sequenced. By aligning to germline sequences 
present in the IMGT database, individual V, D and J segments used in each rearrangement 
were identified, as were the number of SHM mutations present in the V segment (V 
Mutations) and the amino acid sequence of the CDR3 region (CDR3 Translation). The 
occurrence of identical CDR3 regions (highlighted with different colours) is consistent with 
the emergence of clonality in these cultures. Specific IgVH sequences could be matched to 
spectratype peaks based on fragment size, as indicated in the right hand column (Spectra 
Size). Notably, the appearance of V region mutations in an LCL derived from naive B-cells 
indicates that EBV infection can lead to the acquisition of AID-associated SHM mutations. 
Data courtesy of Dr A. Bell, University of Birmingham. 
V D J V Mutations CDR3 Translation Spectra Size
W
ee
k
 8
IGHV3-74*01 IGHD3-10*01 IGHJ6*03 8 CVRRGEYMDVW 316
IGHV3-74*01 IGHD3-10*01 IGHJ6*03 8 CVRRGEYMDVW 315
IGHV3-74*01 IGHD3-10*01 IGHJ6*03 9 CVRRGEYMDVW 315
IGHV3-74*01 IGHD3-10*01 IGHJ6*03 9 CVRRGEYMDVW 315
IGHV3-74*01 IGHD3-10*01 IGHJ6*03 9 CVRRGEYMDVW 315
IGHV1-46*01 IGHD4-17*01 IGHJ4*02 5 CARDYGDRSSFDYW 324
IGHV3-53*01 IGHD4-11*01 IGHJ5*02 7 CAKDYSNSGWFDLW 321
IGHV4-31*03 IGHD1-20*01 IGHJ5*02 8 CARDNNWLHNWFDPW 330
IGHV4-31*03 IGHD1-20*01 IGHJ5*02 8 CARDNNWLHNWFDPW 330
IGHV4-59*01 IGHD6-13*01 IGHJ5*02 5 CARAAGSITQFWFDPW 327
IGHV1-02*02 IGHD1-1*01 IGHJ6*02 2 CARRLDADYYYFMDVW 329
IGHV3-07*01 IGHD3-3*01 IGHJ6*02 6 CARDLEQQLGYGMDVW 330
IGHV5-51*01 IGHD2-2*01 IGHJ5*01 4 CARQRDRVVVPAGGWFDSW 333
IGHV1-18*01 IGHD3-22*01 IGHJ6*03 3 CARDPYYDSRGYYYYYMDVW 342
W
ee
k
 1
6
IGHV3-74*01 IGHD3-10*01 IGHJ6*03 8 CVRRGEYMDVW 314
IGHV3-74*01 IGHD3-10*01 IGHJ6*03 8 CVRRGEYMDVW 315
IGHV3-74*02 IGHD3-10*01 IGHJ6*03 8 CVRRGEYMDVW 315
IGHV4-31*03 IGHD2-15*01 IGHJ4*02 12 CAKWEGGSGDYW 321
IGHV3-23*04 IGHD6-6*01 IGHJ4*02 20 CAKAAESPFDYW 318
IGHV3-30*01 IGHD3-3*01 IGHJ4*02 11 CARVVFPRSSGGLDSW 330
IGHV1-02*01 IGHD2-2*01 IGHJ4*02 14 CARDLSALVAAAFSDHW 333
IGHV3-11*01 IGHD3-3*01 IGHJ6*03 7 CARTIFGVIPTYSYHMDAW 339
IGHV3-11*01 IGHD3-3*01 IGHJ6*03 7 CARTIFGVIPTYSYHMDAW 339
IGHV3-23*04 IGHD1-26*01 IGHJ3*02 9 CAKILPYRGSSLIVSEAFDIW 346
IGHV3-30*03 IGHD2-15*01 IGHJ4*03 10 CAKDNIGYCSGVSCPGGGFGMDVW 354
IGHV3-30*03 IGHD2-15*01 IGHJ4*03 10 CAKDNIGYCSGVSCPGGGFGMDVW 354
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 (2089) EBV strain, (3) adult B-cells infected with a mutant EBV strain (BZLF1-KO), which 
is defective in virus lytic cycle entry due to lack of the IE gene BZLF1, and (4) umbilical cord 
blood B-cells infected with a wild type (2089) EBV strain.  
 
For each culture, IgH CDR3 spectratypes were determined for the 8 week time point, because 
all EBV cultures previously analysed have exhibited oligoclonality by this time. Figure 46 
shows the resulting spectratypes. Firstly, these data confirm that B-cell blast cultures remain 
polyclonal in comparison to 2089 EBV-infected LCLs generated from total adult B-cells, 
which show clear evidence of oligoclonal outgrowth. Furthermore, adult total B-cell cultures 
were seen to exhibit oligoclonal outgrowth, irrespective of whether they were infected with 
2089 EBV or the BZLF1-KO EBV strain. This suggests that lytic cycle EBV gene expression 
is not important in determining clonal outgrowth. Finally, it was apparent that cultures 
generated from immature umbilical cord blood B-cells also exhibit a similar degree of clonal 
outgrowth to those of mature adult B-cells. 
 
6.2 Assessment of Proliferation Rates and Cell Death in EBV and Blast Cultures 
Growth Rates in EBV-Infected and Blast Cultures 
Although the above results confirm that EBV-infected LCLs, but not mitogen-stimulated B-
cell blast cultures, develop oligoclonality within a few weeks, it is possible that this difference 
may result from differences in growth rates between these 2 culture types, rather than a 
specific effect of EBV infection. Therefore, additional work was carried out to compare 
growth kinetics in the first few weeks for EBV-infected LCLs versus mitogen-stimulated B-
cell blasts. For this, cell counts were determined with an automated cell counter, using trypan 
blue to identify dead cells. At each passage, identical numbers of cells were re-cultured, and  
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Figure 46. CDR3 Spectratype Analysis of Clonal Outgrowth in Different Cultures 
B-cell blasts and LCLs infected with either 2089 or BZLF1-KO (BZKO) EBV strains were 
generated from total B-cells isolated from 2 adult donors. LCLs infected with 2089 EBV were 
also generated from umbilical cord blood B-cells from 2 donors. Duplicate cultures of each 
type were analysed with CDR3 spectratyping to determine clonality at the 8 week time point. 
All LCL cultures exhibited clonal outgrowth whereas the blasts remained polyclonal. 
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2089 LCL
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cell counts recorded at the following passage were used to calculate growth rates, according to 
the following equation: 
 
NT = N0 x e
RT
 
 
where NT is the number of cells at time T, N0 is the initial number of cells, and R is the 
growth rate (it should be noted this equation assumes exponential growth in these cultures). 
 
As shown in Figure 47, after an initial lag period, LCLs were seen to exhibit a reasonably 
stable rate of proliferation. In contrast, following a lag period, the blasts exhibited a 
substantially increased rate of proliferation over the first 3 weeks, after which the rate 
decreased to a level similar to that found in the LCLs. Notably, cultures generated from 
different donors had differing overall growth rates, with those from donor 1 showing the 
fastest growth, demonstrating evidence of donor-dependent influences on proliferation. 
Similar patterns were observed in multiple other LCL and blast cultures generated during the 
course of this work (data not shown). In each case, the blast cultures were typically exhausted 
by around 8 weeks after initiation. 
 
Cell Survival and Growth in Early EBV and Blast Cultures 
Having compared growth rates in LCLs and mitogen-stimulated B-cell blast cultures over 
several weeks, we then sought to analyse cell survival and proliferation in the first few days. 
In the first instance, this was undertaken using flow cytometric FSC and SSC profiles to 
identify 3 informative subsets in early cultures: non-viable cells, viable non-blastoid cells and 
viable blastoid cells (Figure 48). By using a flow cytometer with the capacity to undertake  
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Figure 47. Growth Rates in LCLs and B-Cell Blasts 
Growth rates (plots on the left) and projected cell numbers (plots on the right) were 
determined for LCLs and mitogen-stimulated B-cell blasts generated from total B-cells from 2 
adult donors (3 LCL and 2 blast cultures from each). After an initial lag period, LCLs 
maintained a relatively stable growth rate. In contrast, the blasts exhibited a period of rapid 
growth before slowing. Resulting cell numbers were greater in the B-cell blast cultures than in 
LCLs. 
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Figure 48. Gating to Identify Non-Viable, Non-Blastoid and Blastoid Cell Subsets  
Flow cytometry was used to identify non-blastoid, blastoid and non-viable cell subsets in 
early EBV-infected cultures, on the basis of FSC and SSC profile. A. Propidium iodide 
staining on day 4 confirmed that non-blastoid and blastoid cells were almost all viable, whilst 
a high proportion of non-viable cells stained positive for this late marker of cell death. B. Day 
2 and day 6 cultures were subjected to intracellular staining with an anti-EBNA-LP 
monoclonal antibody (blue histograms) or secondary only control (filled grey histograms). 
Blastoid cells were predominantly positive for EBNA-LP at both time points 
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precise volume measurements, it was also possible to generate absolute cell counts for these 3 
subsets, by analysing aliquots of cell culture media without prior dilution or washing. Total 
cell counts were calculated by measuring the total volume of each culture.  
 
The validity of this '3 subset' approach was firstly confirmed by showing that very few cells in 
the viable gates stained positive with propidium iodide, a marker of dead cells, whereas a 
significantly higher proportion of cells in the non-viable gate showed positive staining (Figure 
48A). Secondly, intracellular staining for EBNA-LP, the earliest protein reliably detected 
after EBV-infection of B-cells, was used to show that almost all cells falling within the 
blastoid gate are indeed EBV-positive (Figure 48B).  
 
Figure 49 illustrates data from a representative experiment in which this approach was used to 
compare changes in non-viable and viable subsets over the first few days in EBV-infected and 
B-cell blast cultures. Importantly, markedly different patterns of cell death and blastoid 
transformation were observed. Thus, whereas almost all cells occupied the non-blastoid gate 
in both cultures at day 0, by day 2 there was a striking increase in the proportion of non-viable 
cells in the EBV culture that was not apparent in the blast culture. Consistent with this, the 
proportion of cells occupying the blastoid gate was considerably higher in the blast culture 
until around day 6. Therefore, it appears that a high proportion of B-cells used to generate 
EBV cultures undergo cell death, whereas almost all cells used to generate a blast culture 
successfully undergo blastoid transformation. 
 
Examination of absolute cell counts also revealed notable differences between the EBV-
infected and B-cell blast cultures. Thus, Figure 50 shows comparison of viable (non-blastoid  
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Figure 49. Non-Viable, Non-Blastoid and Blastoid Cell Subsets in Early Cultures 
Flow cytometry was used to determine the proportion of non-viable, non-blastoid and blastoid 
cell subsets in EBV-infected and B-cell blast cultures. Data from a paired EBV-infected and 
B-cell blast culture is depicted, which is representative of several separate analyses. A. FSC 
and SSC plots for cultures on days 0, 2 and 4. B. Stacked columns summarise the proportions 
of the subsets on days 0 - 10. A marked increase in cell death was observed in day 2 EBV-
infected cultures, which was not apparent in the B-cell blasts. The proportion of blastoid cells 
was very different at this time point. An increase in non-viable cells was also observed on day 
6 in the blast culture; this is likely to reflect contamination from L-cell fibroblasts because the 
blast cells had been re-plated on the previous day. 
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Figure 50. Cell Counts in EBV-Infected and B-Cell Blast Cultures 
Cell counts for EBV-infected or mitogen-stimulated B-cell blast cultures generated from 2 
adult donors were determined using flow cytometry over the first 10 days. Columns show the 
mean number of viable (non-blastoid + blastoid) cells from 2 independent counts per time 
point; error bars show standard deviation. Although an identical input cell number was used 
to generate the cultures, by day 10 the B-cell blast cultures contained a greater number of cells 
than the paired EBV-infected cultures. 
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+ blastoid) cell numbers for EBV-infected and mitogen-stimulated blast cultures generated 
from 2 donors. After 10 days the B-cell blast counts were much higher than those of the EBV 
culture. Together these results suggest key differences in early survival and proliferation 
between these cultures types that might be important for understanding clonal outgrowth.  
 
Assessment of Proliferation Using CFSE Labelling 
We went on to characterise proliferation in early EBV-infected and mitogen-stimulated B-cell 
blasts cultures using the fluorescent dye CFSE. CFSE-labelling allows cell division to be 
traced because each division leads to an approximately 50% reduction in fluorescent signal, 
which can be readily monitored by flow cytometry. Purified total B-cells were labelled with 
CFSE prior to establishing cultures, and daily flow cytometric measurements were performed.  
 
Figure 51 shows CFSE plots for paired EBV-infected and mitogen-stimulated B-cell blast 
cultures generated from the same donor, representative of several experiments. Visual 
inspection of these data suggested that EBV cultures exhibit shorter times to initial 
proliferation and possibly more rapid proliferation rates compared to B-cell blasts. However, 
given that visual inspection of CFSE profiles can be misleading
556
, we went on to analyse 4 
paired EBV and blast cultures in more detail. To do so, we first used the FlowJo Proliferation 
Tool methodology for analysing CFSE data. This calculates a Proliferation Index (PI) i.e. the 
average number of divisions undergone by cells that have divided at least once
555,556
 (Figure 
52). Using this method, EBV-infected cells appear to divide earlier than B-cell blasts, which 
exhibit a more notable lag period (Figure 53A). However, both cultures exhibit relatively 
linear expansion at similar rates once division has commenced. 
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Figure 51. CFSE Proliferation Profiles in EBV-Infected and B-Cell Blast Cultures 
To analyse proliferation in early cultures, B-cells stained with the fluorescent dye CFSE were 
used to establish EBV-infected or B-cell blast cultures, which were then analysed daily using 
flow cytometry. As each CFSE-labelled cell divides, the fluorescent signal is reduced by 
approximately 50%, so each new peak to the left corresponds to a single division. Here, the 
EBV-infected culture appears to be proliferating more quickly than the paired B-cell blast. 
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Figure 52  Analysis of CFSE Data: FlowJo Method 
CFSE-labelled cultures were analysed with flow cytometry to determine the number of cells 
in each generation, as exemplified here by analysis of a day 5 EBV-infected culture. 
Thereafter, data were analysed using the FlowJo (TreeStar) Proliferation Tool method. Thus, 
cell number in each generation was used to estimate precursor frequency, e.g. 64 cells in 
generation 6 correspond to 1 precursor cell. ‘Proliferation Index’ was then calculated as a 
measure of the average number of divisions for responding cells i.e. cells which have 
undergone at least 1 division. 
Generation (i) Events Precursors Divisions
= Events / 2i = Precursors x i
0 4817 4817.0 0.0
1 2579 1289.5 1289.5 
2 5146 1286.5 2573.0
3 6802 850.3 2550.9 
4 5769 360.6 1442.4
5 2780 86.9 434.5 
6 811 12.7 76.2
7 107 0.8 5.6
Total = 8704.3 Total = 8372.1
Dividing cells = Total precursors  – undivided cells
= 8704.3 – 4817.0 
=  3887.3
Proliferation index  = Total divisions / dividing cells
=  8372.1 / 3887.3
=  2.15
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Figure 53. CFSE Proliferation Data for EBV-Infected and B-Cell Blast Cultures 
EBV-infected and B-cell blast cultures, established in parallel from CFSE-labelled total B-
cells from 4 adult donors, were used to generate proliferation data which were analysed using 
2 alternative methods. A. ‘Proliferation index’ was calculated using the FlowJo Proliferation 
Tool method. B. ‘Mean division number’ was calculated using the method of Hawkins et al.; 
results with a mean division number lower than 1.5 (dotted line) are considered unreliable 
according to the authors of this method. 
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In light of these data, we conclude that the reason B-cell blast numbers are greater than EBV-
infected cells after 7-10 days is not because B-cell blasts proliferate more rapidly. Instead, it is 
likely to be a consequence of higher death rates amongst B-cells used to generate EBV-
infected cultures, whereas a higher proportion of cells are successfully transformed in B-cell 
blast cultures. 
 
Hyperproliferation: An Artefact of CFSE Data Analysis? 
We were surprised by our finding that EBV cultures exhibit linear expansion once they enter 
division (Figure 53A) because Nikitin et al. have reported that EBV-infected cultures exhibit 
a period of hyperproliferation around 3 to 5 days after infection
158
, but this was not apparent 
from our analysis. Given this discrepancy, we decided to reanalyse our CFSE data using the 
same method employed by Nikitin et al.
557
 This approach, developed by Hawkins et al., is a 
modification of previous methods which determines ‘Mean Division Number’, by fitting the 
number of cells in each cell division to a Gaussian distribution
557
 (Figure 54). This new 
analysis (Figure 53B) now revealed a period of apparent hyperproliferation for the EBV-
infected cultures, similar to that reported by Nikitin et al. However, it is our opinion that this 
data should be treated with a great deal of caution because, as stated by Hawkins et al., data 
points with a mean division number less than 1.5 should be regarded as unreliable
557
. 
 
Comparison of Clonal Outgrowth with Alternative Culture Conditions 
Given our results demonstrating different patterns of proliferation and cell survival in EBV-
infected and B-cell blast cultures, we hypothesised that differences observed in clonal 
outgrowth might be related to either the feeder layer used to support the blasts cells, or 
CD40L/IL4 signals provided by them. In order to test this, we undertook an experiment to  
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Figure 54. Analysis of CFSE Data: The Hawkins Method 
CFSE data were also analysed according to the method proposed by Hawkins et al557, as 
exemplified here using the same data as in Figure 52. Thus, the number of cells in each 
generation was used to estimate precursor cell frequency, using i+0.5 in the equation to 
account for cells that have entered cell cycle but which are yet to divide. Thereafter, division 
number was plotted against the number of precursors for generations ≥1, and ‘Mean Division 
Number’ was estimated by fitting a normal distribution using Prism 5 software (Graphpad). 
Generation (i) Events Precursors
= Events / 2i+0.5
0 4817 3406.1
1 2579 911.8
2 5146 909.7
3 6802 601.2
4 5769 255.0
5 2780 61.4
6 811 9.0
7 107 0.6
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determine clonal outgrowth in EBV-infected B-cell cultures maintained on irradiated mouse 
fibroblast L-cells transfected with CD40L and supplemented with IL4 added, or control 
irradiated mouse fibroblasts lacking CD40L in the absence of IL4; as a comparator, EBV-
infected cells were also grown in normal media as before. Again, samples harvested at the 8 
week time point were analysed using IgH CDR3 spectratyping. However, this only revealed a 
similar degree of oligoclonality for each of the cultures (data not shown). This suggests that 
feeder layer support and/or CD40L/IL4 signalling probably does not play a significant role in 
determining clonal outgrowth.  
 
In conclusion, although we have demonstrated marked differences in proliferation rates and 
cell survival between EBV-infected and mitogen-stimulated B-cell blast cultures, we have 
been unable to demonstrate whether these factors contribute to differences observed in clonal 
outgrowth. 
 
6.3 Assessment of Genomic Instability in Early EBV and Blast Cultures  
Having characterised proliferation and cell survival in early EBV-infected and B-cell blast 
cultures, work was then undertaken to explore the role of genomic instability and DNA 
damage response signalling in clonal outgrowth. As discussed previously, Nikitin et al. have 
shown that EBV-infection leads to a period of genomic instability, maximal between days 3 
and 7 post-infection
158
, as evidenced by the accumulation of phospho-H2AX (a marker of 
double-stranded DNA breaks which is thought to trigger ATM/Chk2-mediated DNA damage 
response signalling). However, it is notable that in this study cultures were generated by 
infecting PBMCs rather than purified B-cells, and furthermore no comparison was made with 
mitogen-stimulated B-cell blasts.  
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Initially, Western blotting was used to analyse DNA damage response signalling in early 
EBV-infected B-cell cultures (data not shown). However, it rapidly became apparent that this 
strategy was inappropriate as a method to compare DNA damage responses in EBV-infected 
versus B-cell blast cultures. This is because the proportion of non-viable, non-blastoid and 
blastoid cells are substantially different between these cultures, as previously shown in Figure 
49. Furthermore, blasts are maintained on an irradiated fibroblast layer which express high 
levels of DNA damage-induced proteins and which often contaminate harvested B-cell blasts.  
 
Given the limitations of Western blotting, we instead elected to measure genomic instability 
using intracellular flow cytometry to stain for phospo-H2AX. Thus, previous studies have 
demonstrated that flow cytometry is a robust and quantitative method for measuring phospho-
H2AX
603-607
. Furthermore, and of crucial importance to the current application, this technique 
has the advantage of facilitating measurement of phospho-H2AX levels specifically within the 
viable blastoid cell population. The intracellular phospho-H2AX staining technique was first 
validated by analysing an established LCL which had been irradiated with 0 – 16 Gray 
(Figure 55). Plotting radiation dose against median fluorescence intensity (MFI) for phospho-
H2AX staining revealed an excellent dose-response curve, and confirmed the specificity of 
the phospho-H2AX antibody.  
 
Having validated the phopho-H2AX assay, EBV-infected B-cells harvested between 0 and 12 
days after infection were analysed (Figure 56 shows data representative of 2 separate 
experiments). Importantly, this showed that the MFI of phospho-H2AX staining was never 
above that of a control LCL irradiated with 1 Gray. Furthermore, phospho-H2AX levels were 
similar to those detected in 3 established LCLs included as controls. Whilst there was a small  
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Figure 55. Intracellular Flow Cytometry for Phospho-H2AX 
Intracellular flow cytometry was used to quantify levels of phospho-H2AX as a measure of 
genomic instability. To validate the assay, an established LCL was mock-irradiated or 
irradiated with 1 - 16 Gray, incubated for 1 hour and then fixed before being stained. A. 
Histograms for an LCL stained with anti-phospho-H2AX antibody or isotype control (filled 
grey histogram). B. Plot of radiation dose against phospho-H2AX median fluorescence 
intensity (MFI). An excellent dose-response curve was observed. 
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Figure 56. Analysis of Phospho-H2AX in Early EBV-Infected B-Cells   
Phospho-H2AX levels were analysed in early EBV-infected B-cell cultures using intracellular 
flow cytometry. A. Plots showing phospho-H2AX staining versus FSC for a culture harvested 
on days 2 – 12. All plots display events after exclusion of dead cells and doublets. B. Plots for 
an established LCL irradiated with 0 – 8 Gray and harvested after 1 hour. C. Summary of 
phospho-H2AX MFI data for the early EBV-infected culture, the irradiated LCL and 2 other  
established LCLs (non-irradiated). 
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increase in signal for some cells around 3 - 4 days after infection, this was probably 
artefactual due to a co-incident increase in cell size at this time. Consequently, we found little 
evidence to support the occurrence of a prominent period of DNA damage response signalling 
after EBV infection. Thereafter, a direct comparison of phospho-H2AX staining in EBV-
infected cells and mitogen-stimulated B-cell blasts was undertaken (analysing B-cells that had 
been pre-labelled with a proliferation marker similar to CFSE). This showed that B-cell blasts 
contain at least as much phospho-H2AX as EBV-infected B-cells (Figure 57 shows staining 
representative of at least 3 separate experiments). In light of this, we conclude that there 
appears to be little difference in the degree of genomic instability present in early EBV-
infected and B-cells blast cultures. Consequently, this places doubt on the likelihood that 
early DNA damage signalling events are responsible for observed differences in clonal 
outgrowth. 
 
6.4 Evaluation of AID-Associated Mutations in LCLs 
We were also interested in the possibility that 'off-target' AID-induced mutations might 
influence the clonal outgrowth of LCLs. Notably, Epeldegui et al. have previously reported 
that EBV-infection leads to the accrual of AID-induced mutations in the genes BCL6 and 
p53
244
. However, it remains uncertain to what extent these off-target mutations are de novo 
events, or whether they represent pre-existing mutations which are selected during the course 
of clonal outgrowth. 
 
To address these issues, we elected to analyse BCL6 and p53 sequences in LCLs generated 
from alterative cell types. Thus, LCLs were generated from CD19
+
 B-cells isolated from a 
healthy adult donor (Total LCL), as well as CD27
-
IgD
+
 naive B-cells isolated from a healthy  
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Figure 57. Comparison of Phospho-H2AX in EBV-Infected and B-Cell Blast Cultures 
Phospho-H2AX levels were simultaneously analysed in EBV-infected and B-cell blast 
cultures harvested on days 3, 5, 7 and 10 using intracellular flow cytometry. B-cells used to 
generate the cultures were stained with a violet proliferation dye (similar to CFSE) and dead 
cells, contaminating L-cells and doublets were excluded from the displayed plots. Levels of 
phospho-H2AX observed in the B-cell blast were similar to, or higher than, those seen in the 
EBV-infected culture. 
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adult donor (Naive LCL) and CD19
+
 B-cells from an umbilical cord donor (Cord LCL). The 
Total LCL was analysed to assess reproducibility of the observation that mutations 
progressively accumulate in LCLs. Meanwhile, the Naive and Cord LCLs were included as 
important controls; given that naive and umbilical cord blood B-cells are antigen-
inexperienced cells that do not possess AID-induced mutations, we can infer that any 
mutations detected in these LCLs are likely to be the result of de novo mutation events. 
 
All cultures were generated by infecting isolated B-cells with wild type 2089 EBV. Samples 
were collected at intervals following infection and DNA extracted from these was analysed by 
cloning and Sanger sequencing. The PCR primers used for BCL6 and p53 genes were 
identical to those employed by Epeldegui et al.
244
 These amplified a 5' noncoding region of 
the BCL6 gene, and a coding region of p53. These regions had originally been selected as 
they have been found to be mutated in NHL
52,608
. Importantly, PCRs were performed using a 
high-fidelity DNA polymerase with a proofreading capability, in order to minimise the PCR 
error rate. For each time point, a total of 10 BCL6 and 10 p53 sequences were cloned and 
sequenced, and the results were analysed to determine the proportion of mutated sequences 
and the total number of mutations.  
 
As summarised in Figure 58, analysis of BCL6 sequences revealed progressive accumulation 
of mutations in both the Total LCL and the Naive LCL, but not in the Cord LCL. At baseline, 
the Total LCL revealed 3 mutations (in 2 sequences), in keeping with the presence of memory 
B-cells carrying pre-existing BCL6 mutations in this sample. Unfortunately a baseline sample 
for the Naive LCL was not available but we expect this would not have exhibited any 
mutations. Meanwhile, no mutations were observed at baseline for the Cord LCL, as  
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Figure 58. BCL6 Mutations in LCLs 
BCL6 sequences were analysed at 0, 2, 8 and 16 week time points in LCLs generated from 
adult total B-cells, adult naive B-cells or umbilical cord B-cells. 10 sequences were analysed 
for each time point. The number of mutations (plots on the left) and the number of mutated  
sequences (plots on the right) at each time point are displayed. Progressive accumulation of 
mutations was noted in the total B-cell and naive B-cell LCLs but not the cord LCL. 
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expected. By 16 weeks, the Total LCL had accumulated 10 mutations (in 5 sequences). 
Interestingly, the Naive LCL had also accumulated 6 mutations (in 6 sequences) by this time. 
In contrast, the Cord LCL exhibited only 1 mutation, apparent at the 8 week time point. 
Subsequent inspection of the individual BCL6 mutations revealed additional information. As 
such, whilst most BCL6 mutations in the Total LCL were non-recurring, in the 16 week 
sample identical mutations were noted for 2 sequences, and these matched a third sequence 
from the 8 week time point (Table 23). A similar pattern was observed for the Naive LCL, in 
that 3 sequences contained identical mutations at the 16 week time point, with 1 matching 
sequence identified at 8 weeks (Table 24). 
 
Figure 59 shows data for the corresponding p53 sequences. Notably, this revealed a markedly 
different pattern to that observed for the BCL6 sequences, with a lower number of mutations 
generally and, more importantly, no accumulation of mutations. However, single mutations 
were noted in the Cord LCL at 2, 8 and 16 week time points. 
 
6.5 Discussion 
Our group has previously reported that EBV-infected B-cell cultures derived from isolated 
CD27
-
IgD
+
 naive B-cells develop oligo- and mono-clonality within a few weeks of infection, 
a result not seen with naive B-cell blasts generated by CD40L/IL4 stimulation. Interestingly, 
the clones which dominate these naive LCL cultures are often found to carry mutated Ig 
sequences, indicating that EBV may induce SHM in vitro. While it is difficult to envisage a 
scenario in which a mutated Ig gene might confer a growth advantage in vitro, it was 
hypothesised that off-target effects of AID might generate a pool of precursors carrying 
cellular mutations from which the fittest clone would emerge. However AID activity might  
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Table 23. BCL6 Mutations in the Total LCL 
BCL6 sequences from an LCL generated from total adult B-cells, harvested at 0, 2, 8 and 16 
week time points are aligned (10 sequences per sample). Mutations are shown in comparison 
to a reference BCL6 sequence. Recurring mutations are apparent at positions 323 and 352 
(highlighted in red) for 8 and 16 week time points, consistent with emergence of clonality in 
the LCL culture. Notably, 2 mutually exclusive polymorphisms (blue colour font) previously 
described in dbSNP database were observed at positions 423 (G to A; rs114991887) and 441 
(T insertion; rs3832246) for which this donor is heterozygous. Changes at these positions 
were not included in the analysis but they indicate that sequence data was successfully 
obtained from both alleles.  
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Table 24. BCL6 Mutations in the Naive LCL 
BCL6 sequences from an LCL generated from naive adult B-cells, harvested at 2, 8 and 16 
week time points are aligned (10 sequences per sample). Mutations are shown in comparison 
to a reference BCL6 sequence. A known polymorphism (blue font) is observed at position 
441 (T insertion; rs3832246), for which this donor is homozygous; changes at this position 
were not included in the analysis. Recurring mutations are apparent at position 11 
(highlighted in red) for 8 and 16 week time points, consistent with emergence of clonality in 
the LCL culture. 
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Figure 59. p53 Mutations in LCLs 
p53 sequences were analysed at 0, 2, 8 and 16 week time points in LCLs generated from adult 
total B-cells, adult naive B-cells or umbilical cord B-cells. 10 sequences were analysed for 
each time point. The number of mutations (plots on the left) and the number of mutated  
sequences (plots on the right) at each time point are displayed. Progressive accumulation of 
mutations was not observed in any of the cultures. 
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not be sufficient for this observed clonal evolution in LCL cultures, since mitogen stimulation 
also induces AID expression yet does not cause Ig gene mutation or clonal outgrowth. This 
raises the possibility that other mechanisms might drive the emergence of clonality in LCLs 
but not B-cell blasts. Given this, experiments in this chapter were primarily designed to 
investigate differences between EBV-infected B-cells and mitogen-stimulated B-cell blasts 
that might determine their alternative patterns of clonal outgrowth. 
 
Patterns of Clonal Outgrowth 
We first showed that LCLs generated from total and FACS-sorted naive adult B-cells exhibit 
clonal outgrowth within a few weeks of infection, whereas B-cell blasts remain polyclonal. 
These findings confirm our group's previous data demonstrating clonal emergence in naive 
LCLs
236
, and are consistent with earlier reports which have analysed clonality in LCLs 
established from total B-cells. Thus, Ryan et al. used CDR3 spectratyping to show that LCLs 
generated from 5 adult donors developed monoclonality by around 8 weeks 
238
, whereas 
Plagnol et al. made similar observations using X chromosome inactivation as a measure of 
clonality
239
. Lacoste et al. subsequently demonstrated the acquisition of clonality in LCLs 
using karyotyping
237
. 
 
We extended our understanding by showing that LCLs generated from umbilical cord blood 
B-cells also exhibit clonal outgrowth. This result is important because preliminary data had 
suggested that umbilical cord LCLs might remain polyclonal in culture. Given that our group 
has also previously shown that umbilical cord LCLs rarely acquire AID-associated Ig gene 
mutations, we speculated that this might be linked to the preservation of polyclonality within 
these cultures. Therefore, our current findings that umbilical cord LCLs do develop clonality, 
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provides evidence that clonal outgrowth is not necessarily related to the occurrence of AID-
induced Ig gene mutation.  
 
We also assessed the effect on clonal outgrowth of a BZLF1 defective strain of EBV. This 
was performed since EBV lytic cycle gene expression has been demonstrated as a potentially 
important influence in the pathogenesis of PTLD
445-448
. Thus lytic gene expression is often 
found within PTLD tumours, and BZLF1 KO LCLs show impaired growth when transplanted 
into SCID mice
445
, an effect that may result, at least in part, by up-regulation of paracrine 
factors such as IL6 in response to IE lytic gene expression
445,446
. Lytic cycle gene expression 
has also been associated with increased DNA damage response signalling; it is also at least 
conceivable that low level lytic cycle gene expression might contribute to clonality if it were 
to trigger the generation of mutations in cells that subsequently revert to latent infection. 
However, our results for BZLF1 KO LCLs were indistinguishable from those generated using 
the wild type 2089 strain of EBV. This indicates that lytic cycle gene expression probably 
does not have a significant effect on clonal outgrowth.  
 
It should be noted that in undertaking these studies, we employed IgH CDR3 spectratyping as 
the principal method to assess clonal outgrowth. This technique is advantageous compared to 
the previously employed ‘clone and sequence’ approach because it simultaneously samples all 
available IgVH loci, and it is also much less labour intensive. However, the technique also has 
significant limitations. Thus, it is important to acknowledge that it is a qualitative rather than 
quantitative measure of clonality. Indeed, several groups have attempted to derive quantitative 
data from spectratypes using a variety of algorithms, but Euroclonality Guidelines state these 
are unreliable and that the assay should be regarded more as a 'molecular morphological 
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assay'
602
. Therefore, the technique may be unable to detect more subtle differences in 
clonality.  Our validation of the assay also revealed that it is possible for a single spectratype 
peak to contain more than 1 clone, due to clones that by chance exhibiting CDR3 amplicons 
of identical length. Furthermore, unlike the conventional ‘clone and sequence’ approach, it 
does not provide information on individual CDR3 sequences and thus cannot be used to detect 
IgVH mutations. These limitations mean that, in retrospect, IgH CDR3 spectratyping may not 
have been best suited to the current experiments. 
 
Differences in Cell Proliferation and Survival 
A series of investigations were also undertaken to explore how differences in proliferation and 
cell survival might explain the contrasting patterns of clonal outgrowth observed in LCL and 
B-cell blast cultures. Thus, comparison of growth rates in the first 6 weeks revealed that LCLs 
exhibit a relatively stable growth rate after an initial lag period. In contrast, B-cell blast 
cultures showed a brisk growth rate for the first 3 - 4 weeks before slowing considerably, 
consistent with previous studies
32
. Despite these differences in growth kinetics, estimated 
total cell counts showed that B-cell blasts had undergone at least as many cell divisions as the 
LCLs over these first weeks when clonality emerges. We therefore conclude that the 
alternative patterns of clonality do not simply reflect differences in the overall degree of 
proliferation between cultures. 
 
Analysis of events in the first few days of culture revealed other potentially important 
differences between EBV-infected and B-cell blast cultures. In particular, the proportion of B-
cells activated to a blastoid state was found to differ substantially between them. Thus, in B-
cell blast cultures almost all cells were successfully activated to became blastoid, whereas in 
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EBV-infected cultures a high proportion of cells appeared to die rather than become blastoid 
(Figure 49). As a consequence B-cell blasts were found to be numerically superior after 10 
days of culture, despite evidence of a longer delay before the first cell division provided by 
analysis of CFSE data (FlowJo methodology).     
 
Interestingly, others have already observed relatively high rates of cell death following EBV-
infection of B-cells
609
, although this finding has not been emphasised in the literature. Why 
this occurs is not clear, but we speculate that some cells may apoptose because they fail to be 
infected, or because they are infected by a defective virus that fails to initiate transcription, or 
even because they do not enter cell cycle despite EBNA-LP or EBNA2 expression; however, 
the latter theory is contrary to evidence that successful B-cell infection almost always leads to 
cell cycle entry
228
. In contrast, B-cell blasts may show superior blastoid activation thanks to 
the CD40L expressing fibroblast layer on which they are grown, as well as the presence of 
soluble IL4. These factors may provide an environment that efficiently maintains cell survival 
and promotes activation such that almost all input B-cells become blastoid. 
 
In light of these results we hypothesised that clonal emergence might be favoured in LCLs, 
either because the number of infected cells is reduced by the amount of early cell death, or 
because the feeder layer and/or IL4 might deliver signals throughout the life of a B-cell blast 
culture that ameliorate the processes that drive clonal selection in LCLs. However, when these 
possibilities were tested by culturing LCLs on feeder layers, with or without CD40L 
stimulation and supplementary IL4, they were found to exhibit clonal emergence just as 
normal. 
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Hyperproliferation and Genomic Instability 
Previous studies have suggested that EBV might cause genomic instability in infected cells. 
Thus, Lacoste et al. showed that LCLs often display karyotypic abnormalities and increased 
numbers of phospho-H2AX foci compared to B-cell blasts
237
. Meanwhile work from the 
Masucci group has shown that the EBV latent proteins EBNA1, LMP1 and EBNA3C can also 
contribute to genomic instability
242,243
. Furthermore,  Nikitin et al. have reported that a period 
of hyperproliferation-associated genomic instability follows EBV-infection of B-cells, as 
measured by the accumulation of phospho-H2AX foci
158
. Prompted by such work, we 
speculated that patterns of clonal outgrowth might be related to genomic instability and/or 
DNA damage signalling during the first few days in culture. Indeed, if early genomic 
instability results in mutations that are not repaired (EBV might even block repair pathways) 
then this might generate a pool of cells carrying genetic damage from which the fittest clone 
may emerge.  
 
Initial work focussed on characterising proliferation rates in EBV-infected and B-cell blast 
cultures, in anticipation of finding a similar period of hyperproliferation in EBV cultures to 
that found by Nikitin et al. (who had not included B-cells blasts as a comparator). However, 
we were surprised to find little evidence for hyperproliferation. Thus, analysis of CFSE data, 
using FlowJo methodology, revealed linear outgrowth of EBV-infected B-cells (Figure 53). 
Importantly, although reanalysis of our CFSE data using the Hawkins et al. methodology 
(which had been employed by Nikitin et al.) revealed a period of apparent hyperproliferation 
in EBV-infected cultures, closer inspection revealed this to be artefactual. Thus, as stated by 
Hawkins et al., data points with a mean division number less than 1.5 should be regarded as 
unreliable
557
. Interestingly, it is also notable that Nikitin et al. analysed CFSE-labelled 
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cultures at time points as long as 13 days post-infection. Notably, CSFE data is highly 
unreliable at these time points and their inclusion is likely to grossly underestimate the 
number of cell divisions and give a false impression that cells are proliferating more slowly 
than previously.  
 
Subsequent work involved the characterisation of DNA damage signalling in early cultures, 
which was initially attempted with Western blotting. However, it rapidly became apparent 
that this was inappropriate for the current application, due to the hitherto underappreciated 
differences in the ratio of dead cells to blastoid cells in these cultures, as well as the 
significant risk of contamination by irradiated fibroblast cells. Consequently, intracellular 
flow cytometry was developed as a method to assay phospho-H2AX. This technique proved 
particularly useful because it was possible to gate out non-viable cells from the analysed 
cultures, allowing for a fair comparison of EBV-infected and B-cell blast cultures. However, 
newly infected B-cells were only found to exhibit levels of phospho-H2AX similar to those 
found in established LCLs. Furthermore, phospho-H2AX levels were not found to be 
substantially different in a direct comparison of EBV-infected B-cells versus B-cells blasts.  
 
From these data we conclude that there is insufficient evidence to suggest that levels of 
genomic instability in EBV-infected cultures are any greater than those found in B-cell blasts, 
or that this is a mechanism to explain the observed differences in clonal outgrowth found in 
these cultures. Additionally, our data contradict the findings of Nikitin et al., as we found 
little evidence for a period of hyperproliferation-induced DNA damage signalling. 
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Assessment of Off-Target AID Mutations in LCLs 
We were also interested by the observation of Epeldegui et al. that AID-associated mutations 
in BCL6 and p53 genes accumulate in newly generated LCLs
244
. Given that our laboratory 
has previously demonstrated that dominant clonotypes in naive LCLs often exhibit AID-
induce Ig mutations
236
, we hypothesised that new off-target AID-induced mutations might 
contribute to clonal outgrowth observed in LCLs. However, given that Epeldegui et al. had 
generated LCLs from total adult B-cells, which contain memory B-cells with pre-existing off 
target AID-induced mutations , we could not be confident that these findings did not represent 
selection of cells carrying pre-existing mutations rather the appearance of de novo mutations. 
In support of the former possibility, several groups have reported that AID expression is up-
regulated following EBV-induced growth transformation
219,227-229
. Furthermore, analysis of Ig 
gene sequences has indicated evidence of ongoing SHM in EBV-infected cultures
236
. On the 
other hand, up to 30% of GC-experienced cells are thought to carry off-target AID-induced 
mutations
49
. If memory B-cells carrying such mutations exhibit clonal outgrowth, either 
randomly or due to selective growth or survival advantage, this could also explain the 
apparent accumulation of mutations in LCLs. On this point, AID is also reported to only 
target genes that are actively transcribed, which is at odds with the observation that BCL6 is 
not expressed in LCLs
236,610
. 
 
Using a ‘clone and sequence’ approach to compare BCL6 and p53 sequences in LCLs 
generated from either total adult B-cells, naive adult B-cells or umbilical cord B-cells, we 
showed an accumulation of BCL6 mutations in the Total and Naive LCL cultures. As such, 
our findings are in keeping with the work of Epeldegui et al.
244
 However, it is also notable 
that fewer mutations were noted in the Naive LCL than in the Total LCL. Also, as evidenced 
6. Results 
Page 251  
 
by the appearance of recurrent mutations in these cultures (Tables 23 and 24), it is apparent 
that at least some of the progressive increase in mutations could be accounted for by the 
emergence of clonality. Given this, we conclude that clonal outgrowth may act to exaggerate 
the apparent mutation rate in LCLs. 
 
Interestingly, whilst the BCL6 data was very similar to that of Epeldegui et al., a different 
pattern was observed for p53 sequences. As such, no progressive accumulation of mutations 
was observed in p53. It is uncertain why these results should be so different but it is notable 
that p53 has been shown to be an infrequent target of AID mutation
51
. Also, the p53 amplicon 
lies within a coding region of the gene and this is a less common target for AID, which 
preferentially causes mutations in 5' noncoding regions
51,52
. Furthermore, mutations affecting 
this coding region may have resulted in amino acid changes in the p53 protein, and these will 
have been subject to selection pressures in culture. 
 
The results for the umbilical cord LCL were particularly intriguing because this showed no  
accumulation of mutations in either the BCL6 or p53 loci. This is remarkable in light of our 
previous data showing that umbilical cord LCLs exhibit clonal outgrowth, because it suggests 
that BCL6 mutations are unimportant as drivers of clonal selection. Furthermore, the result 
suggests 2 alternative interpretations as to why umbilical cord LCLs fail to develop AID-
induced mutations. Thus, one possibility is that umbilical cord blood LCLs exhibit a unique 
property such that they are insensitive to AID-induced mutations. This may be due to 
differences in the chromatin configuration at the Ig locus, or other epigenetic changes, that 
preclude AID-induced mutation in these cells. However, an alternative explanation is that the 
principal mechanism by which mutations accumulate in LCLs may be by selection of pre-
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existing mutations. These are absent in cord blood B-cells but may be present at low 
frequency in FACS-sorted naive B-cell populations as a result of contamination with memory 
B-cells. If this is the case then it would imply remarkably strong selection of the 
contaminating memory B-cells, given that FACS purity is typically >98%. 
 
Ultimately, due to the relatively low number of sequences analysed at each time point during 
the course of these experiments, it is difficult to draw firm conclusions as to whether the 
accumulation of mutations apparent in LCLs primarily derives from the appearance of de 
novo AID-induced off-target events, or whether selection of pre-exciting mutations is the 
predominant mechanism. This needs to be addressed in future experiments, with analysis of 
larger numbers of sequences, amplified from a broader range of loci. 
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7. DLI Salvage Therapy for Rituximab-Refractory PTLD arising after Allo-
HSCT: In Vivo Expansion of Functional EBV Epitope-Specific T-Cells 
 
Rituximab has significantly improved PTLD-related mortality following allo-HSCT
521
. In 
particular, its use to pre-emptively treat individuals who develop high-level EBV DNAemia 
in the weeks following transplant, as identified by EBV qPCR monitoring, has led to a 
marked reduction in mortality relative to historic cohorts
498-501
. Nevertheless, a proportion of 
patients develop Rituximab-refractory PTLD and are consequently at high risk of 
mortality
520,521
. The management of such patients is often challenging. Thus, whilst cytotoxic 
chemotherapy such as CHOP may result in good outcomes for Rituximab-refractory PTLD in 
the setting of solid organ transplantation, this has not been the case after allo-HSCT, where 
very poor outcomes are likely to be a consequence of increased toxicity in this patient 
group.
520,572
 However, considerably better responses have been achieved using cellular 
therapies. Thus, transplant donor-derived unselected donor lymphocyte infusions (DLI), 
which contain EBV-specific T-cells whenever the donor is EBV-seropositive, have 
successfully been used as salvage therapy for established PTLD, with response rates of 
around 70%
523-526
. Unfortunately this approach is limited by the risk of generating alloreactive 
T-cell responses, which may result in potentially life threatening GvHD. Alternatively, EBV 
CTL infusions, prepared by in vitro stimulation of donor or third party lymphocytes, 
overcome this problem. These have been used both as effective prophylaxis for PTLD and in 
the treatment of established disease, resulting in response rates similar to those achieved with 
DLI, without evidence of alloreactivity
499,527,530,531
. 
 
Despite their benefits, EBV CTLs are still not universally available, due in part to the 
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laborious and costly nature of their production
611
. Novel approaches including the 
development of protocols for rapid ex vivo selection of virus-specific T-cells
534,535,612
, or the 
use of genetically engineered T-cells
613
, are seeking to address this issue. Yet these are reliant 
on knowledge of the antigenic specificity and function of cells with greatest therapeutic 
potential. Whilst DLI and EBV CTLs appear efficacious for the treatment of PTLD, to date 
little is known about the factors which might determine response to treatment. Thus, although 
the expansion of adoptively transferred cells has been correlated with successful clinical 
outcome, additional properties such as dynamic changes in the specificity and functional 
characteristics of individual EBV epitope-specific T-cells remain poorly characterised. In 
order to address this issue, EBV-specific T-cell responses were studied in 2 patients with 
Rituximab-refractory PTLD who were successfully treated with DLI. 
 
7.1 Patient Presentation and Treatment 
This study used clinical data and samples collected from 2 patients who underwent treatment 
with DLI for Rituximab-refractory PTLD arising after allo-HSCT. Baseline and transplant 
characteristics for the patients are summarised in Table 25. Patient A underwent allo-HSCT 
for lymphocytoplasmacytic lymphoma in partial remission using fludarabine and BEAM 
preparative conditioning, with an HLA-matched unrelated donor with a single HLA-A antigen 
mismatch (HLA A26 for A32). Due to graft failure, a second transplant from the same donor 
was performed using fludarabine, cyclophosphamide and ATG conditioning. EBV qPCR 
testing of whole blood revealed low-level EBV DNAemia on day 71 (post second transplant), 
with a virus load of 760 copies/ml (Figure 60). Despite weaning cyclosporin, this 
subsequently rose to high-level EBV DNAemia (28,150 copies/ml) by day 99. The patient 
was therefore pre-emptively treated with Rituximab 375 mg/m
2
, administered weekly to a 
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  Patient A Patient B 
Age at Transplant, years 51 62 
Sex Female Female 
Diagnosis LPL AML 
First Transplant     
     Donor Unrelated Sibling 
     Conditioning Flu BEAM Flu Mel 
     T Depletion Alemtuzumab Alemtuzumab 
Second Transplant    
     Donor Unrelated Sibling 
     Conditioning Flu-Cy FLAMSA-Bu 
     T Depletion ATG ATG 
EBV Serology     
     Recipient 
+
 
+
 
     Donor 
+
 
+
 
HLA Type     
     A 02, 32* 01, 24 
     B 44, 49 07, 14 
     C 05, 07 07, 08 
     DRB1 01, 15 07, 15 
     DQB1 05, 06 02, 06 
Table 25. Characteristics of Patients Treated with DLI for Rituximab-Refractory PTLD 
Both patients developed PTLD following a second allo-HSCT which used ATG for T-cell 
depletion. *Patient A had a single HLA-A antigen mismatch with their donor (A26 for A32). 
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Figure 60. Use of DLI for Rescue of Rituximab-Refractory PTLD after Allo-HSCT 
Serial EBV load in whole blood following allo-HSCT for patients A and B. Day 0 is the time 
of second transplant. The dotted line represents the 500 copies/ml threshold of sensitivity for 
the EBV qPCR assay. Values <500 copies/ml are arbitrarily shown as 250 copies/ml. R 
indicates infusion of Rituximab 375 mg/m2; DLI, donor lymphocyte infusion of 1 x106/Kg. 
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total of 4 infusions, resulting in a decline in EBV load to a nadir of 5470 copies/ml on day 
127. However, 7 days after the fourth infusion of Rituximab there was recrudescence of EBV 
DNAemia which progressed on further testing. This was accompanied by severe 
oropharyngeal inflammation and ulceration causing absolute dysphagia and airway 
compromise which progressed despite empirical antimicrobial therapy and systemic steroids. 
Imaging including PET-CT revealed active disease principally involving Waldeyer’s Ring 
and confluent, full-length oesophageal involvement (Figure 61A). An oropharyngeal biopsy 
confirmed monomorphic PTLD of DLBCL subtype, which was positive for EBV by EBER in 
situ hybridisation but negative for CD20 immunohistochemistry, consistent with prior 
Rituximab exposure (Figure 61B)
614
.  
 
Patient B underwent allo-HSCT for AML in first complete remission, with fludarabine, 
melphalan and Alemtuzumab preparative conditioning, using PBSC from a fully HLA-
antigen matched sibling donor. A second allograft from the same donor was performed 
approximately 18 months later (day 0) following relapse of primary disease, with FLAMSA 
and busulphan conditioning. EBV monitoring revealed a viral load of 9810 copies/ml on day 
63 (post second transplant) which progressed to 370,000 copies/ml on day 71 (Figure 60). 
Consequently, pre-emptive therapy with Rituximab 375 mg/m
2 
was administered to a total of 
4 weekly infusions. This resulted in reduction of EBV load to a nadir of 8625 copies/ml after 
the third infusion of Rituximab. However, 6 days following the fourth infusion there was 
recrudescence of EBV DNAemia with a virus load of 20,760 copies/ml which subsequently 
increased. This was associated with general malaise and B symptoms, and PET imaging 
revealed active disease involving the nasopharynx, spleen and multiple lymph nodes (Figure 
61A). In the absence of an amenable biopsy site, a diagnosis of probable PTLD was made  
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Figure 61. Investigations Pre- and Post-DLI 
A. Positron emission tomography imaging taken pre- and post-DLI treatment for Patients A 
and B. Patient A had active disease principally located in the oropharynx and oesophagus. 
Patient B had active disease in the oropharynx, spleen and lymph nodes. Excellent responses 
were observed following DLI. Day 0 is the day of DLI treatment. B. Sections of formalin-
fixed and paraffin-embedded biopsy tissue from Patient A showing widespread positivity for 
EBERs on in situ hybridisation but predominantly negative immunohistochemistry for CD20. 
Images are magnified 40x. 
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consistent with published diagnostic criteria
496
. 
 
The patients were subsequently treated with single infusions of 1 x10
6
/Kg unselected donor 
lymphocytes derived from their EBV immune stem cell donors. In both, a rapid and sustained 
response to DLI was observed, comprising reduction of EBV load to undetectable levels 
(Figure 60), resolution of symptoms, and complete metabolic response defined by CT-PET 
(Figure 61A). Except for stage 1 skin GvHD in Patient A, administration of DLI was tolerated 
without complication. Patient A remains well after more than 2 years of follow-up. Patient B 
remained in remission from PTLD but died from treatment-refractory AML around 8 months 
following their second transplant. 
 
7.2 Expansion of Lymphocyte Subsets Following DLI 
Blood samples were collected prospectively following administration of DLI, with the aim of 
monitoring in vivo immune responses. Inspection of total lymphocyte counts revealed a 
similar pattern of lymphocyte expansion following DLI infusion in both patients (Figure 62). 
Thus, lymphopenia was noted prior to infusion, with lymphocyte counts of only 300 cells/μl 
in both (normal range 1000 – 4000 cells/μl). Although the counts were unchanged at 2 weeks 
following infusion, by 4 weeks there was a marked increase to 2500 cells/μl and 1100 cells/μl 
for Patients A and B respectively. Thereafter, the lymphocyte counts decreased to near 
baseline frequencies by 13 weeks in Patient A, and by 8 weeks in Patient B (although there 
was a further increase at the 10 week time point in the latter). In order to characterise 
lymphocyte subsets, PBMCs were analysed using a multicolour flow cytometry panel to 
enumerate CD3
+
 T-cells (including CD8
+
 and CD4
+
 subsets), CD56
+
 NK-cells and CD19
+
 B-
cells (Figure 62). This revealed a predominance of NK-cells, and few T-cells, in the pre-DLI  
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Figure 62. Lymphocyte Counts and Subsets after DLI 
Total lymphocyte (joined black dots) and main lymphocyte subset counts (stacked columns) 
pre- and post-DLI infusion for Patients A and B. NT indicates not tested. Expansion of CD4
+
 
and CD8
+
 T-cell and NK-cell subsets was observed at 4 weeks after DLI treatment in both 
patients. 
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and 2 week time points. However, by 4 weeks both the CD8
+
 and CD4
+
 T-cell subsets 
underwent marked expansion, accompanied by a similar increase in NK-cells. Regarding 
CD19
+
 B-cells, despite prior Rituximab therapy these constituted 1.0% of lymphocytes at 2 
weeks post DLI-infusion in Patient A but reduced to 0.1% by the 4 week time point, and 
remained at trace levels at 13 weeks (maximum 0.3%). In Patient B, B-cells made up 1.6% of 
lymphocytes pre-DLI, falling to 0.6% at 2 weeks post-DLI and remained at trace levels at 10 
weeks (maximum 0.2%). Overall, these data suggest that DLI-derived CD8
+
 and CD4
+
 T-cells 
and NK-cells had undergone in vivo expansion following infusion, co-incident with 
elimination of residual circulating B-cells. 
 
7.3 Characterisation of EBV Epitope-Specific T-cell Responses 
Whilst previous studies have demonstrated expansion of EBV-specific T-cells following 
administration of DLI, the antigenic specificities of these cells have not been 
characterised
525,615
. To enumerate EBV epitope-specific T-cell responses for study patients, 
PBMCs were stimulated overnight with EBV peptides and responding CD8
+
 and CD4
+
 T-
cells were quantified using IFN-γ release Elispot assay. Initially, aliquots of donor 
lymphocytes were tested, revealing EBV-specific CD8
+
 and CD4
+
 T-cell responses typical of 
healthy EBV seropositive individuals
287
. Thus, responses to a range of EBV antigens were 
observed, with prominent responses to immunodominant epitopes (Figure 63). Patient A 
exhibited strong responses to the CD8
+
 T-cell peptides EEN (EBNA3C), KEH (EBNA3C), 
CLG (LMP2) and YVL (BRLF1), whilst the DLI for Patient B showed prominent responses 
against the CD8
+
 T-cell peptides TYS (EBNA3B), TYG (LMP2) and RPP (EBNA3A), and 
the CD4
+
 T-cell peptide PRS (EBNA2). In contrast, analysis of patient PBMCs collected prior 
to DLI infusion showed responses undetectable above background DMSO. Responses  
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Figure 63. IFN-γ Elispot Analysis of EBV Epitope-Specific T-Cells after DLI 
Aliquots of donor lymphocytes or PBMCs from patients A and B were stimulated overnight 
with selected panels of previously determined HLA class I and II EBV epitope-specific 
peptides before responding cells were enumerated using IFN-γ Elispot. Mean spot forming 
units (SFUs) per 2 x105 cells are displayed. NT, indicates not tested; † indicates death. 
V
E
I
E
E
N
K
E
H
C
LG FL
Y
LL
W
Y
LL
Y
V
L
G
LC FL
D
C
D
4 
la
te
nt
C
D
4 
ly
tic
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
R
Y
S
TY
S
TY
G
R
P
G
K
IP
G
R
P
P
Q
P
R
C
D
8 
P
oo
l
V
Y
G
P
R
S
M
V
F
E
D
L
S
N
P
C
D
4 
P
oo
l
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
V
E
I
E
E
N
K
E
H
C
LG FL
Y
LL
W
Y
LL
Y
V
L
G
LC FL
D
C
D
4 
la
te
nt
C
D
4 
ly
tic
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
R
Y
S
TY
S
TY
G
R
P
G
K
IP
G
R
P
P
Q
P
R
C
D
8 
P
oo
l
V
Y
G
P
R
S
M
V
F
E
D
L
S
N
P
C
D
4 
P
oo
l
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
V
E
I
E
E
N
K
E
H
C
LG FL
Y
LL
W
Y
LL
Y
V
L
G
LC FL
D
C
D
4 
la
te
nt
C
D
4 
ly
tic
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
R
Y
S
TY
S
TY
G
R
P
G
K
IP
G
R
P
P
Q
P
R
C
D
8 
P
oo
l
V
Y
G
P
R
S
M
V
F
E
D
L
S
N
P
C
D
4 
P
oo
l
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
V
E
I
E
E
N
K
E
H
C
LG FL
Y
LL
W
Y
LL
Y
V
L
G
LC FL
D
C
D
4 
la
te
nt
C
D
4 
ly
tic
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
R
Y
S
TY
S
TY
G
R
P
G
K
IP
G
R
P
P
Q
P
R
C
D
8 
P
oo
l
V
Y
G
P
R
S
M
V
F
E
D
L
S
N
P
C
D
4 
P
oo
l
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
R
Y
S
TY
S
TY
G
R
P
G
K
IP
G
R
P
P
Q
P
R
C
D
8 
P
oo
l
V
Y
G
P
R
S
M
V
F
E
D
L
S
N
P
C
D
4 
P
oo
l
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
V
E
I
E
E
N
K
E
H
C
LG FL
Y
LL
W
Y
LL
Y
V
L
G
LC FL
D
C
D
4 
la
te
nt
C
D
4 
ly
tic
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
R
Y
S
TY
S
TY
G
R
P
G
K
IP
G
R
P
P
Q
P
R
C
D
8 
P
oo
l
V
Y
G
P
R
S
M
V
F
E
D
L
S
N
P
C
D
4 
P
oo
l
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
V
E
I
E
E
N
K
E
H
C
LG FL
Y
LL
W
Y
LL
Y
V
L
G
LC FL
D
C
D
4 
la
te
nt
C
D
4 
ly
tic
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
R
Y
S
TY
S
TY
G
R
P
G
K
IP
G
R
P
P
Q
P
R
C
D
8 
P
oo
l
V
Y
G
P
R
S
M
V
F
E
D
L
S
N
P
C
D
4 
P
oo
l
D
M
S
O
0
100
200
200
400
600
S
F
U
 /
 2
x
1
0
5
 P
B
M
C
s
Patient A Patient B
D
L
I
P
re
 D
L
I
W
e
e
k
 2
W
e
e
k
 4
W
e
e
k
 6
W
e
e
k
 8
W
e
e
k
 5
2
NT
†
7. Results 
Page 263  
 
remained poor at 2 weeks after DLI. However, by 4 weeks there was a very marked increase 
in EBV-specific T-cell frequency. Importantly, these responses included some, but not all, of 
the epitope specificities identified in the corresponding DLI samples. Thus, in Patient A the 
CD8
+
 response was dominated by reactivity against the CD8
+
 YVL (BRLF1) peptide, with 
weaker responses to the LMP2 peptides FLY, CLG and LLW, whereas in Patient B the RPP 
(EBNA3A) peptide and the CD8
+
 peptide pool (a composite of lytic antigen peptides) elicited 
the strongest responses. Epitope-specific CD4
+
 T-cells were also detected in both patients, 
most evidently against the pool of CD4
+
 latent epitope peptides in Patient A, and the MVF 
(EBNA1) peptide and CD4
+
 peptide pool (a composite of lytic antigens plus EBNA3C 
peptides) in Patient B. Interestingly, CD4
+
 T-cell responses may have preceded those of CD8
+
 
T-cells in Patient A, as responses to the CD4
+
 latent pool were detected at 2 weeks. The 
responses persisted in both patients, most notably in Patient A in whom EBV-specific T-cells 
were detected at 2 years following DLI (data not shown).  
 
Given that IFN-γ release may underestimate the total frequency of antigen-specific T-cells302, 
we subsequently sought to quantify EBV-specific T-cells by flow cytometry, using MHC 
class I tetramers. Reagents were available for the HLA A*02 restricted EBV latent epitope 
CLG (LMP2) and the EBV lytic epitopes YVL (BRLF1) and GLC (BMLF1). These were 
used to analyse PBMCs from the HLA A*02-positive Patient A, to determine  responding T-
cells as a proportion of circulating CD8
+
 T-cells (Figure 64). Responses to all 3 tetramers 
were undetectable at 2 weeks following DLI, consistent with a general absence of CD8
+
 T-
cells at this time point (as demonstrated by Figure 62). However, by 4 weeks after DLI, 
responses to YVL (BRLF1) and GLC (BMLF1) tetramers were markedly increased, 
comprising 5.7% and 1.9% of circulating CD8
+
 T-cells respectively (Figure 64). These  
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Figure 64. HLA Class I Tetramer-Specific CD8
+
 T-Cells after DLI 
PBMCs from HLA A*02-positive Patient A were stained with the HLA A*02 tetramers YVL 
(BRLF1), CLG (LMP2) and GLC (BMLF1). Cell populations within the boxes indicate the 
percentage of tetramer-positive cells within the CD8
+
 T-cell population. A no tetramer control 
(left column) was also included. Tetramer staining performed by Dr H. Long, University of 
Birmingham. 
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responses were maximal at this time point and remained elevated at 8 weeks. The response to 
GLC (BMLF1) was less marked but also increased to a maximum of 1.0% of CD8
+
 T-cells at 
8 weeks. Notably, by 12 months after infusion of DLI, the frequencies of MHC class I 
tetramer-specific cells within the CD8
+
 T-cell subset had fallen to levels typically found in 
healthy EBV-seropositive adults
287. The frequency (cells/μl) of EBV tetramer-specific CD8+ 
T-cells was subsequently calculated (Figure 65), revealing the full magnitude and kinetics of 
these responses. Importantly, this demonstrated a close correlation between EBV epitope-
specific CD8
+
 T-cell expansion and resolution of viral DNAemia, particularly for the 
immunodominant EBV lytic peptide epitope YVL (BRLF1). 
 
7.4 Expression of EBV T-cell Target Antigens in PTLD Tissue 
Having documented EBV antigen-specific CD8
+
 and CD4
+
 T-cell responses following DLI, 
we wished to confirm the presence of corresponding viral antigens within PTLD tumour 
tissue. As such, sections from the PTLD biopsy available from Patient A were subjected to 
immunohistochemistry for a selected range of EBV proteins (Figure 66). This showed 
expression of EBNA1, EBNA2, LMP1 and LMP2 latent proteins, consistent with a Latency 
III, growth-transforming, pattern of virus gene expression. Importantly, these included several 
proteins recognised by the T-cells that had been found to expand in vivo post-DLI (Figures 63 
and 64). Notably, the EBV lytic cycle antigen BZLF1, expression of which is responsible for 
initiating the virus replication programme, was also readily detected. However, late lytic cycle 
gp350, which contributes to the virus envelope and is one of the final proteins to be expressed 
from the EBV genome, was absent. 
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Figure 65. Frequency of HLA Class I Tetramer-Specific CD8
+
 T-Cells after DLI 
The number of CD8
+
 T-cells specific to the HLA class I tetramers YVL (BRLF1), CLG 
(LMP2) and GLC (BMLF1) were determined for Patient A following DLI.  Responses are 
plotted alongside whole blood EBV loads. The dotted lines indicate the timing of DLI 
treatment. 
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Figure 66. EBV Antigen Expression in PTLD Biopsy Tissue 
Immunohistochemistry performed on sections of formalin-fixed and paraffin-embedded 
PTLD biopsy material from Patient A revealed strong positivity for EBV latent antigens 
EBNA1, EBNA2, LMP1 and LMP1, as well as the EBV lytic antigen BZLF1, but absence of 
late lytic antigen gp350. Images are magnified 60x. Immunohistochemistry was performed by 
Dr E. Nagy, Cancer Sciences, University of Birmingham. 
EBNA1 LMP1 BZLF1
EBNA2 LMP2 gp350
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7.5 Discussion 
Whilst pre-emptive Rituximab therapy constitutes an effective strategy to reduce the 
incidence of PTLD-associated mortality after allo-HSCT, it nevertheless remains suboptimal. 
Treatment itself is not devoid of side effects
616
, and a significant proportion of patients 
develop established, Rituximab-refractory, disease. Given the disappointing outcomes 
observed with cytotoxic chemotherapy, cellular therapies currently offer the best chance of 
rescue. However, effective responses to DLI or EBV CTLs are also not universal, and 
approximately 30% of patients exhibit treatment failure
525
. Retrospective analysis of the viral 
and immunological variables that may influence outcome is therefore likely to be crucial for 
the optimisation of future adoptive immunotherapeutic approaches. In this chapter the 
potential value of performing detailed immune characterisation following administration of 
cellular therapy is exemplified with 2 cases of Rituximab-refractory PTLD successfully 
rescued with DLI.  
 
Both study patients received single doses of 1 x10
6
/kg unselected transplant donor-derived 
lymphocytes. In each, infusion resulted in complete clinical response, comprising sustained 
resolution of EBV DNAemia and remission of radiological abnormalities. Notably, this was 
accompanied by marked expansion in circulating lymphocytes, with peak frequencies 
observed within 4 weeks of DLI therapy. The lymphocyte expansions contained both CD8
+
 
and CD4
+
 T-cells, consistent with previous reports that successful treatment of established 
PTLD correlates with restoration of T-cell numbers
525
. Interestingly, we also observed 
simultaneous increases in CD3
-
CD56
+
 NK-cell numbers. Notably, in vitro studies have shown 
that this lymphocyte subset, some of which are primed for rapid IFN-γ production617, may 
play a role in limiting B-cell transformation by EBV
306,307
. However, their contribution to the 
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clinical responses seen against established PTLD following DLI is yet to be determined.  
 
We went on to analyse the specificity of the expanded CD8
+
 and CD4
+
 T-cells in PBMCs 
collected before and after DLI. Previous studies, undertaken in similarly treated patients, have 
estimated EBV-specific T-cell numbers using LCL or peptide pool stimulation followed by 
limiting dilution or  chromium release assays
382,525
, and  by detecting IFN-γ production by 
flow cytometry
525
 or Elispot
532
. Whilst these assays are good measures of total EBV-specific 
responses, data regarding individual epitope specificities are not captured. In the present 
study, we instead used panels of patient HLA-relevant EBV epitope peptides to determine the 
frequency of individual responses, initially by IFN-γ Elispot. This approach has previously 
been used to track the kinetics of infused peptide-selected T-cells of known specificity
534
. In 
both patients, expanded T-cells contained immunodominant responses identical to those 
present in the DLI prior to infusion, i.e. YVL (BRLF1) for Patient A, and RPP (EBNA3A) for 
Patient B, and subdominant responses to a range of other CD8
+
 and CD4
+
 peptides. Crucially, 
detection of IFN-γ release in these assays demonstrated that the expanded T-cells are able to 
function in response to their cognate antigen.  Furthermore, we were also able to quantify 
absolute numbers of EBV epitope-specific CD8
+
 T-cells for Patient A, whose HLA I type was 
amenable to analysis with HLA-A*02 restricted EBV peptide MHC I tetramers. Significantly, 
the peak frequencies of tetramer positive cells in the blood coincided with the dynamics of 
total lymphocyte expansion, in line with reports of clinical responses occurring concurrently 
with expansion of LCL-reactive cells
525,615
. At this time, greater than 8% of all circulating 
CD8
+
 T-cells were specific for the 3 available MHC I tetramers. Given that the observed 
responses represent only 3 epitopes from the entire virus genome, restricted through a single 
HLA I allele, it is likely that detected responses are under-representative of all those present 
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and that the majority of the expanded CD8
+
 T-cells are in fact virus-specific.  
 
Importantly, we also observed notable differences in the repertoire of responses present in the 
DLI prior to infusion compared to those appearing in vivo after infusion. Thus, for Patient A 
the FLY (LMP2) peptide elicited the second largest response following infusion, whilst 2 
stronger responses in the DLI, EEN (EBNA3C) and KEH (EBNA3C), were almost 
undetectable. Similarly, in Patient B, reactivity against the CD8
+
 peptide pool was more 
prominent 4 weeks post infusion than in the DLI, whereas the TYS response of the DLI was 
undetectable after infusion. These differing patterns indicate non-uniform expansion of EBV 
epitope-specific T-cells present in the DLI following administration, and suggest that antigen 
encounter in vivo may shape the observed responses. Furthermore, they may explain why 
attempts to simply correlate antigen specificities present in heterogeneous therapeutic cell 
preparations with clinical outcome have thus far been unsuccessful
532,618
.  
 
Immunohistochemistry on biopsy material from Patient A demonstrated expression of several 
proteins associated with the viral latency III programme. Importantly, this included proteins 
that were targets of the expanded CD8
+
 T-cell response. Additionally, we detected 
unequivocal expression of the IE lytic cycle protein BZLF1. This transcription factor is the 
key initiator of EBV lytic cycle, and drives sequential expression of over 80 viral proteins 
involved in virus replication
10
. However, despite widespread BZLF1 expression in the biopsy, 
we could not detect expression of the L structural protein gp350. Such observations accord 
with earlier evidence that lytic cycle does not always progress to the final stages in PTLD 
tumours
439,443
, and that lytic cycle expression may therefore be abortive. Interestingly, it has 
been suggested that IE and E lytic gene expression, whether abortive or not, might enhance 
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PTLD tumourigenesis, possibly by stimulating the secretion of cytokines
445,448
. Notably, this 
pattern was reflected in the T-cell specificities expanded in vivo. Thus the immunodominant 
reactivity in the blood of Patient A following DLI was against the IE epitope YVL (BRLF1), 
whereas L epitope FLD (BALF4) responses were absent during the time of PTLD resolution. 
Together, these data indicate that tumour antigen expression can drive T-cell expansion, and 
suggest that T-cells active against latent and early lytic antigens may be more therapeutically 
important than L antigen-specific responses in the setting of PTLD. Further analysis of post-
DLI expanded T-cells in a larger series of patients will help to identify key therapeutic 
responses required for clinical efficacy. Such knowledge will be crucial to enhance the 
success of novel approaches using ex vivo selected T-cells
534,535
 or genetically engineered T-
cells
613
. 
 
In summary, this work confirms that DLI can be an effective therapeutic option for 
Rituximab-refractory PTLD arising after allo-HSCT when EBV CTLS are not available, 
although the risk of alloreactivity should be borne in mind. Moreover, we have described 
several novel properties pertaining to the virus-specific immune response which develops in 
vivo following adoptive transfer. Thus, resolution of disease coincided with a marked increase 
in lymphocytes, including in particular functional EBV epitope-specific CD8
+
 and CD4
+
 T-
cells. These exhibited reactivity against a range of latent and IE lytic antigens expressed in 
biopsy material. Importantly, expansion of specificities present in the DLI did not appear to 
be uniform, indicating that presentation of epitopes from viral antigens expressed in the 
tumour can drive the in vivo immune response. Further analyses on similarly treated patients 
are required to define the most clinically important epitopes against which therapy should be 
targeted. 
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8. Conclusions and Further Work 
 
This thesis presents a series of complementary studies exploring a central theme of EBV-
associated PTLD. Initially, retrospective studies undertaken in the solid allograft and allo-
HSCT clinical settings are reported; focusing on outcomes, incidence and risk factors, these 
studies exemplify the problem posed by PTLD and provide important clinical context for 
subsequent data. Thereafter, emphasis shifts to exploring the pathogenesis of PTLD, with 
insights generated by ex vivo analysis of samples collected from patients undergoing allo-
HSCT, and work exploring the clonal evolution of LCLs in vitro as a model for PTLD. 
Finally, consideration is given to the treatment of PTLD using DLI, with findings relevant to 
the future optimisation of adoptive immunotherapeutic strategies. 
 
8.1 PTLD Arising after Solid Organ Transplant 
For patients with biopsy-proven PTLD following solid organ transplant we report 74% versus 
59% (P = 0.52) 2-year overall survival for those treated with first-line R-mono or R-CHOP 
chemotherapy respectively, noting that those selected to receive R-CHOP generally had 
higher risk disease. This work confirms that R-mono can be a successful therapy for some 
patients with low risk disease. More importantly, using a modified prognostic scoring system 
we were able to identify a subset of patients who exhibited very poor outcome, irrespective of 
initial therapy. Thus, patients scoring ≥2 points using the 4-point modified IPI had a 2-year 
overall survival of only 43%. Notably, these results represent an interim analysis, because 
data on at least 50 further cases of PTLD are still due to be contributed from collaborating 
centres. Once completed, this will be among the largest series of its kind. 
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Given the current paucity of data on outcomes and prognostic factors for PTLD treated in the 
Rituximab era, this study is of substantial value. However, more importantly, it also provides 
a foundation for the development of future studies. In this respect, it is hoped that the 
availability of a large series of clinically annotated PTLD cases, drawn from a network of 
collaborating centres, will facilitate future work to undertake molecular profiling of PTLD 
tumours, in order to identify markers of prognostic or therapeutic importance. Furthermore, in 
follow-up to our study, a Phase II/III randomised controlled trial is currently being developed, 
with Dr Sridhar Chaganti as chief investigator, to address the pressing need for novel 
therapeutic strategies for patients with high risk PTLD. Examining the role of upfront EBV 
CTLs in PTLD after solid allograft, this trial will randomise patients with high risk or R-mono 
refractory (EBV-associated) PTLD between R-CHOP chemotherapy or third party EBV 
CTLs. The latter will be sourced from a cryopreserved bank of EBV CTLs generated from 
third party donors by Prof Mark Vickers from the University of Aberdeen. These will be 
selected on the basis of partial HLA-antigen matching, an approach already used for PTLD 
unresponsive to other therapies with encouraging results
531
. If the EBV CTLs prove non-
inferior to conventional upfront chemotherapy then this will be a landmark study in the field 
of adoptive immunotherapy. 
 
8.2 EBV Reactivation and PTLD after Allo-HSCT 
In what is, as far as we know, the largest study to examine incidence and risk factors for EBV 
reactivation and PTLD in patients undergoing Alemtuzumab-conditioned T-cell deplete allo-
HSCT, we report a cumulative incidence of high-level EBV reactivation (≥ 20,000 copies/ml 
whole blood) of 18% by 1 year after transplant amongst a cohort of 186 adults patients, with 8 
cases of PTLD and 3 PTLD-related deaths. We therefore conclude that Alemtuzumab-
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conditioned allo-HSCT does carry a significant risk of risk of PTLD, even in the context of 
EBV monitoring and pre-emptive Rituximab therapy. Interestingly, viral reactivation events 
occurred up to, and beyond, 6 months post-transplant. This suggests that monitoring for a 
period of 3 months, as recommended in current guidelines from the Second European 
Conference on Infections in Leukemia
496
, may be insufficient. Importantly, we also report the 
novel finding that patients with a diagnosis of NHL, most of whom received Rituximab 
therapy within 6 months prior to transplant, appear to exhibit a greatly reduced incidence of 
EBV reactivation and PTLD compared to other diagnostic groups. This is intriguing because 
it suggests that pre-transplant Rituximab might protect such patients from developing PTLD.  
 
In light of the above findings, it is foreseeable that Rituximab delivered in the peri-transplant 
period i.e. shortly before or after transplant, might be an effective method of prophylaxis for 
patients undergoing allo-HSCT, perhaps where the risk of PTLD is particularly high, such as 
after a second transplant or when ATG has been used. Given this, further research should be 
performed to explore the mechanism by which pre-transplant Rituximab might confer 
protection. Thus, efforts should be made to confirm or refute the observation by Van Dorp et 
al. that pre-transplant Rituximab therapy (delivered within 6 months prior to transplant) 
results in delayed reconstitution of the B-cell compartment
578
. Furthermore, studies to 
characterise the origin of EBV strains contributing to viral reactivation and PTLD, similar to 
those presented in Section 5.15, should be undertaken on larger patient cohorts. If the 
predominant viral strain present at the time of EBV reactivation is shown to be of recipient 
origin, then this would support the hypothesis that Rituximab results in protection by 
suppressing recipient virus prior to transplant. Ultimately, a randomised controlled clinical 
trial will be required to determine if Rituximab can indeed provide effective prophylaxis from 
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PTLD. One possibility would be to randomise patients undergoing T-cell deplete allo-HSCT 
to receive infusions of Rituximab on transplant day -7 and day +7,  or not. The primary 
outcome measure for such a trial should be incidence of EBV DNAemia, with secondary 
outcomes including incidence of PTLD and non-relapse morality. 
  
8.3 Studies on the Persistence of EBV in Patients Undergoing Allo-HSCT 
To explore the relationship between EBV persistence and immune reconstitution following 
allo-HSCT, blood samples collected from patients who exhibited high-level EBV reactivation 
were compared to those from patients who had never developed significant EBV DNA. This 
led to the novel finding that whereas most allo-HSCT patients exhibit a marked deficiency of 
CD27
+
 memory B-cells for many months after transplant, those with high-level EBV 
reactivation show a highly significant increase in both the proportion and number of 
circulating CD27
+
 memory B-cells. These cells were not present prior to viral reactivation, 
and up to around 90% were shown to carry viral genomes. Intriguingly, a high proportion of 
these CD27
+
 memory B-cells also exhibited an activated phenotype, given that they expressed 
plasmablastic-cell surface markers, had increased cell size, and around half of the cells 
showed positivity for the proliferation marker Ki-67. Importantly, although analysis of EBV 
gene expression revealed some Latency III expression within FACS-sorted CD27
+
 B-cells, 
the finding of a disproportionately low level of these transcripts suggested that a highly 
restricted pattern of viral gene expression is present in most EBV-infected cells. These data 
are important because they allow us to establish a more complete understanding of the  
pathophysiology of EBV reactivation after allo-HSCT. Furthermore, they show that EBV, 
quite remarkably, maintains selectivity for the memory B-cell compartment even in the setting 
of allo-HSCT where naive B-cells normally predominate. This raises important questions as 
8. Conclusions and Future Work 
Page 277  
 
to how this selectivity is maintained. 
 
In future work, effort should be directed at confirming our observation that a high proportion 
of circulating CD27
+
 memory B-cells are indeed activated cells, many of which are 
proliferating. One strategy would be to perform cell cycle analysis using non-toxic DNA-
specific fluorescent dyes, in combination with cell surface marker staining, in order to 
facilitate the FACS-sorting of CD27
+
 memory B-cells in S or G2/M phases of the cell cycle. 
These cells could be subsequently analysed using EBV qPCR in order to confirm the presence 
of EBV within actively proliferating cells. Furthermore, FACS-sorted single cells could be 
analysed with emerging techniques to assay EBV gene expression within single cells, in order 
to further characterise patterns of EBV latent gene expression. Such aims could also be 
addressed at the protein level by performing immunofluorescence staining on  
FACS-sorted cells, assuming that the significant technical challenges associated with such an 
approach could be overcome. Meanwhile, other work should be undertaken to address the 
question as to the origin of the CD27
+
 memory B-cells i.e. do they derive from mature B-cells 
transferred across with the donor stem cell graft, or do they originate from engrafted donor 
haematopoietic stem cells? One potential approach to this challenging problem would be to 
perform 'kappa-deleting recombination excision' (KREC) analysis, which provides an 
indication of the replication history of B-cells
619,620
. Additional insights may be obtained by 
examining EBV reactivation in recipients of umbilical cord stem cell grafts, given that these 
do not contain memory B-cells.    
 
8.4 Modelling the Clonal Evolution of PTLD in Vitro 
A series of investigations were also undertaken to explore the previously observed 
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phenomenon of clonal outgrowth in LCLs. Thus, IgH CDR3 spectratyping was used to 
confirm that LCLs generated from total or naive B-cells exhibit this effect, whereas B-cell 
blasts remain polyclonal in culture. Thereafter, novel observations were made that clonal 
outgrowth also occurs in LCLs generated from umbilical cord B-cells, and those established 
using a BZLF1 KO strain of EBV. Subsequently, differences observed in early EBV-infected 
and B-cell blast cultures led to the hypothesis that effects on cell survival and proliferation, 
possibly conferred by the mouse fibroblast layer used to generate B-cell blasts, might explain 
the observed patterns of clonal outgrowth. However, it was ultimately revealed that LCLs 
exhibit clonal outgrowth even when cultured on mouse fibroblasts, with or without 
CD40L/IL4 stimulation. Interestingly, little evidence was found to support the hypothesis that 
genomic instability or DNA damage response signalling in the first few days of culture has a 
significant influence on clonal outgrowth, particularly as levels of phospo-H2AX were found 
to be no lower in B-cell blasts that they are in LCLs. Furthermore, our data appear to 
contradict the results of Nikitin et al.
158
 because EBV-infection of B-cells was not found to be 
associated with a period of hyperproliferation or DNA damage response signalling.  
 
In light of the above findings, further studies are required to characterise potential influences 
on clonal outgrowth. Although no evidence was found to suggest that DNA damage response 
signalling, or genomic instability, in the first few days influence clonal outgrowth, further 
experiments are required to examine these factors, particularly at later time points. One 
approach may be to maintain cultures in the presence of small molecule inhibitors of the 
signalling proteins ATM and Chk2, to assess the effect of inhibition on outgrowth. 
Furthermore, cultures generated from individuals with inherited mutations of ATM or AID 
could be studied. Notably, to overcome difficulties with the comparison of LCL and B-cell 
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blast cultures, introduced by the requirement for a fibroblast feeder layer to generate the 
blasts, it would also be beneficial to assess clonal outgrowth in blasts generated using only 
soluble factors; this would allow better comparison using techniques such as Western 
blotting. In addition, given limitations identified with the current methods for assessing 
clonality, including the qualitative (as opposed to quantitative) nature of the data generated by 
IgH CDR3 spectratyping, and the labour intensive demands of sequencing individually cloned 
IgVH rearrangements, Next Generation Sequencing (NGS) technologies could be used to 
analyse Ig sequences. By simultaneously sequencing huge numbers of rearranged IgVH loci, 
NGS technologies would allow quantitative assessment of clonality in such a way that subtle 
differences in the clonal evolution of in vitro cultures (or PTLD tumours) might be studied, as 
well as yielding data on the evolution of specific sequences in culture. 
 
The acquisition of off-target AID-induced mutations was also explored as a possible influence 
on clonal outgrowth. This revealed that BCL6 (but not p53) mutations accumulate in LCLs 
following infection but also that clonal outgrowth may exaggerate the apparent number of 
mutations found. Importantly, the finding that umbilical cord LCLs do not accumulate BCL6 
mutations, yet they still exhibit clonal outgrowth, suggests that these mutations are not 
important drivers of clonal selection, contrary to expectation. However, the relatively small 
number of sequences analysed during these studies precluded definite conclusions. In follow-
up to this work, mutations accumulating in LCLs and B-cell blasts generated from alternative 
B-cells subsets, including umbilical cord B-cells, should be characterised with NGS. This 
would allow mutation rates at multiple target loci to be determined from high numbers of 
sequence reads. It would also be interesting to perform experiments to confirm whether, and 
why, umbilical cord B-cells remain refractory to AID-induced mutations. Furthermore, 
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additional experiments are warranted to explore why LCLs apparently accumulate BCL6 
mutations when they do not express BCL6, which is contradictory to the view that only 
transcribed genes can acquire AID-associated mutations. 
 
8.5 DLI Therapy for Rituximab-Refractory PTLD 
By studying patients treated with DLI for Rituximab-refractory PTLD arising after allo-
HSCT, insights about the properties of in vivo EBV-specific immune responses consequent 
upon DLI treatment were gained. Thus, in both patients studied, CD8
+
 and CD4
+
 T-cells, as 
well as NK-cells, were shown to exhibit marked expansion around 4 weeks after DLI 
treatment, coincident with excellent clinical responses. Furthermore, using IFN-γ Elispot and 
MHC-class I tetramer staining, individual EBV epitope-specific T-cell responses were 
characterised, revealing evidence of in vivo antigen-driven T-cell expansion. Importantly, this 
work highlights the value of adoptive immunotherapy as effective treatment for PTLD. 
Furthermore, it demonstrates a potentially informative approach by which adoptive 
immunotherapy might be optimised in future, by facilitating the identification of EBV 
antigens, and specific epitopes, against which CTL preparations should be directed to achieve 
effective anti-tumour responses. 
 
In follow-up to this work, we aim to undertake further studies in the near future to 
characterise in vivo immune responses in other patients with PTLD treated with adoptive 
immunotherapy. In particular, we are currently preparing a project proposal, with Dr Heather 
Long as chief investigator, to characterise EBV-specific immune responses in patients treated 
with EBV CTL therapy in the context of the aforementioned clinical trial for patients with 
PTLD arising after solid organ transplant. Thus, we aim to prospectively follow all patients 
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treated with cell therapy, in order to determine the kinetics, specificity and functional 
characteristics of EBV specific T-cell responses. Additional work will be undertaken to 
characterise the banked EBV CTLs used to treat patients. These findings will be correlated 
with clinical responses in order to identify potentially important determinants of clinical 
outcome. 
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10. Appendix 
Assay Primer/Probe 
Genome  
Co-ordinates* 
Sequence 20x conc. 
Wp W0 14391–14410 CGCCAGGAGTCCACACAAAT 2µM 
 W1W2 
14709–14701/ 
14619–14612 
GAGGGGACCCTCTGGCC 2µM 
Cp C1C2 
11467–11479/ 
11626–11639 
AATCATCTAAACCGACTGAAGAAACAG 20µM 
 W1W2 
14709–14701/ 
14619–14612 
GAGGGGACCCTCTGGCC 20µM 
Wp/Cp W probe 14564–14588 ACCGAAGTGAAGGCCCTGGACCAAC 10µM 
     
EBNA1 Q 62440–62456 GTGCGCTACCGGATGGC 20µM 
 Y3 48422–48440 TGCCTGAACCTGTGGTTGG 20µM 
 F primer 50099-50115 GGGTGAGGCCACGCTTT 20µM 
 U 55247-55269 CTGCAGCCCAGAGAGTAGTCTCA 20µM 
 U1 55326-55304 CAGGTCTACTGGCGGTCTATGAT  
 K 
107952–107941/ 
67649–67636 
CATGATTCACACTTAAAGGAGACGG 20µM 
 U probe 67563–67587 TCCTCTGGAGCCTGACCTGTGATCG 10µM 
     
EBNA2 EBNA2 Type1 F 
35702-35711 
36098-36109/ 
GCTTAGCCAGTAACCCAGCACT 6 µM 
 EBNA2 Type2 F  GCTTAGCCAGTAACTCAGCGCT 6 µM 
 EBNA2 R 36181-36160 TGCTTAGAAGGTTGTTGGCATG 6 µM 
 EBNA2 probe 36127-36153 CCCAACCACAGGTTCAGGCAAAACTTT 10µM 
     
EBNA3A EBNA3A F 81944-81929 CCCCTTAACTCAACCCATTAACC 6 µM 
 EBNA3A R 82313-82335 CGGCCCCTCCATTGGT 6 µM 
 EBNA3A probe 82343-82363 ACCCGCAGCCCATTTCCTCCA 10µM 
     
EBNA3B EBNA3B F 83265-83281 TGCCGCTGCAAGAGAGG 20µM 
 EBNA3B R 
83510-83500/ 
83421-83413 
AGGTCCGATTGCAACATGGA 20µM 
 EBNA3B probe 83347-83374 CCTAGATTTGTGGATGTGAACCCAACGC 10µM 
     
EBNA3C EBNA3C F 88813-88831 TACGCCCCATTCCAACAAG 6 µM 
 EBNA3C R 88876-88858 CCCACGGCCATGCTATCTT 6 µM 
 EBNA3C probe 88835-88856 CCCCCCTCCCCCTATGCCGTTA 10µM 
     
BHRF1 W2 14810-14830 TGGTAAGCGGTTCACCTTCAG 6µM 
 Y2 35706-35680 GAGGATGAAGACTAAGTCACAGGCTTA 6µM 
 H2 
41596-41607/ 
42047-42055 
GGCTTACCTCGGTTCCCTCTT 6µM 
 HF 42134-42111 TCCCGTATACACAGGGCTAACAGT 6µM 
 Probe  42067-42097 TGCCAGATCTTGTAGAGCAAGATGGCCTATT 10µM 
     
LMP1 LMP1 F 168644-168625 AATTTGCACGGACAGGCATT 6 µM 
 LMP1R 168435-168454 AAGGCCAAAAGCTGCCAGAT 6 µM 
 LMP 1 probe (B95) 
168951-168965/ 
169042-169060 
TCCAGATACCTAAGACAAGTAAGCACCCGAAGAT 10µM 
 LMP1 probe (Cao)  TCCAGAGACCTAAGACAAGTAAGCAGCCAAAGAT 10µM 
     
LMP1-TR LMP1-TR F (B95) 169013-168994 CCCCTCTCAAGGTCGTGTTC 6 µM 
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 LMP1-TR F (Cao)  GCGTCTCAAGGTCGCGTTC 6 µM 
 LMP1-TR R (B95) 169099-169080 CGTAGCCGCCCTACATAAGC 6 µM 
 LMP1-TR R (Cao)  TCGTAGGCGGCCTACATAACC 6 µM 
 LMP1-TR probe (B95) 169017-169040 CCTCAGGGCAGTGTGTCAGGAGCA 10µM 
 LMP1-TR probe (Cao)  TGCTCCTGCCACACTACCCTGACCA 10µM 
     
LMP2 (total) LMP2exon6 F 1027-1049 GGTTCTCCTGATTTGCTCTTCGT 6 µM 
 LMP2exon6 R 1129-1113 CGCGGAGGCTAGCAACA 6 µM 
 LMP2exon6 probe 1074-1103 TCCTTCTGGCACGACTGTTCCTATATGCTC 10µM 
     
LMP2A LMP2A exon1 F 166109-166129 TCCCTAGAAATGGTGCCAATG 6 µM 
 LMP2A exon1 R 166215-166195 GAAGAGCCAGAAGCAGATGGA 6 µM 
 LMP2A probe 166142-166160 CCTAGCCCCGGCGGGGATC 10µM 
     
LMP2B LMP2B exon1F 169365-169385 GTAATCTGCACAAAGAGGCGC 6 µM 
 LMP2B exon1R 169436-169421 AAAGCACGGCCTCCCG 6 µM 
 LMP2B probe 169399-169418 TGCCGCCAACGACCTCCCAA 10µM 
     
LMP2-TR LMP2-TR F 28-50 ACTTTTCTTCTTGCCCGTTCTCT 6 µM 
 LMP2-TR R 114-133 GAAACACGAGGCGGCAATAG 6 µM 
 LMP2-TR probe 66-92 CAGTATGCCTGCCTGTAATTGTTGCGC 10µM 
     
BZLF1 BZLF1 F 90859-90835 CCCAAACTCGACTTCTGAAGATGTA 20x  
 BZLF1 R 90767-90791 TGATAGACTCTGGTAGCTTGGTCAA custom 
 BZLF1probe 90803-90820 CCCATACCAGGTGCCTTT assay 
     
BRLF1 BRLF1 F 92662-92644 TTGGGCCATTCTCCGAAAC 6 µM 
 BRLF1 R 92581-92590 TATAGGGCACGCGATGGAA 6 µM 
 BRLF1probe 92611-92631 AGACGGGCTGAGAATGCCGGC 10µM 
     
BMLF1 BMLF1 F 71978-71958 CCCGAACTAGCAGCATTTCCT 6 µM 
 BMLF1 R 71805-71824 GACCGCTTCGAGTTCCAGAA 6 µM 
 BMLF1 probe 71941-71955 AACGAGGATCCCGCAGAGAGCCA 10µM 
     
BALF1 BALF1 F 164694-169676 GGGCAAAGACACGCACGTA 6 µM 
 BALF1 R 164615-164633 GCCGCGACCAGTAGTCGTA 6 µM 
 BALF1 probe 164650-164670 CATCATCAGCGTCCTGCGCGC 10µM 
     
BALF2 BALF2F 164131-164113 CGGGCTTCAGCATCAATGT 6 µM 
 BALF2R 164053-164074 TGATAGGAGGTAGCGCGTAGGA 6 µM 
 BALF2 probe 164080-164101 ACAGGAGGCCCGACCCCAACTG 10µM 
     
BARF1 BARF1 F 165586-165606 GGGAGCCTCTCTGTTGCTGTT 6 µM 
 BARF1 R 165658-165639 TTTTCCCAACGCAGGTCACT 6 µM 
 BARF1 probe 165608-165631 ACCTGTCACTTCCCAAGCCCTGGC 10µM 
     
BGLF5 BGLF5F 108930-108913 GCAAGCCCGGGAGAGACT 6 µM 
 BGFL5R 108862-108879 GAGGCGACCGTTTTCGAA 6 µM 
 BGLF5 probe 108881-108904 CGGGTGAACATTGTGACGGCCTTC 10µM 
Table 26. Primers and Probes for Fluidigm RT-PCR 
* Coordinates taken from accession number NC007605 (Human Herpesvirus 4 type 1, 
complete genome) 
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Figure 67. Whole Blood versus PBMC EBV Loads for High EBV Allo-HSCT Patients 
EBV loads determined by the clinical whole blood EBV qPCR assay (EBV copies / ml of 
whole blood) are plotted against corresponding virus loads determined within isolated 
PBMCs (EBV copies / 10
6
 PBMCs) for allo-HSCT patients with high-level EBV reactivation. 
Pearson correlation was non-significant within the group. 
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